447482	Androgens	Kaighn ME	Establishment and characterization of a human prostatic carcinoma cell line (PC-3).	Investigative urology	1979	316
1458483	Androgens	McDonnell TJ	Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.	Cancer research	1992	151
9214605	Androgens	Bello D	Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.	Carcinogenesis	1997	129
9916127	Androgens	Benjamin LE	Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.	The Journal of clinical investigation	1999	230
10550143	Androgens	Bubley GJ	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.	Journal of clinical oncology 	1999	178
10835690	Androgens	Zhao XY	Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.	Nature medicine	2000	98
11032808	Androgens	Migliaccio A	Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.	The EMBO journal	2000	157
11404460	Androgens	Lin HK	Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2001	102
11717329	Androgens	Grossmann ME	Androgen receptor signaling in androgen-refractory prostate cancer.	Journal of the National Cancer Institute	2001	112
11792709	Androgens	Yang F	Linking beta-catenin to androgen-signaling pathway.	The Journal of biological chemistry	2002	101
11861374	Androgens	Zegarra-Moro OL	Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.	Cancer research	2002	119
11943742	Androgens	Heinlein CA	Androgen receptor (AR) coregulators: an overview.	Endocrine reviews	2002	189
12351684	Androgens	Heinlein CA	The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions.	Molecular endocrinology	2002	97
12429632	Androgens	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	93
14755679	Androgens	Taplin ME	Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.	Journal of cellular biochemistry	2004	96
14760063	Androgens	Mohler JL	The androgen axis in recurrent prostate cancer.	Clinical cancer research 	2004	217
15042618	Androgens	Halkidou K	Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.	The Prostate	2004	128
15316903	Androgens	Chen G	Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.	Cancer	2004	77
15389811	Androgens	Miyamoto H	Androgen deprivation therapy for prostate cancer: current status and future prospects.	The Prostate	2004	77
15668482	Androgens	Lukanova A	Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.	Cancer epidemiology, biomarkers & prevention 	2005	74
15930347	Androgens	Murphy C	Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.	Clinical cancer research 	2005	67
16140968	Androgens	Agoulnik IU	Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.	Cancer research	2005	67
16254181	Androgens	Tomlins SA	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.	Science	2005	1164
16491124	Androgens	Doane AS	An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.	Oncogene	2006	154
16518832	Androgens	Dehm SM	Molecular regulation of androgen action in prostate cancer.	Journal of cellular biochemistry	2006	74
17045208	Androgens	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	149
17079484	Androgens	Agoulnik IU	Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.	Cancer research	2006	71
17185378	Androgens	Srinivasan S	Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.	Cancer research	2007	67
17494760	Androgens	Mahajan NP	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.	Proceedings of the National Academy of Sciences of the United States of America	2007	93
18056640	Androgens	Shi XB	An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	161
18066052	Androgens	Metzger E	Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation.	Nature cell biology	2008	62
18174313	Androgens	Lin SL	Loss of mir-146a function in hormone-refractory prostate cancer.	RNA	2008	122
18483239	Androgens	Mehra R	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.	Cancer research	2008	80
18519708	Androgens	Montgomery RB	Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.	Cancer research	2008	377
18676866	Androgens	Locke JA	Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.	Cancer research	2008	226
18701501	Androgens	Jin RJ	The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.	Cancer research	2008	65
18723679	Androgens	Niu Y	Androgen receptor is a tumor suppressor and proliferator in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	104
18782595	Androgens	Dillard PR	Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.	Molecular and cellular endocrinology	2008	58
18794152	Androgens	Han B	A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.	Cancer research	2008	54
18794802	Androgens	Schaeffer EM	Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.	Oncogene	2008	66
18821585	Androgens	Cirillo D	Leptin signaling in breast cancer: an overview.	Journal of cellular biochemistry	2008	65
19212411	Androgens	Sreekumar A	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.	Nature	2009	522
19244107	Androgens	Guo Z	A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.	Cancer research	2009	275
19289629	Androgens	Mendiratta P	Genomic strategy for targeting therapy in castration-resistant prostate cancer.	Journal of clinical oncology 	2009	44
19345326	Androgens	Xu K	Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.	Cancer cell	2009	76
19552894	Androgens	Gannon PO	Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.	Journal of immunological methods	2009	53
19620249	Androgens	Vigneri P	Diabetes and cancer.	Endocrine-related cancer	2009	199
19738047	Androgens	Ribas J	miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.	Cancer research	2009	133
19796750	Androgens	Chen Y	Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.	The Lancet. Oncology	2009	84
19917249	Androgens	Norris JD	The homeodomain protein HOXB13 regulates the cellular response to androgens.	Molecular cell	2009	68
20086173	Androgens	Hofland J	Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.	Cancer research	2010	58
20133657	Androgens	McPherson SJ	Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20138542	Androgens	Knudsen KE	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.	Trends in endocrinology and metabolism	2010	107
20220849	Androgens	Ammirante M	B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.	Nature	2010	148
20228790	Androgens	Metzger E	Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.	Nature	2010	96
20440270	Androgens	Niu Y	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.	Oncogene	2010	46
20945501	Androgens	Waltering KK	Androgen regulation of micro-RNAs in prostate cancer.	The Prostate	2011	47
21098087	Androgens	Frigo DE	CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.	Cancer research	2011	39
21224358	Androgens	Hodgson MC	Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.	Cancer research	2011	37
21372223	Androgens	Attard G	New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.	Clinical cancer research 	2011	49
21400613	Androgens	Kauffman EC	Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.	Molecular carcinogenesis	2011	47
21499299	Androgens	Jeter CR	NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.	Oncogene	2011	110
21620560	Androgens	Nicholson TM	Androgens and estrogens in benign prostatic hyperplasia: past, present and future.	Differentiation; research in biological diversity	2011	45
21741601	Androgens	Ni M	Targeting androgen receptor in estrogen receptor-negative breast cancer.	Cancer cell	2011	100
22083957	Androgens	Tan PY	Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.	Molecular and cellular biology	2012	57
22108827	Androgens	Sun Y	Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.	Cancer research	2012	94
22114732	Androgens	Zhang X	Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.	PloS one	2011	101
22265403	Androgens	Li Z	Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer.	Cell	2012	92
22438320	Androgens	Germann M	Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.	Stem cells	2012	35
22447389	Androgens	Willmann D	Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.	International journal of cancer	2012	38
22453214	Androgens	Green SM	Androgen action and metabolism in prostate cancer.	Molecular and cellular endocrinology	2012	40
22479342	Androgens	Nadiminty N	MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.	PloS one	2012	42
22831834	Androgens	Lee SO	New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.	Journal of molecular cell biology	2013	33
22971343	Androgens	Mitsiades N	Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.	Cancer research	2012	57
23019221	Androgens	Decker KF	Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.	Nucleic acids research	2012	35
23300485	Androgens	Francis JC	β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.	PLoS genetics	2013	28
23426182	Androgens	Cai C	ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.	The Journal of clinical investigation	2013	44
23435229	Androgens	Coffey K	The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.	Nucleic acids research	2013	26
23503464	Androgens	Sun D	Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells.	Oncogene	2014	25
23512661	Androgens	Baena E	ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.	Genes & development	2013	38
23517348	Androgens	Schiaffino S	Mechanisms regulating skeletal muscle growth and atrophy.	The FEBS journal	2013	163
23727860	Androgens	Lunardi A	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.	Nature genetics	2013	43
23729330	Androgens	Ayala G	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.	The Journal of pathology	2013	28
23806491	Androgens	Schrecengost R	Molecular pathogenesis and progression of prostate cancer.	Seminars in oncology	2013	26
23851510	Androgens	Liu LL	Mechanisms of the androgen receptor splicing in prostate cancer cells.	Oncogene	2014	61
23993097	Androgens	Chang KH	A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.	Cell	2013	80
23993415	Androgens	Wen S	Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.	Cancer treatment reviews	2014	25
23995860	Androgens	Yepuru M	Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.	Clinical cancer research 	2013	27
24054868	Androgens	Chen R	Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers.	Urologic oncology	2014	22
24186207	Androgens	Tennakoon JB	Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.	Oncogene	2014	45
24706793	Androgens	McAllister JM	Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
24731978	Androgens	Ali S	Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.	Gerontology	2014	27
24909511	Androgens	Tan MH	Androgen receptor: structure, role in prostate cancer and drug discovery.	Acta pharmacologica Sinica	2015	41
25065599	Androgens	Kroiss A	Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.	Oncogene	2015	26
25267627	Androgens	Ammirante M	Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
25535248	Androgens	Chen Z	Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.	The EMBO journal	2015	17
25591066	Androgens	Njar VC	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.	Journal of medicinal chemistry	2015	26
25645929	Androgens	Zhang L	The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.	Molecular and cellular biology	2015	23
25830880	Androgens	Gundem G	The evolutionary history of lethal metastatic prostate cancer.	Nature	2015	136
26060018	Androgens	Xu D	Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.	Cancer research	2015	33
26342199	Androgens	Kawahara T	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.	Oncotarget	2015	18
26411689	Androgens	Zhang A	LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.	Cell reports	2015	28
27049719	Androgens	Liu C	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.	Oncotarget	2016	15
27052658	Androgens	Bonnefoi H	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).	Annals of oncology 	2016	12
27184811	Androgens	Antonarakis ES	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.	Prostate cancer and prostatic diseases	2016	14
27487144	Androgens	Wadosky KM	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.	Oncotarget	2016	18
27801901	Androgens	Benzon B	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.	Prostate cancer and prostatic diseases	2017	6
8248223	Estrogens	Lubahn DB	Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.	Proceedings of the National Academy of Sciences of the United States of America	1993	312
8405201	Estrogens	Pike MC	Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.	Epidemiologic reviews	1993	171
9111344	Estrogens	Hong H	GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors.	Molecular and cellular biology	1997	125
9504686	Estrogens	Allred DC	Prognostic and predictive factors in breast cancer by immunohistochemical analysis.	Modern pathology 	1998	420
9662379	Estrogens	Kononen J	Tissue microarrays for high-throughput molecular profiling of tumor specimens.	Nature medicine	1998	777
10227624	Estrogens	Jack CR Jr	Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.	Neurology	1999	322
10334533	Estrogens	Harvey JM	Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.	Journal of clinical oncology 	1999	417
10713699	Estrogens	Cogswell PC	Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.	Oncogene	2000	126
10833057	Estrogens	Roof RL	Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone.	Journal of neurotrauma	2000	114
11016622	Estrogens	Eads CA	Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.	Cancer research	2000	102
11140706	Estrogens	Camp RL	Validation of tissue microarray technology in breast carcinoma.	Laboratory investigation; a journal of technical methods and pathology	2000	121
11181778	Estrogens	Bos R	Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.	Journal of the National Cancer Institute	2001	143
11289127	Estrogens	Roger P	Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.	Cancer research	2001	92
11438457	Estrogens	Leav I	Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.	The American journal of pathology	2001	97
11517191	Estrogens	Lazennec G	ER beta inhibits proliferation and invasion of breast cancer cells.	Endocrinology	2001	101
11581496	Estrogens	Nilsson S	Mechanisms of estrogen action.	Physiological reviews	2001	343
11733374	Estrogens	Torhorst J	Tissue microarrays for rapid linking of molecular changes to clinical endpoints.	The American journal of pathology	2001	88
11751417	Estrogens	Xie D	Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.	Cancer research	2001	90
11751582	Estrogens	Bauer UM	Methylation at arginine 17 of histone H3 is linked to gene activation.	EMBO reports	2002	95
11981002	Estrogens	Lakhani SR	The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.	Journal of clinical oncology 	2002	177
12060624	Estrogens	Schindl M	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.	Clinical cancer research 	2002	102
12400004	Estrogens	Real PJ	Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.	Oncogene	2002	88
12498683	Estrogens	Daujat S	Crosstalk between CARM1 methylation and CBP acetylation on histone H3.	Current biology 	2002	85
12529347	Estrogens	Konecny G	Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.	Journal of the National Cancer Institute	2003	91
12627523	Estrogens	Bos R	Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.	Cancer	2003	141
12657462	Estrogens	Wu C	The function of the protein tyrosine phosphatase SHP-1 in cancer.	Gene	2003	76
12705869	Estrogens	Fujita N	MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.	Cell	2003	149
12743151	Estrogens	Bardou VJ	Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.	Journal of clinical oncology 	2003	122
12824206	Estrogens	Li CI	Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.	JAMA	2003	77
14576841	Estrogens	Clarke R	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.	Oncogene	2003	132
14578209	Estrogens	Lin EY	Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.	The American journal of pathology	2003	356
14871808	Estrogens	Foulkes WD	The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.	Cancer research	2004	73
14993287	Estrogens	Glading A	Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation.	Molecular and cellular biology	2004	81
15041722	Estrogens	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	77
15084238	Estrogens	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	115
15169792	Estrogens	Nevalainen MT	Signal transducer and activator of transcription-5 activation and breast cancer prognosis.	Journal of clinical oncology 	2004	71
15207254	Estrogens	Platet N	Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion.	Critical reviews in oncology/hematology	2004	94
15220474	Estrogens	Biswas DK	NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2004	115
15221988	Estrogens	Giordano SH	Breast carcinoma in men: a population-based study.	Cancer	2004	114
15223047	Estrogens	Dontu G	Breast cancer, stem/progenitor cells and the estrogen receptor.	Trends in endocrinology and metabolism	2004	95
15328174	Estrogens	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	631
15339660	Estrogens	Cuthbert GL	Histone deimination antagonizes arginine methylation.	Cell	2004	199
15342389	Estrogens	Kubo M	Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer.	Cancer research	2004	110
15369453	Estrogens	Bardin A	Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.	Endocrine-related cancer	2004	80
15380517	Estrogens	Torres-Arzayus MI	High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.	Cancer cell	2004	148
15455388	Estrogens	Lengyel E	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.	International journal of cancer	2005	88
15475452	Estrogens	Colleoni M	Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.	Clinical cancer research 	2004	73
15534099	Estrogens	Camp RL	X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.	Clinical cancer research 	2004	337
15574759	Estrogens	Al-Kuraya K	Prognostic relevance of gene amplifications and coamplifications in breast cancer.	Cancer research	2004	82
15574760	Estrogens	Loo LW	Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.	Cancer research	2004	70
15674344	Estrogens	Foster KW	Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.	Oncogene	2005	83
15746036	Estrogens	Takahashi Y	Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.	Clinical cancer research 	2005	89
15762276	Estrogens	Nadji M	Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.	American journal of clinical pathology	2005	70
15899795	Estrogens	Dai H	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.	Cancer research	2005	91
16012726	Estrogens	Tsutsui S	Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.	Oncology reports	2005	92
16019138	Estrogens	Chen DC	Serum adiponectin and leptin levels in Taiwanese breast cancer patients.	Cancer letters	2006	86
16103053	Estrogens	Iorio MV	MicroRNA gene expression deregulation in human breast cancer.	Cancer research	2005	1201
16172792	Estrogens	Zhang Z	Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.	Breast cancer research and treatment	2005	71
16299229	Estrogens	Willipinski-Stapelfeldt B	Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.	Clinical cancer research 	2005	81
16317585	Estrogens	Li SY	PIK3CA mutations in breast cancer are associated with poor outcome.	Breast cancer research and treatment	2006	60
16341146	Estrogens	Livasy CA	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.	Modern pathology 	2006	250
16357129	Estrogens	Mehra R	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.	Cancer research	2005	84
16368942	Estrogens	McCabe A	Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.	Journal of the National Cancer Institute	2005	81
16469706	Estrogens	Zhu P	Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.	Cell	2006	94
16478745	Estrogens	Sotiriou C	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.	Journal of the National Cancer Institute	2006	549
16533778	Estrogens	Rodríguez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	73
16603601	Estrogens	Pestalozzi BC	Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).	Annals of oncology 	2006	76
16611412	Estrogens	Ghebeh H	The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.	Neoplasia	2006	142
16626501	Estrogens	Perreard L	Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.	Breast cancer research 	2006	62
16648502	Estrogens	Wapnir IL	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.	Journal of clinical oncology 	2006	71
16707433	Estrogens	Bond GL	MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.	Cancer research	2006	111
16757721	Estrogens	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	1027
16931954	Estrogens	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	71
16938528	Estrogens	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	84
16940181	Estrogens	Hossain A	Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.	Molecular and cellular biology	2006	171
16951137	Estrogens	Amend K	Breast cancer in African-American women: differences in tumor biology from European-American women.	Cancer research	2006	67
16954471	Estrogens	Buyse M	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.	Journal of the National Cancer Institute	2006	257
17028294	Estrogens	Hecht JL	Molecular and pathologic aspects of endometrial carcinogenesis.	Journal of clinical oncology 	2006	94
17085646	Estrogens	Filardo EJ	Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.	Clinical cancer research 	2006	101
17113977	Estrogens	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	82
17116942	Estrogens	Haffty BG	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.	Journal of clinical oncology 	2006	226
17123779	Estrogens	Prins GS	Developmental estrogen exposures predispose to prostate carcinogenesis with aging.	Reproductive toxicology	2007	69
17135638	Estrogens	Bates GJ	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.	Journal of clinical oncology 	2006	234
17234468	Estrogens	Livasy CA	Identification of a basal-like subtype of breast ductal carcinoma in situ.	Human pathology	2007	60
17239243	Estrogens	Dunnwald LK	Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.	Breast cancer research 	2007	158
17308356	Estrogens	Zhao H	Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke.	Molecular neurobiology	2006	77
17332353	Estrogens	Huang F	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.	Cancer research	2007	105
17403429	Estrogens	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	77
17409397	Estrogens	Pick E	High HSP90 expression is associated with decreased survival in breast cancer.	Cancer research	2007	78
17417639	Estrogens	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	77
17440086	Estrogens	Fu Y	GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis.	Cancer research	2007	92
17488799	Estrogens	Rometo AM	Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys.	The Journal of clinical endocrinology and metabolism	2007	88
17491024	Estrogens	Armstrong VJ	Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha.	The Journal of biological chemistry	2007	95
17493263	Estrogens	Herschkowitz JI	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.	Genome biology	2007	443
17502350	Estrogens	Shi B	Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.	Molecular and cellular biology	2007	107
17554627	Estrogens	Bauer M	Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.	Breast cancer research and treatment	2008	58
17586727	Estrogens	Sasser AK	Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.	FASEB journal 	2007	70
17626182	Estrogens	Liu X	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
17652280	Estrogens	Glass AG	Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.	Journal of the National Cancer Institute	2007	99
17663798	Estrogens	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	104
17671124	Estrogens	Badve S	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.	Clinical cancer research 	2007	69
17671126	Estrogens	Dent R	Triple-negative breast cancer: clinical features and patterns of recurrence.	Clinical cancer research 	2007	767
17910759	Estrogens	Kreike B	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.	Breast cancer research 	2007	171
17954709	Estrogens	Harris L	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.	Journal of clinical oncology 	2007	496
18006846	Estrogens	Mertens-Talcott SU	The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.	Cancer research	2007	152
18037158	Estrogens	Tomsová M	Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.	Gynecologic oncology	2008	64
18048329	Estrogens	Gupta GP	ID genes mediate tumor reinitiation during breast cancer lung metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2007	91
18089790	Estrogens	Sempere LF	Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.	Cancer research	2007	212
18230721	Estrogens	Liu S	BRCA1 regulates human mammary stem/progenitor cell fate.	Proceedings of the National Academy of Sciences of the United States of America	2008	157
18240539	Estrogens	Mundy GR	Osteoporosis and inflammation.	Nutrition reviews	2007	102
18250347	Estrogens	Liedtke C	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.	Journal of clinical oncology 	2008	473
18285604	Estrogens	Kyndi M	Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.	Journal of clinical oncology 	2008	89
18297396	Estrogens	Lu X	Predicting features of breast cancer with gene expression patterns.	Breast cancer research and treatment	2008	90
18316557	Estrogens	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	318
18317227	Estrogens	Soslow RA	Histologic subtypes of ovarian carcinoma: an overview.	International journal of gynecological pathology 	2008	63
18324472	Estrogens	Lund MJ	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.	Breast cancer research and treatment	2009	114
18339859	Estrogens	Cheng AS	Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.	Cancer research	2008	54
18375767	Estrogens	Tan-Wong SM	Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18381931	Estrogens	Wu JM	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.	Clinical cancer research 	2008	68
18391223	Estrogens	Horwitz KB	Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18407820	Estrogens	D'Amelio P	Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis.	Bone	2008	63
18413639	Estrogens	Nguyen PL	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.	Journal of clinical oncology 	2008	162
18438407	Estrogens	Stacey SN	Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.	Nature genetics	2008	219
18443585	Estrogens	Ben-Porath I	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.	Nature genetics	2008	811
18451146	Estrogens	Yang XH	CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization.	Cancer research	2008	63
18451221	Estrogens	Ignatiadis M	Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.	Clinical cancer research 	2008	52
18451222	Estrogens	Ma XJ	A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.	Clinical cancer research 	2008	66
18458044	Estrogens	Pestalozzi BC	Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.	Journal of clinical oncology 	2008	54
18487567	Estrogens	Badve SS	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.	Journal of clinical oncology 	2008	60
18505969	Estrogens	Setlur SR	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.	Journal of the National Cancer Institute	2008	110
18506688	Estrogens	Shabo I	Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.	International journal of cancer	2008	52
18515733	Estrogens	Ross JS	Commercialized multigene predictors of clinical outcome for breast cancer.	The oncologist	2008	55
18543098	Estrogens	Dent R	Pattern of metastatic spread in triple-negative breast cancer.	Breast cancer research and treatment	2009	88
18559090	Estrogens	Honeth G	The CD44+/CD24- phenotype is enriched in basal-like breast tumors.	Breast cancer research 	2008	186
18593897	Estrogens	Kondo N	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.	Cancer research	2008	106
18612148	Estrogens	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	159
18657504	Estrogens	Le Romancer M	Regulation of estrogen rapid signaling through arginine methylation by PRMT1.	Molecular cell	2008	76
18662380	Estrogens	Wirapati P	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.	Breast cancer research 	2008	249
18698033	Estrogens	Desmedt C	Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.	Clinical cancer research 	2008	235
18698041	Estrogens	Shaaban AM	Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.	Clinical cancer research 	2008	63
18714348	Estrogens	Martin KJ	Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.	PloS one	2008	90
18755890	Estrogens	Foekens JA	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	132
18779615	Estrogens	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	113
18806226	Estrogens	Dumont N	Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2008	81
18841463	Estrogens	Tan AR	Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?	Breast cancer research and treatment	2009	48
18974155	Estrogens	Studebaker AW	Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.	Cancer research	2008	70
19001334	Estrogens	Chia S	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.	Journal of clinical oncology 	2008	57
19027010	Estrogens	Liu WH	MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.	Gastroenterology	2009	65
19079346	Estrogens	Gonzalez ME	Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.	Oncogene	2009	75
19112174	Estrogens	Yamnik RL	S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.	The Journal of biological chemistry	2009	62
19116762	Estrogens	Toh Y	The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.	Clinical & experimental metastasis	2009	67
19147748	Estrogens	Andre F	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.	Clinical cancer research 	2009	97
19188147	Estrogens	Beck AH	The macrophage colony-stimulating factor 1 response signature in breast carcinoma.	Clinical cancer research 	2009	59
19237579	Estrogens	Yang J	Lipocalin 2 promotes breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19275906	Estrogens	Solomon MB	Sex differences in psychopathology: of gonads, adrenals and mental illness.	Physiology & behavior	2009	64
19317994	Estrogens	Gnerlich JL	Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.	Journal of the American College of Surgeons	2009	69
19349544	Estrogens	Anderson SJ	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.	Journal of clinical oncology 	2009	63
19385968	Estrogens	Morimoto K	Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.	Cancer science	2009	59
19421758	Estrogens	Fang YJ	Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.	International journal of colorectal disease	2009	47
19436038	Estrogens	Cheang MC	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.	Journal of the National Cancer Institute	2009	447
19451693	Estrogens	Bierie B	Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.	The Journal of clinical investigation	2009	46
19498003	Estrogens	Paulsson J	Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.	The American journal of pathology	2009	59
19549922	Estrogens	Lin BC	Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.	Cancer research	2009	47
19567422	Estrogens	Milne RL	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.	Journal of the National Cancer Institute	2009	52
19574486	Estrogens	Onitilo AA	Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.	Clinical medicine & research	2009	165
19581928	Estrogens	Sullivan NJ	Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.	Oncogene	2009	186
19582160	Estrogens	Kao J	Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.	PloS one	2009	264
19596702	Estrogens	Liedtke C	Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.	Annals of oncology 	2009	71
19602591	Estrogens	Hartman J	Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells.	Cancer research	2009	52
19664291	Estrogens	Fehm T	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.	Breast cancer research 	2009	61
19706001	Estrogens	Kjaer M	From mechanical loading to collagen synthesis, structural changes and function in human tendon.	Scandinavian journal of medicine & science in sports	2009	49
19730444	Estrogens	Spizzo R	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.	Cell death and differentiation	2010	85
19764994	Estrogens	Parise CA	Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.	The breast journal	2009	73
19819674	Estrogens	Fairweather D	Alternatively activated macrophages in infection and autoimmunity.	Journal of autoimmunity	2009	77
19826037	Estrogens	Maillot G	Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.	Cancer research	2009	92
19838210	Estrogens	Hao L	Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.	Oncogene	2010	43
19858088	Estrogens	Aitken SJ	Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.	Annals of oncology 	2010	43
19887463	Estrogens	Park S	Expression of androgen receptors in primary breast cancer.	Annals of oncology 	2010	71
19898421	Estrogens	Niemeier LA	Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.	Modern pathology 	2010	81
19911270	Estrogens	Resetkova E	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.	Breast cancer research and treatment	2010	60
19994911	Estrogens	Giskeødegård GF	Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.	Journal of proteome research	2010	43
20020197	Estrogens	Györffy B	An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.	Breast cancer research and treatment	2010	524
20031276	Estrogens	Rasgon NL	Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.	Neurobiology of aging	2011	48
20042638	Estrogens	Lim S	Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.	Carcinogenesis	2010	129
20080637	Estrogens	Lovén J	MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2010	48
20081107	Estrogens	Rajkumar R	Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.	American journal of physiology. Heart and circulatory physiology	2010	57
20082448	Estrogens	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	52
20194857	Estrogens	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	247
20231686	Estrogens	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	58
20332136	Estrogens	Cancello G	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.	Annals of oncology 	2010	41
20404251	Estrogens	Hammond ME	American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.	Journal of clinical oncology 	2010	560
20427430	Estrogens	Kerlikowske K	Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.	Journal of the National Cancer Institute	2010	84
20442245	Estrogens	Hsu PY	Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping.	Genome research	2010	41
20459607	Estrogens	Staaf J	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.	Breast cancer research 	2010	52
20501593	Estrogens	Bernardo GM	FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.	Development	2010	71
20501637	Estrogens	Leung YK	Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.	Endocrine-related cancer	2010	43
20509143	Estrogens	Storci G	TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.	Journal of cellular physiology	2010	41
20537966	Estrogens	Podo F	Triple-negative breast cancer: present challenges and new perspectives.	Molecular oncology	2010	70
20586616	Estrogens	Hammond ME	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).	Archives of pathology & laboratory medicine	2010	150
20629078	Estrogens	Stark A	African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.	Cancer	2010	54
20647302	Estrogens	Weigel MT	Current and emerging biomarkers in breast cancer: prognosis and prediction.	Endocrine-related cancer	2010	99
20663194	Estrogens	Tuominen VJ	ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.	Breast cancer research 	2010	142
20664043	Estrogens	Reeves GK	Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.	JAMA	2010	51
20664514	Estrogens	Ismail-Khan R	A review of triple-negative breast cancer.	Cancer control 	2010	42
20679727	Estrogens	Jiang Z	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.	The Journal of clinical investigation	2010	58
20821253	Estrogens	Grossmann ME	Obesity and breast cancer: status of leptin and adiponectin in pathological processes.	Cancer metastasis reviews	2010	52
20852631	Estrogens	Antoniou AC	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.	Nature genetics	2010	160
20861225	Estrogens	Toft DJ	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.	Molecular endocrinology	2011	40
20863372	Estrogens	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	52
20876186	Estrogens	Suzuki HI	Emerging complexity of microRNA generation cascades.	Journal of biochemistry	2011	38
20935677	Estrogens	Zhang XT	A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.	Oncogene	2011	41
20946665	Estrogens	Yau C	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.	Breast cancer research 	2010	52
20956553	Estrogens	Madak-Erdogan Z	Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.	Molecular and cellular biology	2011	48
20978187	Estrogens	de Souza Rocha Simonini P	Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells.	Cancer research	2010	78
21057539	Estrogens	Patel JB	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.	Oncogene	2011	39
21059212	Estrogens	Thompson AM	Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).	Breast cancer research 	2010	63
21067385	Estrogens	Foulkes WD	Triple-negative breast cancer.	The New England journal of medicine	2010	625
21084273	Estrogens	Wynendaele J	An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.	Cancer research	2010	51
21127264	Estrogens	Fedele CG	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2010	77
21164480	Estrogens	Tsai WW	TRIM24 links a non-canonical histone signature to breast cancer.	Nature	2010	123
21191116	Estrogens	Iwamoto T	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.	Journal of the National Cancer Institute	2011	69
21191117	Estrogens	Yang XR	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.	Journal of the National Cancer Institute	2011	223
21220595	Estrogens	Loo CE	Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.	Journal of clinical oncology 	2011	42
21235772	Estrogens	Grober OM	Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation.	BMC genomics	2011	49
21310761	Estrogens	Park S	Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.	Annals of oncology 	2011	43
21324165	Estrogens	Soini Y	Transcription factors zeb1, twist and snai1 in breast carcinoma.	BMC cancer	2011	37
21356373	Estrogens	Conklin MW	Aligned collagen is a prognostic signature for survival in human breast carcinoma.	The American journal of pathology	2011	217
21363912	Estrogens	Hill VK	Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.	Cancer research	2011	47
21369698	Estrogens	Catchpole S	PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.	International journal of oncology	2011	45
21375733	Estrogens	Hannafon BN	Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.	Breast cancer research 	2011	57
21387260	Estrogens	Lara-Medina F	Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.	Cancer	2011	47
21472708	Estrogens	Anders CK	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.	Cancer	2011	35
21482677	Estrogens	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	43
21483002	Estrogens	Mahmoud SM	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.	Journal of clinical oncology 	2011	287
21490305	Estrogens	Gonzalez-Angulo AM	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.	Molecular cancer therapeutics	2011	76
21505063	Estrogens	Sieuwerts AM	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.	Clinical cancer research 	2011	65
21552212	Estrogens	Collins LC	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.	Modern pathology 	2011	49
21553120	Estrogens	Guttilla IK	Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.	Breast cancer research and treatment	2012	38
21605893	Estrogens	Aktas B	Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.	Gynecologic oncology	2011	37
21622563	Estrogens	Zhou H	Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK).	The Journal of biological chemistry	2011	39
21670451	Estrogens	Abdulkarim BS	Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.	Journal of clinical oncology 	2011	57
21677874	Estrogens	Davison Z	Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.	Neoplasia	2011	50
21690342	Estrogens	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	31
21701558	Estrogens	Robinson JL	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.	The EMBO journal	2011	73
21713035	Estrogens	Al Saleh S	Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells.	PloS one	2011	39
21737487	Estrogens	Buffa FM	microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.	Cancer research	2011	115
21795664	Estrogens	Yaghjyan L	Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.	Journal of the National Cancer Institute	2011	50
21796367	Estrogens	van Nes JG	Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.	Breast cancer research and treatment	2012	30
21807638	Estrogens	Filipits M	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.	Clinical cancer research 	2011	96
21825015	Estrogens	Fackler MJ	Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.	Cancer research	2011	72
21830014	Estrogens	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	59
21846820	Estrogens	Palmer JR	Parity and lactation in relation to estrogen receptor negative breast cancer in African American women.	Cancer epidemiology, biomarkers & prevention 	2011	57
21852249	Estrogens	Figueroa JD	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.	Human molecular genetics	2011	41
21859480	Estrogens	Li J	A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.	BMC cancer	2011	50
21868760	Estrogens	Qian P	Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis.	Cancer research	2011	51
21870331	Estrogens	Pinheiro C	GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.	Histology and histopathology	2011	52
21878914	Estrogens	Kong SL	Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.	Molecular systems biology	2011	57
21893191	Estrogens	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	66
21900114	Estrogens	Arvold ND	Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.	Journal of clinical oncology 	2011	67
21908496	Estrogens	Rojo F	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.	Annals of oncology 	2012	42
21914172	Estrogens	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	50
21920899	Estrogens	Elangovan S	SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer.	Cancer research	2011	37
21940501	Estrogens	Keller PJ	Defining the cellular precursors to human breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2012	84
21969591	Estrogens	Haughian JM	Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
21983130	Estrogens	Chen X	Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma.	Cancer letters	2012	31
21984977	Estrogens	Brough R	Functional viability profiles of breast cancer.	Cancer discovery	2011	49
22028449	Estrogens	Hammes SR	Minireview: Recent advances in extranuclear steroid receptor actions.	Endocrinology	2011	50
22042860	Estrogens	Santagata S	High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22083089	Estrogens	Andò S	The multifactorial role of leptin in driving the breast cancer microenvironment.	Nature reviews. Endocrinology	2011	40
22125492	Estrogens	Magnani L	PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.	PLoS genetics	2011	50
22138582	Estrogens	Gerhardt J	FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.	The American journal of pathology	2012	32
22144499	Estrogens	Mavaddat N	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).	Cancer epidemiology, biomarkers & prevention 	2012	80
22151997	Estrogens	Chimge NO	Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.	Breast cancer research 	2011	38
22158945	Estrogens	Nasser MW	S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.	Cancer research	2012	38
22178456	Estrogens	Amir E	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.	Cancer treatment reviews	2012	35
22217937	Estrogens	Ross-Innes CS	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.	Nature	2012	270
22223266	Estrogens	Markowski DN	MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.	International journal of cancer	2012	38
22257677	Estrogens	Guttilla IK	ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer.	Trends in endocrinology and metabolism	2012	31
22262870	Estrogens	Haibe-Kains B	A three-gene model to robustly identify breast cancer molecular subtypes.	Journal of the National Cancer Institute	2012	86
22264274	Estrogens	Chan SR	STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.	Breast cancer research 	2012	56
22270867	Estrogens	Krzeslak A	Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.	Pathology oncology research 	2012	39
22282662	Estrogens	Barone I	Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.	Cancer research	2012	30
22301780	Estrogens	Baumgarten SC	Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.	Molecular endocrinology	2012	46
22331459	Estrogens	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	50
22391567	Estrogens	Bernardo GM	FOXA1 represses the molecular phenotype of basal breast cancer cells.	Oncogene	2013	41
22420471	Estrogens	Liu S	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.	Breast cancer research 	2012	82
22430211	Estrogens	Yeramian A	Endometrial carcinoma: molecular alterations involved in tumor development and progression.	Oncogene	2013	26
22496457	Estrogens	Palafox M	RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.	Cancer research	2012	44
22544643	Estrogens	Lin NU	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.	Cancer	2012	64
22562122	Estrogens	Niraula S	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.	Breast cancer research and treatment	2012	36
22632819	Estrogens	Zhi X	YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.	The American journal of pathology	2012	33
22648069	Estrogens	Burns KA	Estrogen receptors and human disease: an update.	Archives of toxicology	2012	44
22660634	Estrogens	Han SJ	A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis.	Nature medicine	2012	40
22692575	Estrogens	Leth-Larsen R	Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.	Molecular medicine	2012	36
22770227	Estrogens	Kim J	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.	Breast cancer research 	2012	31
22773826	Estrogens	Clarke CA	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.	Journal of the National Cancer Institute	2012	61
22821401	Estrogens	Kabos P	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.	Breast cancer research and treatment	2012	40
22824040	Estrogens	Medrek C	The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.	BMC cancer	2012	113
22847191	Estrogens	Liu Y	MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis.	Medical science monitor 	2012	35
22923429	Estrogens	Khosla S	Pathogenesis of age-related bone loss in humans.	The journals of gerontology. Series A, Biological sciences and medical sciences	2013	34
22936542	Estrogens	Rose DP	The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.	Endocrine-related cancer	2012	33
23035882	Estrogens	Bastien RR	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.	BMC medical genomics	2012	75
23112837	Estrogens	Castilla MÁ	MicroRNA-200 family modulation in distinct breast cancer phenotypes.	PloS one	2012	34
23136233	Estrogens	Eiermann W	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.	Annals of oncology 	2013	36
23139210	Estrogens	McCleland ML	An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.	Cancer research	2012	33
23171949	Estrogens	Craig DW	Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.	Molecular cancer therapeutics	2013	56
23251644	Estrogens	Budczies J	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.	PloS one	2012	159
23319610	Estrogens	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23319822	Estrogens	Wik E	Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.	Clinical cancer research 	2013	38
23334326	Estrogens	D'Assoro AB	The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.	Oncogene	2014	38
23344024	Estrogens	García-Becerra R	Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.	International journal of molecular sciences	2012	59
23358903	Estrogens	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	35
23403292	Estrogens	Mohammed H	Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.	Cell reports	2013	78
23436342	Estrogens	De Los Santos JF	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.	Cancer	2013	27
23442322	Estrogens	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	62
23505378	Estrogens	Di Leva G	Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.	PLoS genetics	2013	45
23532539	Estrogens	Dethlefsen C	The role of intratumoral and systemic IL-6 in breast cancer.	Breast cancer research and treatment	2013	67
23535731	Estrogens	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	199
23535733	Estrogens	Garcia-Closas M	Genome-wide association studies identify four ER negative-specific breast cancer risk loci.	Nature genetics	2013	173
23542418	Estrogens	Nagpal N	MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer.	Carcinogenesis	2013	29
23607871	Estrogens	Falk RT	Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study.	Breast cancer research 	2013	32
23629941	Estrogens	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes & cancer	2013	33
23711559	Estrogens	Feng S	Role of aryl hydrocarbon receptor in cancer.	Biochimica et biophysica acta	2013	35
23739063	Estrogens	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	37
23748853	Estrogens	Eichelser C	Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.	Clinical chemistry	2013	41
23791814	Estrogens	Jiang X	The immune system and inflammation in breast cancer.	Molecular and cellular endocrinology	2014	28
23861811	Estrogens	Lamb R	Wnt pathway activity in breast cancer sub-types and stem-like cells.	PloS one	2013	41
23920327	Estrogens	Engebraaten O	Triple-negative breast cancer and the need for new therapeutic targets.	The American journal of pathology	2013	34
23939688	Estrogens	Piva R	From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review).	International journal of oncology	2013	31
23954741	Estrogens	Haldosén LA	Estrogen receptor beta in breast cancer.	Molecular and cellular endocrinology	2014	26
23958744	Estrogens	Howe LR	Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer.	Clinical cancer research 	2013	78
23985562	Estrogens	-	Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.	Menopause	2013	55
23993780	Estrogens	Rivenbark AG	Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.	The American journal of pathology	2013	31
24013225	Estrogens	Zhou ZN	Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.	Oncogene	2014	26
24028341	Estrogens	Zhang Z	Folate receptor α associated with triple-negative breast cancer and poor prognosis.	Archives of pathology & laboratory medicine	2014	21
24029245	Estrogens	Sestak I	Factors predicting late recurrence for estrogen receptor-positive breast cancer.	Journal of the National Cancer Institute	2013	41
24031087	Estrogens	Dey P	Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS.	Journal of molecular endocrinology	2013	26
24055055	Estrogens	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	146
24058649	Estrogens	Babayan A	Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.	PloS one	2013	29
24077289	Estrogens	Dey P	Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.	Oncogene	2014	29
24185510	Estrogens	Robinson DR	Activating ESR1 mutations in hormone-resistant metastatic breast cancer.	Nature genetics	2013	197
24188089	Estrogens	Bertrand KA	Mammographic density and risk of breast cancer by age and tumor characteristics.	Breast cancer research 	2013	34
24188694	Estrogens	Bilir B	Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.	Journal of translational medicine	2013	29
24258260	Estrogens	Sørensen KP	Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer.	Breast cancer research and treatment	2013	66
24273215	Estrogens	Vera-Badillo FE	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	56
24298069	Estrogens	Zhang XH	Metastasis dormancy in estrogen receptor-positive breast cancer.	Clinical cancer research 	2013	32
24337597	Estrogens	Auvinen P	Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.	Breast cancer research and treatment	2014	24
24343304	Estrogens	Palmer JR	A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.	Cancer causes & control 	2014	33
24353241	Estrogens	Park SH	Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.	Journal of magnetic resonance imaging 	2015	17
24398047	Estrogens	Jeselsohn R	Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	102
24431073	Estrogens	Cheng Y	XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.	Molecular cancer therapeutics	2014	31
24449868	Estrogens	Huang B	Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24463450	Estrogens	Santagata S	Taxonomy of breast cancer based on normal cell phenotype predicts outcome.	The Journal of clinical investigation	2014	60
24469049	Estrogens	Cyr AR	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.	Oncogene	2015	22
24477977	Estrogens	Anderson KN	Reproductive risk factors and breast cancer subtypes: a review of the literature.	Breast cancer research and treatment	2014	57
24521995	Estrogens	Sweeney C	Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.	Cancer epidemiology, biomarkers & prevention 	2014	30
24523301	Estrogens	Gross MI	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.	Molecular cancer therapeutics	2014	113
24722644	Estrogens	Soussan M	Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.	PloS one	2014	33
24803582	Estrogens	Silwal-Pandit L	TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.	Clinical cancer research 	2014	41
24876105	Estrogens	Dinami R	miR-155 drives telomere fragility in human breast cancer by targeting TRF1.	Cancer research	2014	23
24889938	Estrogens	Sun Y	Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation.	Molecular cancer	2014	35
24895374	Estrogens	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	40
24915873	Estrogens	Ali HR	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.	Annals of oncology 	2014	60
25009010	Estrogens	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	63
25013076	Estrogens	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	167
25038752	Estrogens	Lim WK	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.	Nature genetics	2014	37
25185096	Estrogens	Partridge AH	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2014	43
25208879	Estrogens	Burstein MD	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.	Clinical cancer research 	2015	92
25224496	Estrogens	Palmer JR	Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.	Journal of the National Cancer Institute	2014	43
25277734	Estrogens	Sabatier R	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.	Molecular cancer	2014	20
25307233	Estrogens	Zhao W	Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications.	Scientific reports	2014	26
25313140	Estrogens	Hashim A	RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer.	Oncotarget	2014	28
25347744	Estrogens	Mahajan K	ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.	Oncogene	2015	21
25361981	Estrogens	Tobin NP	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.	Annals of oncology 	2015	17
25381338	Estrogens	Paoletti C	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.	Clinical cancer research 	2015	20
25388283	Estrogens	Bailey ST	Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.	Cancer research	2015	17
25433206	Estrogens	Huang B	Estrogen receptors in breast carcinogenesis and endocrine therapy.	Molecular and cellular endocrinology	2015	29
25488809	Estrogens	Wade MA	The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.	Nucleic acids research	2015	18
25489079	Estrogens	Whitesell L	HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
25529635	Estrogens	Glubb DM	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.	American journal of human genetics	2015	23
25538079	Estrogens	Martz CA	Systematic identification of signaling pathways with potential to confer anticancer drug resistance.	Science signaling	2014	47
25713166	Estrogens	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	21
25816016	Estrogens	Necela BM	Folate receptor-α (FOLR1) expression and function in triple negative tumors.	PloS one	2015	15
25825707	Estrogens	Tang H	Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.	EBioMedicine	2015	22
25855707	Estrogens	Mavaddat N	Prediction of breast cancer risk based on profiling with common genetic variants.	Journal of the National Cancer Institute	2015	85
25964252	Estrogens	Warner ET	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.	Journal of clinical oncology 	2015	25
25979954	Estrogens	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	27
25995301	Estrogens	Dieci MV	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.	Annals of oncology 	2015	23
26033453	Estrogens	Stückrath I	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.	Oncotarget	2015	16
26056290	Estrogens	den Boon JA	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
26166704	Estrogens	Li W	Condensin I and II Complexes License Full Estrogen Receptor α-Dependent Enhancer Activation.	Molecular cell	2015	18
26181262	Estrogens	Santa-Maria CA	Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.	JAMA oncology	2015	17
26195705	Estrogens	Van Poznak C	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2015	37
26201402	Estrogens	Barton VN	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.	Hormones & cancer	2015	17
26257067	Estrogens	Merino D	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.	Oncogene	2016	14
26261103	Estrogens	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	32
26286584	Estrogens	Strong AL	Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.	Breast cancer research 	2015	20
26311719	Estrogens	Deng L	MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.	Circulation research	2015	26
26341644	Estrogens	Kumar P	An overview of triple-negative breast cancer.	Archives of gynecology and obstetrics	2016	19
26487756	Estrogens	Chen X	Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.	Circulation	2016	21
26541326	Estrogens	Baptista MZ	Prognostic significance of PD-L1 and PD-L2 in breast cancer.	Human pathology	2016	27
26573797	Estrogens	Wang X	p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.	Cancer research	2015	25
26586665	Estrogens	Meeks HD	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.	Journal of the National Cancer Institute	2016	14
26598746	Estrogens	Levine MN	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.	Journal of clinical oncology 	2016	17
26621851	Estrogens	Miano V	Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer.	Oncotarget	2016	16
26683709	Estrogens	Jiang T	Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.	Oncotarget	2016	14
26769139	Estrogens	Thompson E	The immune microenvironment of breast ductal carcinoma in situ.	Modern pathology 	2016	13
26772397	Estrogens	Asch-Kendrick R	The role of GATA3 in breast carcinomas: a review.	Human pathology	2016	12
26855592	Estrogens	Xu H	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.	OncoTargets and therapy	2016	15
26858339	Estrogens	Harris LN	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2016	73
26899533	Estrogens	Masuda T	Clinical and biological significance of circulating tumor cells in cancer.	Molecular oncology	2016	14
26909695	Estrogens	Rostami R	Brain metastasis in breast cancer: a comprehensive literature review.	Journal of neuro-oncology	2016	13
26919573	Estrogens	Klair JS	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.	Hepatology	2016	12
26926676	Estrogens	Gluz O	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.	Journal of clinical oncology 	2016	21
26928228	Estrogens	Dunning AM	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.	Nature genetics	2016	18
26947176	Estrogens	Sflomos G	A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.	Cancer cell	2016	22
26960396	Estrogens	Piscuoglio S	The Genomic Landscape of Male Breast Cancers.	Clinical cancer research 	2016	16
27020862	Estrogens	Weir HM	AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.	Cancer research	2016	17
27029038	Estrogens	Micucci C	Current perspectives between metabolic syndrome and cancer.	Oncotarget	2016	13
27073890	Estrogens	Mao Y	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.	PloS one	2016	16
27144536	Estrogens	Li H	MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.	Radiology	2016	20
27160528	Estrogens	Mamtani A	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.	Annals of surgical oncology	2016	13
27191888	Estrogens	Huang NS	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer.	Oncotarget	2016	17
27225691	Estrogens	Speers C	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.	Clinical cancer research 	2016	13
27226503	Estrogens	Gradishar W	NCCN Guidelines Update: Breast Cancer.	Journal of the National Comprehensive Cancer Network 	2016	10
27277684	Estrogens	Singh R	Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis.	Cell death & disease	2016	12
27348297	Estrogens	Gibson WJ	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.	Nature genetics	2016	23
27388585	Estrogens	Millis SZ	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.	JAMA oncology	2016	15
27513155	Estrogens	Giuliano AE	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.	Annals of surgery	2016	30
27694385	Estrogens	Svoronos N	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.	Cancer discovery	2017	12
27721408	Estrogens	Yu T	Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance.	Oncogene	2017	5
27725895	Estrogens	Hon JD	Breast cancer molecular subtypes: from TNBC to QNBC.	American journal of cancer research	2016	11
27748765	Estrogens	Harrod A	Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.	Oncogene	2017	8
27886589	Estrogens	Angus L	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.	Cancer treatment reviews	2017	5
27893717	Estrogens	Feng J	Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.	Oncogene	2017	6
27903149	Estrogens	Jiralerspong S	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.	Journal of clinical oncology 	2016	14
27914795	Estrogens	Wintrob ZA	Insulin use, adipokine profiles and breast cancer prognosis.	Cytokine	2017	11
27926948	Estrogens	Priedigkeit N	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.	JAMA oncology	2017	9
27935867	Estrogens	Vázquez R	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.	Oncotarget	2017	5
27939373	Estrogens	Nault JC	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.	Gastroenterology	2017	7
27940449	Estrogens	Page K	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.	Clinical chemistry	2017	6
28030809	Estrogens	McDaniel JM	Genomic regulation of invasion by STAT3 in triple negative breast cancer.	Oncotarget	2017	6
28052940	Estrogens	Busch EL	Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction.	Cancer epidemiology, biomarkers & prevention 	2017	6
28108967	Estrogens	Inoue M	Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.	Breast cancer	2017	5
28249905	Estrogens	Cejalvo JM	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.	Cancer research	2017	9
28259011	Estrogens	Duffy MJ	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).	European journal of cancer	2017	12
28270386	Estrogens	Iyengar NM	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.	Cancer prevention research	2017	8
28356971	Estrogens	Luo Y	Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients.	Oncology letters	2017	5
3288530	Insulin	Ricordi C	Automated method for isolation of human pancreatic islets.	Diabetes	1988	215
9710447	Insulin	Barber AJ	Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.	The Journal of clinical investigation	1998	280
10774732	Insulin	Man HY	Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization.	Neuron	2000	155
10878750	Insulin	Moller DE	Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.	Trends in endocrinology and metabolism	2000	104
11151758	Insulin	Weyer C	Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance.	Diabetologia	2000	137
11673759	Insulin	Festa A	The relation of body fat mass and distribution to markers of chronic inflammation.	International journal of obesity and related metabolic disorders 	2001	115
11686294	Insulin	Lawlor MA	PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?	Journal of cell science	2001	231
11826410	Insulin	Pagano G	Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.	Hepatology	2002	109
12167664	Insulin	Dan HC	Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.	The Journal of biological chemistry	2002	100
12512031	Insulin	Ruhl CE	Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.	Gastroenterology	2003	120
12843179	Insulin	Bonafè M	Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control.	The Journal of clinical endocrinology and metabolism	2003	87
12879249	Insulin	Rorsman P	Insulin granule dynamics in pancreatic beta cells.	Diabetologia	2003	159
14713953	Insulin	Miyauchi H	Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.	The EMBO journal	2004	82
14767595	Insulin	Donath MY	Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications.	Diabetologia	2004	77
14960526	Insulin	Hickman IJ	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.	Gut	2004	73
14970219	Insulin	Roy M	IQGAP1 binds ERK2 and modulates its activity.	The Journal of biological chemistry	2004	77
14988838	Insulin	Shintani Y	Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.	Gastroenterology	2004	133
15199412	Insulin	Horie Y	Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.	The Journal of clinical investigation	2004	165
15205477	Insulin	Cohen HY	Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.	Science	2004	554
15750214	Insulin	de la Monte SM	Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.	Journal of Alzheimer's disease 	2005	129
15889096	Insulin	Kent SC	Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.	Nature	2005	113
15924147	Insulin	Foti D	Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice.	Nature medicine	2005	69
16215165	Insulin	Thrailkill KM	Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.	American journal of physiology. Endocrinology and metabolism	2005	71
16239255	Insulin	Frezza EE	Influence of obesity on the risk of developing colon cancer.	Gut	2006	63
16284649	Insulin	Morino K	Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents.	The Journal of clinical investigation	2005	218
16339897	Insulin	Pinkse GG	Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2005	87
16388523	Insulin	Basaria S	Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.	Cancer	2006	66
16399206	Insulin	Qiu WQ	Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.	Neurobiology of aging	2006	106
16627931	Insulin	Lester-Coll N	Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.	Journal of Alzheimer's disease 	2006	109
16731817	Insulin	Cancello R	Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity.	Diabetes	2006	112
16855264	Insulin	Florez JC	TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.	The New England journal of medicine	2006	230
16873964	Insulin	de la Monte SM	Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease.	Journal of Alzheimer's disease 	2006	67
17341558	Insulin	Balagopal P	Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation.	The Journal of clinical endocrinology and metabolism	2007	63
17430239	Insulin	Craft S	Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.	Current Alzheimer research	2007	138
17472435	Insulin	Parikh H	TXNIP regulates peripheral glucose metabolism in humans.	PLoS medicine	2007	130
17615265	Insulin	Karnieli O	Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation.	Stem cells	2007	73
17620421	Insulin	Kolak M	Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity.	Diabetes	2007	79
18081738	Insulin	Jarrar MH	Adipokines and cytokines in non-alcoholic fatty liver disease.	Alimentary pharmacology & therapeutics	2008	74
18197184	Insulin	Trapp EG	The effects of high-intensity intermittent exercise training on fat loss and fasting insulin levels of young women.	International journal of obesity	2008	69
18342602	Insulin	Ozcan U	Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.	Molecular cell	2008	165
18408164	Insulin	Engel MF	Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane.	Proceedings of the National Academy of Sciences of the United States of America	2008	114
18769445	Insulin	Cohen E	The insulin paradox: aging, proteotoxicity and neurodegeneration.	Nature reviews. Neuroscience	2008	94
19128359	Insulin	Willcox A	Analysis of islet inflammation in human type 1 diabetes.	Clinical and experimental immunology	2009	147
19141606	Insulin	Maratou E	Studies of insulin resistance in patients with clinical and subclinical hypothyroidism.	European journal of endocrinology	2009	56
19149564	Insulin	Potenza MA	Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets.	Current medicinal chemistry	2009	66
19188682	Insulin	Qatanani M	Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice.	The Journal of clinical investigation	2009	51
19207680	Insulin	Ricchi M	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes.	Journal of gastroenterology and hepatology	2009	83
19208913	Insulin	Sutherland AP	Interleukin-21 is required for the development of type 1 diabetes in NOD mice.	Diabetes	2009	46
19357636	Insulin	Borisov N	Systems-level interactions between insulin-EGF networks amplify mitogenic signaling.	Molecular systems biology	2009	72
19401422	Insulin	Capel F	Macrophages and adipocytes in human obesity: adipose tissue gene expression and insulin sensitivity during calorie restriction and weight stabilization.	Diabetes	2009	45
19475663	Insulin	Wiltzius JJ	Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process.	Protein science 	2009	64
19649631	Insulin	Haluska P	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.	Cancer chemotherapy and pharmacology	2010	46
19651814	Insulin	Kantartzis K	Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.	Diabetes	2009	72
19662657	Insulin	Raji CA	Brain structure and obesity.	Human brain mapping	2010	161
19682539	Insulin	Maury E	Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.	Molecular and cellular endocrinology	2010	170
19824817	Insulin	Roberts DL	Biological mechanisms linking obesity and cancer risk: new perspectives.	Annual review of medicine	2010	134
20216312	Insulin	Summers SA	Sphingolipids and insulin resistance: the five Ws.	Current opinion in lipidology	2010	51
20339361	Insulin	Preis SR	Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study.	Obesity	2010	85
20562852	Insulin	Marcheva B	Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes.	Nature	2010	345
20739649	Insulin	Matsuzaki T	Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study.	Neurology	2010	89
20841504	Insulin	Spencer M	Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation.	American journal of physiology. Endocrinology and metabolism	2010	90
20858492	Insulin	Williams CD	Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.	Gastroenterology	2011	398
21102589	Insulin	Gualberto A	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.	British journal of cancer	2011	37
21109577	Insulin	Lawlor DA	Association between general and central adiposity in childhood, and change in these, with cardiovascular risk factors in adolescence: prospective cohort study.	BMJ	2010	78
21115858	Insulin	Duggan C	Associations of insulin resistance and adiponectin with mortality in women with breast cancer.	Journal of clinical oncology 	2011	65
21355045	Insulin	Zhang T	TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling.	Human molecular genetics	2011	39
21690251	Insulin	Daniel C	Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope.	The Journal of experimental medicine	2011	45
21829446	Insulin	Anand SS	Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE).	PloS one	2011	36
22055501	Insulin	Bornfeldt KE	Insulin resistance, hyperglycemia, and atherosclerosis.	Cell metabolism	2011	116
22074781	Insulin	Akirav EM	Detection of β cell death in diabetes using differentially methylated circulating DNA.	Proceedings of the National Academy of Sciences of the United States of America	2011	60
22162568	Insulin	Goodwin PJ	Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.	Journal of clinical oncology 	2012	48
22213807	Insulin	Coppieters KT	Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.	The Journal of experimental medicine	2012	145
22278418	Insulin	Chen G	Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.	The Journal of clinical endocrinology and metabolism	2012	37
22328150	Insulin	Kriegel MA	Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2012	31
22330739	Insulin	Tiano JP	Importance of oestrogen receptors to preserve functional β-cell mass in diabetes.	Nature reviews. Endocrinology	2012	41
22385956	Insulin	Samuel VT	Mechanisms for insulin resistance: common threads and missing links.	Cell	2012	436
22426422	Insulin	Liao GY	Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin.	Nature medicine	2012	52
22476196	Insulin	Bomfim TR	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.	The Journal of clinical investigation	2012	123
22476197	Insulin	Talbot K	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.	The Journal of clinical investigation	2012	269
22577490	Insulin	Longato L	Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease.	Oxidative medicine and cellular longevity	2012	36
22609549	Insulin	Straßburger K	Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP.	Developmental biology	2012	42
22768844	Insulin	Taneera J	A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets.	Cell metabolism	2012	84
22796579	Insulin	Sparks JD	Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia.	Arteriosclerosis, thrombosis, and vascular biology	2012	31
23169676	Insulin	Girgis CM	The roles of vitamin D in skeletal muscle: form, function, and metabolism.	Endocrine reviews	2013	62
23183535	Insulin	Thatava T	Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells.	Molecular therapy 	2013	29
23187122	Insulin	Bradley D	Gastric bypass and banding equally improve insulin sensitivity and β cell function.	The Journal of clinical investigation	2012	55
23207292	Insulin	Djiogue S	Insulin resistance and cancer: the role of insulin and IGFs.	Endocrine-related cancer	2013	42
23349537	Insulin	Costes S	β-Cell failure in type 2 diabetes: a case of asking too much of too few?	Diabetes	2013	31
23620761	Insulin	Sarfstein R	Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.	PloS one	2013	32
23728177	Insulin	Oury F	Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis.	The Journal of clinical investigation	2013	29
23737756	Insulin	Nogueira TC	GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim.	PLoS genetics	2013	39
23832089	Insulin	Pajvani UB	Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability.	Nature medicine	2013	38
24130353	Insulin	Sell H	Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.	Diabetes care	2013	29
24184209	Insulin	Ellis BC	CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.	Biochimica et biophysica acta	2014	41
24380887	Insulin	de la Monte SM	Brain metabolic dysfunction at the core of Alzheimer's disease.	Biochemical pharmacology	2014	55
24462370	Insulin	Holmes MV	Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.	American journal of human genetics	2014	42
24529663	Insulin	Werner H	Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects.	European neuropsychopharmacology 	2014	24
24567379	Insulin	Cai W	Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24603685	Insulin	Dayeh T	Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion.	PLoS genetics	2014	101
24670599	Insulin	Pirazzi C	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.	Human molecular genetics	2014	43
25015099	Insulin	Zhou Y	TCF7L2 is a master regulator of insulin production and processing.	Human molecular genetics	2014	30
25036708	Insulin	Rivera JF	Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity.	The Journal of clinical investigation	2014	49
25062042	Insulin	Arnold N	Regulation of cardiac expression of the diabetic marker microRNA miR-29.	PloS one	2014	21
25101872	Insulin	Park S	A genetic strategy to measure circulating Drosophila insulin reveals genes regulating insulin production and secretion.	PLoS genetics	2014	28
25182023	Insulin	Ballak DB	IL-37 protects against obesity-induced inflammation and insulin resistance.	Nature communications	2014	27
25362253	Insulin	Hasnain SZ	Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress.	Nature medicine	2014	31
25375650	Insulin	Olsson AH	Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets.	PLoS genetics	2014	33
25625282	Insulin	Mahajan A	Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus.	PLoS genetics	2015	33
25642774	Insulin	Herold KC	β cell death and dysfunction during type 1 diabetes development in at-risk individuals.	The Journal of clinical investigation	2015	36
25673412	Insulin	Shungin D	New genetic loci link adipose and insulin biology to body fat distribution.	Nature	2015	208
25673413	Insulin	Locke AE	Genetic studies of body mass index yield new insights for obesity biology.	Nature	2015	564
25697093	Insulin	Rutter GA	Pancreatic β-cell identity, glucose sensing and the control of insulin secretion.	The Biochemical journal	2015	40
25729921	Insulin	Wensveen FM	NK cells link obesity-induced adipose stress to inflammation and insulin resistance.	Nature immunology	2015	56
25733449	Insulin	Rahman SA	Molecular mechanisms of congenital hyperinsulinism.	Journal of molecular endocrinology	2015	17
25740979	Insulin	Goodwin PJ	Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.	Journal of the National Cancer Institute	2015	17
26076035	Insulin	van der Meulen T	Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion.	Nature medicine	2015	29
26159692	Insulin	Dibble CC	Regulation of mTORC1 by PI3K signaling.	Trends in cell biology	2015	103
26257839	Insulin	Keane KN	Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance and β-Cell Dysfunction.	Oxidative medicine and cellular longevity	2015	23
26576641	Insulin	Hasnain SZ	Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes.	Journal of molecular endocrinology	2016	17
26581594	Insulin	Campbell-Thompson M	Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.	Diabetes	2016	38
26607638	Insulin	Acosta JR	Increased fat cell size: a major phenotype of subcutaneous white adipose tissue in non-obese individuals with type 2 diabetes.	Diabetologia	2016	18
26808499	Insulin	Khamaisi M	PKCδ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts.	The Journal of clinical investigation	2016	11
26824656	Insulin	Hu H	Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.	Cell	2016	30
26858360	Insulin	Leete P	Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes.	Diabetes	2016	15
27432942	Insulin	Stanley M	Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?	The Journal of experimental medicine	2016	13
27594187	Insulin	Frid AH	New Insulin Delivery Recommendations.	Mayo Clinic proceedings	2016	11
27814523	Insulin	Li P	Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance.	Cell	2016	16
27916275	Insulin	Li J	Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity.	Cell	2017	22
28112808	Insulin	Skaper SD	Nerve growth factor: a neuroimmune crosstalk mediator for all seasons.	Immunology	2017	6
2993906	Peptides	Cuttitta F	Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.	Nature	1985	169
8446617	Peptides	Strittmatter WJ	Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	664
10742146	Peptides	Lu DC	A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor.	Nature medicine	2000	101
10768988	Peptides	Krisanaprakornkit S	Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier.	Infection and immunity	2000	97
11017151	Peptides	Kappos L	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.	Nature medicine	2000	92
11371646	Peptides	Hashimoto Y	A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.	Proceedings of the National Academy of Sciences of the United States of America	2001	100
12118245	Peptides	Fulda S	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.	Nature medicine	2002	133
12438321	Peptides	Tang YQ	Antimicrobial peptides from human platelets.	Infection and immunity	2002	86
12509463	Peptides	Weng AP	Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.	Molecular and cellular biology	2003	145
12826605	Peptides	Phan GQ	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2003	339
15205345	Peptides	Liang Z	Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.	Cancer research	2004	91
15269340	Peptides	Brain SD	Vascular actions of calcitonin gene-related peptide and adrenomedullin.	Physiological reviews	2004	104
15353804	Peptides	Walensky LD	Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.	Science	2004	295
15728188	Peptides	Döppler H	A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D.	The Journal of biological chemistry	2005	68
15958392	Peptides	Ishihama Y	Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein.	Molecular & cellular proteomics 	2005	513
16061848	Peptides	Arumugam T	S100P promotes pancreatic cancer growth, survival, and invasion.	Clinical cancer research 	2005	65
16061868	Peptides	Liau LM	Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.	Clinical cancer research 	2005	144
16147978	Peptides	Sylwester AW	Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.	The Journal of experimental medicine	2005	402
16177248	Peptides	Wang X	Autoantibody signatures in prostate cancer.	The New England journal of medicine	2005	155
16837572	Peptides	Rajendran L	Alzheimer's disease beta-amyloid peptides are released in association with exosomes.	Proceedings of the National Academy of Sciences of the United States of America	2006	251
16971810	Peptides	Palucka AK	Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.	Journal of immunotherapy	2006	74
18000063	Peptides	Ghosh A	Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2007	119
18007679	Peptides	Felix NJ	Specificity of T-cell alloreactivity.	Nature reviews. Immunology	2007	76
18166587	Peptides	Matysiak-Budnik T	Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease.	The Journal of experimental medicine	2008	52
18346832	Peptides	Anisman H	Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders.	Progress in neurobiology	2008	68
18577591	Peptides	Serada S	IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.	Proceedings of the National Academy of Sciences of the United States of America	2008	93
19255147	Peptides	Beauvais DM	Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.	The Journal of experimental medicine	2009	81
19433061	Peptides	Kawasaki T	A minimal regulatory domain in the C terminus of STIM1 binds to and activates ORAI1 CRAC channels.	Biochemical and biophysical research communications	2009	96
19494001	Peptides	Wise HM	A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA.	Journal of virology	2009	126
19494300	Peptides	Loffredo JT	Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity.	Journal of immunology	2009	55
19528258	Peptides	Campbell JD	Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression.	The Journal of experimental medicine	2009	64
19581601	Peptides	Britschgi M	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2009	46
19720923	Peptides	Disis ML	Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.	Journal of clinical oncology 	2009	85
19805273	Peptides	Teesalu T	C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.	Proceedings of the National Academy of Sciences of the United States of America	2009	116
20068138	Peptides	Arakawa M	Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.	Diabetes	2010	102
20190765	Peptides	Li J	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.	Nature chemical biology	2010	95
20354185	Peptides	Standley SM	Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide.	Cancer research	2010	44
20544025	Peptides	Jin G	An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.	PloS one	2010	43
21199956	Peptides	Sethi DK	A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC.	The Journal of experimental medicine	2011	44
21233403	Peptides	Huang H	Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.	Clinical cancer research 	2011	43
21421568	Peptides	Dhayalan A	The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9.	Human molecular genetics	2011	46
21653320	Peptides	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	111
21795678	Peptides	Zarrabi K	Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.	The Journal of biological chemistry	2011	49
22418738	Peptides	Dutoit V	Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.	Brain 	2012	39
22622039	Peptides	LaBelle JL	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.	The Journal of clinical investigation	2012	62
22776426	Peptides	Kono K	Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.	Journal of translational medicine	2012	39
22872572	Peptides	Crane CA	Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.	Clinical cancer research 	2013	43
22999885	Peptides	Cohen NA	A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.	Chemistry & biology	2012	43
23150796	Peptides	Yan H	Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.	eLife	2012	288
23241962	Peptides	Leoni G	Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair.	The Journal of clinical investigation	2013	67
23298779	Peptides	Hu QL	Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model.	Biomaterials	2013	26
23375101	Peptides	Rapraeger AC	Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.	The FEBS journal	2013	26
23395677	Peptides	Su LF	Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults.	Immunity	2013	129
23415312	Peptides	Ash PE	Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.	Neuron	2013	255
23714121	Peptides	Shi P	Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.	Journal of controlled release 	2013	26
23770775	Peptides	Linette GP	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.	Blood	2013	195
23817469	Peptides	Wang W	Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues.	Journal of the American Heart Association	2013	31
23868944	Peptides	Woo JS	Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.	Arteriosclerosis, thrombosis, and vascular biology	2013	31
23974116	Peptides	Kim W	Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.	Nature chemical biology	2013	83
24239002	Peptides	Gottlieb PA	Chromogranin A is a T cell antigen in human type 1 diabetes.	Journal of autoimmunity	2014	23
24325867	Peptides	Gomez-Sanchez CE	Development of monoclonal antibodies against human CYP11B1 and CYP11B2.	Molecular and cellular endocrinology	2014	51
24491438	Peptides	Yang Y	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.	Cancer discovery	2014	33
25072595	Peptides	Ghatnekar GS	The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.	The Journal of investigative dermatology	2015	21
25092142	Peptides	Berlin C	Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.	Leukemia	2015	21
25496365	Peptides	Tan MP	T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.	Clinical and experimental immunology	2015	22
25703647	Peptides	Grek CL	Topical administration of a connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: A multicenter, randomized trial.	Wound repair and regeneration 	2015	17
25818419	Peptides	Jiang L	Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.	Biomaterials	2015	20
25990016	Peptides	Jones MV	Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.	Acta neuropathologica communications	2015	16
26621454	Peptides	Arakawa A	Melanocyte antigen triggers autoimmunity in human psoriasis.	The Journal of experimental medicine	2015	27
26828202	Peptides	Davis ZB	A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells.	PLoS pathogens	2016	21
26885535	Peptides	Sugimoto MA	Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance.	Journal of immunology research	2016	17
28250417	Peptides	Song I	Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope.	Nature structural & molecular biology	2017	7
3282647	Glucose	Jain RK	Determinants of tumor blood flow: a review.	Cancer research	1988	237
6949641	Glucose	Tsuchiya S	Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.	Cancer research	1982	187
9357784	Glucose	Turner JR	Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation.	The American journal of physiology	1997	131
10571771	Glucose	Gilbert RE	The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?	Kidney international	1999	121
11022058	Glucose	Vila N	Proinflammatory cytokines and early neurological worsening in ischemic stroke.	Stroke	2000	110
11157411	Glucose	Geffken DF	Association between physical activity and markers of inflammation in a healthy elderly population.	American journal of epidemiology	2001	103
11287357	Glucose	Kern PA	Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.	American journal of physiology. Endocrinology and metabolism	2001	300
11445252	Glucose	De Santi S	Hippocampal formation glucose metabolism and volume losses in MCI and AD.	Neurobiology of aging	2001	128
11705489	Glucose	van Oosterom AT	Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.	Lancet	2001	155
11916953	Glucose	Peila R	Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.	Diabetes	2002	265
12021250	Glucose	Petersen KF	Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.	The Journal of clinical investigation	2002	172
12086956	Glucose	Romeo G	Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes.	Diabetes	2002	89
12162730	Glucose	Abbott NJ	Astrocyte-endothelial interactions and blood-brain barrier permeability.	Journal of anatomy	2002	180
12589027	Glucose	Duan W	Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice.	Proceedings of the National Academy of Sciences of the United States of America	2003	116
12598526	Glucose	Bach D	Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity.	The Journal of biological chemistry	2003	187
12728191	Glucose	Mattson MP	Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.	Neuromolecular medicine	2003	90
12858170	Glucose	Mattiasson G	Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma.	Nature medicine	2003	111
15094078	Glucose	Hoyer S	Glucose metabolism and insulin receptor signal transduction in Alzheimer disease.	European journal of pharmacology	2004	75
15272020	Glucose	Kamei Y	Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control.	The Journal of biological chemistry	2004	146
15677538	Glucose	Vleugel MM	Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.	Journal of clinical pathology	2005	71
15747110	Glucose	Bugianesi E	Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.	Diabetologia	2005	117
15750215	Glucose	Steen E	Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?	Journal of Alzheimer's disease 	2005	298
15837624	Glucose	Shankar DB	The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia.	Cancer cell	2005	65
15932949	Glucose	Reiman EM	Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.	Proceedings of the National Academy of Sciences of the United States of America	2005	124
16026270	Glucose	Caldwell RB	Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.	Current drug targets	2005	65
16110338	Glucose	Corbo JC	A hybrid photoreceptor expressing both rod and cone genes in a mouse model of enhanced S-cone syndrome.	PLoS genetics	2005	66
16306329	Glucose	Kristiansen OP	Interleukin-6 and diabetes: the good, the bad, or the indifferent?	Diabetes	2005	106
16306358	Glucose	Rahmoune H	Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.	Diabetes	2005	113
16373444	Glucose	O'Leary VB	Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat.	Journal of applied physiology	2006	62
16412224	Glucose	Baker AR	Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease.	Cardiovascular diabetology	2006	129
16463046	Glucose	Adiels M	Overproduction of large VLDL particles is driven by increased liver fat content in man.	Diabetologia	2006	110
16473887	Glucose	Neumann J	Microglia provide neuroprotection after ischemia.	FASEB journal 	2006	73
16492903	Glucose	Nigro J	Insulin resistance and atherosclerosis.	Endocrine reviews	2006	63
16550171	Glucose	Coucke PJ	Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome.	Nature genetics	2006	77
16567827	Glucose	Stefan N	Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.	Diabetes care	2006	96
16678181	Glucose	Hunt NH	Immunopathogenesis of cerebral malaria.	International journal for parasitology	2006	84
16707446	Glucose	Gatenby RA	Acid-mediated tumor invasion: a multidisciplinary study.	Cancer research	2006	164
16861902	Glucose	Fu Y	Glucose regulated proteins in cancer progression, drug resistance and immunotherapy.	Cancer biology & therapy	2006	74
17079810	Glucose	Mosconi L	Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease.	Journal of nuclear medicine 	2006	77
17141632	Glucose	Zhang W	PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.	Cell metabolism	2006	99
17200485	Glucose	Zhang Y	Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease.	Neurology	2007	156
17241871	Glucose	Shkoda A	Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation.	Gastroenterology	2007	73
17261637	Glucose	Gromada J	Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.	Endocrine reviews	2007	158
17311546	Glucose	Maiese K	Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus.	Current neurovascular research	2007	62
17328689	Glucose	Mattson MP	Calcium and neurodegeneration.	Aging cell	2007	168
17332274	Glucose	Frost RA	Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass.	Journal of applied physiology	2007	64
17334651	Glucose	Boushel R	Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle.	Diabetologia	2007	118
17374712	Glucose	Harman-Boehm I	Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity.	The Journal of clinical endocrinology and metabolism	2007	114
17493050	Glucose	Chang L	Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.	Addiction	2007	139
17609686	Glucose	Cucullo L	Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies.	Journal of cerebral blood flow and metabolism 	2008	51
17618858	Glucose	Klöting N	Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass.	Cell metabolism	2007	92
17624581	Glucose	Gillies RJ	Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?	Journal of bioenergetics and biomembranes	2007	66
17627510	Glucose	Maiese K	Mechanistic insights into diabetes mellitus and oxidative stress.	Current medicinal chemistry	2007	63
17640713	Glucose	Daneshmand S	Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.	Human pathology	2007	66
17640997	Glucose	Bozaoglu K	Chemerin is a novel adipokine associated with obesity and metabolic syndrome.	Endocrinology	2007	147
17646672	Glucose	Huang H	Dynamic FoxO transcription factors.	Journal of cell science	2007	344
17671651	Glucose	Lyssenko V	Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.	The Journal of clinical investigation	2007	204
17687336	Glucose	Gatenby RA	Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer.	British journal of cancer	2007	91
17726542	Glucose	Chandalia M	Insulin resistance and body fat distribution in South Asian men compared to Caucasian men.	PloS one	2007	58
17785433	Glucose	Kim JW	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.	Molecular and cellular biology	2007	162
17889646	Glucose	Dai C	Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.	Cell	2007	300
17906960	Glucose	Marchetti P	The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients.	Diabetologia	2007	110
17940659	Glucose	Dias WB	O-GlcNAc modification in diabetes and Alzheimer's disease.	Molecular bioSystems	2007	77
18039092	Glucose	Waki H	Endocrine functions of adipose tissue.	Annual review of pathology	2007	83
18048764	Glucose	Eizirik DL	The role for endoplasmic reticulum stress in diabetes mellitus.	Endocrine reviews	2008	306
18094705	Glucose	Tomlinson DR	Glucose neurotoxicity.	Nature reviews. Neuroscience	2008	102
18220694	Glucose	Ziyadeh FN	Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.	Current diabetes reviews	2008	91
18223655	Glucose	Danial NN	Dual role of proapoptotic BAD in insulin secretion and beta cell survival.	Nature medicine	2008	103
18259200	Glucose	Loor G	Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion.	Cell death and differentiation	2008	63
18304378	Glucose	Young CD	Sugar and fat - that's where it's at: metabolic changes in tumors.	Breast cancer research 	2008	53
18397542	Glucose	Trayhurn P	Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?	The British journal of nutrition	2008	87
18455122	Glucose	Weihua Z	Survival of cancer cells is maintained by EGFR independent of its kinase activity.	Cancer cell	2008	144
18482745	Glucose	Zheng HC	Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.	Human pathology	2008	53
18541534	Glucose	McFate T	Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells.	The Journal of biological chemistry	2008	96
18563385	Glucose	Di Marzo V	The endocannabinoid system in obesity and type 2 diabetes.	Diabetologia	2008	57
18577716	Glucose	Maciver NJ	Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival.	Journal of leukocyte biology	2008	109
18579779	Glucose	Villeneuve LM	Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2008	106
18616529	Glucose	Fujii S	Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome.	Cancer science	2008	65
18689793	Glucose	Zhang QJ	Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice.	Cardiovascular research	2008	95
18701488	Glucose	Kotliarova S	Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.	Cancer research	2008	79
18752331	Glucose	Fracanzani AL	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.	Hepatology	2008	105
18834431	Glucose	Rahier J	Pancreatic beta-cell mass in European subjects with type 2 diabetes.	Diabetes, obesity & metabolism	2008	191
18852465	Glucose	Lewis EC	alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	54
19026743	Glucose	Zhao WQ	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.	Biochimica et biophysica acta	2009	59
19033652	Glucose	Semenza GL	Tumor metabolism: cancer cells give and take lactate.	The Journal of clinical investigation	2008	82
19033663	Glucose	Sonveaux P	Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.	The Journal of clinical investigation	2008	332
19075268	Glucose	Koschmieder S	Dysregulation of the C/EBPalpha differentiation pathway in human cancer.	Journal of clinical oncology 	2009	51
19076441	Glucose	Mosconi L	Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.	Annals of the New York Academy of Sciences	2008	100
19189073	Glucose	Yan SF	Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.	Journal of molecular medicine	2009	54
19208907	Glucose	Brasacchio D	Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.	Diabetes	2009	113
19286567	Glucose	Amann T	GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.	The American journal of pathology	2009	59
19331544	Glucose	Gonzalez-Gronow M	GRP78: a multifunctional receptor on the cell surface.	Antioxidants & redox signaling	2009	71
19399017	Glucose	Fève B	The role of interleukins in insulin resistance and type 2 diabetes mellitus.	Nature reviews. Endocrinology	2009	48
19451179	Glucose	Liu F	Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.	Brain 	2009	68
19460373	Glucose	Sassone J	Huntington's disease: the current state of research with peripheral tissues.	Experimental neurology	2009	46
19470762	Glucose	Sudarshan S	Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.	Molecular and cellular biology	2009	78
19478200	Glucose	Verschuren L	MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease.	Circulation research	2009	47
19541609	Glucose	Shackelford DB	mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
19641507	Glucose	Danial NN	BAD: undertaker by night, candyman by day.	Oncogene	2008	98
19723875	Glucose	Palmieri D	Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis.	Molecular cancer research 	2009	52
19779498	Glucose	Colell A	Novel roles for GAPDH in cell death and carcinogenesis.	Cell death and differentiation	2009	49
19805772	Glucose	Helfand M	Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force.	Annals of internal medicine	2009	63
19881548	Glucose	DeBerardinis RJ	Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer.	Oncogene	2010	311
19897009	Glucose	Saji M	The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.	Molecular and cellular endocrinology	2010	47
19903865	Glucose	Chen S	Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells.	American journal of physiology. Endocrinology and metabolism	2010	50
19920251	Glucose	Hitosugi T	Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.	Science signaling	2009	221
19934006	Glucose	Oudit GY	Human recombinant ACE2 reduces the progression of diabetic nephropathy.	Diabetes	2010	71
20026663	Glucose	Yin F	Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice.	The Journal of experimental medicine	2010	137
20048154	Glucose	Inoue K	Zinc-induced neurotoxicity mediated by transient receptor potential melastatin 7 channels.	The Journal of biological chemistry	2010	43
20065132	Glucose	Baker LD	Effects of aerobic exercise on mild cognitive impairment: a controlled trial.	Archives of neurology	2010	223
20065246	Glucose	Honea RA	Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease.	Neurology	2010	52
20086171	Glucose	Dang CV	Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.	Cancer research	2010	126
20092409	Glucose	Jain SK	Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation?	Antioxidants & redox signaling	2010	56
20100866	Glucose	Fogal V	Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation.	Molecular and cellular biology	2010	77
20140248	Glucose	Xin H	Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse.	PloS one	2010	42
20150287	Glucose	Curtis JM	Downregulation of adipose glutathione S-transferase A4 leads to increased protein carbonylation, oxidative stress, and mitochondrial dysfunction.	Diabetes	2010	69
20165834	Glucose	Kanazawa I	Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus.	Osteoporosis international 	2011	44
20206201	Glucose	Ralph SJ	The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.	Molecular aspects of medicine	2010	87
20215450	Glucose	Kayaniyil S	Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes.	Diabetes care	2010	67
20227367	Glucose	Godlewski J	MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells.	Molecular cell	2010	134
20228846	Glucose	Zhao F	Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.	Oncogene	2010	51
20363910	Glucose	Baba Y	HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.	The American journal of pathology	2010	44
20371626	Glucose	Solinas G	JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction.	FASEB journal 	2010	65
20376506	Glucose	Nicolucci A	Epidemiological aspects of neoplasms in diabetes.	Acta diabetologica	2010	48
20381449	Glucose	Mathupala SP	The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.	Biochimica et biophysica acta	2010	46
20489155	Glucose	Wang WX	miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease.	The American journal of pathology	2010	61
20497976	Glucose	Widyantoro B	Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition.	Circulation	2010	85
20512147	Glucose	Zhu H	Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies.	Nature genetics	2010	103
20688814	Glucose	Villain N	Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease.	Brain 	2010	58
20803499	Glucose	Santoro N	A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents.	Hepatology	2010	51
20926834	Glucose	Zheng B	PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.	Science translational medicine	2010	184
20972457	Glucose	El Mjiyad N	Sugar-free approaches to cancer cell killing.	Oncogene	2011	58
20978194	Glucose	Chen M	Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.	Cancer research	2010	46
21080476	Glucose	Lee M	Inverse association between adiposity and telomere length: The Fels Longitudinal Study.	American journal of human biology 	2011	36
21119005	Glucose	Lock R	Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation.	Molecular biology of the cell	2011	142
21145489	Glucose	Lowman XH	The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose.	Molecular cell	2010	50
21193740	Glucose	Boström KI	Activation of vascular bone morphogenetic protein signaling in diabetes mellitus.	Circulation research	2011	57
21220732	Glucose	Caporali A	Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia.	Circulation	2011	108
21435176	Glucose	Bosco D	Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis.	Journal of cellular and molecular medicine	2011	45
21481590	Glucose	Gurzov EN	Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and dysfunction.	Trends in cell biology	2011	50
21499269	Glucose	Winer DA	B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.	Nature medicine	2011	228
21516129	Glucose	Lee C	Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients.	Oncogene	2011	74
21599535	Glucose	Leavens KF	Insulin signaling to hepatic lipid metabolism in health and disease.	Critical reviews in biochemistry and molecular biology	2011	41
21638209	Glucose	Samarakoon R	TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis.	Cell and tissue research	2012	39
21670080	Glucose	Coloff JL	Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.	Cancer research	2011	50
21685543	Glucose	Ross AC	Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals.	Antiviral therapy	2011	37
21700219	Glucose	Lv L	Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth.	Molecular cell	2011	134
21778425	Glucose	Zhou S	Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction.	Circulation research	2011	49
21804546	Glucose	Locasale JW	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.	Nature genetics	2011	271
21811634	Glucose	Caillou B	Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma.	PloS one	2011	36
21847114	Glucose	Gaglio D	Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.	Molecular systems biology	2011	124
21865645	Glucose	Ravassard P	A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion.	The Journal of clinical investigation	2011	90
21911743	Glucose	Eller K	Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy.	Diabetes	2011	58
21925173	Glucose	Seifert G	Neuron-astrocyte signaling and epilepsy.	Experimental neurology	2013	29
21933988	Glucose	Kowluru RA	Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage.	Diabetes	2011	43
21968997	Glucose	Mauro C	NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration.	Nature cell biology	2011	76
21978918	Glucose	Qin Z	The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature.	Atherosclerosis	2012	62
22008454	Glucose	Ryan AS	Exercise with calorie restriction improves insulin sensitivity and glycogen synthase activity in obese postmenopausal women with impaired glucose tolerance.	American journal of physiology. Endocrinology and metabolism	2012	32
22038520	Glucose	Rees MG	Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.	Diabetologia	2012	31
22079671	Glucose	Marzec M	GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.	Biochimica et biophysica acta	2012	68
22106302	Glucose	Wise DR	Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.	Proceedings of the National Academy of Sciences of the United States of America	2011	277
22191795	Glucose	de la Monte SM	Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.	Drugs	2012	43
22226221	Glucose	Wronska A	Structural and biochemical characteristics of various white adipose tissue depots.	Acta physiologica	2012	64
22265971	Glucose	Fei X	MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression.	FEBS letters	2012	37
22328245	Glucose	Steinhäuser C	Astrocyte dysfunction in temporal lobe epilepsy: K+ channels and gap junction coupling.	Glia	2012	34
22335797	Glucose	Vallon V	Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.	Annual review of physiology	2012	54
22343897	Glucose	Ichimura A	Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human.	Nature	2012	126
22351933	Glucose	Conley ME	Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.	The Journal of experimental medicine	2012	44
22354151	Glucose	del Zoppo GJ	Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation.	Journal of cerebral blood flow and metabolism 	2012	37
22426159	Glucose	Li Z	Glucose regulated protein 78: a critical link between tumor microenvironment and cancer hallmarks.	Biochimica et biophysica acta	2012	33
22452979	Glucose	McBrayer SK	Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.	Blood	2012	36
22466288	Glucose	Herman MA	A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism.	Nature	2012	138
22563482	Glucose	Martino L	Palmitate activates autophagy in INS-1E β-cells and in isolated rat and human pancreatic islets.	PloS one	2012	37
22572877	Glucose	Cani PD	Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity.	Gut microbes	2012	81
22576210	Glucose	Ros S	Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.	Cancer discovery	2012	60
22661548	Glucose	Tan MJ	Emerging roles of angiopoietin-like 4 in human cancer.	Molecular cancer research 	2012	34
22693349	Glucose	Paneni F	Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes.	Circulation research	2012	38
22751133	Glucose	Grkovic S	IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments.	Oncogene	2013	26
22850421	Glucose	Fiaschi T	Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.	Cancer research	2012	100
22883423	Glucose	Díaz-Prado S	Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes.	BMC musculoskeletal disorders	2012	42
22895557	Glucose	Sun Y	miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect.	Oncology reports	2012	35
22936011	Glucose	Craft S	Insulin and Alzheimer's disease: untangling the web.	Journal of Alzheimer's disease 	2013	42
22959024	Glucose	Bailey KM	Targeting the metabolic microenvironment of tumors.	Advances in pharmacology	2012	35
22960655	Glucose	Aggarwal G	Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice.	Gastroenterology	2012	31
22972646	Glucose	Lo RY	Vascular burden and Alzheimer disease pathologic progression.	Neurology	2012	50
22997257	Glucose	Yuen DA	eNOS deficiency predisposes podocytes to injury in diabetes.	Journal of the American Society of Nephrology 	2012	39
23123197	Glucose	Wei PC	Loss of the oxidative stress sensor NPGPx compromises GRP78 chaperone activity and induces systemic disease.	Molecular cell	2012	33
23151455	Glucose	Rodriguez OC	Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.	Cell cycle	2012	37
23177934	Glucose	Favaro E	Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.	Cell metabolism	2012	64
23197693	Glucose	Sato A	Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.	Stem cells translational medicine	2012	40
23221071	Glucose	Zhong Q	Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation.	Investigative ophthalmology & visual science	2013	28
23236214	Glucose	Brauer HA	Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer.	Clinical cancer research 	2013	38
23273980	Glucose	Chocarro-Calvo A	Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer.	Molecular cell	2013	32
23274086	Glucose	Faubert B	AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.	Cell metabolism	2013	183
23297826	Glucose	Agani F	Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer.	Current cancer drug targets	2013	40
23332916	Glucose	Martin E	Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia.	American journal of human genetics	2013	32
23337530	Glucose	Ervinna N	Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.	Endocrinology	2013	40
23342163	Glucose	Mortuza R	High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway.	PloS one	2013	40
23388637	Glucose	Qian SW	BMP4-mediated brown fat-like changes in white adipose tissue alter glucose and energy homeostasis.	Proceedings of the National Academy of Sciences of the United States of America	2013	59
23439261	Glucose	Safar Zadeh E	The liver diseases of lipodystrophy: the long-term effect of leptin treatment.	Journal of hepatology	2013	26
23440242	Glucose	Ambrose M	Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions.	Blood	2013	39
23453623	Glucose	Dong C	Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer.	Cancer cell	2013	149
23470539	Glucose	Zhao Y	Targeting cellular metabolism to improve cancer therapeutics.	Cell death & disease	2013	208
23523103	Glucose	Zhao D	Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer.	Cancer cell	2013	48
23539729	Glucose	Yoneda S	Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes.	The Journal of clinical endocrinology and metabolism	2013	28
23562747	Glucose	Newman G	Leptin-cytokine crosstalk in breast cancer.	Molecular and cellular endocrinology	2014	32
23582329	Glucose	Lee YS	The fractalkine/CX3CR1 system regulates β cell function and insulin secretion.	Cell	2013	31
23592772	Glucose	Ma Z	Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.	The Journal of biological chemistry	2013	54
23599929	Glucose	Protas HD	Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease.	JAMA neurology	2013	31
23786764	Glucose	Supinski GS	Diaphragm weakness in mechanically ventilated critically ill patients.	Critical care	2013	32
23823329	Glucose	Bouchonville M	Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial.	International journal of obesity	2014	30
23826303	Glucose	Wang X	Regional differences in islet distribution in the human pancreas--preferential beta-cell loss in the head region in patients with type 2 diabetes.	PloS one	2013	27
23836420	Glucose	Ma Z	O-GlcNAc in cancer biology.	Amino acids	2013	42
23852538	Glucose	Yao Y	A role for the endothelium in vascular calcification.	Circulation research	2013	44
23886976	Glucose	Geurts L	Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.	Beneficial microbes	2014	46
23932046	Glucose	Palomer X	An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.	International journal of cardiology	2013	35
23995067	Glucose	Flavahan WA	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.	Nature neuroscience	2013	83
23999440	Glucose	Semenza GL	HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.	The Journal of clinical investigation	2013	246
24008734	Glucose	Fann DY	Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke.	Cell death & disease	2013	46
24014835	Glucose	Jansen F	Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles.	Circulation	2013	77
24096870	Glucose	Liu PP	Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.	Cell death and differentiation	2014	48
24103379	Glucose	Murray PS	Psychosis in Alzheimer's disease.	Biological psychiatry	2014	24
24113348	Glucose	Liu J	Receptor for advanced glycation end-products promotes premature senescence of proximal tubular epithelial cells via activation of endoplasmic reticulum stress-dependent p21 signaling.	Cellular signalling	2014	23
24127133	Glucose	Winer DA	B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance.	Cellular and molecular life sciences 	2014	22
24141775	Glucose	Chen WT	GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN.	Oncogene	2014	24
24166096	Glucose	Yan JW	The emerging role of miR-375 in cancer.	International journal of cancer	2014	38
24204837	Glucose	Alvarez ML	Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy.	PloS one	2013	25
24215793	Glucose	Mezza T	Insulin resistance alters islet morphology in nondiabetic humans.	Diabetes	2014	31
24269021	Glucose	Johnson SC	Amyloid burden and neural function in people at risk for Alzheimer's Disease.	Neurobiology of aging	2014	35
24371138	Glucose	Das A	Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression.	The Journal of biological chemistry	2014	29
24388967	Glucose	Bryant KL	KRAS: feeding pancreatic cancer proliferation.	Trends in biochemical sciences	2014	99
24411018	Glucose	Morris JK	Impaired glycemia increases disease progression in mild cognitive impairment.	Neurobiology of aging	2014	23
24438746	Glucose	Kugel S	Chromatin and beyond: the multitasking roles for SIRT6.	Trends in biochemical sciences	2014	56
24469106	Glucose	Parmenter TJ	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.	Cancer discovery	2014	54
24508027	Glucose	Wong N	PKM2 contributes to cancer metabolism.	Cancer letters	2015	42
24520123	Glucose	Dalmas E	T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes.	Diabetes	2014	32
24531552	Glucose	Lee RJ	Bitter and sweet taste receptors regulate human upper respiratory innate immunity.	The Journal of clinical investigation	2014	74
24570140	Glucose	Mortuza R	miR-195 regulates SIRT1-mediated changes in diabetic retinopathy.	Diabetologia	2014	27
24584071	Glucose	Flannick J	Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.	Nature genetics	2014	118
24632615	Glucose	Leithner K	PCK2 activation mediates an adaptive response to glucose depletion in lung cancer.	Oncogene	2015	28
24634381	Glucose	Cui J	FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.	Clinical cancer research 	2014	28
24662521	Glucose	Karnevi E	Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.	Immunology and cell biology	2014	24
24662831	Glucose	Xiao L	Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.	Oncogene	2014	30
24676639	Glucose	Fiorina P	Role of podocyte B7-1 in diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	31
24723555	Glucose	Gaens KH	Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance.	Arteriosclerosis, thrombosis, and vascular biology	2014	25
24732809	Glucose	Lu J	The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism.	Cancer letters	2015	49
24744147	Glucose	Olivier-Van Stichelen S	O-GlcNAcylation stabilizes β-catenin through direct competition with phosphorylation at threonine 41.	FASEB journal 	2014	23
24819450	Glucose	Trayhurn P	Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity.	Annual review of nutrition	2014	31
24825347	Glucose	Pate KT	Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer.	The EMBO journal	2014	76
24838911	Glucose	Liu Y	APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis.	Journal of neurology, neurosurgery, and psychiatry	2015	23
24846769	Glucose	Ghosh S	Elevated muscle TLR4 expression and metabolic endotoxemia in human aging.	The journals of gerontology. Series A, Biological sciences and medical sciences	2015	25
24925721	Glucose	Yoo TH	Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.	Journal of the American Society of Nephrology 	2015	25
24930970	Glucose	Macintyre AN	The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function.	Cell metabolism	2014	137
24949970	Glucose	Soleimanpour SA	The diabetes susceptibility gene Clec16a regulates mitophagy.	Cell	2014	34
24951764	Glucose	Paulin R	The metabolic theory of pulmonary arterial hypertension.	Circulation research	2014	42
24951766	Glucose	Ryan JJ	The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.	Circulation research	2014	42
24997364	Glucose	Slominski A	The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.	Archives of biochemistry and biophysics	2014	40
25002027	Glucose	Valencia T	Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.	Cancer cell	2014	53
25035342	Glucose	Lim S	Links between ectopic fat and vascular disease in humans.	Arteriosclerosis, thrombosis, and vascular biology	2014	32
25038584	Glucose	Wahlström T	Impact of MYC in regulation of tumor cell metabolism.	Biochimica et biophysica acta	2015	36
25056438	Glucose	Chondronikola M	Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans.	Diabetes	2014	114
25102180	Glucose	Ng MC	Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes.	PLoS genetics	2014	46
25204974	Glucose	Carlsson PO	Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.	Diabetes	2015	22
25204977	Glucose	Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.	Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.	Diabetes	2015	33
25211370	Glucose	Rezania A	Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells.	Nature biotechnology	2014	165
25239387	Glucose	Gilon P	Calcium signaling in pancreatic β-cells in health and in Type 2 diabetes.	Cell calcium	2014	23
25242226	Glucose	Kratz M	Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages.	Cell metabolism	2014	76
25262977	Glucose	Hodgson K	Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections.	Immunology	2015	27
25295788	Glucose	Turpin SM	Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.	Cell metabolism	2014	80
25304371	Glucose	Chen B	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer.	Cancer letters	2015	21
25307742	Glucose	Haeusler RA	Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors.	Nature communications	2014	32
25324472	Glucose	Olivieri F	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells.	Aging	2014	22
25336656	Glucose	Zhu Y	The emerging link between O-GlcNAc and Alzheimer disease.	The Journal of biological chemistry	2014	36
25341798	Glucose	McLaughlin T	T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans.	Arteriosclerosis, thrombosis, and vascular biology	2014	39
25387570	Glucose	Menegazzo L	NETosis is induced by high glucose and associated with type 2 diabetes.	Acta diabetologica	2015	17
25448601	Glucose	Sekar S	Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes.	Neurobiology of aging	2015	25
25482439	Glucose	Pan T	Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer.	Biochemical and biophysical research communications	2015	16
25524916	Glucose	Palmer ND	Genetic Variants Associated With Quantitative Glucose Homeostasis Traits Translate to Type 2 Diabetes in Mexican Americans: The GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium.	Diabetes	2015	18
25528771	Glucose	Shibuya K	Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells.	Oncotarget	2015	28
25542180	Glucose	Obre E	Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy.	The international journal of biochemistry & cell biology	2015	27
25563886	Glucose	Goos JA	Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis.	Annals of surgery	2016	10
25587098	Glucose	Yan B	lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA.	Circulation research	2015	65
25607458	Glucose	Blagih J	The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo.	Immunity	2015	77
25607840	Glucose	Sellers K	Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation.	The Journal of clinical investigation	2015	84
25621950	Glucose	Fong MY	Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis.	Nature cell biology	2015	93
25637831	Glucose	Satin LS	Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes.	Molecular aspects of medicine	2015	19
25668019	Glucose	Valdearcos M	Hypothalamic inflammation in the control of metabolic function.	Annual review of physiology	2015	25
25678702	Glucose	Møller AB	Physical exercise increases autophagic signaling through ULK1 in human skeletal muscle.	Journal of applied physiology	2015	18
25703085	Glucose	Francque S	PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.	Journal of hepatology	2015	24
25732824	Glucose	Zhang D	Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation.	Cell reports	2015	27
25747274	Glucose	Monga SP	β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis.	Gastroenterology	2015	58
25787249	Glucose	Puthanveetil P	Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells.	Journal of cellular and molecular medicine	2015	32
25870263	Glucose	Shen L	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.	Proceedings of the National Academy of Sciences of the United States of America	2015	20
25887760	Glucose	Fu QF	Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.	Journal of hematology & oncology	2015	25
25948776	Glucose	Luan W	PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop.	Oncotarget	2015	17
25956158	Glucose	Zadra G	Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.	Molecular cancer research 	2015	24
26122028	Glucose	Togliatto G	Obesity reduces the pro-angiogenic potential of adipose tissue stem cell-derived extracellular vesicles (EVs) by impairing miR-126 content: impact on clinical applications.	International journal of obesity	2016	11
26179207	Glucose	Phan L	The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming.	Nature communications	2015	19
26214150	Glucose	Willette AA	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.	JAMA neurology	2015	36
26241401	Glucose	Mishra M	Epigenetic Modification of Mitochondrial DNA in the Development of Diabetic Retinopathy.	Investigative ophthalmology & visual science	2015	19
26277545	Glucose	Israelsen WJ	Pyruvate kinase: Function, regulation and role in cancer.	Seminars in cell & developmental biology	2015	34
26365179	Glucose	Dupuy F	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.	Cell metabolism	2015	51
26373605	Glucose	Portelius E	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.	Brain 	2015	34
26386349	Glucose	Munasinghe PE	Type-2 diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway.	International journal of cardiology	2016	12
26386558	Glucose	Ti D	LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b.	Journal of translational medicine	2015	22
26387865	Glucose	Altman BJ	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.	Cell metabolism	2015	34
26409295	Glucose	Dongiovanni P	Genetics of nonalcoholic fatty liver disease.	Metabolism	2016	14
26435271	Glucose	Koo JH	Endoplasmic Reticulum Stress in Hepatic Stellate Cells Promotes Liver Fibrosis via PERK-Mediated Degradation of HNRNPA1 and Up-regulation of SMAD2.	Gastroenterology	2016	13
26443705	Glucose	Zhang H	Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1.	Science signaling	2015	24
26445512	Glucose	Kajimura S	Brown and Beige Fat: Physiological Roles beyond Heat Generation.	Cell metabolism	2015	88
26474064	Glucose	Vincent EE	Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth.	Molecular cell	2015	25
26481663	Glucose	Montal ED	PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth.	Molecular cell	2015	17
26513002	Glucose	Martino J	Maternal Body Weight and Gestational Diabetes Differentially Influence Placental and Pregnancy Outcomes.	The Journal of clinical endocrinology and metabolism	2016	13
26523864	Glucose	Zhao E	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.	Nature immunology	2016	51
26598716	Glucose	Ranger TA	Is there an association between tendinopathy and diabetes mellitus? A systematic review with meta-analysis.	British journal of sports medicine	2016	12
26624892	Glucose	van de Bunt M	Transcript Expression Data from Human Islets Links Regulatory Signals from Genome-Wide Association Studies for Type 2 Diabetes and Glycemic Traits to Their Downstream Effectors.	PLoS genetics	2015	31
26643952	Glucose	Soriano-Tárraga C	Epigenome-wide association study identifies TXNIP gene associated with type 2 diabetes mellitus and sustained hyperglycemia.	Human molecular genetics	2016	17
26711459	Glucose	Love S	Cerebrovascular disease in ageing and Alzheimer's disease.	Acta neuropathologica	2016	21
26718499	Glucose	Hanssen MJ	Short-term Cold Acclimation Recruits Brown Adipose Tissue in Obese Humans.	Diabetes	2016	20
26743041	Glucose	Akhtar MW	Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation.	Nature communications	2016	15
26773935	Glucose	Barron CC	Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment.	Metabolism	2016	20
26786898	Glucose	Kwon O	Leptin signalling pathways in hypothalamic neurons.	Cellular and molecular life sciences 	2016	16
26813969	Glucose	Rodriguez-Vieitez E	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.	Brain 	2016	24
26853146	Glucose	Redis RS	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.	Molecular cell	2016	25
26902416	Glucose	Xiao X	The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer.	Scientific reports	2016	14
26919392	Glucose	Klemann C	Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.	Clinical and experimental immunology	2016	12
26926996	Glucose	Shirai T	The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease.	The Journal of experimental medicine	2016	34
26947067	Glucose	Kung CP	The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction.	Cell reports	2016	18
26950362	Glucose	Helman A	p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion.	Nature medicine	2016	30
26997759	Glucose	Ye EA	miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-κB and TNFα to Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose.	Mediators of inflammation	2016	12
27009267	Glucose	Yang Z	Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis.	Science translational medicine	2016	20
27027351	Glucose	D'Esposito V	Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.	Oncotarget	2016	12
27064285	Glucose	Dai C	Stress-impaired transcription factor expression and insulin secretion in transplanted human islets.	The Journal of clinical investigation	2016	10
27075628	Glucose	Ribas V	Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females.	Science translational medicine	2016	15
27162351	Glucose	Chen Z	Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort.	Proceedings of the National Academy of Sciences of the United States of America	2016	14
27197151	Glucose	Hirata H	Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.	Cancer research	2016	12
27233446	Glucose	Abolhassani N	Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer's disease brain.	Mechanisms of ageing and development	2017	6
27245224	Glucose	Peiró C	Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway.	Cardiovascular diabetology	2016	11
27256476	Glucose	Kusminski CM	Targeting adipose tissue in the treatment of obesity-associated diabetes.	Nature reviews. Drug discovery	2016	29
27347932	Glucose	Laganà AS	Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.	International journal of molecular sciences	2016	12
27479178	Glucose	Qorraj M	The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.	Leukemia	2017	5
27511728	Glucose	Siska PJ	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.	Journal of immunology	2016	14
27557514	Glucose	Zou ZW	LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells.	Oncotarget	2016	17
27557534	Glucose	Lien EC	Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer	2016	11
27591677	Glucose	Talasila KM	The angiogenic switch leads to a metabolic shift in human glioblastoma.	Neuro-oncology	2017	11
27636730	Glucose	Gross B	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.	Nature reviews. Endocrinology	2017	26
27928162	Glucose	Hashimoto N	Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus.	Journal of human genetics	2017	6
27964927	Glucose	Li X	Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy.	Experimental cell research	2017	5
27993896	Glucose	San-Millán I	Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect.	Carcinogenesis	2017	7
28039838	Glucose	Gómez-Sámano MÁ	Fibroblast growth factor 21 and its novel association with oxidative stress.	Redox biology	2017	7
28065883	Glucose	Rawal S	Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy.	Cardiovascular research	2017	7
28351381	Glucose	von Ahrens D	The role of stromal cancer-associated fibroblasts in pancreatic cancer.	Journal of hematology & oncology	2017	10
28436964	Glucose	Zhang Y	SWELL1 is a regulator of adipocyte size, insulin signalling and glucose homeostasis.	Nature cell biology	2017	6
28559417	Glucose	Kleinberger G	The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism.	The EMBO journal	2017	6
8235596	Zinc	Ye BH	Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.	Science	1993	126
10228159	Zinc	Brehm A	The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.	The EMBO journal	1999	97
10357558	Zinc	Kleiner DE	Matrix metalloproteinases and metastasis.	Cancer chemotherapy and pharmacology	1999	107
11040213	Zinc	Raymond CS	Dmrt1, a gene related to worm and fly sexual regulators, is required for mammalian testis differentiation.	Genes & development	2000	123
11103818	Zinc	Foster KW	Increase of GKLF messenger RNA and protein expression during progression of breast cancer.	Cancer research	2000	97
12082640	Zinc	Blanco MJ	Correlation of Snail expression with histological grade and lymph node status in breast carcinomas.	Oncogene	2002	163
12402037	Zinc	Bereshchenko OR	Acetylation inactivates the transcriptional repressor BCL6.	Nature genetics	2002	97
12576332	Zinc	Elagib KE	RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.	Blood	2003	92
12778173	Zinc	Person RE	Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2.	Nature genetics	2003	86
12875979	Zinc	An WL	Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.	The American journal of pathology	2003	84
14641026	Zinc	Fischer OM	EGFR signal transactivation in cancer cells.	Biochemical Society transactions	2003	98
15000152	Zinc	Zucker S	Role of matrix metalloproteinases (MMPs) in colorectal cancer.	Cancer metastasis reviews	2004	104
15448698	Zinc	Zhou BP	Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.	Nature cell biology	2004	462
15577913	Zinc	Phan RT	The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.	Nature	2004	187
15647282	Zinc	Yook JI	Wnt-dependent regulation of the E-cadherin repressor snail.	The Journal of biological chemistry	2005	133
15653317	Zinc	Heyninck K	A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions.	Trends in biochemical sciences	2005	67
15825076	Zinc	Katz JP	Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach.	Gastroenterology	2005	98
15833848	Zinc	Yang Z	Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.	Cancer research	2005	87
16153295	Zinc	Franklin RB	hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.	Molecular cancer	2005	73
16252232	Zinc	Krafchak CM	Mutations in TCF8 cause posterior polymorphous corneal dystrophy and ectopic expression of COL4A3 by corneal endothelial cells.	American journal of human genetics	2005	68
16269333	Zinc	Adhikary S	The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation.	Cell	2005	108
16456111	Zinc	Khachigian LM	Early growth response-1 in cardiovascular pathobiology.	Circulation research	2006	67
16492805	Zinc	Pasqualucci L	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.	The Journal of experimental medicine	2006	89
16763212	Zinc	Ma Y	SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.	Blood	2006	73
16952552	Zinc	Spaderna S	A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer.	Gastroenterology	2006	113
16971064	Zinc	Guo Y	Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma.	Gene	2006	104
17072303	Zinc	Yook JI	A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells.	Nature cell biology	2006	212
17508399	Zinc	McConnell BB	The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology.	BioEssays 	2007	111
17587811	Zinc	Doble BW	Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions.	Cells, tissues, organs	2007	60
17952120	Zinc	Beach S	Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.	Oncogene	2008	52
18003899	Zinc	Li M	Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
18054006	Zinc	Nandan MO	Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.	Gastroenterology	2008	57
18235444	Zinc	Wendt KS	Cohesin mediates transcriptional insulation by CCCTC-binding factor.	Nature	2008	450
18385818	Zinc	Prasad AS	Zinc in human health: effect of zinc on immune cells.	Molecular medicine	2008	68
18483486	Zinc	Burk U	A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.	EMBO reports	2008	570
18583420	Zinc	Taylor KM	ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.	Endocrinology	2008	52
18587387	Zinc	Perez EE	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.	Nature biotechnology	2008	358
18604447	Zinc	Evans PM	Roles of Krüpel-like factor 4 in normal homeostasis, cancer and stem cells.	Acta biochimica et biophysica Sinica	2008	68
18657511	Zinc	Maeder ML	Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.	Molecular cell	2008	234
18703361	Zinc	Savage AK	The transcription factor PLZF directs the effector program of the NKT cell lineage.	Immunity	2008	240
18832382	Zinc	Thuault S	HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition.	The Journal of biological chemistry	2008	99
19011757	Zinc	Vandewalle C	The role of the ZEB family of transcription factors in development and disease.	Cellular and molecular life sciences 	2009	132
19208838	Zinc	Devy L	Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.	Cancer research	2009	92
19308701	Zinc	Wendt KS	How cohesin and CTCF cooperate in regulating gene expression.	Chromosome research 	2009	46
19339596	Zinc	Deshpande A	A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses.	The Journal of neuroscience 	2009	67
19544444	Zinc	Kong D	miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.	Stem cells	2009	123
19566488	Zinc	Niu J	Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications.	Clinical science	2009	46
19701203	Zinc	Han YG	Dual and opposing roles of primary cilia in medulloblastoma development.	Nature medicine	2009	134
19706168	Zinc	ten Haaf A	Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival.	BMC cancer	2009	50
19797115	Zinc	Dennler S	Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation.	The Journal of biological chemistry	2009	48
19909263	Zinc	Lee JE	Pathogenic mechanisms of myotonic dystrophy.	Biochemical Society transactions	2009	97
20424117	Zinc	Ohashi S	Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.	Cancer research	2010	57
20666778	Zinc	Sun Q	Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression.	Cancer science	2010	49
20719862	Zinc	Vitart V	New loci associated with central cornea thickness include COL5A1, AKAP13 and AVGR8.	Human molecular genetics	2010	48
20974010	Zinc	Lee SJ	Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes.	Molecular brain	2010	46
21575912	Zinc	Ramirez-Ortiz ZG	A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus.	Cell host & microbe	2011	39
21602820	Zinc	Martin D	Genome-wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes.	Nature structural & molecular biology	2011	39
21670465	Zinc	Hsu AP	Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.	Blood	2011	123
21673316	Zinc	Stinson S	TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.	Science signaling	2011	73
21765025	Zinc	Dickinson RE	Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.	Blood	2011	90
21765466	Zinc	Kim K	Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.	Oncogene	2012	57
21770894	Zinc	Liu X	MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines.	The Biochemical journal	2011	64
21890822	Zinc	Ohashi S	A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.	Cancer research	2011	47
21892162	Zinc	Hahn CN	Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.	Nature genetics	2011	124
22024162	Zinc	Kim NH	A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition.	The Journal of cell biology	2011	130
22045813	Zinc	Mihelich BL	miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.	The Journal of biological chemistry	2011	48
22241470	Zinc	Tan EJ	Regulation of transcription factor Twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition.	The Journal of biological chemistry	2012	31
22311119	Zinc	Kurashige J	MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma.	Annals of surgical oncology	2012	45
22388088	Zinc	Aceto N	Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.	Nature medicine	2012	71
22797073	Zinc	Neilsen PM	Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.	Oncogene	2013	46
23123196	Zinc	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	61
23360514	Zinc	Maier DA	Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.	Human gene therapy	2013	36
23434374	Zinc	Chauhan S	ZKSCAN3 is a master transcriptional repressor of autophagy.	Molecular cell	2013	48
23584475	Zinc	Rajabi H	MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.	Oncogene	2014	38
23741301	Zinc	Itsumura N	Compound heterozygous mutations in SLC30A2/ZnT2 results in low milk zinc concentrations: a novel mechanism for zinc deficiency in a breast-fed infant.	PloS one	2013	27
23851495	Zinc	Kao SH	GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug.	Oncogene	2014	27
23891471	Zinc	Moore DJ	Mutations in ZMYND10, a gene essential for proper axonemal assembly of inner and outer dynein arms in humans and flies, cause primary ciliary dyskinesia.	American journal of human genetics	2013	33
24168186	Zinc	Wang Y	The Role of Snail in EMT and Tumorigenesis.	Current cancer drug targets	2013	85
24332369	Zinc	Stankic M	TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition.	Cell reports	2013	54
24434208	Zinc	Wang L	CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis.	Cancer cell	2014	48
24529376	Zinc	Kim JH	Regulation of the catabolic cascade in osteoarthritis by the zinc-ZIP8-MTF1 axis.	Cell	2014	39
24608905	Zinc	Tuggle KL	Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats.	PloS one	2014	34
24626089	Zinc	Nakaya T	KLF5 regulates the integrity and oncogenicity of intestinal stem cells.	Cancer research	2014	24
24769727	Zinc	Denecker G	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.	Cell death and differentiation	2014	27
24879559	Zinc	Turelli P	Interplay of TRIM28 and DNA methylation in controlling human endogenous retroelements.	Genome research	2014	34
24952462	Zinc	Whissell G	The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression.	Nature cell biology	2014	25
25267526	Zinc	Ilagan JO	U2AF1 mutations alter splice site recognition in hematological malignancies.	Genome research	2015	40
25296715	Zinc	Ren D	Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.	Cell and tissue research	2014	33
25421577	Zinc	Addison JB	KAP1 promotes proliferation and metastatic progression of breast cancer cells.	Cancer research	2015	16
25492562	Zinc	Ousterout DG	Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.	Molecular therapy 	2015	33
25531323	Zinc	Weber CE	Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.	Oncogene	2015	30
25547151	Zinc	Deng X	MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3.	Cellular physiology and biochemistry 	2015	22
25702619	Zinc	Huang X	Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.	Stem cells	2015	42
25733580	Zinc	Hoban MD	Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.	Blood	2015	67
25945841	Zinc	Huang N	MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.	Oncotarget	2015	27
25964473	Zinc	Haley KP	The Human Antimicrobial Protein Calgranulin C Participates in Control of Helicobacter pylori Growth and Regulation of Virulence.	Infection and immunity	2015	15
26023187	Zinc	Koo BK	Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
26207617	Zinc	Liu H	Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.	Molecular carcinogenesis	2016	11
26214525	Zinc	Kazenwadel J	GATA2 is required for lymphatic vessel valve development and maintenance.	The Journal of clinical investigation	2015	21
26502055	Zinc	Ismail IH	The RNF138 E3 ligase displaces Ku to promote DNA end resection and regulate DNA repair pathway choice.	Nature cell biology	2015	26
26544536	Zinc	Xue M	Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway.	Cancer science	2016	29
26684803	Zinc	Kulemann B	KRAS mutations in pancreatic circulating tumor cells: a pilot study.	Tumour biology 	2016	11
26943042	Zinc	Olivieri M	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.	Oncotarget	2016	14
27162353	Zinc	Madan B	USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds.	Proceedings of the National Academy of Sciences of the United States of America	2016	14
27274087	Zinc	Taylor KM	Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates embryonic development and cell migration.	The Biochemical journal	2016	13
27610572	Zinc	Singer M	A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.	Cell	2016	32
27624489	Zinc	Zhou D	Matrix Metalloproteinase-7 Is a Urinary Biomarker and Pathogenic Mediator of Kidney Fibrosis.	Journal of the American Society of Nephrology 	2017	7
27862275	Zinc	Fang C	Long non-coding ribonucleic acid zinc finger antisense 1 promotes the progression of colonic cancer by modulating ZEB1 expression.	Journal of gastroenterology and hepatology	2017	9
28211215	Zinc	Yao Z	ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.	Molecular oncology	2017	22
28349823	Zinc	Lv QL	Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma.	Tumour biology 	2017	6
28481222	Zinc	Lin W	Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity.	The Journal of clinical investigation	2017	10
9180083	Iron	Babcock M	Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin.	Science	1997	178
9482913	Iron	Zhou XY	HFE gene knockout produces mouse model of hereditary hemochromatosis.	Proceedings of the National Academy of Sciences of the United States of America	1998	113
9493273	Iron	Rabinowitz YS	Keratoconus.	Survey of ophthalmology	1998	375
9884342	Iron	Yachie A	Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency.	The Journal of clinical investigation	1999	257
10573511	Iron	Angulo P	Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.	Hepatology	1999	237
10747949	Iron	Abboud S	A novel mammalian iron-regulated protein involved in intracellular iron metabolism.	The Journal of biological chemistry	2000	246
10756000	Iron	Ribes JA	Zygomycetes in human disease.	Clinical microbiology reviews	2000	214
11175786	Iron	Puccio H	Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits.	Nature genetics	2001	159
11438811	Iron	Curtis AR	Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease.	Nature genetics	2001	92
12393428	Iron	Weinstein DA	Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.	Blood	2002	109
12510040	Iron	Hayflick SJ	Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.	The New England journal of medicine	2003	88
14757427	Iron	Pietrangelo A	The ferroportin disease.	Blood cells, molecules & diseases	2004	76
15124018	Iron	Nemeth E	IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.	The Journal of clinical investigation	2004	477
15625418	Iron	Hill ID	Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.	Journal of pediatric gastroenterology and nutrition	2005	145
15711640	Iron	Mori K	Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.	The Journal of clinical investigation	2005	229
16075059	Iron	Huang FW	A mouse model of juvenile hemochromatosis.	The Journal of clinical investigation	2005	119
16508012	Iron	O'Donnell KA	Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.	Molecular and cellular biology	2006	65
16775460	Iron	Schmidt-Ott KM	Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia.	Current opinion in nephrology and hypertension	2006	62
16848710	Iron	Nemeth E	Regulation of iron metabolism by hepcidin.	Annual review of nutrition	2006	144
16946298	Iron	Verga Falzacappa MV	STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation.	Blood	2007	144
16952548	Iron	Bekri S	Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.	Gastroenterology	2006	92
17101452	Iron	Rouault TA	Brain iron metabolism.	Seminars in pediatric neurology	2006	62
17194590	Iron	Dunn LL	Iron uptake and metabolism in the new millennium.	Trends in cell biology	2007	60
17261733	Iron	Hua Y	Brain injury after intracerebral hemorrhage: the role of thrombin and iron.	Stroke	2007	63
17475779	Iron	De Domenico I	The molecular mechanism of hepcidin-mediated ferroportin down-regulation.	Molecular biology of the cell	2007	114
17485548	Iron	Camaschella C	The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload.	Blood	2007	89
17540841	Iron	Lin L	Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.	Blood	2007	77
17557118	Iron	Peyssonnaux C	Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).	The Journal of clinical investigation	2007	161
17607367	Iron	Martineau AR	Neutrophil-mediated innate immune resistance to mycobacteria.	The Journal of clinical investigation	2007	100
17623039	Iron	Uversky VN	Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.	Journal of neurochemistry	2007	134
17699374	Iron	Wish JB	Assessing iron status: beyond serum ferritin and transferrin saturation.	Clinical journal of the American Society of Nephrology 	2006	65
18305254	Iron	Shinzawa K	Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.	The Journal of neuroscience 	2008	61
18326817	Iron	Xia Y	Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin.	Blood	2008	81
18355723	Iron	Yang WS	Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.	Chemistry & biology	2008	78
18408718	Iron	Finberg KE	Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).	Nature genetics	2008	164
18443312	Iron	McNeill A	T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation.	Neurology	2008	52
18570303	Iron	Paisan-Ruiz C	Characterization of PLA2G6 as a locus for dystonia-parkinsonism.	Annals of neurology	2009	75
18760763	Iron	Whatley SD	C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.	American journal of human genetics	2008	51
18799783	Iron	Gregory A	Neurodegeneration associated with genetic defects in phospholipase A(2).	Neurology	2008	63
18981035	Iron	Gregory A	Clinical and genetic delineation of neurodegeneration with brain iron accumulation.	Journal of medical genetics	2009	63
19011085	Iron	Salazar J	Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2008	101
19018762	Iron	Toyokuni S	Role of iron in carcinogenesis: cancer as a ferrotoxic disease.	Cancer science	2009	75
19234114	Iron	De Domenico I	Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19293425	Iron	Theurl I	Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.	Blood	2009	79
19412178	Iron	Guernsey DL	Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia.	Nature genetics	2009	60
19414861	Iron	Tanno T	Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.	Blood	2009	109
19457088	Iron	Schipper HM	Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement.	Journal of neurochemistry	2009	59
19540040	Iron	Bolignano D	Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene.	Cancer letters	2010	47
19805308	Iron	Huang ML	Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant.	Proceedings of the National Academy of Sciences of the United States of America	2009	52
19931264	Iron	Valenti L	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.	Gastroenterology	2010	50
20062075	Iron	Yamaguchi K	Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.	Oncogene	2010	42
20194272	Iron	Skinner AC	Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood.	Pediatrics	2010	52
20200349	Iron	Finberg KE	Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis.	Blood	2010	45
20378845	Iron	Nagy E	Red cells, hemoglobin, heme, iron, and atherogenesis.	Arteriosclerosis, thrombosis, and vascular biology	2010	57
20481466	Iron	Ye H	Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease.	Biochemistry	2010	70
20484814	Iron	Liu M	The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.	The Journal of clinical investigation	2010	42
20495089	Iron	Richardson DR	Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol.	Proceedings of the National Academy of Sciences of the United States of America	2010	100
20542038	Iron	Pietrangelo A	Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.	Gastroenterology	2010	87
20580464	Iron	Sierra-Filardi E	Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release.	Immunobiology	2010	54
20619503	Iron	Paisán-Ruiz C	Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.	Neurobiology of aging	2012	42
20686179	Iron	Pinnix ZK	Ferroportin and iron regulation in breast cancer progression and prognosis.	Science translational medicine	2010	83
20728697	Iron	Sawyer DB	Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?	Progress in cardiovascular diseases	2010	44
20736190	Iron	Péran P	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.	Brain 	2010	90
20817278	Iron	Duce JA	Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease.	Cell	2010	142
21363917	Iron	Torti SV	Ironing out cancer.	Cancer research	2011	37
21427356	Iron	Josson S	β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.	Cancer research	2011	44
21768301	Iron	Ginzburg Y	β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.	Blood	2011	53
21953442	Iron	Kowdley KV	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	2012	75
21981780	Iron	Hartig MB	Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation.	American journal of human genetics	2011	36
21992109	Iron	Grochot-Przeczek A	Haem oxygenase-1: non-canonical roles in physiology and pathology.	Clinical science	2012	46
22021369	Iron	Hod EA	Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron.	Blood	2011	71
22032835	Iron	Munksgaard PS	The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations.	Gynecologic oncology	2012	35
22052915	Iron	Boyle JJ	Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection.	Circulation research	2012	34
22154776	Iron	Finn AV	Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques.	Journal of the American College of Cardiology	2012	54
22171355	Iron	Bagnato F	Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla.	Brain 	2011	65
22323289	Iron	Sheftel AD	The human mitochondrial ISCA1, ISCA2, and IBA57 proteins are required for 4Fe-4S protein maturation.	Molecular biology of the cell	2012	34
22462691	Iron	Kovacevic Z	The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways.	Antioxidants & redox signaling	2013	38
22706697	Iron	Fan K	Magnetoferritin nanoparticles for targeting and visualizing tumour tissues.	Nature nanotechnology	2012	40
22719876	Iron	Kawaguchi T	Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.	PloS one	2012	50
22826563	Iron	Visconte V	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.	Blood	2012	55
23136396	Iron	Hick A	Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia.	Disease models & mechanisms	2013	43
23176820	Iron	Haack TB	Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA.	American journal of human genetics	2012	66
23474058	Iron	Boeve BF	Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.	Sleep medicine	2013	41
23843466	Iron	Blazejewska AI	Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI.	Neurology	2013	26
23853581	Iron	Leal SM Jr	Targeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum.	PLoS pathogens	2013	30
23859340	Iron	Pastore A	Frataxin: a protein in search for a function.	Journal of neurochemistry	2013	36
23868451	Iron	Hametner S	Iron and neurodegeneration in the multiple sclerosis brain.	Annals of neurology	2013	65
23959881	Iron	Sohn YS	NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24269900	Iron	Fang BA	Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.	Biochimica et biophysica acta	2014	27
24334290	Iron	Baker PR 2nd	Variant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5.	Brain 	2014	24
24462711	Iron	Stehling O	Mitochondrial iron-sulfur protein biogenesis and human disease.	Biochimie	2014	53
24622774	Iron	Schuh C	Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.	Acta neuropathologica	2014	20
24705334	Iron	Perdomini M	Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia.	Nature medicine	2014	32
24805231	Iron	Myers SS	Increasing CO2 threatens human nutrition.	Nature	2014	46
24904118	Iron	Wu XG	HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression.	Blood	2014	21
25394715	Iron	Bulycheva E	Myelodysplasia is in the niche: novel concepts and emerging therapies.	Leukemia	2015	15
25527668	Iron	Karakochuk CD	Genetic hemoglobin disorders rather than iron deficiency are a major predictor of hemoglobin concentration in women of reproductive age in rural prey Veng, Cambodia.	The Journal of nutrition	2015	18
25713362	Iron	Lakhal-Littleton S	Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
25728673	Iron	Sun X	HSPB1 as a novel regulator of ferroptotic cancer cell death.	Oncogene	2015	25
25825391	Iron	White K	Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.	EMBO molecular medicine	2015	22
25858146	Iron	Tesfay L	Hepcidin regulation in prostate and its disruption in prostate cancer.	Cancer research	2015	20
26125440	Iron	Lui GY	Targeting cancer by binding iron: Dissecting cellular signaling pathways.	Oncotarget	2015	18
26144971	Iron	Schiavi A	Iron-Starvation-Induced Mitophagy Mediates Lifespan Extension upon Mitochondrial Stress in C. elegans.	Current biology 	2015	23
26291319	Iron	Michels K	Hepcidin and Host Defense against Infectious Diseases.	PLoS pathogens	2015	19
26385212	Iron	de Swart L	Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.	Haematologica	2016	11
26403645	Iron	Sun X	Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.	Hepatology	2016	34
26461092	Iron	Schonberg DL	Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells.	Cancer cell	2015	35
26471505	Iron	Pavlides M	Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.	Journal of hepatology	2016	14
26894396	Iron	Zhang Z	Microglial Polarization and Inflammatory Mediators After Intracerebral Hemorrhage.	Molecular neurobiology	2017	16
27296779	Iron	Lowe VJ	An autoradiographic evaluation of AV-1451 Tau PET in dementia.	Acta neuropathologica communications	2016	57
28060743	Iron	González N	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.	Oncotarget	2017	5
28185035	Iron	McGowan JV	Anthracycline Chemotherapy and Cardiotoxicity.	Cardiovascular drugs and therapy	2017	12
28319068	Iron	Basuli D	Iron addiction: a novel therapeutic target in ovarian cancer.	Oncogene	2017	5
9053458	Adenosine Triphosphate	Ferrari D	Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin.	The Journal of experimental medicine	1997	108
9157970	Adenosine Triphosphate	Eguchi Y	Intracellular ATP levels determine cell death fate by apoptosis or necrosis.	Cancer research	1997	166
9233643	Adenosine Triphosphate	Ferrari D	Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages.	Journal of immunology	1997	152
9351836	Adenosine Triphosphate	Evans E	Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.	The EMBO journal	1997	145
9815080	Adenosine Triphosphate	Sprague RS	Deformation-induced ATP release from red blood cells requires CFTR activity.	The American journal of physiology	1998	105
10393078	Adenosine Triphosphate	Crompton M	The mitochondrial permeability transition pore and its role in cell death.	The Biochemical journal	1999	421
10508238	Adenosine Triphosphate	Lipton P	Ischemic cell death in brain neurons.	Physiological reviews	1999	461
10562547	Adenosine Triphosphate	Szalai G	Apoptosis driven by IP(3)-linked mitochondrial calcium signals.	The EMBO journal	1999	120
11054482	Adenosine Triphosphate	White BC	Brain ischemia and reperfusion: molecular mechanisms of neuronal injury.	Journal of the neurological sciences	2000	112
11385574	Adenosine Triphosphate	Nadler MJ	LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability.	Nature	2001	234
11739410	Adenosine Triphosphate	Madesh M	VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release.	The Journal of cell biology	2001	114
11817589	Adenosine Triphosphate	Gergely P Jr	Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus.	Arthritis and rheumatism	2002	82
12438266	Adenosine Triphosphate	Cuezva JM	The bioenergetic signature of cancer: a marker of tumor progression.	Cancer research	2002	96
12623848	Adenosine Triphosphate	Branford S	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.	Blood	2003	115
12808136	Adenosine Triphosphate	Stump CS	Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts.	Proceedings of the National Academy of Sciences of the United States of America	2003	106
14749273	Adenosine Triphosphate	Duchen MR	Roles of mitochondria in health and disease.	Diabetes	2004	75
14962470	Adenosine Triphosphate	Halestrap AP	Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection.	Cardiovascular research	2004	217
15192144	Adenosine Triphosphate	Andrei C	Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.	Proceedings of the National Academy of Sciences of the United States of America	2004	105
15236194	Adenosine Triphosphate	Tamborini E	A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.	Gastroenterology	2004	70
15456405	Adenosine Triphosphate	Barnett SF	Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.	The Biochemical journal	2005	132
15543203	Adenosine Triphosphate	de Kok JB	Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.	Laboratory investigation; a journal of technical methods and pathology	2005	148
15559249	Adenosine Triphosphate	Meijer L	Pharmacological inhibitors of glycogen synthase kinase 3.	Trends in pharmacological sciences	2004	136
15695406	Adenosine Triphosphate	Xu RH	Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.	Cancer research	2005	181
15706348	Adenosine Triphosphate	Kasper D	Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration.	The EMBO journal	2005	71
15831501	Adenosine Triphosphate	David DC	Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice.	The Journal of biological chemistry	2005	81
15841208	Adenosine Triphosphate	Timmins JM	Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.	The Journal of clinical investigation	2005	149
15894266	Adenosine Triphosphate	Plescia J	Rational design of shepherdin, a novel anticancer agent.	Cancer cell	2005	67
15944221	Adenosine Triphosphate	Pellegatti P	A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion.	Molecular biology of the cell	2005	69
15998811	Adenosine Triphosphate	Dannenberg JH	mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival.	Genes & development	2005	86
16098463	Adenosine Triphosphate	Moeller BJ	Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.	Cancer cell	2005	111
16357216	Adenosine Triphosphate	Maniataki E	A human, ATP-independent, RISC assembly machine fueled by pre-miRNA.	Genes & development	2005	142
16378731	Adenosine Triphosphate	Sultana R	Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach.	Neurobiology of disease	2006	90
16547218	Adenosine Triphosphate	Ferrari D	The P2X7 receptor: a key player in IL-1 processing and release.	Journal of immunology	2006	285
16685256	Adenosine Triphosphate	Kanmogne GD	HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis.	Journal of cerebral blood flow and metabolism 	2007	81
16787253	Adenosine Triphosphate	Shoshan-Barmatz V	The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death.	Current pharmaceutical design	2006	80
16862155	Adenosine Triphosphate	Wong CW	Connexin37 protects against atherosclerosis by regulating monocyte adhesion.	Nature medicine	2006	77
16880519	Adenosine Triphosphate	Griswold IJ	Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.	Molecular and cellular biology	2006	62
16935882	Adenosine Triphosphate	Fuller-Pace FV	DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation.	Nucleic acids research	2006	127
17110937	Adenosine Triphosphate	Vanakker OM	Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity.	The Journal of investigative dermatology	2007	59
17158952	Adenosine Triphosphate	Pelicano H	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.	The Journal of cell biology	2006	126
17215403	Adenosine Triphosphate	Baloh RH	Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.	The Journal of neuroscience 	2007	105
17322922	Adenosine Triphosphate	Lou H	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters.	Oncogene	2007	62
17360912	Adenosine Triphosphate	Thies E	Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1.	The Journal of neuroscience 	2007	85
17510466	Adenosine Triphosphate	Mulya A	Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1.	Arteriosclerosis, thrombosis, and vascular biology	2007	57
17524805	Adenosine Triphosphate	Boucher RC	Cystic fibrosis: a disease of vulnerability to airway surface dehydration.	Trends in molecular medicine	2007	59
17692395	Adenosine Triphosphate	Di Virgilio F	Liaisons dangereuses: P2X(7) and the inflammasome.	Trends in pharmacological sciences	2007	149
17728465	Adenosine Triphosphate	Matute C	P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis.	The Journal of neuroscience 	2007	80
17911267	Adenosine Triphosphate	Zhou J	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.	Proceedings of the National Academy of Sciences of the United States of America	2007	193
17938633	Adenosine Triphosphate	Klempan TA	Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression.	Molecular psychiatry	2009	69
18083779	Adenosine Triphosphate	De La Fuente R	Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel.	Molecular pharmacology	2008	65
18222991	Adenosine Triphosphate	Zanna C	OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.	Brain 	2008	80
18301398	Adenosine Triphosphate	Murphy R	Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes.	Nature clinical practice. Endocrinology & metabolism	2008	95
18393293	Adenosine Triphosphate	Komuta M	Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.	Hepatology	2008	74
18458094	Adenosine Triphosphate	Shadel GS	Expression and maintenance of mitochondrial DNA: new insights into human disease pathology.	The American journal of pathology	2008	53
18816186	Adenosine Triphosphate	Orellana JA	Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.	Antioxidants & redox signaling	2009	60
19008857	Adenosine Triphosphate	Nishida M	P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis.	The EMBO journal	2008	54
19050078	Adenosine Triphosphate	Wang X	Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins.	Proceedings of the National Academy of Sciences of the United States of America	2008	232
19118021	Adenosine Triphosphate	Chiche J	Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.	Cancer research	2009	121
19251738	Adenosine Triphosphate	Schnetz MP	Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns.	Genome research	2009	87
19270741	Adenosine Triphosphate	Gegg ME	Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells.	PloS one	2009	60
19383919	Adenosine Triphosphate	Dong X	Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.	Cancer research	2009	56
19428331	Adenosine Triphosphate	Lucas R	Regulators of endothelial and epithelial barrier integrity and function in acute lung injury.	Biochemical pharmacology	2009	63
19442513	Adenosine Triphosphate	Yoo AS	ATP-dependent chromatin remodeling in neural development.	Current opinion in neurobiology	2009	51
19523516	Adenosine Triphosphate	Serenó L	A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.	Neurobiology of disease	2009	69
19546216	Adenosine Triphosphate	Lutz AK	Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation.	The Journal of biological chemistry	2009	133
19593530	Adenosine Triphosphate	Kostenko S	Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology.	Cellular and molecular life sciences 	2009	89
19693011	Adenosine Triphosphate	Schafer ZT	Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.	Nature	2009	234
19711346	Adenosine Triphosphate	Zhu Z	Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.	International journal of cancer	2010	106
19717510	Adenosine Triphosphate	Muñoz-Planillo R	A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome.	Journal of immunology	2009	111
19753307	Adenosine Triphosphate	Chen Y	Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect.	PloS one	2009	55
19789351	Adenosine Triphosphate	Wang X	Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.	Cancer research	2009	53
19825957	Adenosine Triphosphate	Mandapathil M	Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.	Clinical cancer research 	2009	56
19892975	Adenosine Triphosphate	Cartier N	Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.	Science	2009	382
19939921	Adenosine Triphosphate	Chambers JW	Glutamine metabolism is essential for human cytomegalovirus infection.	Journal of virology	2010	59
20032281	Adenosine Triphosphate	Hernández-Alvarez MI	Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity.	Diabetes care	2010	48
20038799	Adenosine Triphosphate	Samudio I	Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.	The Journal of clinical investigation	2010	138
20049710	Adenosine Triphosphate	Morais VA	Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.	EMBO molecular medicine	2009	93
20086177	Adenosine Triphosphate	Aymeric L	Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.	Cancer research	2010	79
20087650	Adenosine Triphosphate	Martin FT	Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).	Breast cancer research and treatment	2010	59
20101004	Adenosine Triphosphate	Hartz AM	Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.	Molecular pharmacology	2010	66
20130576	Adenosine Triphosphate	Hatzivassiliou G	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.	Nature	2010	402
20148667	Adenosine Triphosphate	Baines CP	The cardiac mitochondrion: nexus of stress.	Annual review of physiology	2010	51
20167368	Adenosine Triphosphate	Szydlowska K	Calcium, ischemia and excitotoxicity.	Cell calcium	2010	126
20215500	Adenosine Triphosphate	Ben Sahra I	Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.	Cancer research	2010	133
20360943	Adenosine Triphosphate	Gandhirajan RK	Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.	Neoplasia	2010	45
20386866	Adenosine Triphosphate	Ost A	Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes.	Molecular medicine	2010	65
20413686	Adenosine Triphosphate	Rawat R	Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle.	The American journal of pathology	2010	45
20428236	Adenosine Triphosphate	Wang L	Abundant lipid and protein components of drusen.	PloS one	2010	84
20442200	Adenosine Triphosphate	Yang XR	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma.	Gut	2010	73
20453110	Adenosine Triphosphate	Adinolfi E	Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor.	FASEB journal 	2010	42
20538956	Adenosine Triphosphate	Carré JE	Survival in critical illness is associated with early activation of mitochondrial biogenesis.	American journal of respiratory and critical care medicine	2010	77
20562527	Adenosine Triphosphate	Migneco G	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.	Cell cycle	2010	58
20585624	Adenosine Triphosphate	Ashrafian H	A mutation in the mitochondrial fission gene Dnm1l leads to cardiomyopathy.	PLoS genetics	2010	46
20593179	Adenosine Triphosphate	Xi H	2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.	Cancer chemotherapy and pharmacology	2011	46
20658967	Adenosine Triphosphate	Halestrap AP	A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection.	Biochemical Society transactions	2010	79
20682644	Adenosine Triphosphate	Singh A	Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.	Molecular cancer therapeutics	2010	43
20819940	Adenosine Triphosphate	Tang D	Endogenous HMGB1 regulates autophagy.	The Journal of cell biology	2010	236
20847263	Adenosine Triphosphate	Vander Heiden MG	Evidence for an alternative glycolytic pathway in rapidly proliferating cells.	Science	2010	207
20880502	Adenosine Triphosphate	Yenari MA	Microglial activation in stroke: therapeutic targets.	Neurotherapeutics 	2010	84
21092862	Adenosine Triphosphate	Birdsong WT	Sensing muscle ischemia: coincident detection of acid and ATP via interplay of two ion channels.	Neuron	2010	58
21132003	Adenosine Triphosphate	Morris MR	Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.	Oncogene	2011	56
21145355	Adenosine Triphosphate	Reddy PH	Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases.	Brain research reviews	2011	76
21212411	Adenosine Triphosphate	Frank NY	VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.	Cancer research	2011	51
21216854	Adenosine Triphosphate	Schmid AI	Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.	Diabetes care	2011	39
21240260	Adenosine Triphosphate	Itzhaki I	Modelling the long QT syndrome with induced pluripotent stem cells.	Nature	2011	294
21250988	Adenosine Triphosphate	Matute C	Glutamate and ATP signalling in white matter pathology.	Journal of anatomy	2011	39
21278237	Adenosine Triphosphate	Kim TH	NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.	Cancer research	2011	65
21326199	Adenosine Triphosphate	Clausen T	HTRA proteases: regulated proteolysis in protein quality control.	Nature reviews. Molecular cell biology	2011	96
21390132	Adenosine Triphosphate	Simsek D	Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair.	Nature	2011	77
21396365	Adenosine Triphosphate	Alexander A	The role of LKB1 and AMPK in cellular responses to stress and damage.	FEBS letters	2011	46
21441104	Adenosine Triphosphate	Hu J	Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.	Proceedings of the National Academy of Sciences of the United States of America	2011	42
21480217	Adenosine Triphosphate	Kryczek I	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.	International journal of cancer	2012	78
21531766	Adenosine Triphosphate	Jeon HM	ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.	Cancer research	2011	54
21576264	Adenosine Triphosphate	Zaugg K	Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress.	Genes & development	2011	123
21684291	Adenosine Triphosphate	Liu W	Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system.	Life sciences	2011	55
21709020	Adenosine Triphosphate	Avivar-Valderas A	PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment.	Molecular and cellular biology	2011	71
21715610	Adenosine Triphosphate	Eugenin EA	Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism.	The Journal of neuroscience 	2011	74
21734725	Adenosine Triphosphate	Saxena M	Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.	Cell death & disease	2011	56
21873242	Adenosine Triphosphate	Aung T	Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21900605	Adenosine Triphosphate	Vlashi E	Metabolic state of glioma stem cells and nontumorigenic cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	113
22003197	Adenosine Triphosphate	Hoegen T	The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release.	Journal of immunology	2011	46
22077634	Adenosine Triphosphate	Sheng B	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.	Journal of neurochemistry	2012	66
22084398	Adenosine Triphosphate	Zhou Y	Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells.	Cancer research	2012	59
22085932	Adenosine Triphosphate	Zhang J	UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells.	The EMBO journal	2011	135
22198378	Adenosine Triphosphate	Gusdon AM	ATP13A2 regulates mitochondrial bioenergetics through macroautophagy.	Neurobiology of disease	2012	39
22266115	Adenosine Triphosphate	Zaytseva YY	Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.	Cancer research	2012	35
22415665	Adenosine Triphosphate	Hoque R	Sterile inflammatory response in acute pancreatitis.	Pancreas	2012	34
22447075	Adenosine Triphosphate	Sorge RE	Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity.	Nature medicine	2012	75
22449631	Adenosine Triphosphate	Garrido C	The small heat shock proteins family: the long forgotten chaperones.	The international journal of biochemistry & cell biology	2012	48
22460906	Adenosine Triphosphate	Liu L	Deregulated MYC expression induces dependence upon AMPK-related kinase 5.	Nature	2012	83
22525272	Adenosine Triphosphate	Galavotti S	The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells.	Oncogene	2013	55
22544529	Adenosine Triphosphate	Franke H	Pathophysiology of astroglial purinergic signalling.	Purinergic signalling	2012	34
22613083	Adenosine Triphosphate	Trang T	Brain-derived neurotrophic factor from microglia: a molecular substrate for neuropathic pain.	Neuron glia biology	2011	43
22647602	Adenosine Triphosphate	Dehay B	Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.	Proceedings of the National Academy of Sciences of the United States of America	2012	63
22722202	Adenosine Triphosphate	Banerji S	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012	352
22771709	Adenosine Triphosphate	Dahl G	Pannexin: from discovery to bedside in 11±4 years?	Brain research	2012	43
22878108	Adenosine Triphosphate	Kalogeris T	Cell biology of ischemia/reperfusion injury.	International review of cell and molecular biology	2012	142
22892528	Adenosine Triphosphate	Onat OE	Missense mutation in the ATPase, aminophospholipid transporter protein ATP8A2 is associated with cerebellar atrophy and quadrupedal locomotion.	European journal of human genetics 	2013	30
22926141	Adenosine Triphosphate	Manczak M	Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.	Human molecular genetics	2012	37
22948162	Adenosine Triphosphate	Juliana C	Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.	The Journal of biological chemistry	2012	116
23051977	Adenosine Triphosphate	Coen PM	Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults.	The journals of gerontology. Series A, Biological sciences and medical sciences	2013	62
23071146	Adenosine Triphosphate	Dass S	Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.	Circulation. Cardiovascular imaging	2012	60
23128392	Adenosine Triphosphate	Zhao J	Mitochondrial dynamics regulates migration and invasion of breast cancer cells.	Oncogene	2013	102
23129651	Adenosine Triphosphate	Lin CS	Mouse mtDNA mutant model of Leber hereditary optic neuropathy.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
23151605	Adenosine Triphosphate	Krysko DV	Immunogenic cell death and DAMPs in cancer therapy.	Nature reviews. Cancer	2012	210
23175232	Adenosine Triphosphate	Oikawa T	Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.	Hepatology	2013	51
23235493	Adenosine Triphosphate	Sánchez-Lozada LG	Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations.	Nephron. Experimental nephrology	2012	37
23271701	Adenosine Triphosphate	Mills KH	The role of inflammasome-derived IL-1 in driving IL-17 responses.	Journal of leukocyte biology	2013	41
23313576	Adenosine Triphosphate	Calì T	Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics.	Biochimica et biophysica acta	2013	37
23318458	Adenosine Triphosphate	Kang R	The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.	Oncogene	2014	62
23355908	Adenosine Triphosphate	Shain AH	The spectrum of SWI/SNF mutations, ubiquitous in human cancers.	PloS one	2013	101
23365660	Adenosine Triphosphate	Kenney MC	Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration.	PloS one	2013	27
23371930	Adenosine Triphosphate	Xiong Q	Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling.	Circulation	2013	32
23460667	Adenosine Triphosphate	Golebiewska A	Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.	Brain 	2013	28
23477399	Adenosine Triphosphate	Lai RC	Mesenchymal stem cell exosome ameliorates reperfusion injury through proteomic complementation.	Regenerative medicine	2013	28
23483818	Adenosine Triphosphate	Basaranoglu M	From fatty liver to fibrosis: a tale of "second hit".	World journal of gastroenterology	2013	39
23498975	Adenosine Triphosphate	Bartolome F	Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels.	Neuron	2013	38
23523468	Adenosine Triphosphate	Gonzalvez F	Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.	Biochimica et biophysica acta	2013	34
23542178	Adenosine Triphosphate	Ducker GS	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.	Oncogene	2014	31
23603840	Adenosine Triphosphate	Hall A	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.	Oncotarget	2013	43
23665396	Adenosine Triphosphate	Tseng AH	SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage.	Free radical biology & medicine	2013	51
23681226	Adenosine Triphosphate	Krysko O	Many faces of DAMPs in cancer therapy.	Cell death & disease	2013	41
23716663	Adenosine Triphosphate	Jiang D	Letm1, the mitochondrial Ca2+/H+ antiporter, is essential for normal glucose metabolism and alters brain function in Wolf-Hirschhorn syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
23785148	Adenosine Triphosphate	Staahl BT	Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways.	The Journal of neuroscience 	2013	28
23792284	Adenosine Triphosphate	Ji RR	Glia and pain: is chronic pain a gliopathy?	Pain	2013	154
23878142	Adenosine Triphosphate	Asgari E	C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation.	Blood	2013	53
23886165	Adenosine Triphosphate	Jin J	miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9.	Asian Pacific journal of cancer prevention 	2013	27
23945235	Adenosine Triphosphate	Byers DE	Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease.	The Journal of clinical investigation	2013	57
23953109	Adenosine Triphosphate	Hertz NT	A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.	Cell	2013	42
24037090	Adenosine Triphosphate	Ko A	Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling.	Cell death and differentiation	2014	54
24117156	Adenosine Triphosphate	Bubici C	JNK signalling in cancer: in need of new, smarter therapeutic targets.	British journal of pharmacology	2014	32
24144321	Adenosine Triphosphate	Križaj D	From mechanosensitivity to inflammatory responses: new players in the pathology of glaucoma.	Current eye research	2014	40
24200652	Adenosine Triphosphate	Kenney MC	Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: implications for population susceptibility to diseases.	Biochimica et biophysica acta	2014	34
24211491	Adenosine Triphosphate	Tahara T	Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.	Gastroenterology	2014	23
24236104	Adenosine Triphosphate	Bhattacharyya S	Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.	PloS one	2013	37
24332968	Adenosine Triphosphate	Tornovsky-Babeay S	Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells.	Cell metabolism	2014	32
24398940	Adenosine Triphosphate	de Rivero Vaccari JP	Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury.	Journal of cerebral blood flow and metabolism 	2014	42
24399447	Adenosine Triphosphate	Mourier A	Loss of LRPPRC causes ATP synthase deficiency.	Human molecular genetics	2014	30
24457989	Adenosine Triphosphate	Koilkonda RD	Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.	JAMA ophthalmology	2014	26
24474669	Adenosine Triphosphate	Garcia PD	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.	Clinical cancer research 	2014	27
24568860	Adenosine Triphosphate	Tan W	Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis.	Biochimica et biophysica acta	2014	23
24585446	Adenosine Triphosphate	Zhu B	Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population.	Molecular carcinogenesis	2015	18
24619111	Adenosine Triphosphate	Götzl JK	Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis.	Acta neuropathologica	2014	38
24669934	Adenosine Triphosphate	Lindoso RS	Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury.	Stem cells and development	2014	24
24713656	Adenosine Triphosphate	Amato KR	Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.	The Journal of clinical investigation	2014	21
24727893	Adenosine Triphosphate	Bonora M	Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition.	Oncogene	2015	39
24746669	Adenosine Triphosphate	Wang Z	Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression.	Developmental cell	2014	37
24768297	Adenosine Triphosphate	Liang H	PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism.	Cell metabolism	2014	45
24770881	Adenosine Triphosphate	Nelson PT	ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology.	Acta neuropathologica	2014	23
24777293	Adenosine Triphosphate	Shi L	miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.	Neuromolecular medicine	2014	24
24875192	Adenosine Triphosphate	Pearce D	Collecting duct principal cell transport processes and their regulation.	Clinical journal of the American Society of Nephrology 	2015	36
25017063	Adenosine Triphosphate	Quirós PM	ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity.	Cell reports	2014	31
25030174	Adenosine Triphosphate	Ksander BR	ABCB5 is a limbal stem cell gene required for corneal development and repair.	Nature	2014	48
25043816	Adenosine Triphosphate	Petruzzelli M	A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.	Cell metabolism	2014	83
25119037	Adenosine Triphosphate	Van Nostrand JL	Inappropriate p53 activation during development induces features of CHARGE syndrome.	Nature	2014	33
25119045	Adenosine Triphosphate	Han P	A long noncoding RNA protects the heart from pathological hypertrophy.	Nature	2014	97
25136135	Adenosine Triphosphate	Nguyen TT	Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease.	Proceedings of the National Academy of Sciences of the United States of America	2014	36
25188341	Adenosine Triphosphate	Beecham GW	Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias.	PLoS genetics	2014	54
25223574	Adenosine Triphosphate	Sperlágh B	P2X7 receptor: an emerging target in central nervous system diseases.	Trends in pharmacological sciences	2014	48
25241037	Adenosine Triphosphate	LeBleu VS	PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.	Nature cell biology	2014	167
25262208	Adenosine Triphosphate	Miranda-Lorenzo I	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells.	Nature methods	2014	36
25281745	Adenosine Triphosphate	Cole SP	Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter.	The Journal of biological chemistry	2014	24
25326666	Adenosine Triphosphate	Ronan B	A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.	Nature chemical biology	2014	56
25447846	Adenosine Triphosphate	Maléth J	Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis.	Gastroenterology	2015	23
25556000	Adenosine Triphosphate	Bakthisaran R	Small heat shock proteins: Role in cellular functions and pathology.	Biochimica et biophysica acta	2015	44
25730877	Adenosine Triphosphate	Carta S	Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
25840885	Adenosine Triphosphate	Zhang YK	Multidrug Resistance Proteins (MRPs) and Cancer Therapy.	The AAPS journal	2015	24
25840982	Adenosine Triphosphate	Sadok A	Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.	Cancer research	2015	19
25941621	Adenosine Triphosphate	Kepp O	Consensus guidelines for the detection of immunogenic cell death.	Oncoimmunology	2014	114
26027935	Adenosine Triphosphate	Cullen SP	Diverse Activators of the NLRP3 Inflammasome Promote IL-1β Secretion by Triggering Necrosis.	Cell reports	2015	33
26062441	Adenosine Triphosphate	Wang J	Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer.	Oncotarget	2015	24
26183239	Adenosine Triphosphate	Kawamukai M	Biosynthesis of coenzyme Q in eukaryotes.	Bioscience, biotechnology, and biochemistry	2016	13
26311743	Adenosine Triphosphate	Heerma van Voss MR	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.	Oncotarget	2015	18
26418144	Adenosine Triphosphate	Lee S	Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.	American journal of respiratory cell and molecular biology	2016	12
26436840	Adenosine Triphosphate	Poepsel S	Determinants of amyloid fibril degradation by the PDZ protease HTRA1.	Nature chemical biology	2015	19
26477888	Adenosine Triphosphate	Dumont LJ	CO2 -dependent metabolic modulation in red blood cells stored under anaerobic conditions.	Transfusion	2016	10
26519060	Adenosine Triphosphate	Zhai L	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.	Clinical cancer research 	2015	24
26549853	Adenosine Triphosphate	Engel T	ATPergic signalling during seizures and epilepsy.	Neuropharmacology	2016	11
26698230	Adenosine Triphosphate	Nitulescu GM	Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).	International journal of oncology	2016	27
26744319	Adenosine Triphosphate	Wang MD	HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.	Oncotarget	2016	11
26777405	Adenosine Triphosphate	Jain S	ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure.	Cell	2016	79
26836503	Adenosine Triphosphate	Kadoch C	PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.	Biochemistry	2016	10
26860875	Adenosine Triphosphate	Migdalska-Richards A	The relationship between glucocerebrosidase mutations and Parkinson disease.	Journal of neurochemistry	2016	15
27117941	Adenosine Triphosphate	Kleszczyński K	Melatonin enhances mitochondrial ATP synthesis, reduces reactive oxygen species formation, and mediates translocation of the nuclear erythroid 2-related factor 2 resulting in activation of phase-2 antioxidant enzymes (γ-GCS, HO-1, NQO1) in ultraviolet radiation-treated normal human epidermal keratinocytes (NHEK).	Journal of pineal research	2016	12
27180306	Adenosine Triphosphate	Fletcher JI	ABC transporters as mediators of drug resistance and contributors to cancer cell biology.	Drug resistance updates 	2016	13
27219534	Adenosine Triphosphate	Bhattacharya A	The microglial ATP-gated ion channel P2X7 as a CNS drug target.	Glia	2016	17
27254664	Adenosine Triphosphate	Ali YO	NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies.	PLoS biology	2016	13
27269284	Adenosine Triphosphate	Li X	Nucleosome disassembly during human non-homologous end joining followed by concerted HIRA- and CAF-1-dependent reassembly.	eLife	2016	17
27350397	Adenosine Triphosphate	Daulatzai MA	Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease.	Journal of neuroscience research	2017	14
27413115	Adenosine Triphosphate	Hodges C	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.	Cold Spring Harbor perspectives in medicine	2016	16
27599716	Adenosine Triphosphate	Kim DI	Aβ-Induced Drp1 phosphorylation through Akt activation promotes excessive mitochondrial fission leading to neuronal apoptosis.	Biochimica et biophysica acta	2016	11
27693323	Adenosine Triphosphate	Shouval DS	Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency.	Gastroenterology	2016	10
27879251	Adenosine Triphosphate	Milewicz DM	Altered Smooth Muscle Cell Force Generation as a Driver of Thoracic Aortic Aneurysms and Dissections.	Arteriosclerosis, thrombosis, and vascular biology	2017	10
27941796	Adenosine Triphosphate	Kadoch C	Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states.	Nature genetics	2017	16
28060726	Adenosine Triphosphate	Ogawa M	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.	Oncotarget	2017	11
28192788	Adenosine Triphosphate	Chan LN	Metabolic gatekeeper function of B-lymphoid transcription factors.	Nature	2017	10
28234357	Adenosine Triphosphate	Garg AD	Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.	Cell death and differentiation	2017	11
28333713	Adenosine Triphosphate	Aryal B	MicroRNAs and lipid metabolism.	Current opinion in lipidology	2017	5
28337542	Adenosine Triphosphate	Paillusson S	α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production.	Acta neuropathologica	2017	9
28360422	Adenosine Triphosphate	Weyand CM	Immunometabolism in early and late stages of rheumatoid arthritis.	Nature reviews. Rheumatology	2017	6
28663500	Adenosine Triphosphate	Adebesin F	Emission of volatile organic compounds from petunia flowers is facilitated by an ABC transporter.	Science	2017	7
1981239	Bromodeoxyuridine	Hall PA	Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.	The Journal of pathology	1990	152
8895767	Bromodeoxyuridine	Nagane M	A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.	Cancer research	1996	113
9809557	Bromodeoxyuridine	Eriksson PS	Neurogenesis in the adult human hippocampus.	Nature medicine	1998	1036
11748275	Bromodeoxyuridine	Kovacs JA	Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.	The Journal of experimental medicine	2001	86
14734483	Bromodeoxyuridine	Tang XH	Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice.	Clinical cancer research 	2004	85
15161630	Bromodeoxyuridine	Galiano RD	Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells.	The American journal of pathology	2004	144
16140970	Bromodeoxyuridine	Zhou HJ	SRC-3 is required for prostate cancer cell proliferation and survival.	Cancer research	2005	82
16449977	Bromodeoxyuridine	Patrawala L	Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.	Oncogene	2006	302
17077815	Bromodeoxyuridine	Li Y	Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice.	Journal of cerebral blood flow and metabolism 	2007	65
17287398	Bromodeoxyuridine	Christov C	Muscle satellite cells and endothelial cells: close neighbors and privileged partners.	Molecular biology of the cell	2007	119
17526595	Bromodeoxyuridine	Masri FA	Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.	American journal of physiology. Lung cellular and molecular physiology	2007	109
17615543	Bromodeoxyuridine	Seigel GM	Human embryonic and neuronal stem cell markers in retinoblastoma.	Molecular vision	2007	56
18366788	Bromodeoxyuridine	Fillmore CM	Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.	Breast cancer research 	2008	368
18455396	Bromodeoxyuridine	Stuart-Harris R	Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.	Breast	2008	85
18803808	Bromodeoxyuridine	Yamasaki N	Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders.	Molecular brain	2008	100
19072981	Bromodeoxyuridine	Chu P	Characterization of a subpopulation of colon cancer cells with stem cell-like properties.	International journal of cancer	2009	51
19424421	Bromodeoxyuridine	Brown KN	Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection.	PLoS pathogens	2009	74
20419144	Bromodeoxyuridine	Burdo TH	Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma.	PLoS pathogens	2010	91
20811150	Bromodeoxyuridine	Teekakirikul P	Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.	The Journal of clinical investigation	2010	132
21343390	Bromodeoxyuridine	Chang Q	Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer.	Cancer research	2011	58
22338017	Bromodeoxyuridine	Christie LA	Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy.	Clinical cancer research 	2012	44
23944957	Bromodeoxyuridine	Perry MM	Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma.	American journal of respiratory cell and molecular biology	2014	36
24284627	Bromodeoxyuridine	Li Q	Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.	Nature	2013	32
24423924	Bromodeoxyuridine	Hou T	MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1.	British journal of cancer	2014	28
24586944	Bromodeoxyuridine	Di Martino MT	In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.	PloS one	2014	24
24744439	Bromodeoxyuridine	Zhou D	Sonic hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury.	Journal of the American Society of Nephrology 	2014	28
24884509	Bromodeoxyuridine	Tu K	Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.	Molecular cancer	2014	30
25028469	Bromodeoxyuridine	Zhang YX	Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.	Molecular cancer therapeutics	2014	29
26840018	Bromodeoxyuridine	Sun C	Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.	Oncotarget	2016	26
26909600	Bromodeoxyuridine	Sun CC	Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer.	Oncotarget	2016	20
27166267	Bromodeoxyuridine	Sun CC	Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.	Oncotarget	2016	19
28403886	Bromodeoxyuridine	Li S	The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation.	Journal of experimental & clinical cancer research 	2017	9
8799830	Biotin	Iborra FJ	Active RNA polymerases are localized within discrete transcription "factories' in human nuclei.	Journal of cell science	1996	122
10397265	Biotin	Chang SS	Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.	Cancer research	1999	123
18495537	Biotin	Bartolazzi A	Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.	The Lancet. Oncology	2008	53
19903735	Biotin	Walker AK	Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.	Brain 	2010	45
20463395	Biotin	Bossy B	S-Nitrosylation of DRP1 does not affect enzymatic activity and is not specific to Alzheimer's disease.	Journal of Alzheimer's disease 	2010	56
23929266	Biotin	Thike AA	Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.	Modern pathology 	2014	22
7768953	Cysteine	Mu FT	EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif.	The Journal of biological chemistry	1995	210
8099202	Cysteine	Mulligan LM	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.	Nature	1993	188
8681377	Cysteine	Muzio M	FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.	Cell	1996	479
9600969	Cysteine	Babic AM	CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	1998	113
9811737	Cysteine	Cocchi F	The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells.	Journal of virology	1998	135
10027396	Cysteine	Nör JE	Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.	The American journal of pathology	1999	129
10458605	Cysteine	Bromberg JF	Stat3 as an oncogene.	Cell	1999	799
10648003	Cysteine	Buechler C	Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli.	Journal of leukocyte biology	2000	137
10728374	Cysteine	Saraste A	Morphologic and biochemical hallmarks of apoptosis.	Cardiovascular research	2000	147
10949293	Cysteine	Rea S	Regulation of chromatin structure by site-specific histone H3 methyltransferases.	Nature	2000	730
11067861	Cysteine	Zheng T	Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema.	The Journal of clinical investigation	2000	161
11113131	Cysteine	Park CH	Hepcidin, a urinary antimicrobial peptide synthesized in the liver.	The Journal of biological chemistry	2001	352
11574398	Cysteine	Savage DB	Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans.	Diabetes	2001	106
11714645	Cysteine	Rabkin E	Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.	Circulation	2001	148
12353035	Cysteine	Chun HJ	Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.	Nature	2002	141
15094120	Cysteine	Bellail AC	Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion.	The international journal of biochemistry & cell biology	2004	124
15178558	Cysteine	Liu J	Lysosomal cysteine proteases in atherosclerosis.	Arteriosclerosis, thrombosis, and vascular biology	2004	83
15568026	Cysteine	Sedy JR	B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.	Nature immunology	2005	156
16046058	Cysteine	Liaudet-Coopman E	Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.	Cancer letters	2006	73
16362181	Cysteine	Büki A	All roads lead to disconnection?--Traumatic axonal injury revisited.	Acta neurochirurgica	2006	121
16481467	Cysteine	Gocheva V	Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.	Genes & development	2006	129
17235047	Cysteine	Infante JR	Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.	Journal of clinical oncology 	2007	118
17245112	Cysteine	Gocheva V	Cysteine cathepsins and the cutting edge of cancer invasion.	Cell cycle	2007	96
17420353	Cysteine	Jaffer FA	Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor.	Circulation	2007	76
17545618	Cysteine	DeAlmeida VI	The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.	Cancer research	2007	62
17893322	Cysteine	Atcha FA	A unique DNA binding domain converts T-cell factors into strong Wnt effectors.	Molecular and cellular biology	2007	57
18711745	Cysteine	Junn E	Mitochondrial localization of DJ-1 leads to enhanced neuroprotection.	Journal of neuroscience research	2009	80
19065049	Cysteine	Park YM	CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima.	The Journal of clinical investigation	2009	118
19342591	Cysteine	Cho DH	S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury.	Science	2009	300
19381019	Cysteine	Qing J	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.	The Journal of clinical investigation	2009	66
19539236	Cysteine	Chabriat H	Cadasil.	The Lancet. Neurology	2009	135
19567589	Cysteine	Lucio-Eterovic AK	Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.	Clinical cancer research 	2009	75
20170166	Cysteine	Rauser S	Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry.	Journal of proteome research	2010	48
20213804	Cysteine	Sonnylal S	Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.	Arthritis and rheumatism	2010	57
20357106	Cysteine	Li X	Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.	The Journal of neuroscience 	2010	56
21124317	Cysteine	Wang K	Integrative genomics identifies LMO1 as a neuroblastoma oncogene.	Nature	2011	95
21308479	Cysteine	Arvatz G	The heparanase system and tumor metastasis: is heparanase the seed and soil?	Cancer metastasis reviews	2011	39
21523780	Cysteine	Dinarello CA	A clinical perspective of IL-1β as the gatekeeper of inflammation.	European journal of immunology	2011	164
21536738	Cysteine	Shochat C	Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.	The Journal of experimental medicine	2011	98
21734079	Cysteine	Lamkanfi M	Modulation of inflammasome pathways by bacterial and viral pathogens.	Journal of immunology	2011	64
21820099	Cysteine	Nosková L	Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis.	American journal of human genetics	2011	79
21844361	Cysteine	Qu J	S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide.	Proceedings of the National Academy of Sciences of the United States of America	2011	45
21856739	Cysteine	Ostman A	Regulation of protein tyrosine phosphatases by reversible oxidation.	Journal of biochemistry	2011	70
22045338	Cysteine	Lynes EM	Palmitoylated TMX and calnexin target to the mitochondria-associated membrane.	The EMBO journal	2012	50
22056874	Cysteine	Harris LG	Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61.	Oncogene	2012	35
22193716	Cysteine	Cohen TJ	Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking.	The EMBO journal	2012	35
22388478	Cysteine	Shang YC	Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL.	Aging	2012	46
22464443	Cysteine	Rafn B	ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.	Molecular cell	2012	36
22632748	Cysteine	Vendramini-Costa DB	Molecular link mechanisms between inflammation and cancer.	Current pharmaceutical design	2012	101
22657837	Cysteine	Nakamura T	Emerging role of protein-protein transnitrosylation in cell signaling pathways.	Antioxidants & redox signaling	2013	34
23016862	Cysteine	Voronkov A	Wnt/beta-catenin signaling and small molecule inhibitors.	Current pharmaceutical design	2013	55
23174564	Cysteine	Goldsmith EC	Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression.	American journal of physiology. Cell physiology	2013	35
23177194	Cysteine	Miyata Y	Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70.	Chemistry & biology	2012	31
23333463	Cysteine	Wei Z	STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.	Cellular signalling	2013	29
23649698	Cysteine	Monet-Leprêtre M	Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL.	Brain 	2013	25
24078004	Cysteine	Zhao H	MiR-25 promotes gastric cancer cells growth and motility by targeting RECK.	Molecular and cellular biochemistry	2014	27
24256730	Cysteine	Ostrem JM	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.	Nature	2013	221
24647965	Cysteine	Kazlauskaite A	Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.	Open biology	2014	37
24675529	Cysteine	Nagaraju GP	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.	Carcinogenesis	2014	26
25002527	Cysteine	Ye P	Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.	Molecular and cellular biology	2014	24
25205735	Cysteine	Kao L	Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.	Journal of the American Society of Nephrology 	2015	25
25326800	Cysteine	Zhang Z	Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease.	Nature medicine	2014	47
25823923	Cysteine	Qin L	WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis.	Oncotarget	2015	23
26006010	Cysteine	Bradshaw JM	Prolonged and tunable residence time using reversible covalent kinase inhibitors.	Nature chemical biology	2015	33
26597162	Cysteine	Hristova M	Airway epithelial dual oxidase 1 mediates allergen-induced IL-33 secretion and activation of type 2 immune responses.	The Journal of allergy and clinical immunology	2016	23
26722841	Cysteine	Heppner DE	Redox-dependent regulation of epidermal growth factor receptor signaling.	Redox biology	2016	12
26788256	Cysteine	Santos L	Potential Modulation of Sirtuins by Oxidative Stress.	Oxidative medicine and cellular longevity	2016	11
26805760	Cysteine	Zhang L	Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy.	Cancer letters	2016	10
26908579	Cysteine	Bornholdt ZA	Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.	mBio	2016	15
27066895	Cysteine	Vince JE	The intersection of cell death and inflammasome activation.	Cellular and molecular life sciences 	2016	17
27368101	Cysteine	Briggs KJ	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.	Cell	2016	20
27416066	Cysteine	Puerta-Guardo H	Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability.	PLoS pathogens	2016	20
27465842	Cysteine	Chen CY	CCN1 Promotes VEGF Production in Osteoblasts and Induces Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-126 Expression in Rheumatoid Arthritis.	Journal of bone and mineral research 	2017	7
27626662	Cysteine	Yan D	STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation.	Cell reports	2016	11
28262504	Cysteine	Dong Z	Mitochondrial Ca2+ Uniporter Is a Mitochondrial Luminal Redox Sensor that Augments MCU Channel Activity.	Molecular cell	2017	14
10964946	Proteoglycans	Chang A	NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions.	The Journal of neuroscience 	2000	147
11292372	Proteoglycans	Knudson CB	Cartilage proteoglycans.	Seminars in cell & developmental biology	2001	91
12102052	Proteoglycans	Corsi A	Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues.	Journal of bone and mineral research 	2002	92
15142969	Proteoglycans	Wight TN	Proteoglycans in atherosclerosis and restenosis: key roles for versican.	Circulation research	2004	74
15800625	Proteoglycans	Stanton H	ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.	Nature	2005	198
16135983	Proteoglycans	Séguin CA	Tumor necrosis factor-alpha modulates matrix production and catabolism in nucleus pulposus tissue.	Spine	2005	66
16322790	Proteoglycans	Li QZ	Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.	The Journal of clinical investigation	2005	81
18180376	Proteoglycans	Belnoue E	APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.	Blood	2008	81
18469852	Proteoglycans	Chekenya M	The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.	Oncogene	2008	54
18688028	Proteoglycans	Goldoni S	An antimetastatic role for decorin in breast cancer.	The American journal of pathology	2008	52
18798267	Proteoglycans	Goldoni S	Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs.	International journal of cancer	2008	69
19433454	Proteoglycans	Goldoni S	Decorin is a novel antagonistic ligand of the Met receptor.	The Journal of cell biology	2009	86
20840585	Proteoglycans	Manon-Jensen T	Proteoglycans in health and disease: the multiple roles of syndecan shedding.	The FEBS journal	2010	68
21123584	Proteoglycans	Tripathi RB	NG2 glia generate new oligodendrocytes but few astrocytes in a murine experimental autoimmune encephalomyelitis model of demyelinating disease.	The Journal of neuroscience 	2010	69
21907924	Proteoglycans	Sugiarto S	Asymmetry-defective oligodendrocyte progenitors are glioma precursors.	Cancer cell	2011	72
22353005	Proteoglycans	De Paepe A	The Ehlers-Danlos syndrome, a disorder with many faces.	Clinical genetics	2012	53
22595228	Proteoglycans	de Boer TN	Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage.	Osteoarthritis and cartilage	2012	46
23281850	Proteoglycans	Wade A	Proteoglycans and their roles in brain cancer.	The FEBS journal	2013	27
23925489	Proteoglycans	You WK	NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function.	Angiogenesis	2014	29
25547119	Proteoglycans	Yuan P	Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B.	Cell research	2015	21
25849134	Proteoglycans	Caruana I	Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.	Nature medicine	2015	51
26177309	Proteoglycans	Neill T	Decoding the Matrix: Instructive Roles of Proteoglycan Receptors.	Biochemistry	2015	19
9111868	Hyaluronic Acid	Naor D	CD44: structure, function, and association with the malignant process.	Advances in cancer research	1997	194
9887098	Hyaluronic Acid	Yu Q	Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.	Genes & development	1999	145
11731267	Hyaluronic Acid	Csoka AB	The six hyaluronidase-like genes in the human and mouse genomes.	Matrix biology 	2001	112
12819017	Hyaluronic Acid	de la Motte CA	Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function.	The American journal of pathology	2003	93
15047232	Hyaluronic Acid	Burleson KM	Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.	Gynecologic oncology	2004	81
16959784	Hyaluronic Acid	Misra S	Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells.	The Journal of biological chemistry	2006	60
16963454	Hyaluronic Acid	Singleton PA	Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family.	The Journal of biological chemistry	2006	69
17079438	Hyaluronic Acid	Götte M	Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective.	Cancer research	2006	100
17208295	Hyaluronic Acid	Kim J	Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells.	Biomaterials	2007	67
19218337	Hyaluronic Acid	Bharadwaj AG	Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.	The American journal of pathology	2009	52
20197461	Hyaluronic Acid	Xu Y	CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.	Cancer research	2010	59
20303742	Hyaluronic Acid	Orian-Rousseau V	CD44, a therapeutic target for metastasising tumours.	European journal of cancer	2010	116
20332231	Hyaluronic Acid	Lokeshwar VB	Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.	Cancer research	2010	50
20843787	Hyaluronic Acid	Bourguignon LY	Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.	The Journal of biological chemistry	2010	57
21278789	Hyaluronic Acid	Kwak HJ	Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas.	Oncogene	2011	38
21356346	Hyaluronic Acid	Wang SJ	Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.	The American journal of pathology	2011	48
21362136	Hyaluronic Acid	Wang A	Hyaluronan matrices in pathobiological processes.	The FEBS journal	2011	51
21362138	Hyaluronic Acid	Misra S	Hyaluronan-CD44 interactions as potential targets for cancer therapy.	The FEBS journal	2011	81
21571904	Hyaluronic Acid	Lennon FE	Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology.	American journal of physiology. Lung cellular and molecular physiology	2011	36
21685938	Hyaluronic Acid	Bourguignon LY	Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells.	Oncogene	2012	72
22753277	Hyaluronic Acid	Auvinen P	Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer.	International journal of cancer	2013	27
23085635	Hyaluronic Acid	Vlahu CA	Damage of the endothelial glycocalyx in dialysis patients.	Journal of the American Society of Nephrology 	2012	34
23176112	Hyaluronic Acid	Filardo G	Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial.	BMC musculoskeletal disorders	2012	56
23410679	Hyaluronic Acid	Ganesh S	Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.	Biomaterials	2013	40
23463525	Hyaluronic Acid	Preston M	Digestion products of the PH20 hyaluronidase inhibit remyelination.	Annals of neurology	2013	26
23523583	Hyaluronic Acid	Lichtinghagen R	The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.	Journal of hepatology	2013	34
23827186	Hyaluronic Acid	Pedron S	Regulation of glioma cell phenotype in 3D matrices by hyaluronic acid.	Biomaterials	2013	32
24084631	Hyaluronic Acid	Chauhan VP	Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.	Nature communications	2013	116
24134926	Hyaluronic Acid	Vigetti D	Metabolic control of hyaluronan synthases.	Matrix biology 	2014	21
24145190	Hyaluronic Acid	Ju SY	Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression.	Stem cell research	2014	21
24256086	Hyaluronic Acid	Nobili V	Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance.	American journal of respiratory and critical care medicine	2014	23
24399703	Hyaluronic Acid	Karbownik MS	Hyaluronan: towards novel anti-cancer therapeutics.	Pharmacological reports 	2013	29
24712441	Hyaluronic Acid	Wang C	Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels.	Molecular pharmaceutics	2014	27
25157350	Hyaluronic Acid	Tolg C	Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues.	BioMed research international	2014	22
25387851	Hyaluronic Acid	Tiainen S	High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer.	Histopathology	2015	15
25979846	Hyaluronic Acid	Panou V	The established and future biomarkers of malignant pleural mesothelioma.	Cancer treatment reviews	2015	17
26005723	Hyaluronic Acid	Li L	Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells.	International journal of molecular medicine	2015	19
26485284	Hyaluronic Acid	Cui Y	Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection.	The Journal of clinical investigation	2015	17
27694932	Hyaluronic Acid	Liang J	Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice.	Nature medicine	2016	20
10653870	Cyclophosphamide	Kantarjian HM	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.	Journal of clinical oncology 	2000	103
11248153	Cyclophosphamide	Slamon DJ	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	The New England journal of medicine	2001	1772
15016643	Cyclophosphamide	Pfreundschuh M	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.	Blood	2004	72
15897552	Cyclophosphamide	Mamounas EP	Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.	Journal of clinical oncology 	2005	110
15955905	Cyclophosphamide	Sehn LH	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.	Journal of clinical oncology 	2005	144
16230674	Cyclophosphamide	Fisher RI	New treatment options have changed the survival of patients with follicular lymphoma.	Journal of clinical oncology 	2005	69
16720851	Cyclophosphamide	Bernstein M	Ewing's sarcoma family of tumors: current management.	The oncologist	2006	82
16809727	Cyclophosphamide	Perez EA	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.	Journal of clinical oncology 	2006	87
17284714	Cyclophosphamide	Hershman D	Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.	Journal of the National Cancer Institute	2007	72
17438091	Cyclophosphamide	Carey LA	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.	Clinical cancer research 	2007	472
18165643	Cyclophosphamide	Garcia AA	Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.	Journal of clinical oncology 	2008	135
18226581	Cyclophosphamide	Pfreundschuh M	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).	The Lancet. Oncology	2008	154
18281474	Cyclophosphamide	Furuta E	Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.	Cancer research	2008	91
18316569	Cyclophosphamide	Laheru D	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.	Clinical cancer research 	2008	106
18378569	Cyclophosphamide	Wilson WH	Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.	Journal of clinical oncology 	2008	58
18505968	Cyclophosphamide	Martín M	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.	Journal of the National Cancer Institute	2008	51
18662969	Cyclophosphamide	Marcus R	Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.	Journal of clinical oncology 	2008	91
18756521	Cyclophosphamide	Castillo J	HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.	American journal of hematology	2008	51
19038878	Cyclophosphamide	Lenz G	Stromal gene signatures in large-B-cell lymphomas.	The New England journal of medicine	2008	349
19085934	Cyclophosphamide	Slominski A	Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.	International journal of cancer	2009	54
19706817	Cyclophosphamide	Choi WW	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.	Clinical cancer research 	2009	115
19770373	Cyclophosphamide	Arndt CA	Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.	Journal of clinical oncology 	2009	56
20113825	Cyclophosphamide	Gianni L	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.	Lancet	2010	184
20528872	Cyclophosphamide	Romaguera JE	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.	British journal of haematology	2010	46
20631380	Cyclophosphamide	Campbell KJ	Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.	Blood	2010	44
20660290	Cyclophosphamide	Schmitz N	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.	Blood	2010	55
20697084	Cyclophosphamide	Perez EA	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.	Journal of clinical oncology 	2010	53
21109570	Cyclophosphamide	Tamura K	FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.	Annals of oncology 	2011	47
21135273	Cyclophosphamide	Meyer PN	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.	Journal of clinical oncology 	2011	78
21148486	Cyclophosphamide	Viaud S	Cyclophosphamide induces differentiation of Th17 cells in cancer patients.	Cancer research	2011	40
21189393	Cyclophosphamide	Ruan J	Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.	Journal of clinical oncology 	2011	56
21482186	Cyclophosphamide	Peyrade F	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2011	42
21512138	Cyclophosphamide	Ling S	An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer.	Cancer research	2011	37
21690475	Cyclophosphamide	Slingluff CL Jr	Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.	Journal of clinical oncology 	2011	40
21788566	Cyclophosphamide	Untch M	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.	Journal of clinical oncology 	2011	77
21917518	Cyclophosphamide	Di Leo A	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.	The Lancet. Oncology	2011	36
21933893	Cyclophosphamide	Iqbal J	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.	Clinical cancer research 	2011	37
22151962	Cyclophosphamide	West NR	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.	Breast cancer research 	2011	92
22173060	Cyclophosphamide	Trappe R	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.	The Lancet. Oncology	2012	33
22231041	Cyclophosphamide	Munster PN	Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2012	33
22393002	Cyclophosphamide	Chapuis AG	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2012	54
22451162	Cyclophosphamide	Quek AM	Autoimmune epilepsy: clinical characteristics and response to immunotherapy.	Archives of neurology	2012	47
22665537	Cyclophosphamide	Green TM	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	91
22721387	Cyclophosphamide	Tang Z	The role of mesothelin in tumor progression and targeted therapy.	Anti-cancer agents in medicinal chemistry	2013	27
22851556	Cyclophosphamide	d'Amore F	Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.	Journal of clinical oncology 	2012	55
22884505	Cyclophosphamide	Ismael G	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.	The Lancet. Oncology	2012	43
22911837	Cyclophosphamide	Li ZM	Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.	PloS one	2012	36
22987084	Cyclophosphamide	Romond EH	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	72
23335369	Cyclophosphamide	Horn H	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	Blood	2013	79
23490655	Cyclophosphamide	Harbeck N	Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.	European journal of cancer	2013	28
24136883	Cyclophosphamide	Gerber B	Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).	Annals of oncology 	2013	26
24220563	Cyclophosphamide	Huang X	Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.	Journal of clinical oncology 	2013	35
24331154	Cyclophosphamide	Butts C	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2014	77
24336156	Cyclophosphamide	Tzankov A	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.	Modern pathology 	2014	27
24443618	Cyclophosphamide	Prat A	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.	Clinical cancer research 	2014	33
24485462	Cyclophosphamide	Pallasch CP	Sensitizing protective tumor microenvironments to antibody-mediated therapy.	Cell	2014	27
24506200	Cyclophosphamide	Perry AM	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.	British journal of haematology	2014	32
24669015	Cyclophosphamide	Gonzalez-Angulo AM	Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.	Annals of oncology 	2014	22
24942756	Cyclophosphamide	Lutz ER	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.	Cancer immunology research	2014	70
24943107	Cyclophosphamide	Oki Y	Double hit lymphoma: the MD Anderson Cancer Center clinical experience.	British journal of haematology	2014	31
25239573	Cyclophosphamide	Green DM	Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.	The Lancet. Oncology	2014	20
25415283	Cyclophosphamide	Soares KC	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.	Journal of immunotherapy	2015	66
25499448	Cyclophosphamide	Sehn LH	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.	Blood	2015	50
25687405	Cyclophosphamide	Acharya MM	Stem cell transplantation reverses chemotherapy-induced cognitive dysfunction.	Cancer research	2015	16
26240231	Cyclophosphamide	Scott DW	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.	Journal of clinical oncology 	2015	26
26256760	Cyclophosphamide	Pastore A	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	The Lancet. Oncology	2015	40
26469139	Cyclophosphamide	Perez EA	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.	JAMA oncology	2016	16
26578779	Cyclophosphamide	Tolaney SM	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26579125	Cyclophosphamide	Gottschalk TA	Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.	Frontiers in immunology	2015	21
26738796	Cyclophosphamide	Singh N	Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.	Science translational medicine	2016	18
26860465	Cyclophosphamide	Naipal KA	Tumor slice culture system to assess drug response of primary breast cancer.	BMC cancer	2016	11
27992268	Cyclophosphamide	Trappe RU	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.	Journal of clinical oncology 	2017	7
28135148	Cyclophosphamide	Symmans WF	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.	Journal of clinical oncology 	2017	11
28405610	Cyclophosphamide	Katewa A	Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.	JCI insight	2017	5
28679654	Cyclophosphamide	Karagiannis GS	Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.	Science translational medicine	2017	7
9661897	Doxorubicin	Baselga J	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Cancer research	1998	130
9831867	Doxorubicin	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	110
10029595	Doxorubicin	Damiano JS	Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.	Blood	1999	166
10080586	Doxorubicin	Kuerer HM	Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.	Journal of clinical oncology 	1999	225
10458228	Doxorubicin	Van Glabbeke M	Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.	Journal of clinical oncology 	1999	96
11119611	Doxorubicin	Rivas C	Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53.	Journal of virology	2001	103
11948130	Doxorubicin	Park JW	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.	Clinical cancer research 	2002	106
12203114	Doxorubicin	Budanov AV	Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.	Oncogene	2002	90
15756033	Doxorubicin	Cohen BD	Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.	Clinical cancer research 	2005	86
15899824	Doxorubicin	Frank NY	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.	Cancer research	2005	139
16115903	Doxorubicin	Rouzier R	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.	Clinical cancer research 	2005	370
16170171	Doxorubicin	Hershman D	Racial disparities in treatment and survival among women with early-stage breast cancer.	Journal of clinical oncology 	2005	93
16569192	Doxorubicin	Fu X	Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1.	DNA and cell biology	2006	70
16854453	Doxorubicin	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	168
16912156	Doxorubicin	Lee E	GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer.	Cancer research	2006	75
17329180	Doxorubicin	Takemura G	Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.	Progress in cardiovascular diseases	2007	127
17415413	Doxorubicin	Biswas S	Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.	The Journal of clinical investigation	2007	100
17692808	Doxorubicin	Deng J	BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.	Cancer cell	2007	183
17823410	Doxorubicin	Corney DC	MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.	Cancer research	2007	223
17974990	Doxorubicin	Sankala HM	Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin.	Cancer research	2007	60
18039953	Doxorubicin	Nefedova Y	Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.	Blood	2008	54
18645025	Doxorubicin	Kovalchuk O	Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.	Molecular cancer therapeutics	2008	147
18758960	Doxorubicin	Tsang WP	Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.	Apoptosis 	2008	65
18818206	Doxorubicin	Nasser MW	Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.	The Journal of biological chemistry	2008	137
19092120	Doxorubicin	Ronconi E	Regeneration of glomerular podocytes by human renal progenitors.	Journal of the American Society of Nephrology 	2009	155
19336515	Doxorubicin	Li QQ	Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.	Clinical cancer research 	2009	91
19380866	Doxorubicin	Dunleavy K	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.	Blood	2009	111
19584283	Doxorubicin	Fornari F	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2009	117
19628668	Doxorubicin	Dai C	Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria.	Journal of the American Society of Nephrology 	2009	129
19780069	Doxorubicin	Chen AM	Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.	Small	2009	89
19840887	Doxorubicin	Fleming GF	Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.	Gynecologic oncology	2010	43
20038740	Doxorubicin	De Angelis A	Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.	Circulation	2010	70
20098429	Doxorubicin	Li Y	Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.	Nature medicine	2010	94
20224986	Doxorubicin	Liu T	Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.	Molecular and cellular biochemistry	2010	43
20388796	Doxorubicin	Yoo BK	Molecular mechanism of chemoresistance by astrocyte elevated gene-1.	Cancer research	2010	46
20442777	Doxorubicin	Bandyopadhyay A	Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.	PloS one	2010	50
20460510	Doxorubicin	Adhikari AS	CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.	Cancer research	2010	80
20495188	Doxorubicin	Horie T	Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.	Cardiovascular research	2010	47
20501828	Doxorubicin	Fornari F	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2010	129
20505657	Doxorubicin	Kang YS	Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria.	Kidney international	2010	45
20668064	Doxorubicin	Zhang X	Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.	Cancer research	2010	48
20798686	Doxorubicin	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	45
20935265	Doxorubicin	Calcagno AM	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.	Journal of the National Cancer Institute	2010	76
21055388	Doxorubicin	Henry JC	miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.	Biochemical and biophysical research communications	2010	48
21527554	Doxorubicin	Chen J	Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.	Cancer research	2011	42
21565979	Doxorubicin	Tsuchiya N	Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21.	Cancer research	2011	41
21642992	Doxorubicin	Hung T	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters.	Nature genetics	2011	323
21839714	Doxorubicin	Nijenhuis T	Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.	The American journal of pathology	2011	46
22281424	Doxorubicin	Xiao Y	Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.	Biomaterials	2012	42
22308459	Doxorubicin	Meirelles K	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
22461640	Doxorubicin	Munson JM	Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.	Science translational medicine	2012	37
22521303	Doxorubicin	Bao L	Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.	The American journal of pathology	2012	42
22698404	Doxorubicin	Jackson JG	p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.	Cancer cell	2012	72
22817844	Doxorubicin	Liu Z	Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.	Journal of translational medicine	2012	30
23277563	Doxorubicin	Hirsch HA	Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.	Proceedings of the National Academy of Sciences of the United States of America	2013	106
23278683	Doxorubicin	Tacar O	Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.	The Journal of pharmacy and pharmacology	2013	184
23289892	Doxorubicin	Meng H	Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.	ACS nano	2013	68
23411815	Doxorubicin	Piegari E	Doxorubicin induces senescence and impairs function of human cardiac progenitor cells.	Basic research in cardiology	2013	30
23435381	Doxorubicin	Johnsson P	A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells.	Nature structural & molecular biology	2013	141
23526568	Doxorubicin	Qu J	MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA.	Journal of cellular physiology	2015	16
23648833	Doxorubicin	Taratula O	Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.	Journal of controlled release 	2013	35
23715267	Doxorubicin	Pang B	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.	Nature communications	2013	46
23801752	Doxorubicin	Oehme I	Histone deacetylase 10 promotes autophagy-mediated cell survival.	Proceedings of the National Academy of Sciences of the United States of America	2013	35
24211739	Doxorubicin	Xu L	MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.	Journal of hepatology	2014	35
24565525	Doxorubicin	Deng X	Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.	Biomaterials	2014	41
24590287	Doxorubicin	Daehn I	Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.	The Journal of clinical investigation	2014	57
24733904	Doxorubicin	Ma X	Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
24786471	Doxorubicin	Jiang L	MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.	FEBS letters	2014	24
24958102	Doxorubicin	Wang Y	Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines.	Molecular and cellular biology	2014	29
25079333	Doxorubicin	Tavora B	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.	Nature	2014	21
25292190	Doxorubicin	Xu M	miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1.	Molecular therapy 	2015	18
25368020	Doxorubicin	Park EY	Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.	Cancer research	2014	38
25407491	Doxorubicin	Zhang Y	miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.	Tumour biology 	2015	17
25504623	Doxorubicin	Jiang T	Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene.	Advanced materials	2015	21
25512109	Doxorubicin	Amornsupak K	Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.	BMC cancer	2014	26
25675296	Doxorubicin	Moriwaki K	Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.	Cell death & disease	2015	18
25689250	Doxorubicin	Mallipattu SK	Krüppel-like factor 6 regulates mitochondrial function in the kidney.	The Journal of clinical investigation	2015	17
25714029	Doxorubicin	Zhang H	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression.	Oncotarget	2015	16
25726524	Doxorubicin	Rincón R	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.	Oncotarget	2015	18
25789975	Doxorubicin	Hall JR	Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes.	Cell death & disease	2015	16
25909227	Doxorubicin	Go H	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	Oncotarget	2015	20
26004286	Doxorubicin	Rao W	Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells.	ACS nano	2015	22
26028030	Doxorubicin	Niu J	Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.	Oncogene	2016	19
26552700	Doxorubicin	Picaud S	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.	Cancer research	2015	36
26572075	Doxorubicin	Zheng Y	MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression.	Oncology reports	2016	11
26781446	Doxorubicin	Shang C	Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma.	Cancer chemotherapy and pharmacology	2016	13
26876203	Doxorubicin	Zhang ZM	Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.	Oncogene	2016	11
27056384	Doxorubicin	Shang C	Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.	Cancer chemotherapy and pharmacology	2016	21
27279912	Doxorubicin	Wang C	Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.	Theranostics	2016	15
27286459	Doxorubicin	Murakami T	Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.	Oncotarget	2016	23
28079894	Doxorubicin	Jin F	MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.	Cell death & disease	2017	16
28126034	Doxorubicin	Xu J	Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.	Journal of experimental & clinical cancer research 	2017	9
8358726	Antineoplastic Agents	Kaufmann SH	Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.	Cancer research	1993	281
9841917	Antineoplastic Agents	Müller M	p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.	The Journal of experimental medicine	1998	123
10446993	Antineoplastic Agents	Chang BD	A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.	Cancer research	1999	119
12639809	Antineoplastic Agents	Maeda H	Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.	International immunopharmacology	2003	83
14561896	Antineoplastic Agents	Bocci G	Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2003	88
16890600	Antineoplastic Agents	Takayasu K	Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.	Gastroenterology	2006	144
17318448	Antineoplastic Agents	Kuo MT	The roles of copper transporters in cisplatin resistance.	Cancer metastasis reviews	2007	67
17854227	Antineoplastic Agents	Bagalkot V	Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.	Nano letters	2007	126
18187804	Antineoplastic Agents	Blower PE	MicroRNAs modulate the chemosensitivity of tumor cells.	Molecular cancer therapeutics	2008	97
19625999	Antineoplastic Agents	Filipski KK	Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.	Clinical pharmacology and therapeutics	2009	71
19860903	Antineoplastic Agents	Yuan R	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.	Journal of hematology & oncology	2009	61
20124483	Antineoplastic Agents	Li Y	miR-146a suppresses invasion of pancreatic cancer cells.	Cancer research	2010	149
20200537	Antineoplastic Agents	Rouleau M	PARP inhibition: PARP1 and beyond.	Nature reviews. Cancer	2010	360
20215516	Antineoplastic Agents	Jin Y	Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.	Cancer research	2010	92
20980833	Antineoplastic Agents	Vucicevic L	Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.	Autophagy	2011	44
21297102	Antineoplastic Agents	Li Q	3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.	Journal of biomolecular screening	2011	36
21303969	Antineoplastic Agents	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	99
21566064	Antineoplastic Agents	Shrivastava A	Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.	Molecular cancer therapeutics	2011	51
22102692	Antineoplastic Agents	Huang J	HMGB1 promotes drug resistance in osteosarcoma.	Cancer research	2012	84
22239440	Antineoplastic Agents	Santarpia L	Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	127
22301993	Antineoplastic Agents	Huang J	Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.	Autophagy	2012	33
22305612	Antineoplastic Agents	Xia Y	Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.	European journal of medicinal chemistry	2012	61
22310279	Antineoplastic Agents	Clendening JW	Targeting tumor cell metabolism with statins.	Oncogene	2012	50
22454417	Antineoplastic Agents	Metzger-Filho O	Dissecting the heterogeneity of triple-negative breast cancer.	Journal of clinical oncology 	2012	121
22460905	Antineoplastic Agents	Barretina J	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2012	1427
22588880	Antineoplastic Agents	Ni J	Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.	Cancer discovery	2012	56
23073759	Antineoplastic Agents	Masuda H	Role of epidermal growth factor receptor in breast cancer.	Breast cancer research and treatment	2012	98
23079083	Antineoplastic Agents	Selimovic D	Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.	Cellular signalling	2013	35
23349734	Antineoplastic Agents	Godugu C	AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies.	PloS one	2013	33
23674815	Antineoplastic Agents	Clem BF	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.	Molecular cancer therapeutics	2013	45
23811941	Antineoplastic Agents	Shi Z	AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.	Cancer research	2013	40
23870513	Antineoplastic Agents	Wierstra I	FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.	Advances in cancer research	2013	35
24361892	Antineoplastic Agents	Cheng P	Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways.	Biochemical and biophysical research communications	2014	20
24481312	Antineoplastic Agents	Fruman DA	PI3K and cancer: lessons, challenges and opportunities.	Nature reviews. Drug discovery	2014	313
24577086	Antineoplastic Agents	Feng Y	Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.	Cell death & disease	2014	56
24732808	Antineoplastic Agents	Li Y	Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.	Cancer letters	2014	36
24874432	Antineoplastic Agents	Takahashi K	Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy.	Molecular cancer research 	2014	29
25028336	Antineoplastic Agents	Yallapu MM	Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.	Biomaterials	2014	25
25043604	Antineoplastic Agents	Mason JM	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.	Cancer cell	2014	27
25173780	Antineoplastic Agents	van Waarde A	Potential applications for sigma receptor ligands in cancer diagnosis and therapy.	Biochimica et biophysica acta	2015	16
25623213	Antineoplastic Agents	Boi M	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.	Clinical cancer research 	2015	37
25897862	Antineoplastic Agents	Fasano E	Long-chain n-3 PUFA against breast and prostate cancer: Which are the appropriate doses for intervention studies in animals and humans?	Critical reviews in food science and nutrition	2017	7
26604648	Antineoplastic Agents	Song A	Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.	World journal of gastroenterology	2015	17
26625127	Antineoplastic Agents	Griss T	Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.	PLoS biology	2015	32
26976114	Antineoplastic Agents	Stathis A	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.	Cancer discovery	2016	32
27555605	Antineoplastic Agents	Kurmasheva RT	Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.	Pediatric blood & cancer	2017	7
27635045	Antineoplastic Agents	Wallace EM	A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.	Cancer research	2016	17
10430607	Fluorouracil	Bunz F	Disruption of p53 in human cancer cells alters the responses to therapeutic agents.	The Journal of clinical investigation	1999	255
10700175	Fluorouracil	Scherf U	A gene expression database for the molecular pharmacology of cancer.	Nature genetics	2000	247
10778957	Fluorouracil	Salonga D	Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.	Clinical cancer research 	2000	124
11309634	Fluorouracil	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	177
15774776	Fluorouracil	Ghadimi BM	Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.	Journal of clinical oncology 	2005	67
16246976	Fluorouracil	Rödel C	Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.	Journal of clinical oncology 	2005	191
17906203	Fluorouracil	Collette L	Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.	Journal of clinical oncology 	2007	71
18692501	Fluorouracil	Shibata T	Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.	Gastroenterology	2008	124
19074875	Fluorouracil	Braun CJ	p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.	Cancer research	2008	165
19244128	Fluorouracil	Dallas NA	Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.	Cancer research	2009	149
19276252	Fluorouracil	Sakamoto K	Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.	Clinical cancer research 	2009	62
19439999	Fluorouracil	Takagi T	Decreased expression of microRNA-143 and -145 in human gastric cancers.	Oncology	2009	94
19603024	Fluorouracil	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	80
19734943	Fluorouracil	Song B	Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.	Oncogene	2009	125
20081809	Fluorouracil	Ong CW	CD133 expression predicts for non-response to chemotherapy in colorectal cancer.	Modern pathology 	2010	44
20498393	Fluorouracil	Sargent DJ	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.	Journal of clinical oncology 	2010	237
20501503	Fluorouracil	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	77
20647341	Fluorouracil	Boni V	miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.	Molecular cancer therapeutics	2010	48
20697159	Fluorouracil	Haraguchi N	CD13 is a therapeutic target in human liver cancer stem cells.	The Journal of clinical investigation	2010	135
20737575	Fluorouracil	Zhang J	Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene.	Cancer	2011	41
20978511	Fluorouracil	Tomimaru Y	MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.	British journal of cancer	2010	57
21048039	Fluorouracil	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	58
21245094	Fluorouracil	Papageorgis P	Smad4 inactivation promotes malignancy and drug resistance of colon cancer.	Cancer research	2011	38
21969819	Fluorouracil	Shibata T	NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.	Neoplasia	2011	40
22072615	Fluorouracil	Nie J	microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2.	Carcinogenesis	2012	57
22205702	Fluorouracil	Xiong H	Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.	The Journal of biological chemistry	2012	72
22248601	Fluorouracil	Hecht JR	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.	Gastrointestinal endoscopy	2012	31
22260991	Fluorouracil	Funkhouser WK Jr	Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.	The Journal of molecular diagnostics 	2012	30
22322955	Fluorouracil	Nishida N	MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.	Annals of surgical oncology	2012	42
22623155	Fluorouracil	Li L	MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.	Clinical and experimental medicine	2013	62
22993328	Fluorouracil	Izumiya M	Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells.	Anticancer research	2012	33
23167930	Fluorouracil	Svoboda M	MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.	Radiation oncology	2012	32
23744359	Fluorouracil	Karaayvaz M	miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.	Cell death & disease	2013	37
23934972	Fluorouracil	Spitzner M	STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.	International journal of cancer	2014	21
24009080	Fluorouracil	Siemens H	Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.	Oncotarget	2013	51
24077681	Fluorouracil	Redis RS	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.	Oncotarget	2013	55
24170546	Fluorouracil	Dunne PD	AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.	Clinical cancer research 	2014	29
24275137	Fluorouracil	Deng J	Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.	Biochemical and biophysical research communications	2014	26
24323901	Fluorouracil	Touil Y	Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.	Clinical cancer research 	2014	40
24345883	Fluorouracil	Li Z	The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.	Oncotarget	2013	26
24446491	Fluorouracil	Shin JY	High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias.	The Journal of experimental medicine	2014	38
24658854	Fluorouracil	Xie L	MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer.	Molecular and cellular biochemistry	2014	25
24743738	Fluorouracil	Kang KA	Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation.	Cell death & disease	2014	22
24859412	Fluorouracil	Honjo S	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.	International journal of oncology	2014	24
24885567	Fluorouracil	Du T	Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.	Molecular cancer	2014	21
25406793	Fluorouracil	Kim IY	Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer.	BMC surgery	2014	24
25449431	Fluorouracil	Zhang H	MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.	Cancer letters	2015	26
25733851	Fluorouracil	Conde J	Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
25739674	Fluorouracil	Song S	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.	Clinical cancer research 	2015	38
25820415	Fluorouracil	Kawai T	Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.	Clinical cancer research 	2015	23
26031544	Fluorouracil	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	24
26351341	Fluorouracil	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	33
26494468	Fluorouracil	Alam SK	DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.	Cell death and differentiation	2016	11
26603945	Fluorouracil	Meulendijks D	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.	The Lancet. Oncology	2015	18
26673620	Fluorouracil	Wang L	MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.	Oncotarget	2016	15
27046651	Fluorouracil	Bian Z	LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p.	Scientific reports	2016	49
27145382	Fluorouracil	Otvos B	Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.	Stem cells	2016	18
27840990	Fluorouracil	Liu N	MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells.	Oncology reports	2017	6
28114937	Fluorouracil	Zhang JX	Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.	Molecular cancer	2017	9
28287424	Fluorouracil	Ogawa R	Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis.	International journal of molecular sciences	2017	11
8194005	Cisplatin	Mandard AM	Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.	Cancer	1994	246
9176490	Cisplatin	Heise C	ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.	Nature medicine	1997	133
9704716	Cisplatin	Pegram MD	Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.	Journal of clinical oncology 	1998	115
9927204	Cisplatin	Blandino G	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.	Oncogene	1999	97
10446958	Cisplatin	Yuan SS	BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.	Cancer research	1999	142
11280739	Cisplatin	Asselin E	XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.	Cancer research	2001	87
12509415	Cisplatin	Mandic A	Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling.	The Journal of biological chemistry	2003	89
12637505	Cisplatin	Mansouri A	Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.	The Journal of biological chemistry	2003	85
12860938	Cisplatin	Vogelzang NJ	Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.	Journal of clinical oncology 	2003	413
14645242	Cisplatin	Dan HC	Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).	The Journal of biological chemistry	2004	122
14702041	Cisplatin	Katayama H	Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.	Nature genetics	2004	159
15469940	Cisplatin	Liu Q	Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215.	The Journal of biological chemistry	2004	85
15811630	Cisplatin	Albertella MR	The overexpression of specialized DNA polymerases in cancer.	DNA repair	2005	75
16314626	Cisplatin	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	171
16357177	Cisplatin	Nawrocki ST	Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.	Cancer research	2005	95
16540663	Cisplatin	Yang X	Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.	Cancer research	2006	83
16951222	Cisplatin	Sok JC	Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.	Clinical cancer research 	2006	141
17021608	Cisplatin	Zhou H	Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury.	Kidney international	2006	78
17222355	Cisplatin	Hebert C	High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.	Molecular cancer	2007	122
17227995	Cisplatin	Lewis IJ	Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.	Journal of the National Cancer Institute	2007	64
17646646	Cisplatin	Huang PH	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	149
17918180	Cisplatin	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	51
18206965	Cisplatin	Lim ST	Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.	Molecular cell	2008	151
18256356	Cisplatin	Zhang B	TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity.	Journal of the American Society of Nephrology 	2008	76
18316592	Cisplatin	Ohta T	Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.	Cancer research	2008	174
18495226	Cisplatin	Gotlieb WH	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.	Gynecologic oncology	2008	67
18509321	Cisplatin	Zhou H	Urinary exosomal transcription factors, a new class of biomarkers for renal disease.	Kidney international	2008	53
18519691	Cisplatin	Zhang S	Identification and characterization of ovarian cancer-initiating cells from primary human tumors.	Cancer research	2008	391
18649131	Cisplatin	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	76
18728788	Cisplatin	Levina V	Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.	PloS one	2008	140
18754698	Cisplatin	Chou AJ	Therapy for osteosarcoma: where do we go from here?	Paediatric drugs	2008	67
19387469	Cisplatin	Vaidya VS	A rapid urine test for early detection of kidney injury.	Kidney international	2009	54
19417020	Cisplatin	Homma S	Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.	Clinical cancer research 	2009	96
19706487	Cisplatin	Sayan AE	SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	48
19802016	Cisplatin	Abedini MR	Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.	Oncogene	2010	42
19805294	Cisplatin	Bertolini G	Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.	Proceedings of the National Academy of Sciences of the United States of America	2009	248
20041317	Cisplatin	Liu D	Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells.	Medical oncology	2011	52
20049901	Cisplatin	Morigi M	Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury.	Stem cells	2010	51
20068070	Cisplatin	Kwok JM	FOXM1 confers acquired cisplatin resistance in breast cancer cells.	Molecular cancer research 	2010	72
20074550	Cisplatin	Teng Y	Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells.	Biochemical and biophysical research communications	2010	67
20099276	Cisplatin	Pogribny IP	Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.	International journal of cancer	2010	94
20145120	Cisplatin	Holland SJ	R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.	Cancer research	2010	121
20215556	Cisplatin	Sikora AG	Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.	Clinical cancer research 	2010	43
20371173	Cisplatin	Guo L	Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.	European journal of cancer	2010	48
20530669	Cisplatin	Jiang T	High levels of Nrf2 determine chemoresistance in type II endometrial cancer.	Cancer research	2010	80
20581869	Cisplatin	Cooke SL	Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.	Oncogene	2010	52
20670951	Cisplatin	Harrington KJ	Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.	Clinical cancer research 	2010	60
20696752	Cisplatin	Ceppi P	Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.	Molecular cancer research 	2010	92
20943624	Cisplatin	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	58
20943634	Cisplatin	Chan AT	Nasopharyngeal carcinoma.	Annals of oncology 	2010	48
20947521	Cisplatin	Hall CA	Hippo pathway effector Yap is an ovarian cancer oncogene.	Cancer research	2010	71
21124918	Cisplatin	Leung EL	Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.	PloS one	2010	115
21160028	Cisplatin	Brooks C	Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis.	American journal of physiology. Cell physiology	2011	48
21224400	Cisplatin	Ye G	MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.	Journal of cell science	2011	40
21225626	Cisplatin	Sun S	Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis.	International journal of cancer	2011	37
21325880	Cisplatin	O'Donovan TR	Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.	Autophagy	2011	78
21327457	Cisplatin	Yang Z	Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.	Annals of surgical oncology	2011	221
21442631	Cisplatin	Schrader J	Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.	Hepatology	2011	81
21532889	Cisplatin	Rattan R	Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.	Neoplasia	2011	85
21550168	Cisplatin	Noguchi S	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells.	Cancer letters	2011	38
21702042	Cisplatin	Vinall RL	MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.	International journal of cancer	2012	31
21725369	Cisplatin	Sun L	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.	Oncogene	2012	79
21726833	Cisplatin	Lee TK	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.	Cell stem cell	2011	148
21782914	Cisplatin	Op de Beeck K	Apoptosis in acquired and genetic hearing impairment: the programmed death of the hair cell.	Hearing research	2011	37
21903745	Cisplatin	Curran WJ Jr	Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.	Journal of the National Cancer Institute	2011	174
21909139	Cisplatin	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	43
21947824	Cisplatin	Thieblemont C	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.	Journal of clinical oncology 	2011	44
22112324	Cisplatin	Kim CH	miRNA signature associated with outcome of gastric cancer patients following chemotherapy.	BMC medical genomics	2011	39
22131882	Cisplatin	Stronach EA	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.	Neoplasia	2011	41
22142828	Cisplatin	Steg AD	Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.	Clinical cancer research 	2012	92
22178121	Cisplatin	Lee NY	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.	The Lancet. Oncology	2012	61
22193543	Cisplatin	Donzelli S	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.	Cell death and differentiation	2012	43
22222640	Cisplatin	Rüschoff J	HER2 testing in gastric cancer: a practical approach.	Modern pathology 	2012	90
22356768	Cisplatin	Huang Y	Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation.	Cell cycle	2012	40
22429801	Cisplatin	Haslehurst AM	EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.	BMC cancer	2012	64
22431999	Cisplatin	Bruno S	Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury.	PloS one	2012	135
22440905	Cisplatin	Zager RA	Plasma and urinary heme oxygenase-1 in AKI.	Journal of the American Society of Nephrology 	2012	33
22465665	Cisplatin	Fu X	Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.	FEBS letters	2012	50
22473169	Cisplatin	Rossi A	Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.	Journal of clinical oncology 	2012	46
22562073	Cisplatin	Kaminskyy VO	Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation.	Autophagy	2012	38
22564997	Cisplatin	Ferrari S	Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.	Journal of clinical oncology 	2012	31
22576688	Cisplatin	Wang Y	Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer.	International journal of oncology	2012	46
22647982	Cisplatin	Zhou C	Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells.	Autophagy	2012	43
22665540	Cisplatin	Ebb D	Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.	Journal of clinical oncology 	2012	46
22797058	Cisplatin	Chau WK	c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.	Oncogene	2013	53
22817698	Cisplatin	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	41
22847005	Cisplatin	Bourguignon LY	Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.	The Journal of biological chemistry	2012	64
22854025	Cisplatin	Galluzzi L	Prognostic impact of vitamin B6 metabolism in lung cancer.	Cell reports	2012	38
22928012	Cisplatin	Lohberger B	Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma.	PloS one	2012	31
22987153	Cisplatin	Karanja KK	DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network.	Cell cycle	2012	33
23019585	Cisplatin	McAuliffe SM	Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.	Proceedings of the National Academy of Sciences of the United States of America	2012	87
23045278	Cisplatin	van Jaarsveld MT	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.	Oncogene	2013	59
23071587	Cisplatin	Gout S	Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.	PloS one	2012	33
23135908	Cisplatin	Liu YP	Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.	Cancer research	2013	44
23251001	Cisplatin	Kimple RJ	Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.	Clinical cancer research 	2013	31
23349823	Cisplatin	Barr MP	Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.	PloS one	2013	52
23449973	Cisplatin	Fortier AM	Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation.	The Journal of biological chemistry	2013	41
23460709	Cisplatin	Martins RG	Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.	Journal of clinical oncology 	2013	34
23483142	Cisplatin	Xu Y	miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells.	Oncology reports	2013	39
23524583	Cisplatin	Zhang S	Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.	Oncogene	2014	58
23542177	Cisplatin	Mao B	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma.	Oncogene	2014	30
23554447	Cisplatin	Michels J	Cisplatin resistance associated with PARP hyperactivation.	Cancer research	2013	35
23610451	Cisplatin	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	32
23618405	Cisplatin	Zhou Y	Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro.	Stem cell research & therapy	2013	95
23733761	Cisplatin	Baselga J	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.	Journal of clinical oncology 	2013	80
23746666	Cisplatin	Vermorken JB	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.	The Lancet. Oncology	2013	69
23845449	Cisplatin	Vélayoudom-Céphise FL	Are G3 ENETS neuroendocrine neoplasms heterogeneous?	Endocrine-related cancer	2013	31
23950211	Cisplatin	Zhang L	miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.	Cancer research	2013	39
23967051	Cisplatin	Yasuda K	Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population.	PloS one	2013	29
24068565	Cisplatin	Cao W	miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.	Tumour biology 	2014	21
24099915	Cisplatin	Dong Z	MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.	Cancer letters	2014	24
24165223	Cisplatin	Sun XP	Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.	The FEBS journal	2014	20
24240701	Cisplatin	Shin DH	SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.	Cancer research	2014	20
24318570	Cisplatin	Liu SY	High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer.	Oncotarget	2013	29
24407244	Cisplatin	Zhang P	Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.	Cell death & disease	2014	24
24472409	Cisplatin	Chan JK	The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.	Gynecologic oncology	2014	25
24495516	Cisplatin	Xia JT	MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.	Journal of translational medicine	2014	23
24516043	Cisplatin	Drayton RM	Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.	Clinical cancer research 	2014	33
24525232	Cisplatin	Choi W	Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.	Cancer cell	2014	181
24554720	Cisplatin	Joshi PM	Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.	The Journal of biological chemistry	2014	24
24560445	Cisplatin	Topp MD	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.	Molecular oncology	2014	30
24626199	Cisplatin	Karanja KK	Preventing over-resection by DNA2 helicase/nuclease suppresses repair defects in Fanconi anemia cells.	Cell cycle	2014	22
24668391	Cisplatin	Tsuburaya A	Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.	The British journal of surgery	2014	23
24669930	Cisplatin	He C	Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells.	Journal of the American Chemical Society	2014	31
24709421	Cisplatin	Nör C	Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.	Neoplasia	2014	37
24794870	Cisplatin	Wang J	Role of autophagy in cisplatin resistance in ovarian cancer cells.	The Journal of biological chemistry	2014	34
24821881	Cisplatin	Plimack ER	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.	Journal of clinical oncology 	2014	23
24821883	Cisplatin	Choueiri TK	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.	Journal of clinical oncology 	2014	21
24848258	Cisplatin	Shapiro IM	Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.	Science translational medicine	2014	44
24858042	Cisplatin	Miow QH	Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.	Oncogene	2015	26
24960601	Cisplatin	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	40
24965569	Cisplatin	Iveson T	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.	The Lancet. Oncology	2014	76
24989332	Cisplatin	Hassan R	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.	Cancer	2014	41
25069034	Cisplatin	Sullivan I	Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Cancer letters	2014	22
25096233	Cisplatin	Van Allen EM	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.	Cancer discovery	2014	65
25154822	Cisplatin	Ang KK	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.	Journal of clinical oncology 	2014	120
25165721	Cisplatin	Ozkok A	Pathophysiology of cisplatin-induced acute kidney injury.	BioMed research international	2014	54
25228385	Cisplatin	Tan X	miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.	Breast cancer research 	2014	30
25231400	Cisplatin	Hassan R	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.	Clinical cancer research 	2014	31
25234467	Cisplatin	Guo J	MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.	Molecules and cells	2014	20
25366680	Cisplatin	Nguyen-Tan PF	Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.	Journal of clinical oncology 	2014	34
25537512	Cisplatin	Chiu WT	FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.	Oncotarget	2015	35
25596659	Cisplatin	Giralt J	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	25
25596660	Cisplatin	Mesía R	Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	20
25609015	Cisplatin	Litchfield K	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours.	Nature communications	2015	18
25650716	Cisplatin	He J	Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.	Autophagy	2015	22
25658419	Cisplatin	Xu J	β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.	PloS one	2015	18
25682441	Cisplatin	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	21
25701171	Cisplatin	Paz-Ares L	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.	The Lancet. Oncology	2015	31
25721211	Cisplatin	Zhao Z	miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.	Cancer gene therapy	2015	15
25831546	Cisplatin	Srivastava AK	Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
25847936	Cisplatin	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	54
25867064	Cisplatin	Zhu X	miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.	Oncogene	2016	28
25871967	Cisplatin	Li X	MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer.	Cellular physiology and biochemistry 	2015	16
25888377	Cisplatin	Zhou X	MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.	Journal of experimental & clinical cancer research 	2015	21
25972604	Cisplatin	Challagundla KB	Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.	Journal of the National Cancer Institute	2015	50
25992654	Cisplatin	Liu J	The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.	PloS one	2015	36
25995442	Cisplatin	Liu G	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.	Journal of the National Cancer Institute	2015	24
26020117	Cisplatin	Cioffi M	Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.	Scientific reports	2015	22
26026166	Cisplatin	Tanaka K	miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.	Carcinogenesis	2015	20
26033801	Cisplatin	Bielack SS	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.	Journal of clinical oncology 	2015	46
26045340	Cisplatin	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	69
26061330	Cisplatin	Du F	S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial.	Medicine	2015	18
26119935	Cisplatin	Ciamporcero E	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.	Oncogene	2016	19
26178914	Cisplatin	Balermpas P	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).	International journal of cancer	2016	27
26201611	Cisplatin	Wu HM	Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells.	Scientific reports	2015	18
26234674	Cisplatin	Phatak P	Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1.	Oncogene	2016	15
26238431	Cisplatin	Plimack ER	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.	European urology	2015	37
26325371	Cisplatin	Liu M	RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.	Oncotarget	2015	15
26462739	Cisplatin	Pariente R	Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation.	Journal of pineal research	2016	17
26530471	Cisplatin	Planells-Cases R	Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.	The EMBO journal	2015	19
26598537	Cisplatin	Cierna Z	Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.	Annals of oncology 	2016	16
26654944	Cisplatin	Choi EJ	FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.	Oncotarget	2016	12
26716514	Cisplatin	Cheng H	Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.	Oncotarget	2016	17
26719230	Cisplatin	Zalcman G	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.	Lancet	2016	63
26756568	Cisplatin	Zhou XL	High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.	Molecular carcinogenesis	2016	16
26799420	Cisplatin	Su X	Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-κB signaling pathway.	Oncotarget	2016	12
26801672	Cisplatin	Liu S	NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.	Tumour biology 	2016	10
26801746	Cisplatin	Ai Z	Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.	Cancer letters	2016	11
26822397	Cisplatin	Fujitani K	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.	The Lancet. Oncology	2016	32
26859293	Cisplatin	Su YC	Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma.	PloS one	2016	11
26894974	Cisplatin	Syu JP	Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia.	Oncotarget	2016	11
26909612	Cisplatin	Zhu X	miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein.	Oncotarget	2016	14
27013395	Cisplatin	Morrow CJ	Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.	Annals of oncology 	2016	14
27019355	Cisplatin	Zhu Z	MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.	PloS one	2016	13
27055401	Cisplatin	Sakallı Çetin E	Selenium potentiates the anticancer effect of cisplatin against oxidative stress and calcium ion signaling-induced intracellular toxicity in MCF-7 breast cancer cells: involvement of the TRPV1 channel.	Journal of receptor and signal transduction research	2017	5
27088857	Cisplatin	Lien EC	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.	Nature cell biology	2016	16
27166999	Cisplatin	Báez-Vega PM	Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.	Oncotarget	2016	13
27193186	Cisplatin	Zheng ZG	The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.	Scientific reports	2016	15
27199349	Cisplatin	Langsch S	miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers.	Cancer research	2016	14
27270317	Cisplatin	Jiang P	NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.	Oncotarget	2016	16
27287412	Cisplatin	Shintani Y	IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.	Journal of thoracic oncology 	2016	17
27372520	Cisplatin	Malapelle U	USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.	Lung cancer	2017	5
27381626	Cisplatin	Ter Brugge P	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.	Journal of the National Cancer Institute	2016	11
27609068	Cisplatin	Wang Y	Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.	Cancer letters	2016	18
27875524	Cisplatin	Li X	microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.	British journal of cancer	2017	8
27911863	Cisplatin	Wang Q	Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.	Oncotarget	2017	8
28027578	Cisplatin	Li D	Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis.	Hepatology	2017	17
28163000	Cisplatin	Cunningham D	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.	The Lancet. Oncology	2017	7
28192397	Cisplatin	Shi ZM	Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.	Oncogene	2017	10
28196596	Cisplatin	Gardner EE	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.	Cancer cell	2017	14
28240761	Cisplatin	Elia G	Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.	La Clinica terapeutica	2017	6
28406482	Cisplatin	Wang L	Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.	Cell death & disease	2017	6
28407783	Cisplatin	Zheng P	Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.	Journal of experimental & clinical cancer research 	2017	15
7732003	Cholesterol	Stemme S	T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.	Proceedings of the National Academy of Sciences of the United States of America	1995	147
8035924	Cholesterol	Breteler MM	Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.	Neurology	1994	143
8833906	Cholesterol	Shimano H	Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.	The Journal of clinical investigation	1996	190
9218423	Cholesterol	Sullivan PM	Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.	The Journal of biological chemistry	1997	145
9794114	Cholesterol	Pickup JC	Is type II diabetes mellitus a disease of the innate immune system?	Diabetologia	1998	161
10079097	Cholesterol	Gosling J	MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.	The Journal of clinical investigation	1999	117
10430941	Cholesterol	Trigatti B	Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology.	Proceedings of the National Academy of Sciences of the United States of America	1999	114
11149950	Cholesterol	Laffitte BA	LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.	Proceedings of the National Academy of Sciences of the United States of America	2001	139
11238037	Cholesterol	Sugiyama S	Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.	The American journal of pathology	2001	102
11260414	Cholesterol	Kambham N	Obesity-related glomerulopathy: an emerging epidemic.	Kidney international	2001	169
11282915	Cholesterol	Ridker PM	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.	Circulation	2001	149
11375416	Cholesterol	Werstuck GH	Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways.	The Journal of clinical investigation	2001	156
11440984	Cholesterol	Vasa M	Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.	Circulation research	2001	431
11683410	Cholesterol	Bell SE	Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling.	Journal of cell science	2001	111
11705484	Cholesterol	Tounian P	Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study.	Lancet	2001	107
11956073	Cholesterol	Zhuang L	Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells.	Cancer research	2002	81
12297848	Cholesterol	Forns X	Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.	Hepatology	2002	175
12527752	Cholesterol	Prior IA	Direct visualization of Ras proteins in spatially distinct cell surface microdomains.	The Journal of cell biology	2003	224
12639996	Cholesterol	Sukhova GK	Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice.	The Journal of clinical investigation	2003	94
12658281	Cholesterol	Puglielli L	Alzheimer's disease: the cholesterol connection.	Nature neuroscience	2003	163
14600185	Cholesterol	Li S	Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study.	JAMA	2003	153
14668457	Cholesterol	Kolodgie FD	Intraplaque hemorrhage and progression of coronary atheroma.	The New England journal of medicine	2003	195
14970312	Cholesterol	Cutler RG	Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	223
15023877	Cholesterol	Hsue PY	Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.	Circulation	2004	155
15071184	Cholesterol	Sleat DE	Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport.	Proceedings of the National Academy of Sciences of the United States of America	2004	93
15142859	Cholesterol	Burke AP	Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study.	Arteriosclerosis, thrombosis, and vascular biology	2004	94
15269217	Cholesterol	Wahrle SE	ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE.	The Journal of biological chemistry	2004	114
15314690	Cholesterol	Zheng L	Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.	The Journal of clinical investigation	2004	172
15465426	Cholesterol	Walkley SU	Consequences of NPC1 and NPC2 loss of function in mammalian neurons.	Biochimica et biophysica acta	2004	80
15543155	Cholesterol	Giddings KS	Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin.	Nature structural & molecular biology	2004	76
15699278	Cholesterol	Desvarieux M	Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).	Circulation	2005	116
15829498	Cholesterol	Zareparsi S	Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration.	Human molecular genetics	2005	74
15831805	Cholesterol	Schrijvers DM	Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis.	Arteriosclerosis, thrombosis, and vascular biology	2005	93
15998837	Cholesterol	Nishimoto N	Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.	Blood	2005	128
16079201	Cholesterol	Malek G	Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2005	82
16127462	Cholesterol	Vikramadithyan RK	Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.	The Journal of clinical investigation	2005	68
16140785	Cholesterol	Jolly C	Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity.	Journal of virology	2005	69
16216937	Cholesterol	Jagust W	Central obesity and the aging brain.	Archives of neurology	2005	69
16343994	Cholesterol	Judge AD	Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.	Molecular therapy 	2006	122
16442908	Cholesterol	Kizer JR	Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS).	American heart journal	2006	68
16511589	Cholesterol	Lefebvre P	Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.	The Journal of clinical investigation	2006	191
16565487	Cholesterol	Li YC	Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.	The American journal of pathology	2006	102
16565714	Cholesterol	Bosco DA	Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization.	Nature chemical biology	2006	67
16631505	Cholesterol	Virmani R	Pathology of the vulnerable plaque.	Journal of the American College of Cardiology	2006	329
17071576	Cholesterol	Cowey S	The metabolic syndrome: A high-risk state for cancer?	The American journal of pathology	2006	104
17076584	Cholesterol	Mujawar Z	Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.	PLoS biology	2006	117
17495599	Cholesterol	Lara-Castro C	Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.	Current opinion in lipidology	2007	63
17522380	Cholesterol	Lutgens SP	Cathepsin cysteine proteases in cardiovascular disease.	FASEB journal 	2007	71
17936707	Cholesterol	Li X	SIRT1 deacetylates and positively regulates the nuclear receptor LXR.	Molecular cell	2007	204
17940007	Cholesterol	DiFiglia M	Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.	Proceedings of the National Academy of Sciences of the United States of America	2007	129
17992259	Cholesterol	Hanai J	The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.	The Journal of clinical investigation	2007	72
18160725	Cholesterol	Packard RR	Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction.	Clinical chemistry	2008	191
18166162	Cholesterol	Patra SK	Dissecting lipid raft facilitated cell signaling pathways in cancer.	Biochimica et biophysica acta	2008	89
18223541	Cholesterol	Williams KJ	Rapid regression of atherosclerosis: insights from the clinical and experimental literature.	Nature clinical practice. Cardiovascular medicine	2008	70
18321997	Cholesterol	Waldo SW	Heterogeneity of human macrophages in culture and in atherosclerotic plaques.	The American journal of pathology	2008	71
18376000	Cholesterol	Kastelein JJ	Simvastatin with or without ezetimibe in familial hypercholesterolemia.	The New England journal of medicine	2008	177
18379722	Cholesterol	Hotta K	Variations in the FTO gene are associated with severe obesity in the Japanese.	Journal of human genetics	2008	66
18410513	Cholesterol	Thirumangalakudi L	High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice.	Journal of neurochemistry	2008	68
18440684	Cholesterol	Foster MC	Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study.	American journal of kidney diseases 	2008	62
18617650	Cholesterol	Murphy AJ	High-density lipoprotein reduces the human monocyte inflammatory response.	Arteriosclerosis, thrombosis, and vascular biology	2008	90
18752326	Cholesterol	Ma KL	Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.	Hepatology	2008	59
18782619	Cholesterol	Hong C	Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors.	Current opinion in genetics & development	2008	66
18797930	Cholesterol	Sima AV	Vascular endothelium in atherosclerosis.	Cell and tissue research	2009	49
19074428	Cholesterol	Vetrivel KS	Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.	The Journal of biological chemistry	2009	48
19221221	Cholesterol	McGillicuddy FC	Inflammation impairs reverse cholesterol transport in vivo.	Circulation	2009	118
19236704	Cholesterol	Klintworth GK	Corneal dystrophies.	Orphanet journal of rare diseases	2009	77
19360495	Cholesterol	Esquirol Y	Shift work and metabolic syndrome: respective impacts of job strain, physical activity, and dietary rhythms.	Chronobiology international	2009	58
19629071	Cholesterol	Shackelford DB	The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.	Nature reviews. Cancer	2009	446
19630828	Cholesterol	Ridker PM	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).	Journal of thrombosis and haemostasis 	2009	75
19644959	Cholesterol	McMahon M	Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.	Arthritis and rheumatism	2009	49
19651157	Cholesterol	Nuutinen T	Clusterin: a forgotten player in Alzheimer's disease.	Brain research reviews	2009	86
19660552	Cholesterol	Liu JP	Cholesterol involvement in the pathogenesis of neurodegenerative diseases.	Molecular and cellular neurosciences	2010	48
19698799	Cholesterol	Curcio CA	Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins.	Progress in retinal and eye research	2009	89
19726876	Cholesterol	Hayashi YK	Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy.	The Journal of clinical investigation	2009	96
19797256	Cholesterol	Curcio CA	Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration.	Journal of lipid research	2010	57
19887621	Cholesterol	Yamaguchi H	Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells.	Cancer research	2009	49
19952353	Cholesterol	Crowe SM	The macrophage: the intersection between HIV infection and atherosclerosis.	Journal of leukocyte biology	2010	46
19969070	Cholesterol	Seet RC	Oxidative damage in Parkinson disease: Measurement using accurate biomarkers.	Free radical biology & medicine	2010	40
20035627	Cholesterol	Salminen A	ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology.	Journal of neuroinflammation	2009	75
20138281	Cholesterol	Fitzgerald ML	ABC transporters, atherosclerosis and inflammation.	Atherosclerosis	2010	46
20300641	Cholesterol	Rajab A	Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations.	PLoS genetics	2010	61
20335529	Cholesterol	Gleissner CA	CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages.	Journal of immunology	2010	50
20375212	Cholesterol	Sell H	Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.	The Journal of clinical endocrinology and metabolism	2010	51
20543107	Cholesterol	McLaren JE	IL-33 reduces macrophage foam cell formation.	Journal of immunology	2010	41
20600583	Cholesterol	Batarseh A	Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.	Molecular and cellular endocrinology	2010	63
20809793	Cholesterol	Jia L	Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.	Annual review of physiology	2011	37
20847045	Cholesterol	Lewis TL	Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.	The Journal of biological chemistry	2010	46
20937689	Cholesterol	Calori G	Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study.	Diabetes care	2011	65
21343302	Cholesterol	Zhu H	Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair.	The Journal of biological chemistry	2011	38
21350215	Cholesterol	Chinetti-Gbaguidi G	Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways.	Circulation research	2011	79
21399642	Cholesterol	Huang R	Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma.	Nature structural & molecular biology	2011	62
21414625	Cholesterol	Recio-Mayoral A	Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients.	Atherosclerosis	2011	39
21447678	Cholesterol	Yu Y	Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration.	Investigative ophthalmology & visual science	2011	45
21527913	Cholesterol	Verweij FJ	LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation.	The EMBO journal	2011	53
21601592	Cholesterol	McLaren JE	Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.	Progress in lipid research	2011	53
21690377	Cholesterol	Ding JD	Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2011	64
21792295	Cholesterol	Kones R	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.	Drug design, development and therapy	2011	42
21818333	Cholesterol	Shiels PG	Accelerated telomere attrition is associated with relative household income, diet and inflammation in the pSoBid cohort.	PloS one	2011	39
21866103	Cholesterol	Carette JE	Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.	Nature	2011	321
21885853	Cholesterol	Ramirez CM	MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1.	Arteriosclerosis, thrombosis, and vascular biology	2011	62
21900234	Cholesterol	Bate C	Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins.	The Journal of biological chemistry	2011	40
21987488	Cholesterol	Bambha K	Ethnicity and nonalcoholic fatty liver disease.	Hepatology	2012	40
22009537	Cholesterol	Park JK	miR-221 silencing blocks hepatocellular carcinoma and promotes survival.	Cancer research	2011	59
22048958	Cholesterol	Maue RA	A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations.	Human molecular genetics	2012	32
22183689	Cholesterol	Lomonaco R	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.	Hepatology	2012	56
22356914	Cholesterol	Oh J	Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation.	The Journal of biological chemistry	2012	63
22467316	Cholesterol	Lacolley P	The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles.	Cardiovascular research	2012	104
22542807	Cholesterol	Osmak M	Statins and cancer: current and future prospects.	Cancer letters	2012	39
22587332	Cholesterol	Gao W	Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.	Lipids in health and disease	2012	47
22750655	Cholesterol	Sorci-Thomas MG	Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers.	Journal of lipid research	2012	45
22820288	Cholesterol	Hsu SH	Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.	The Journal of clinical investigation	2012	184
22872701	Cholesterol	Elrick MJ	Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease.	Human molecular genetics	2012	33
23035117	Cholesterol	Xu M	δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.	The Journal of biological chemistry	2012	37
23065638	Cholesterol	Vance JE	Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases.	Disease models & mechanisms	2012	48
23296339	Cholesterol	Liu CC	Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.	Nature reviews. Neurology	2013	318
23297354	Cholesterol	Nebert DW	Human cytochromes P450 in health and disease.	Philosophical transactions of the Royal Society of London. Series B, Biological sciences	2013	57
23312047	Cholesterol	Superko HR	High-density lipoprotein subclasses and their relationship to cardiovascular disease.	Journal of clinical lipidology	2012	30
23471228	Cholesterol	Shimabukuro M	Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis.	Arteriosclerosis, thrombosis, and vascular biology	2013	25
23485521	Cholesterol	Bernstein DL	Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease.	Journal of hepatology	2013	47
23562078	Cholesterol	Sene A	Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration.	Cell metabolism	2013	56
23585901	Cholesterol	Suzuki T	A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment.	PloS one	2013	29
23663738	Cholesterol	Nagareddy PR	Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis.	Cell metabolism	2013	71
23704105	Cholesterol	Rundek T	Traditional risk factors are not major contributors to the variance in carotid intima-media thickness.	Stroke	2013	25
23782937	Cholesterol	Yu XH	Foam cells in atherosclerosis.	Clinica chimica acta; international journal of clinical chemistry	2013	55
23885072	Cholesterol	Paul D	Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment.	Journal of virology	2013	70
23918283	Cholesterol	Appelqvist H	The lysosome: from waste bag to potential therapeutic target.	Journal of molecular cell biology	2013	115
23966867	Cholesterol	Liu CT	Genome-wide association of body fat distribution in African ancestry populations suggests new loci.	PLoS genetics	2013	38
24060386	Cholesterol	Danilo C	Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development.	Breast cancer research 	2013	26
24077434	Cholesterol	Shinto L	A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease.	Journal of Alzheimer's disease 	2014	20
24092747	Cholesterol	Camont L	Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.	Arteriosclerosis, thrombosis, and vascular biology	2013	36
24366527	Cholesterol	McKee AC	The neuropathology of sport.	Acta neuropathologica	2014	56
24371263	Cholesterol	Herman-Edelstein M	Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.	Journal of lipid research	2014	38
24407029	Cholesterol	Hewing B	Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.	Arteriosclerosis, thrombosis, and vascular biology	2014	26
24481950	Cholesterol	Allahverdian S	Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis.	Circulation	2014	62
24504735	Cholesterol	Du F	MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice.	Arteriosclerosis, thrombosis, and vascular biology	2014	31
24516383	Cholesterol	Petersen J	The major cellular sterol regulatory pathway is required for Andes virus infection.	PLoS pathogens	2014	21
24534455	Cholesterol	Martinet W	mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.	Atherosclerosis	2014	29
24568896	Cholesterol	Bhindi B	Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.	European urology	2015	20
24602293	Cholesterol	Gacci M	Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis.	BJU international	2015	23
24606897	Cholesterol	Yue S	Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.	Cell metabolism	2014	91
24608080	Cholesterol	Zhang M	MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages.	Atherosclerosis	2014	29
24664998	Cholesterol	Vance JE	Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin.	Journal of lipid research	2014	24
24691204	Cholesterol	Longenecker CT	Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.	AIDS	2014	48
24746815	Cholesterol	Reverter M	Cholesterol regulates Syntaxin 6 trafficking at trans-Golgi network endosomal boundaries.	Cell reports	2014	29
24925270	Cholesterol	Casas R	The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial.	PloS one	2014	29
24970568	Cholesterol	Morris MC	Dietary fat composition and dementia risk.	Neurobiology of aging	2014	28
25201911	Cholesterol	Zampetaki A	Role of miR-195 in aortic aneurysmal disease.	Circulation research	2014	24
25341796	Cholesterol	Roche-Molina M	Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.	Arteriosclerosis, thrombosis, and vascular biology	2015	22
25414253	Cholesterol	Foks AC	Treating atherosclerosis with regulatory T cells.	Arteriosclerosis, thrombosis, and vascular biology	2015	28
25524771	Cholesterol	Meiler S	MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis.	Arteriosclerosis, thrombosis, and vascular biology	2015	19
25675507	Cholesterol	Guillaumond F	Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2015	34
25904599	Cholesterol	Zhang H	Functional analysis and transcriptomic profiling of iPSC-derived macrophages and their application in modeling Mendelian disease.	Circulation research	2015	18
25919570	Cholesterol	Lin Y	MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1.	Scientific reports	2015	33
25991857	Cholesterol	Toomey CB	Regulation of age-related macular degeneration-like pathology by complement factor H.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
26072287	Cholesterol	Déliot N	Plasma membrane calcium channels in cancer: Alterations and consequences for cell proliferation and migration.	Biochimica et biophysica acta	2015	20
26199412	Cholesterol	Kang J	Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
26333678	Cholesterol	Giunzioni I	Local effects of human PCSK9 on the atherosclerotic lesion.	The Journal of pathology	2016	14
26493158	Cholesterol	Chistiakov DA	Macrophage-mediated cholesterol handling in atherosclerosis.	Journal of cellular and molecular medicine	2016	15
26501192	Cholesterol	Wagschal A	Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis.	Nature medicine	2015	36
26556368	Cholesterol	Yki-Järvinen H	Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance.	Nutrients	2015	16
26558731	Cholesterol	Nou E	Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.	AIDS	2016	13
26564908	Cholesterol	Tambini MD	ApoE4 upregulates the activity of mitochondria-associated ER membranes.	EMBO reports	2016	18
26607793	Cholesterol	Wang C	CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity.	Cell	2015	33
26632252	Cholesterol	Singh R	MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.	Scientific reports	2015	23
26662987	Cholesterol	Novák J	Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis.	Advances in experimental medicine and biology	2015	22
26712688	Cholesterol	Iyengar NM	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.	Clinical cancer research 	2016	27
26718096	Cholesterol	Banach M	Lipids, blood pressure and kidney update 2015.	Lipids in health and disease	2015	17
26874289	Cholesterol	Lange Y	Active membrane cholesterol as a physiological effector.	Chemistry and physics of lipids	2016	11
26892965	Cholesterol	Ketelhuth DF	Adaptive Response of T and B Cells in Atherosclerosis.	Circulation research	2016	15
26892966	Cholesterol	Sorci-Thomas MG	Microdomains, Inflammation, and Atherosclerosis.	Circulation research	2016	18
27077736	Cholesterol	Salvoza NC	Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.	PloS one	2016	12
27174096	Cholesterol	Mahley RW	Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism.	Arteriosclerosis, thrombosis, and vascular biology	2016	18
27328938	Cholesterol	Muralidharan R	Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration.	Journal of nanobiotechnology	2016	12
27540175	Cholesterol	Franzén O	Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases.	Science	2016	25
27571186	Cholesterol	Dumesic DA	Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.	The Journal of clinical endocrinology and metabolism	2016	11
27592805	Cholesterol	Kaufman HL	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.	The Lancet. Oncology	2016	81
27640307	Cholesterol	Harel T	Recurrent De Novo and Biallelic Variation of ATAD3A, Encoding a Mitochondrial Membrane Protein, Results in Distinct Neurological Syndromes.	American journal of human genetics	2016	14
27841877	Cholesterol	Lotta LA	Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance.	Nature genetics	2017	27
27881302	Cholesterol	Zimmerman B	Crystal Structure of a Full-Length Human Tetraspanin Reveals a Cholesterol-Binding Pocket.	Cell	2016	17
27935183	Cholesterol	Petrie JR	Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.	Diabetes, obesity & metabolism	2017	5
28167322	Cholesterol	Mridha AR	NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.	Journal of hepatology	2017	12
28212521	Cholesterol	Camaré C	Angiogenesis in the atherosclerotic plaque.	Redox biology	2017	5
28286957	Cholesterol	Chen H	Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism.	Journal of proteome research	2017	8
28334899	Cholesterol	Spracklen CN	Association analyses of East Asian individuals and trans-ancestry analyses with European individuals reveal new loci associated with cholesterol and triglyceride levels.	Human molecular genetics	2017	7
28336668	Cholesterol	Castellano BM	Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex.	Science	2017	17
10231453	Creatinine	Stenvinkel P	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.	Kidney international	1999	168
10550418	Creatinine	Meyer TW	Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria.	Diabetologia	1999	111
12081572	Creatinine	Rastaldi MP	Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies.	Kidney international	2002	89
12709468	Creatinine	Imai Y	Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome.	JAMA	2003	106
15327410	Creatinine	Szczech LA	The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.	Kidney international	2004	81
15809451	Creatinine	Greipp PR	International staging system for multiple myeloma.	Journal of clinical oncology 	2005	372
16401840	Creatinine	Gurol ME	Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.	Neurology	2006	123
16528543	Creatinine	Mishra J	Kidney NGAL is a novel early marker of acute injury following transplantation.	Pediatric nephrology	2006	75
16827865	Creatinine	Parikh CR	Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation.	American journal of transplantation 	2006	115
16971655	Creatinine	Zhao HJ	Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.	Journal of the American Society of Nephrology 	2006	111
17962588	Creatinine	Khatri M	Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS).	Stroke	2007	60
18076931	Creatinine	Thompson RH	Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.	The Journal of urology	2008	96
19158356	Creatinine	Schwartz GJ	New equations to estimate GFR in children with CKD.	Journal of the American Society of Nephrology 	2009	415
19720929	Creatinine	Jensen HK	Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.	Journal of clinical oncology 	2009	105
20117878	Creatinine	Jentzmik F	Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.	European urology	2010	48
20332356	Creatinine	Ficociello LH	High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.	Diabetes care	2010	48
20383145	Creatinine	Chambers JC	Genetic loci influencing kidney function and chronic kidney disease.	Nature genetics	2010	90
20385007	Creatinine	Valayannopoulos V	Mucopolysaccharidosis VI.	Orphanet journal of rare diseases	2010	43
20485332	Creatinine	Garin EH	Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.	Kidney international	2010	42
20525986	Creatinine	Shah RV	Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.	European journal of heart failure	2010	55
20581391	Creatinine	Serra AL	Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	129
21309006	Creatinine	Hsieh C	Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.	Arthritis care & research	2011	49
21368745	Creatinine	Trachtman H	A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.	Kidney international	2011	68
21482744	Creatinine	Peralta CA	Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.	JAMA	2011	102
22194591	Creatinine	Udy AA	Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.	Chest	2012	49
22240130	Creatinine	Nickolas TL	Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study.	Journal of the American College of Cardiology	2012	75
22278680	Creatinine	Sancho-Bru P	Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis.	Hepatology	2012	44
22311920	Creatinine	Ferguson MA	Established and emerging markers of kidney function.	Clinical chemistry	2012	30
22328173	Creatinine	Brunner HI	Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis.	Arthritis and rheumatism	2012	32
22403278	Creatinine	Bomback AS	Eculizumab for dense deposit disease and C3 glomerulonephritis.	Clinical journal of the American Society of Nephrology 	2012	72
23411786	Creatinine	Parekh DJ	Tolerance of the human kidney to isolated controlled ischemia.	Journal of the American Society of Nephrology 	2013	32
23667695	Creatinine	Wen MS	Decrease in irisin in patients with chronic kidney disease.	PloS one	2013	28
23886566	Creatinine	Sharma SG	The modern spectrum of renal biopsy findings in patients with diabetes.	Clinical journal of the American Society of Nephrology 	2013	31
24211404	Creatinine	Zubiri I	Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis.	Journal of proteomics	2014	32
24596084	Creatinine	Kawamura T	A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy.	Nephrology, dialysis, transplantation 	2014	21
24623144	Creatinine	Wise AF	Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia-reperfusion injury.	American journal of physiology. Renal physiology	2014	23
24652789	Creatinine	Lu JL	Association of body mass index with outcomes in patients with CKD.	Journal of the American Society of Nephrology 	2014	43
25054777	Creatinine	Freedman BI	APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.	Kidney international	2015	30
25063425	Creatinine	An Y	Renal histologic changes and the outcome in patients with diabetic nephropathy.	Nephrology, dialysis, transplantation 	2015	17
25145934	Creatinine	Lai JY	MicroRNA-21 in glomerular injury.	Journal of the American Society of Nephrology 	2015	27
25195004	Creatinine	Wasung ME	Biomarkers of renal function, which and when?	Clinica chimica acta; international journal of clinical chemistry	2015	31
25311702	Creatinine	Liu KD	Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.	American journal of kidney diseases 	2015	18
25362243	Creatinine	Küffner R	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.	Nature biotechnology	2015	28
25530108	Creatinine	Le Quintrec M	Eculizumab for treatment of rapidly progressive C3 glomerulopathy.	American journal of kidney diseases 	2015	21
25855775	Creatinine	Zhang WR	Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery.	Journal of the American Society of Nephrology 	2015	18
26015453	Creatinine	Schwartzman M	Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure.	Journal of the American Society of Nephrology 	2016	10
26038526	Creatinine	Hodgin JB	Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective.	Journal of the American Society of Nephrology 	2015	35
26040904	Creatinine	Solé C	miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis.	Nephrology, dialysis, transplantation 	2015	25
26566060	Creatinine	Freedman BI	APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.	Transplantation	2016	26
26731754	Creatinine	Hileman CO	Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.	AIDS	2016	18
26837280	Creatinine	Bai X	MicroRNA-130b improves renal tubulointerstitial fibrosis via repression of Snail-induced epithelial-mesenchymal transition in diabetic nephropathy.	Scientific reports	2016	13
27339817	Creatinine	Leung JC	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.	Hepatology	2017	9
27821627	Creatinine	Lafayette RA	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.	Journal of the American Society of Nephrology 	2017	7
28255002	Creatinine	Aubert O	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.	Journal of the American Society of Nephrology 	2017	5
11870167	Platinum	Bristow RE	Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.	Journal of clinical oncology 	2002	270
15173214	Platinum	Gurubhagavatula S	XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.	Journal of clinical oncology 	2004	76
15310767	Platinum	Pérez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	157
17290060	Platinum	Dressman HK	An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.	Journal of clinical oncology 	2007	95
18836486	Platinum	Baba T	Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.	Oncogene	2009	126
19549709	Platinum	Soria JC	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.	Annals of oncology 	2009	45
19667264	Platinum	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	422
20060649	Platinum	Bosch A	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.	Cancer treatment reviews	2010	62
20164691	Platinum	Isakoff SJ	Triple-negative breast cancer: role of specific chemotherapy agents.	Cancer journal	2010	55
20406929	Platinum	Fong PC	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Journal of clinical oncology 	2010	223
20534738	Platinum	Solis LM	Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.	Clinical cancer research 	2010	105
20551945	Platinum	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	63
20889728	Platinum	Landen CN Jr	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.	Molecular cancer therapeutics	2010	114
21216927	Platinum	Rizzo S	Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.	Molecular cancer therapeutics	2011	65
21468130	Platinum	Forster MD	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.	Nature reviews. Clinical oncology	2011	42
21627863	Platinum	Wei J	Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.	Chinese journal of cancer	2011	50
21709188	Platinum	Norquist B	Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.	Journal of clinical oncology 	2011	102
21934105	Platinum	Lowery MA	An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.	The oncologist	2011	43
21990299	Platinum	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	113
22237007	Platinum	Gao W	MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.	Cancer biology & therapy	2012	33
22330607	Platinum	Kim A	Therapeutic strategies in epithelial ovarian cancer.	Journal of experimental & clinical cancer research 	2012	67
22593197	Platinum	Berns EM	The changing view of high-grade serous ovarian cancer.	Cancer research	2012	43
22897840	Platinum	Marchini S	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.	European journal of cancer	2013	43
22996961	Platinum	Castellarin M	Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.	The Journal of pathology	2013	27
23012302	Platinum	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	66
23017820	Platinum	Obermayr E	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.	Gynecologic oncology	2013	26
23129122	Platinum	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	46
23649446	Platinum	Socinski MA	Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	28
23833300	Platinum	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	46
24035405	Platinum	Calabrò L	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2013	48
24240112	Platinum	Pennington KP	Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.	Clinical cancer research 	2014	94
24366937	Platinum	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	26
24439931	Platinum	Rajan A	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2014	25
24727321	Platinum	Beltran H	Aggressive variants of castration-resistant prostate cancer.	Clinical cancer research 	2014	59
25015375	Platinum	Kuhlmann JD	ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.	Clinical chemistry	2014	20
25072261	Platinum	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	31
25091798	Platinum	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	39
25216266	Platinum	Meng E	ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.	PloS one	2014	28
25349291	Platinum	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	35
25398436	Platinum	Galanis E	Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.	Cancer research	2015	44
25597412	Platinum	Fujita Y	The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.	Molecular therapy 	2015	28
25636205	Platinum	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	19
25707631	Platinum	Nick AM	A framework for a personalized surgical approach to ovarian cancer.	Nature reviews. Clinical oncology	2015	28
25719666	Platinum	Waddell N	Whole genomes redefine the mutational landscape of pancreatic cancer.	Nature	2015	297
25770156	Platinum	Watkins J	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.	Cancer discovery	2015	17
25823737	Platinum	Stevanović S	Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.	Journal of clinical oncology 	2015	61
26017449	Platinum	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	158
26181256	Platinum	Beltran H	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.	JAMA oncology	2015	52
26279307	Platinum	He J	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.	Scientific reports	2015	48
26351349	Platinum	Hamanishi J	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.	Journal of clinical oncology 	2015	96
26463832	Platinum	Konstantinopoulos PA	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.	Cancer discovery	2015	39
26511885	Platinum	Alexandrov LB	A mutational signature in gastric cancer suggests therapeutic strategies.	Nature communications	2015	20
26724258	Platinum	Cheng HH	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.	European urology	2016	11
27026676	Platinum	Sul J	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.	The oncologist	2016	24
27041570	Platinum	Özeş AR	NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.	Oncogene	2016	19
27074572	Platinum	Zhou M	Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.	Oncotarget	2016	49
27558151	Platinum	Matulonis UA	Ovarian cancer.	Nature reviews. Disease primers	2016	14
27590317	Platinum	Mateo J	DNA Repair in Prostate Cancer: Biology and Clinical Implications.	European urology	2017	7
27733243	Platinum	Sharma P	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.	The Lancet. Oncology	2016	42
27932068	Platinum	Rudin CM	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.	The Lancet. Oncology	2017	23
27937096	Platinum	Spigel DR	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.	Journal of clinical oncology 	2017	13
28104537	Platinum	Rangachari D	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.	Journal of thoracic oncology 	2017	10
28131785	Platinum	Sharma P	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	58
28328302	Platinum	Bauml J	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.	Journal of clinical oncology 	2017	19
28373005	Platinum	Gulley JL	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.	The Lancet. Oncology	2017	23
28424325	Platinum	Ning YM	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.	The oncologist	2017	11
12759241	Bleomycin	McGuire JK	Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium.	The American journal of pathology	2003	87
15286810	Bleomycin	Phillips RJ	Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.	The Journal of clinical investigation	2004	359
15618458	Bleomycin	Lawson WE	Characterization of fibroblast-specific protein 1 in pulmonary fibrosis.	American journal of respiratory and critical care medicine	2005	69
15933054	Bleomycin	Farinha P	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).	Blood	2005	85
16327802	Bleomycin	Fichtner-Feigl S	IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis.	Nature medicine	2006	227
17178917	Bleomycin	Wang XM	Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis.	The Journal of experimental medicine	2006	142
17195235	Bleomycin	Distler JH	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.	Arthritis and rheumatism	2007	68
17463394	Bleomycin	Xu J	Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis.	American journal of respiratory cell and molecular biology	2007	57
17569781	Bleomycin	Ortiz LA	Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.	Proceedings of the National Academy of Sciences of the United States of America	2007	272
17916809	Bleomycin	Horan GS	Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation.	American journal of respiratory and critical care medicine	2008	98
18162602	Bleomycin	Milam JE	PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.	American journal of physiology. Lung cellular and molecular physiology	2008	64
18165226	Bleomycin	Gao F	Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan.	The Journal of biological chemistry	2008	64
18203815	Bleomycin	Tourkina E	Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo.	American journal of physiology. Lung cellular and molecular physiology	2008	61
19073610	Bleomycin	Kliment CR	Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.	The Journal of biological chemistry	2009	53
19104148	Bleomycin	Kim KK	Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis.	The Journal of clinical investigation	2009	158
19433312	Bleomycin	Mehrad B	Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis.	The international journal of biochemistry & cell biology	2009	63
19497992	Bleomycin	Moodley Y	Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury.	The American journal of pathology	2009	85
19565505	Bleomycin	Ponticos M	Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.	Arthritis and rheumatism	2009	61
19652365	Bleomycin	Scotton CJ	Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.	The Journal of clinical investigation	2009	84
19704068	Bleomycin	Engert A	Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.	Journal of clinical oncology 	2009	49
20201077	Bleomycin	Maurer B	MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.	Arthritis and rheumatism	2010	126
20300636	Bleomycin	Murray LA	Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages.	PloS one	2010	62
20971881	Bleomycin	Cushing L	miR-29 is a major regulator of genes associated with pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2011	145
21044893	Bleomycin	Murray LA	TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.	The international journal of biochemistry & cell biology	2011	88
21092408	Bleomycin	Murphy S	Human amnion epithelial cells prevent bleomycin-induced lung injury and preserve lung function.	Cell transplantation	2011	39
21169555	Bleomycin	Zhong Q	Role of endoplasmic reticulum stress in epithelial-mesenchymal transition of alveolar epithelial cells: effects of misfolded surfactant protein.	American journal of respiratory cell and molecular biology	2011	44
21370225	Bleomycin	Wei J	Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?	Arthritis and rheumatism	2011	45
21391892	Bleomycin	Carnesecchi S	A key role for NOX4 in epithelial cell death during development of lung fibrosis.	Antioxidants & redox signaling	2011	79
21420029	Bleomycin	Pandit KV	MicroRNAs in idiopathic pulmonary fibrosis.	Translational research 	2011	98
21680953	Bleomycin	Gibbons MA	Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis.	American journal of respiratory and critical care medicine	2011	107
21708929	Bleomycin	Li Y	Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44.	The Journal of experimental medicine	2011	97
21722364	Bleomycin	Tourkina E	Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide.	Fibrogenesis & tissue repair	2011	42
21871427	Bleomycin	Yamashita CM	Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis.	The American journal of pathology	2011	37
21990376	Bleomycin	Schneider DJ	Cadherin-11 contributes to pulmonary fibrosis: potential role in TGF-β production and epithelial to mesenchymal transition.	FASEB journal 	2012	40
22095546	Bleomycin	Mackinnon AC	Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3.	American journal of respiratory and critical care medicine	2012	52
22815997	Bleomycin	Patel AS	Autophagy in idiopathic pulmonary fibrosis.	PloS one	2012	74
23141927	Bleomycin	Bhattacharyya S	Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.	The American journal of pathology	2013	41
23457217	Bleomycin	Yang S	miR-145 regulates myofibroblast differentiation and lung fibrosis.	FASEB journal 	2013	38
23526221	Bleomycin	Aumiller V	WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2013	32
23657402	Bleomycin	Zhu H	MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression.	Journal of clinical immunology	2013	28
23759512	Bleomycin	Tang X	Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.	The American journal of pathology	2013	31
23977848	Bleomycin	Jarman ER	An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model.	American journal of respiratory cell and molecular biology	2014	24
24070541	Bleomycin	O'Dwyer DN	The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.	American journal of respiratory and critical care medicine	2013	37
24172847	Bleomycin	Suwara MI	IL-1α released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts.	Mucosal immunology	2014	31
24279830	Bleomycin	Das S	MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2014	36
24920662	Bleomycin	Zhou Y	Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in Mammalian lung fibrosis.	Science translational medicine	2014	29
25029475	Bleomycin	Bauer Y	A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2015	26
25180292	Bleomycin	Zerr P	Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.	Annals of the rheumatic diseases	2016	20
25385603	Bleomycin	Lee RH	TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2014	39
25533958	Bleomycin	Vaughan AE	Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury.	Nature	2015	88
25959210	Bleomycin	Della Latta V	Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions.	Pharmacological research	2015	28
25995225	Bleomycin	Reed NI	The αvβ1 integrin plays a critical in vivo role in tissue fibrosis.	Science translational medicine	2015	37
26436920	Bleomycin	Su S	miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program.	Nature communications	2015	22
26763945	Bleomycin	Zhao XK	Focal Adhesion Kinase Regulates Fibroblast Migration via Integrin beta-1 and Plays a Central Role in Fibrosis.	Scientific reports	2016	12
26849959	Bleomycin	Spanjer AI	TGF-β-induced profibrotic signaling is regulated in part by the WNT receptor Frizzled-8.	FASEB journal 	2016	13
26987798	Bleomycin	Li Y	Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis.	Matrix biology 	2016	10
27069074	Bleomycin	Press OW	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.	Journal of clinical oncology 	2016	16
28062404	Bleomycin	Manetti M	Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.	Annals of the rheumatic diseases	2017	6
11325813	irinotecan	Cusack JC Jr	Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.	Cancer research	2001	87
15175435	irinotecan	Hurwitz H	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.	The New England journal of medicine	2004	1926
15269313	irinotecan	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	932
15677699	irinotecan	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	204
15998951	irinotecan	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	70
16365183	irinotecan	Jubb AM	Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.	Journal of clinical oncology 	2006	106
16809730	irinotecan	Toffoli G	The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2006	67
17947719	irinotecan	Vredenburgh JJ	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.	Journal of clinical oncology 	2007	340
18182667	irinotecan	Sathornsumetee S	Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.	Journal of clinical oncology 	2008	79
18560594	irinotecan	Dylla SJ	Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.	PloS one	2008	174
18842611	irinotecan	Scartozzi M	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.	Annals of oncology 	2009	79
19164213	irinotecan	Bibeau F	Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.	Journal of clinical oncology 	2009	129
19332770	irinotecan	Quant EC	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.	Neuro-oncology	2009	51
19366826	irinotecan	Prenen H	PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.	Clinical cancer research 	2009	86
19470791	irinotecan	Piazza GA	A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.	Cancer prevention research	2009	45
19603018	irinotecan	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	139
19664991	irinotecan	Hoey T	DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.	Cell stem cell	2009	110
19738126	irinotecan	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	87
20167811	irinotecan	de Groot JF	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.	Neuro-oncology	2010	166
20177422	irinotecan	Graziano F	Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.	The pharmacogenomics journal	2010	41
20332776	irinotecan	Fang DD	Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.	British journal of cancer	2010	41
20585341	irinotecan	Boni V	Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.	The pharmacogenomics journal	2011	37
20720216	irinotecan	Lam W	The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.	Science translational medicine	2010	71
21948564	irinotecan	Bitarte N	MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.	Stem cells	2011	70
22147942	irinotecan	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	87
22180495	irinotecan	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	58
23081779	irinotecan	Kobayashi S	LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution.	Stem cells	2012	38
23242585	irinotecan	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	29
23358684	irinotecan	Swindall AF	ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.	Cancer research	2013	36
23649448	irinotecan	Jett JR	Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	45
23725851	irinotecan	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	74
24138831	irinotecan	Loupakis F	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.	European journal of cancer	2014	22
24277455	irinotecan	Grohar PJ	Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.	Clinical cancer research 	2014	21
24859205	irinotecan	Shiovitz S	CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.	Gastroenterology	2014	31
24934408	irinotecan	Al-Ahmadie H	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.	Cancer discovery	2014	32
25110412	irinotecan	Grossi V	p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.	World journal of gastroenterology	2014	30
25577133	irinotecan	Chang TC	Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.	Cancer chemotherapy and pharmacology	2015	16
26294215	irinotecan	Zhang S	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.	Cancer research	2015	20
26989027	irinotecan	Hsu HC	Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.	Oncotarget	2016	19
28414297	irinotecan	Liu X	Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.	The Journal of clinical investigation	2017	6
11156248	vinorelbine	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	98
12409326	vinorelbine	Scagliotti GV	Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2002	123
14559807	vinorelbine	Quinn JE	BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.	Cancer research	2003	99
17947225	vinorelbine	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	61
18594319	vinorelbine	Ramlau R	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.	Journal of thoracic oncology 	2008	52
18927285	vinorelbine	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	93
19410716	vinorelbine	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	310
19491198	vinorelbine	Walker SR	Reciprocal effects of STAT5 and STAT3 in breast cancer.	Molecular cancer research 	2009	53
19884557	vinorelbine	Joensuu H	Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.	Journal of clinical oncology 	2009	90
21990397	vinorelbine	Brufsky AM	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2011	90
22590557	vinorelbine	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	50
22967996	vinorelbine	Awada A	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	Annals of oncology 	2013	27
23666744	vinorelbine	Tan TZ	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.	EMBO molecular medicine	2013	37
24002511	vinorelbine	von Minckwitz G	Response-guided neoadjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2013	38
26822398	vinorelbine	Harbeck N	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2016	12
27058664	vinorelbine	Vecchione L	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.	Cell	2016	12
27265743	vinorelbine	Planchard D	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.	Clinical lung cancer	2016	21
10567572	Paclitaxel	Yamamoto K	BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M.	Molecular and cellular biology	1999	194
15958559	Paclitaxel	Kwok WK	Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.	Cancer research	2005	139
16322248	Paclitaxel	Isakoff SJ	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.	Cancer research	2005	174
16585214	Paclitaxel	Kelly MG	TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.	Cancer research	2006	135
17276342	Paclitaxel	Zachos G	Chk1 is required for spindle checkpoint function.	Developmental cell	2007	80
17332325	Paclitaxel	Cheng GZ	Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.	Cancer research	2007	170
17440056	Paclitaxel	Alexandre J	Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species.	Cancer research	2007	82
17538177	Paclitaxel	Gerstner ER	Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.	Journal of clinical oncology 	2007	58
17611683	Paclitaxel	Kajiyama H	Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.	International journal of oncology	2007	127
18068629	Paclitaxel	Ahmed AA	The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.	Cancer cell	2007	73
18160686	Paclitaxel	Miller K	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.	The New England journal of medicine	2007	666
18824714	Paclitaxel	Schneider BP	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.	Journal of clinical oncology 	2008	171
19458043	Paclitaxel	Swanton C	Chromosomal instability determines taxane response.	Proceedings of the National Academy of Sciences of the United States of America	2009	80
19748175	Paclitaxel	Zhang Q	A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.	Cancer letters	2010	56
19826413	Paclitaxel	Szajnik M	TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.	Oncogene	2009	55
20144215	Paclitaxel	Zhou M	Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.	Molecular cancer	2010	67
20332234	Paclitaxel	To K	Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.	Cancer research	2010	49
20348280	Paclitaxel	Birukova AA	Mechanotransduction by GEF-H1 as a novel mechanism of ventilator-induced vascular endothelial permeability.	American journal of physiology. Lung cellular and molecular physiology	2010	47
20530690	Paclitaxel	Carr JR	FoxM1 mediates resistance to herceptin and paclitaxel.	Cancer research	2010	71
20624637	Paclitaxel	Li Z	MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.	Gynecologic oncology	2010	46
21270667	Paclitaxel	Zhang JG	MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.	Journal of thoracic oncology 	2011	54
21349946	Paclitaxel	Lai D	Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.	Cancer research	2011	107
21354697	Paclitaxel	Li J	miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.	Cancer letters	2011	36
22184370	Paclitaxel	Karlan BY	Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.	Journal of clinical oncology 	2012	61
22278287	Paclitaxel	Ajabnoor GM	Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.	Cell death & disease	2012	33
22768203	Paclitaxel	Singh S	Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.	PloS one	2012	35
23074172	Paclitaxel	Cittelly DM	Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.	Molecular cancer therapeutics	2012	39
23359505	Paclitaxel	Sevko A	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.	Journal of immunology	2013	31
23552883	Paclitaxel	Mitamura T	Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.	Oncogenesis	2013	34
23750239	Paclitaxel	Gao J	MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.	PloS one	2013	34
23871962	Paclitaxel	Swaminathan SK	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.	Journal of controlled release 	2013	27
24063698	Paclitaxel	Dent RA	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.	Breast cancer research 	2013	34
24599932	Paclitaxel	Abraham JE	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.	Clinical cancer research 	2014	22
24812269	Paclitaxel	Zhao Y	YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway.	Cancer research	2014	23
25023699	Paclitaxel	Saqcena M	Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.	Oncogene	2015	15
25153722	Paclitaxel	Konno Y	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.	Oncotarget	2014	53
25240821	Paclitaxel	Wilke H	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.	The Lancet. Oncology	2014	246
25274031	Paclitaxel	Volk-Draper L	Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.	Cancer research	2014	30
25344740	Paclitaxel	Savai R	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension.	Nature medicine	2014	26
25435430	Paclitaxel	Chatterjee A	MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.	Cellular signalling	2015	17
25605244	Paclitaxel	Yang Q	MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.	Oncotarget	2015	27
25759021	Paclitaxel	Jeon YJ	Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.	Cancer cell	2015	28
25961928	Paclitaxel	Khongkow P	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.	Oncogene	2016	22
26071354	Paclitaxel	Chen MB	MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells.	Biochemical and biophysical research communications	2015	28
26092818	Paclitaxel	Hurvitz SA	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.	The Lancet. Oncology	2015	47
26175417	Paclitaxel	Topham C	MYC Is a Major Determinant of Mitotic Cell Fate.	Cancer cell	2015	19
26282658	Paclitaxel	Bang YJ	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.	Journal of clinical oncology 	2015	45
26421710	Paclitaxel	Farnie G	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.	Oncotarget	2015	30
26855150	Paclitaxel	Noll EM	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.	Nature medicine	2016	15
26995633	Paclitaxel	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	25
27021436	Paclitaxel	Au Yeung CL	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.	Nature communications	2016	58
27556950	Paclitaxel	Jordan NV	HER2 expression identifies dynamic functional states within circulating breast cancer cells.	Nature	2016	23
27887917	Paclitaxel	Jeong JY	MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.	Cancer letters	2017	9
28209618	Paclitaxel	Chen MW	The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.	Cancer research	2017	7
2644532	Tamoxifen	Fisher B	A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.	The New England journal of medicine	1989	154
9747868	Tamoxifen	Fisher B	Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.	Journal of the National Cancer Institute	1998	717
11595837	Tamoxifen	Mandlekar S	Mechanisms of tamoxifen-induced apoptosis.	Apoptosis 	2001	89
14555514	Tamoxifen	Girault I	Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.	Clinical cancer research 	2003	80
15197194	Tamoxifen	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	113
15310774	Tamoxifen	Fink AK	Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.	Journal of clinical oncology 	2004	78
15591335	Tamoxifen	Paik S	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.	The New England journal of medicine	2004	1319
15753463	Tamoxifen	Gutierrez MC	Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.	Journal of clinical oncology 	2005	129
15952058	Tamoxifen	Nowell SA	Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.	Breast cancer research and treatment	2005	80
16000569	Tamoxifen	De Laurentiis M	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.	Clinical cancer research 	2005	76
16080193	Tamoxifen	Hiscox S	Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.	International journal of cancer	2006	77
16088978	Tamoxifen	Kirkegaard T	AKT activation predicts outcome in breast cancer patients treated with tamoxifen.	The Journal of pathology	2005	76
16355216	Tamoxifen	Wu H	Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis.	Nature	2005	68
16397211	Tamoxifen	Fiegl H	Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.	Cancer research	2006	65
16609087	Tamoxifen	Berry DA	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.	JAMA	2006	145
16705121	Tamoxifen	Holm C	Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.	Journal of the National Cancer Institute	2006	68
17280616	Tamoxifen	Lin ML	Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.	Breast cancer research 	2007	55
17401012	Tamoxifen	Loi S	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.	Journal of clinical oncology 	2007	271
17512856	Tamoxifen	LHRH-agonists in Early Breast Cancer Overview group.	Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.	Lancet	2007	61
18071188	Tamoxifen	Owusu C	Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2008	77
18193062	Tamoxifen	Kouzine F	The functional response of upstream DNA to dynamic supercoiling in vivo.	Nature structural & molecular biology	2008	121
18386815	Tamoxifen	Davies MP	Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.	International journal of cancer	2008	53
18458534	Tamoxifen	Mercier I	Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.	Cancer biology & therapy	2008	53
18669459	Tamoxifen	Honma N	Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.	Journal of clinical oncology 	2008	58
19005469	Tamoxifen	Hurtado A	Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.	Nature	2008	102
19411448	Tamoxifen	Witkiewicz AK	An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.	The American journal of pathology	2009	116
19487384	Tamoxifen	Shi L	Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.	Journal of clinical oncology 	2009	52
19685490	Tamoxifen	López-Knowles E	PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.	International journal of cancer	2010	66
20065188	Tamoxifen	Mamounas EP	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.	Journal of clinical oncology 	2010	78
20385997	Tamoxifen	Dezentjé VO	Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.	Journal of clinical oncology 	2010	45
20697068	Tamoxifen	Symmans WF	Genomic index of sensitivity to endocrine therapy for breast cancer.	Journal of clinical oncology 	2010	88
20805453	Tamoxifen	Bianchini G	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.	Journal of clinical oncology 	2010	64
20837693	Tamoxifen	Nielsen TO	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	187
20876285	Tamoxifen	Cittelly DM	Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.	Carcinogenesis	2010	57
21172025	Tamoxifen	Cittelly DM	Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.	Molecular cancer	2010	69
21393507	Tamoxifen	Shi W	MicroRNA-301 mediates proliferation and invasion in human breast cancer.	Cancer research	2011	72
21559019	Tamoxifen	Jerevall PL	Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.	British journal of cancer	2011	38
21666713	Tamoxifen	Bergamaschi A	Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.	Oncogene	2012	62
21738599	Tamoxifen	Rothé F	Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.	PloS one	2011	71
21768775	Tamoxifen	Martinez-Outschoorn UE	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.	Cell cycle	2011	42
21802721	Tamoxifen	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.	Lancet	2011	412
22116397	Tamoxifen	Shirabe K	Role of tumor-associated macrophages in the progression of hepatocellular carcinoma.	Surgery today	2012	38
22232212	Tamoxifen	Lapinski PE	RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice.	The Journal of clinical investigation	2012	32
22417809	Tamoxifen	Zhou C	Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.	Breast cancer research 	2012	31
22508479	Tamoxifen	Ward A	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.	Oncogene	2013	73
22565002	Tamoxifen	Bachelot T	Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.	Journal of clinical oncology 	2012	132
22573715	Tamoxifen	Fagan DH	Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.	Cancer research	2012	45
22711706	Tamoxifen	Chia SK	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.	Clinical cancer research 	2012	55
23143302	Tamoxifen	Nishio M	Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.	The Journal of clinical investigation	2012	37
23589310	Tamoxifen	Khurana SS	The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.	The Journal of biological chemistry	2013	32
23690420	Tamoxifen	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.	Journal of clinical oncology 	2013	77
23836010	Tamoxifen	Mihály Z	A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.	Breast cancer research and treatment	2013	53
24060820	Tamoxifen	Province MA	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.	Clinical pharmacology and therapeutics	2014	37
24217577	Tamoxifen	Merenbakh-Lamin K	D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	70
24520391	Tamoxifen	Choi EJ	Novel brain arteriovenous malformation mouse models for type 1 hereditary hemorrhagic telangiectasia.	PloS one	2014	25
24746818	Tamoxifen	Luo X	Isolation and molecular characterization of circulating melanoma cells.	Cell reports	2014	32
25007959	Tamoxifen	Wei Y	Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.	Breast cancer research and treatment	2014	39
25091503	Tamoxifen	Saladores P	Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.	The pharmacogenomics journal	2015	20
25213081	Tamoxifen	Bergamaschi A	The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.	Breast cancer research 	2014	22
25580734	Tamoxifen	Zhou W	Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.	Nature cell biology	2015	88
25663687	Tamoxifen	Nyante SJ	Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.	Journal of the National Cancer Institute	2015	16
25879485	Tamoxifen	Lai A	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.	Journal of medicinal chemistry	2015	29
25939896	Tamoxifen	Coates AS	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.	Annals of oncology 	2015	194
25990368	Tamoxifen	Yuan J	Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.	Breast cancer research 	2015	16
26092816	Tamoxifen	Bernhard J	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.	The Lancet. Oncology	2015	21
26156960	Tamoxifen	Di Caro G	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.	Gut	2016	16
26211827	Tamoxifen	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.	Lancet	2015	65
26243145	Tamoxifen	Sousa S	Human breast cancer cells educate macrophages toward the M2 activation status.	Breast cancer research 	2015	30
26416449	Tamoxifen	Lin L	CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer.	Oncotarget	2015	19
26494233	Tamoxifen	Hu JH	Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice.	Arteriosclerosis, thrombosis, and vascular biology	2015	15
26538583	Tamoxifen	Tran KA	Endothelial β-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System Homeostasis.	Circulation	2016	11
26634606	Tamoxifen	Liu Q	Genetic lineage tracing identifies in situ Kit-expressing cardiomyocytes.	Cell research	2016	23
27210762	Tamoxifen	Georgoudaki AM	Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.	Cell reports	2016	21
27593106	Tamoxifen	Raggi C	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.	Journal of hepatology	2017	16
27977766	Tamoxifen	Liu H	Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.	PloS one	2016	12
28063065	Tamoxifen	Zhang HY	Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.	Cancer chemotherapy and pharmacology	2017	8
28355176	Tamoxifen	Shimokawa M	Visualization and targeting of LGR5+ human colon cancer stem cells.	Nature	2017	23
28514441	Tamoxifen	Gordon SR	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.	Nature	2017	43
15169807	Carboplatin	Johnson DH	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2004	314
16043828	Carboplatin	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	363
16043829	Carboplatin	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	284
16782917	Carboplatin	Robert N	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2006	97
18264088	Carboplatin	Edwards SL	Resistance to therapy caused by intragenic deletion in BRCA2.	Nature	2008	233
18316562	Carboplatin	Dowlati A	Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.	Clinical cancer research 	2008	82
18612151	Carboplatin	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	70
19917840	Carboplatin	Kies MS	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.	Journal of clinical oncology 	2010	40
20085937	Carboplatin	Dahlberg SE	Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.	Journal of clinical oncology 	2010	54
20100958	Carboplatin	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	65
20671266	Carboplatin	Park JT	Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.	The American journal of pathology	2010	44
21676886	Carboplatin	Konstantinopoulos PA	Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.	Cancer research	2011	61
22124101	Carboplatin	Kim KB	BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.	Journal of clinical oncology 	2012	52
22665533	Carboplatin	Carey LA	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.	Journal of clinical oncology 	2012	122
24336327	Carboplatin	Li A	SALL4 is a new target in endometrial cancer.	Oncogene	2015	19
24794243	Carboplatin	von Minckwitz G	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.	The Lancet. Oncology	2014	100
24888810	Carboplatin	Langer CJ	Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2014	45
25481791	Carboplatin	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	87
25795410	Carboplatin	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	332
25867061	Carboplatin	Xue J	MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.	Oncogene	2016	16
25893298	Carboplatin	He Y	Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.	Oncogene	2016	11
26014294	Carboplatin	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	37
26025631	Carboplatin	Brozovic A	The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.	Molecular oncology	2015	15
26497652	Carboplatin	Teschendorff AE	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.	Genome medicine	2015	26
26928463	Carboplatin	Kumar A	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.	Nature medicine	2016	55
27569215	Carboplatin	Bliss SA	Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow.	Cancer research	2016	20
7540722	Nitric Oxide	Giaid A	Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.	The New England journal of medicine	1995	192
8816815	Nitric Oxide	Topper JN	Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress.	Proceedings of the National Academy of Sciences of the United States of America	1996	141
8876227	Nitric Oxide	MacMillan-Crow LA	Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts.	Proceedings of the National Academy of Sciences of the United States of America	1996	126
10430608	Nitric Oxide	Frantz S	Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium.	The Journal of clinical investigation	1999	114
10483914	Nitric Oxide	Fawcett JW	The glial scar and central nervous system repair.	Brain research bulletin	1999	287
10556116	Nitric Oxide	Jatakanon A	Neutrophilic inflammation in severe persistent asthma.	American journal of respiratory and critical care medicine	1999	142
10825356	Nitric Oxide	Bitsch A	Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation.	Brain 	2000	130
10910033	Nitric Oxide	Hussain SP	Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease.	Cancer research	2000	102
10924851	Nitric Oxide	Janssen-Heininger YM	Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB.	Free radical biology & medicine	2000	103
11166270	Nitric Oxide	Zachary I	Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.	Cardiovascular research	2001	128
11544106	Nitric Oxide	Xie K	Interleukin-8 and human cancer biology.	Cytokine & growth factor reviews	2001	152
12183632	Nitric Oxide	Gu Z	S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death.	Science	2002	227
12475801	Nitric Oxide	Phan SH	The myofibroblast in pulmonary fibrosis.	Chest	2002	156
12666098	Nitric Oxide	Hunot S	Neuroinflammatory processes in Parkinson's disease.	Annals of neurology	2003	91
12845153	Nitric Oxide	Brown GC	Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.	Molecular neurobiology	2003	81
15184672	Nitric Oxide	Reynaert NL	Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation.	Proceedings of the National Academy of Sciences of the United States of America	2004	92
15194174	Nitric Oxide	Humbert M	Cellular and molecular pathobiology of pulmonary arterial hypertension.	Journal of the American College of Cardiology	2004	293
15690474	Nitric Oxide	Sirica AE	Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.	Hepatology	2005	98
15722114	Nitric Oxide	Naseem KM	The role of nitric oxide in cardiovascular diseases.	Molecular aspects of medicine	2005	80
15728243	Nitric Oxide	Barshes NR	Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts.	Journal of leukocyte biology	2005	91
15950906	Nitric Oxide	Lo HW	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.	Cancer cell	2005	173
16101524	Nitric Oxide	Korhonen R	Nitric oxide production and signaling in inflammation.	Current drug targets. Inflammation and allergy	2005	99
16192427	Nitric Oxide	Amabile N	Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.	Journal of the American Society of Nephrology 	2005	96
16288777	Nitric Oxide	Jones SP	The ubiquitous role of nitric oxide in cardioprotection.	Journal of molecular and cellular cardiology	2006	123
16380428	Nitric Oxide	Lowes MA	Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).	Proceedings of the National Academy of Sciences of the United States of America	2005	102
16380482	Nitric Oxide	Segal MS	Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes.	Diabetes	2006	69
16503465	Nitric Oxide	Marks DJ	Defective acute inflammation in Crohn's disease: a clinical investigation.	Lancet	2006	107
16632549	Nitric Oxide	Félétou M	Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture).	American journal of physiology. Heart and circulatory physiology	2006	166
16805776	Nitric Oxide	Moncada S	Nitric oxide, cell bioenergetics and neurodegeneration.	Journal of neurochemistry	2006	98
16818701	Nitric Oxide	Pantuck AJ	Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.	Clinical cancer research 	2006	70
16894049	Nitric Oxide	Goldin A	Advanced glycation end products: sparking the development of diabetic vascular injury.	Circulation	2006	336
17059358	Nitric Oxide	Zariwala MA	Genetic defects in ciliary structure and function.	Annual review of physiology	2007	85
17101732	Nitric Oxide	Serafini P	Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.	The Journal of experimental medicine	2006	198
17339326	Nitric Oxide	Hamik A	Kruppel-like factor 4 regulates endothelial inflammation.	The Journal of biological chemistry	2007	129
17360663	Nitric Oxide	Eugenin EA	HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes.	Proceedings of the National Academy of Sciences of the United States of America	2007	88
17379831	Nitric Oxide	Suárez Y	Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells.	Circulation research	2007	222
17533181	Nitric Oxide	Fung E	Delta-like 4 induces notch signaling in macrophages: implications for inflammation.	Circulation	2007	58
17544386	Nitric Oxide	Peluffo G	Biochemistry of protein tyrosine nitration in cardiovascular pathology.	Cardiovascular research	2007	56
17577033	Nitric Oxide	Filipazzi P	Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.	Journal of clinical oncology 	2007	235
17720813	Nitric Oxide	Kelleher ZT	NOS2 regulation of NF-kappaB by S-nitrosylation of p65.	The Journal of biological chemistry	2007	64
17875751	Nitric Oxide	Talmadge JE	Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.	Clinical cancer research 	2007	82
17982277	Nitric Oxide	Walter S	Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease.	Cellular physiology and biochemistry 	2007	103
18344980	Nitric Oxide	Lim KH	Tumour maintenance is mediated by eNOS.	Nature	2008	104
18591664	Nitric Oxide	Ueda K	Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex.	Proceedings of the National Academy of Sciences of the United States of America	2008	115
18661552	Nitric Oxide	Kim YJ	Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.	Glia	2009	52
18674538	Nitric Oxide	Haile LA	Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.	Gastroenterology	2008	93
18803323	Nitric Oxide	Jessen KR	Negative regulation of myelination: relevance for development, injury, and demyelinating disease.	Glia	2008	123
18953332	Nitric Oxide	Kobayashi YM	Sarcolemma-localized nNOS is required to maintain activity after mild exercise.	Nature	2008	114
19234067	Nitric Oxide	Fertuzinhos S	Selective depletion of molecularly defined cortical interneurons in human holoprosencephaly with severe striatal hypoplasia.	Cerebral cortex	2009	51
19289637	Nitric Oxide	Greenstein AS	Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients.	Circulation	2009	125
19488045	Nitric Oxide	Rao JS	Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients.	Molecular psychiatry	2010	89
19572148	Nitric Oxide	Liu CY	Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.	Journal of cancer research and clinical oncology	2010	84
19639676	Nitric Oxide	Krüger M	Titin-based mechanical signalling in normal and failing myocardium.	Journal of molecular and cellular cardiology	2009	54
19789382	Nitric Oxide	Vollmar B	The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair.	Physiological reviews	2009	72
19965817	Nitric Oxide	Cherepanoff S	Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration.	The British journal of ophthalmology	2010	57
20110409	Nitric Oxide	Fijalkowska I	Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.	The American journal of pathology	2010	76
20144787	Nitric Oxide	Charles N	Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.	Cell stem cell	2010	140
20385632	Nitric Oxide	Elmahdy H	Human recombinant erythropoietin in asphyxia neonatorum: pilot trial.	Pediatrics	2010	40
20585552	Nitric Oxide	Das P	Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator.	PLoS pathogens	2010	55
20678595	Nitric Oxide	Sitia S	From endothelial dysfunction to atherosclerosis.	Autoimmunity reviews	2010	52
20971854	Nitric Oxide	Maezawa I	Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.	The Journal of biological chemistry	2011	60
20978357	Nitric Oxide	Glynn SA	Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.	The Journal of clinical investigation	2010	63
21036891	Nitric Oxide	Guazzi M	PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.	Circulation. Heart failure	2011	82
21300066	Nitric Oxide	Grover M	Cellular changes in diabetic and idiopathic gastroparesis.	Gastroenterology	2011	78
21474820	Nitric Oxide	Madhur MS	Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice.	Arteriosclerosis, thrombosis, and vascular biology	2011	60
21544630	Nitric Oxide	Singh S	Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies.	Cancer chemotherapy and pharmacology	2011	39
21597461	Nitric Oxide	Nakamura T	Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases.	Cell death and differentiation	2011	51
21686173	Nitric Oxide	Fernández-Sánchez A	Inflammation, oxidative stress, and obesity.	International journal of molecular sciences	2011	117
21726807	Nitric Oxide	Sarkar S	Complex inhibitory effects of nitric oxide on autophagy.	Molecular cell	2011	87
21768538	Nitric Oxide	Wu W	Flow-Dependent Regulation of Kruppel-Like Factor 2 Is Mediated by MicroRNA-92a.	Circulation	2011	77
21852557	Nitric Oxide	Rautou PE	Microparticles, vascular function, and atherothrombosis.	Circulation research	2011	70
22184204	Nitric Oxide	Knowles MR	Mutations of DNAH11 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure.	Thorax	2012	45
22215724	Nitric Oxide	Bauer PM	Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.	Cardiovascular research	2012	31
22311128	Nitric Oxide	Rao JS	Neuroinflammation and synaptic loss.	Neurochemical research	2012	36
22385633	Nitric Oxide	Bossley CJ	Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines.	The Journal of allergy and clinical immunology	2012	45
22421969	Nitric Oxide	Li W	Mesenchymal stem cells: a double-edged sword in regulating immune responses.	Cell death and differentiation	2012	60
22936024	Nitric Oxide	Tamoutounour S	CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis.	European journal of immunology	2012	113
23007404	Nitric Oxide	Cortese-Krott MM	Human red blood cells at work: identification and visualization of erythrocytic eNOS activity in health and disease.	Blood	2012	32
23077543	Nitric Oxide	Edin S	The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer.	PloS one	2012	98
23197572	Nitric Oxide	Martin EA	Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy.	Science translational medicine	2012	33
23271799	Nitric Oxide	Ridnour LA	Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity.	Clinical cancer research 	2013	35
23306778	Nitric Oxide	Muniyappa R	Role of insulin resistance in endothelial dysfunction.	Reviews in endocrine & metabolic disorders	2013	44
23349247	Nitric Oxide	Riwanto M	Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling.	Circulation	2013	61
23354310	Nitric Oxide	Burke AJ	The yin and yang of nitric oxide in cancer progression.	Carcinogenesis	2013	39
23583836	Nitric Oxide	Bosse K	Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease.	Journal of molecular and cellular cardiology	2013	34
23619421	Nitric Oxide	Davies PF	The atherosusceptible endothelium: endothelial phenotypes in complex haemodynamic shear stress regions in vivo.	Cardiovascular research	2013	53
23684677	Nitric Oxide	Paulus WJ	A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.	Journal of the American College of Cardiology	2013	257
23733335	Nitric Oxide	Mussai F	Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.	Blood	2013	31
23749634	Nitric Oxide	Mattila JT	Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms.	Journal of immunology	2013	84
23797095	Nitric Oxide	Obermajer N	Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling.	The Journal of experimental medicine	2013	28
23935251	Nitric Oxide	More SV	Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease.	Mediators of inflammation	2013	44
24024753	Nitric Oxide	Leigh MW	Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia.	Annals of the American Thoracic Society	2013	40
24088176	Nitric Oxide	Arnold CE	A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo.	Immunology	2014	22
24284821	Nitric Oxide	Andrukhova O	Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice.	Molecular endocrinology	2014	31
24526691	Nitric Oxide	Horio E	Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression.	Arteriosclerosis, thrombosis, and vascular biology	2014	26
24549364	Nitric Oxide	Mukherjee P	Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.	Chemical Society reviews	2014	22
24733928	Nitric Oxide	Heinecke JL	Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
25001649	Nitric Oxide	Iantorno M	Obesity, inflammation and endothelial dysfunction.	Journal of biological regulators and homeostatic agents	2014	25
25012134	Nitric Oxide	Kumar S	Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs.	Arteriosclerosis, thrombosis, and vascular biology	2014	45
25201986	Nitric Oxide	Duque-Correa MA	Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas.	Proceedings of the National Academy of Sciences of the United States of America	2014	29
25331846	Nitric Oxide	Cifuentes D	Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease.	Hypertension	2015	19
25391251	Nitric Oxide	Lee RJ	Bitter and sweet taste receptors in the respiratory epithelium in health and disease.	Journal of molecular medicine	2014	22
25447937	Nitric Oxide	Garry PS	The role of the nitric oxide pathway in brain injury and its treatment--from bench to bedside.	Experimental neurology	2015	29
25575647	Nitric Oxide	Teich AF	Synaptic therapy in Alzheimer's disease: a CREB-centric approach.	Neurotherapeutics 	2015	17
25687683	Nitric Oxide	Bogdan C	Nitric oxide synthase in innate and adaptive immunity: an update.	Trends in immunology	2015	76
25849745	Nitric Oxide	Granados-Principal S	Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.	Breast cancer research 	2015	30
26137590	Nitric Oxide	Premer C	Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells.	EBioMedicine	2015	23
26168216	Nitric Oxide	Wang S	P2Y₂ and Gq/G₁₁ control blood pressure by mediating endothelial mechanotransduction.	The Journal of clinical investigation	2015	21
26289067	Nitric Oxide	Gebhardt C	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.	Clinical cancer research 	2015	32
26335399	Nitric Oxide	Vannini F	The dual role of iNOS in cancer.	Redox biology	2015	29
26676145	Nitric Oxide	Allen DG	Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.	Physiological reviews	2016	21
26732588	Nitric Oxide	Kallaur AP	Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.	Molecular neurobiology	2017	8
26854724	Nitric Oxide	Rasheed Z	MicroRNA-26a-5p regulates the expression of inducible nitric oxide synthase via activation of NF-κB pathway in human osteoarthritis chondrocytes.	Archives of biochemistry and biophysics	2016	12
26871664	Nitric Oxide	Ince C	THE ENDOTHELIUM IN SEPSIS.	Shock	2016	19
26975422	Nitric Oxide	Shiobara T	Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells.	Respiratory research	2016	10
27301879	Nitric Oxide	Thiele Orberg E	The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis.	Mucosal immunology	2017	7
27514990	Nitric Oxide	Balez R	Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer's disease.	Scientific reports	2016	11
27732846	Nitric Oxide	Van den Bossche J	Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages.	Cell reports	2016	20
27865851	Nitric Oxide	Zhang QS	Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.	Toxicology letters	2017	9
28067899	Nitric Oxide	Oller J	Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome.	Nature medicine	2017	13
28209797	Nitric Oxide	Förstermann U	Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis.	Circulation research	2017	25
28306514	Nitric Oxide	Gupta A	PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.	Molecular cell	2017	7
28504669	Nitric Oxide	Mishra BB	Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis.	Nature microbiology	2017	11
12070027	Oligonucleotides, Antisense	Derenne S	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.	Blood	2002	97
15124023	Oligonucleotides, Antisense	Jia SH	Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.	The Journal of clinical investigation	2004	130
15324695	Oligonucleotides, Antisense	Nagata Y	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.	Cancer cell	2004	448
15895073	Oligonucleotides, Antisense	Chiarle R	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.	Nature medicine	2005	134
16289418	Oligonucleotides, Antisense	Sieghart W	Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.	Journal of hepatology	2006	62
17363372	Oligonucleotides, Antisense	Zhu S	MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).	The Journal of biological chemistry	2007	321
17384677	Oligonucleotides, Antisense	Matsubara H	Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92.	Oncogene	2007	109
18429962	Oligonucleotides, Antisense	Takakura S	Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells.	Cancer science	2008	72
18431520	Oligonucleotides, Antisense	Ernst M	STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.	The Journal of clinical investigation	2008	93
19383915	Oligonucleotides, Antisense	Graff JR	eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.	Cancer research	2009	49
19509158	Oligonucleotides, Antisense	Li J	MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.	Clinical cancer research 	2009	102
19535574	Oligonucleotides, Antisense	Williams JH	Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.	The Journal of neuroscience 	2009	54
21285523	Oligonucleotides, Antisense	Sah DW	Oligonucleotide therapeutic approaches for Huntington disease.	The Journal of clinical investigation	2011	41
21297615	Oligonucleotides, Antisense	Kaneko H	DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration.	Nature	2011	213
21971427	Oligonucleotides, Antisense	Carroll JB	Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.	Molecular therapy 	2011	73
21979052	Oligonucleotides, Antisense	Hua Y	Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.	Nature	2011	194
21979053	Oligonucleotides, Antisense	Taniguchi-Ikeda M	Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.	Nature	2011	43
22053214	Oligonucleotides, Antisense	Vanderplanck C	The FSHD atrophic myotube phenotype is caused by DUX4 expression.	PloS one	2011	48
23243023	Oligonucleotides, Antisense	Gutschner T	The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells.	Cancer research	2013	330
23521559	Oligonucleotides, Antisense	Koo T	Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.	Human gene therapy	2013	33
24154603	Oligonucleotides, Antisense	Sareen D	Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion.	Science translational medicine	2013	168
24170860	Oligonucleotides, Antisense	Lagier-Tourenne C	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2013	126
25223704	Oligonucleotides, Antisense	Yin Y	Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth.	Cell research	2014	30
25766528	Oligonucleotides, Antisense	Song B	MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88.	Cellular physiology and biochemistry 	2015	17
26282675	Oligonucleotides, Antisense	Wu H	MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.	Gut	2016	17
26308891	Oligonucleotides, Antisense	Zhang K	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.	Nature	2015	146
26538029	Oligonucleotides, Antisense	Morciano G	Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death.	Molecular biology of the cell	2016	16
26582900	Oligonucleotides, Antisense	Hong D	AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.	Science translational medicine	2015	33
26595814	Oligonucleotides, Antisense	Dewaele M	Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.	The Journal of clinical investigation	2016	16
27106101	Oligonucleotides, Antisense	Garanto A	In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.	Human molecular genetics	2016	15
27281208	Oligonucleotides, Antisense	Fox RG	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.	Nature	2016	16
9508771	Phosphatidylinositols	Honda K	Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion.	The Journal of cell biology	1998	102
10200246	Phosphatidylinositols	Cantley LC	New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.	Proceedings of the National Academy of Sciences of the United States of America	1999	450
10611246	Phosphatidylinositols	Lee RJ	Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.	Molecular and cellular biology	2000	96
10611961	Phosphatidylinositols	Bamburg JR	Proteins of the ADF/cofilin family: essential regulators of actin dynamics.	Annual review of cell and developmental biology	1999	301
11278548	Phosphatidylinositols	Sheng H	Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.	The Journal of biological chemistry	2001	151
11431323	Phosphatidylinositols	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	90
11479209	Phosphatidylinositols	Bachelder RE	Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells.	Cancer research	2001	106
12124177	Phosphatidylinositols	Sattler M	Critical role for Gab2 in transformation by BCR/ABL.	Cancer cell	2002	93
12351634	Phosphatidylinositols	Modur V	FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.	The Journal of biological chemistry	2002	113
12782577	Phosphatidylinositols	Choe G	Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.	Cancer research	2003	109
12824187	Phosphatidylinositols	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	106
12853564	Phosphatidylinositols	Holbro T	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2003	299
14528310	Phosphatidylinositols	Rong R	PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis.	Nature neuroscience	2003	96
14769856	Phosphatidylinositols	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	96
15059275	Phosphatidylinositols	Hwang SY	IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways.	Arthritis research & therapy	2004	84
15143086	Phosphatidylinositols	Chakravarti A	The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.	Journal of clinical oncology 	2004	91
15193142	Phosphatidylinositols	Leslie NR	PTEN function: how normal cells control it and tumour cells lose it.	The Biochemical journal	2004	110
15254419	Phosphatidylinositols	Bachman KE	The PIK3CA gene is mutated with high frequency in human breast cancers.	Cancer biology & therapy	2004	183
15284297	Phosphatidylinositols	Sharples EJ	Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.	Journal of the American Society of Nephrology 	2004	82
15467756	Phosphatidylinositols	Asano T	The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.	Oncogene	2004	91
15494427	Phosphatidylinositols	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	118
15613447	Phosphatidylinositols	Kwabi-Addo B	The role of fibroblast growth factors and their receptors in prostate cancer.	Endocrine-related cancer	2004	81
15641016	Phosphatidylinositols	Foulstone E	Insulin-like growth factor ligands, receptors, and binding proteins in cancer.	The Journal of pathology	2005	67
15647370	Phosphatidylinositols	Kang S	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.	Proceedings of the National Academy of Sciences of the United States of America	2005	218
15766664	Phosphatidylinositols	Kim RH	DJ-1, a novel regulator of the tumor suppressor PTEN.	Cancer cell	2005	133
15942189	Phosphatidylinositols	Nawshad A	Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis.	Cells, tissues, organs	2005	95
15994075	Phosphatidylinositols	Velho S	The prevalence of PIK3CA mutations in gastric and colon cancer.	European journal of cancer	2005	97
16288007	Phosphatidylinositols	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	84
16324768	Phosphatidylinositols	Tang JM	Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.	Lung cancer	2006	87
16339315	Phosphatidylinositols	Zhao JJ	The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	128
16489002	Phosphatidylinositols	Klos KS	ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.	Cancer research	2006	61
16543232	Phosphatidylinositols	Misra UK	Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.	The Journal of biological chemistry	2006	73
16683005	Phosphatidylinositols	Nahta R	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.	Nature clinical practice. Oncology	2006	233
16740687	Phosphatidylinositols	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	79
16912192	Phosphatidylinositols	Chesler L	Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.	Cancer research	2006	62
17068222	Phosphatidylinositols	Ferretti C	Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts.	Human reproduction update	2007	98
17124492	Phosphatidylinositols	Stiff T	ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling.	The EMBO journal	2006	135
17159987	Phosphatidylinositols	Parsa AT	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.	Nature medicine	2007	325
17182864	Phosphatidylinositols	Shiojima I	Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway.	Genes & development	2006	115
17210696	Phosphatidylinositols	Maroulakou IG	Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.	Cancer research	2007	108
17308108	Phosphatidylinositols	Sawada K	c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.	Cancer research	2007	92
17332339	Phosphatidylinositols	Campbell PM	K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.	Cancer research	2007	79
17363567	Phosphatidylinositols	Saxena NK	Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.	Cancer research	2007	118
17409416	Phosphatidylinositols	Kang HG	E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.	Cancer research	2007	62
17452630	Phosphatidylinositols	Saal LH	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.	Proceedings of the National Academy of Sciences of the United States of America	2007	184
17546049	Phosphatidylinositols	Bauer S	KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.	Oncogene	2007	60
17692802	Phosphatidylinositols	Brugge J	A new mutational AKTivation in the PI3K pathway.	Cancer cell	2007	92
17909010	Phosphatidylinositols	Lo HW	Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.	Cancer research	2007	189
17964232	Phosphatidylinositols	Jiang BH	PI3K/PTEN signaling in tumorigenesis and angiogenesis.	Biochimica et biophysica acta	2008	73
18093986	Phosphatidylinositols	Adya R	Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.	Cardiovascular research	2008	74
18177721	Phosphatidylinositols	DeBerardinis RJ	The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.	Cell metabolism	2008	950
18299320	Phosphatidylinositols	Havasi A	Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism.	The Journal of biological chemistry	2008	53
18492751	Phosphatidylinositols	Liu Z	Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.	The Journal of clinical endocrinology and metabolism	2008	109
18625725	Phosphatidylinositols	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	65
18644989	Phosphatidylinositols	Toulany M	Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.	Molecular cancer therapeutics	2008	52
18757405	Phosphatidylinositols	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	145
18829572	Phosphatidylinositols	Oda K	PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.	Cancer research	2008	59
19055754	Phosphatidylinositols	Marty B	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.	Breast cancer research 	2008	63
19147570	Phosphatidylinositols	Mirzoeva OK	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.	Cancer research	2009	116
19176381	Phosphatidylinositols	Almog N	Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.	Cancer research	2009	73
19214224	Phosphatidylinositols	Read RD	A drosophila model for EGFR-Ras and PI3K-dependent human glioma.	PLoS genetics	2009	54
19318560	Phosphatidylinositols	Szczepanski MJ	Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.	Cancer research	2009	64
19426212	Phosphatidylinositols	Rudd CE	CD28 and CTLA-4 coreceptor expression and signal transduction.	Immunological reviews	2009	162
19493313	Phosphatidylinositols	Madhunapantula SV	The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.	Pigment cell & melanoma research	2009	51
19567590	Phosphatidylinositols	Hoeflich KP	In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.	Clinical cancer research 	2009	172
19595306	Phosphatidylinositols	Jiang BH	PI3K/PTEN signaling in angiogenesis and tumorigenesis.	Advances in cancer research	2009	123
19668216	Phosphatidylinositols	Bielas SL	Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies.	Nature genetics	2009	124
19789314	Phosphatidylinositols	Platt FM	Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.	Clinical cancer research 	2009	71
19962665	Phosphatidylinositols	Jaiswal BS	Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.	Cancer cell	2009	109
20081861	Phosphatidylinositols	Houghton AM	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.	Nature medicine	2010	120
20145208	Phosphatidylinositols	Sehat B	SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor.	Science signaling	2010	72
20233997	Phosphatidylinositols	Zhang J	Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.	Journal of the National Cancer Institute	2010	74
20379207	Phosphatidylinositols	Vanhaesebroeck B	The emerging mechanisms of isoform-specific PI3K signalling.	Nature reviews. Molecular cell biology	2010	362
20388916	Phosphatidylinositols	Poliseno L	Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.	Science signaling	2010	166
20399811	Phosphatidylinositols	Martelli AM	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.	Biochimica et biophysica acta	2010	41
20405009	Phosphatidylinositols	Gómez Ravetti M	Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.	PloS one	2010	41
20421047	Phosphatidylinositols	Johnson SM	Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.	Journal of the American College of Surgeons	2010	44
20471940	Phosphatidylinositols	Chin YR	The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.	Molecular cell	2010	55
20668162	Phosphatidylinositols	Goodman CA	A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of rapamycin signaling is sufficient to induce skeletal muscle hypertrophy.	Molecular biology of the cell	2010	42
20686178	Phosphatidylinositols	Andersen JN	Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.	Science translational medicine	2010	57
20922461	Phosphatidylinositols	Castaneda CA	The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.	Cancer metastasis reviews	2010	45
21045158	Phosphatidylinositols	Shultz JC	Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.	Cancer research	2010	46
21320503	Phosphatidylinositols	Ke AW	CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells.	Gastroenterology	2011	43
21628414	Phosphatidylinositols	Kuchenbauer F	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.	Blood	2011	38
21707707	Phosphatidylinositols	Sun CH	Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.	Histopathology	2011	38
21818118	Phosphatidylinositols	Qiang L	HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway.	Cell death and differentiation	2012	59
21820331	Phosphatidylinositols	Martínez-Martín N	T cell receptor internalization from the immunological synapse is mediated by TC21 and RhoG GTPase-dependent phagocytosis.	Immunity	2011	46
21951552	Phosphatidylinositols	Debaisieux S	The ins and outs of HIV-1 Tat.	Traffic	2012	55
22002674	Phosphatidylinositols	Florey O	Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes.	Nature cell biology	2011	112
22133722	Phosphatidylinositols	Roychowdhury S	Personalized oncology through integrative high-throughput sequencing: a pilot study.	Science translational medicine	2011	190
22248929	Phosphatidylinositols	Garrett JT	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?	Oncotarget	2011	35
22264730	Phosphatidylinositols	Thapa N	Phosphoinositide signaling regulates the exocyst complex and polarized integrin trafficking in directionally migrating cells.	Developmental cell	2012	44
22416079	Phosphatidylinositols	Romero I	Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.	Endocrinology	2012	76
22473959	Phosphatidylinositols	Lee K	Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.	The Journal of experimental medicine	2012	43
22494966	Phosphatidylinositols	Torsvik A	Mesenchymal stem cell signaling in cancer progression.	Cancer treatment reviews	2013	27
22624718	Phosphatidylinositols	Lapalombella R	Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.	Cancer cell	2012	31
22674982	Phosphatidylinositols	Shrivastava S	Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling.	Journal of virology	2012	48
22727489	Phosphatidylinositols	Lai Y	The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury.	Immunity	2012	33
22880008	Phosphatidylinositols	Huang WC	Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB.	PloS one	2012	31
23112296	Phosphatidylinositols	Wang RC	Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.	Science	2012	167
23348690	Phosphatidylinositols	Ha GH	TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways.	Cancer letters	2013	28
23487788	Phosphatidylinositols	Takeuchi K	Dysregulation of synaptic plasticity precedes appearance of morphological defects in a Pten conditional knockout mouse model of autism.	Proceedings of the National Academy of Sciences of the United States of America	2013	27
23554977	Phosphatidylinositols	Lau MT	Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.	PloS one	2013	26
23624914	Phosphatidylinositols	Ye Q	ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.	Oncogene	2014	47
23643389	Phosphatidylinositols	Hao Y	Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.	Cancer cell	2013	25
23671130	Phosphatidylinositols	Sun J	Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.	Carcinogenesis	2013	25
23708729	Phosphatidylinositols	Ryter SW	Autophagy: a critical regulator of cellular metabolism and homeostasis.	Molecules and cells	2013	53
24065147	Phosphatidylinositols	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	61
24067654	Phosphatidylinositols	Tian Y	Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy.	Proceedings of the National Academy of Sciences of the United States of America	2013	36
24393708	Phosphatidylinositols	Francipane MG	mTOR pathway in colorectal cancer: an update.	Oncotarget	2014	31
24440701	Phosphatidylinositols	Wang Y	MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.	Biochemical and biophysical research communications	2014	24
24440717	Phosphatidylinositols	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	59
24533074	Phosphatidylinositols	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	28
24607406	Phosphatidylinositols	Todaro M	CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.	Cell stem cell	2014	116
24703947	Phosphatidylinositols	Wang H	Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3.	Molecular cell	2014	198
24777052	Phosphatidylinositols	Ocana A	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.	PloS one	2014	36
24867100	Phosphatidylinositols	Wang F	MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.	Tumour biology 	2014	22
25001183	Phosphatidylinositols	Hu J	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.	European journal of cancer	2014	33
25086744	Phosphatidylinositols	Li H	PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.	Archives of gynecology and obstetrics	2014	23
25183785	Phosphatidylinositols	Rubashkin MG	Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.	Cancer research	2014	41
25475121	Phosphatidylinositols	Huang XP	MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.	The FEBS journal	2015	20
25512523	Phosphatidylinositols	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	62
25534823	Phosphatidylinositols	Kaul A	Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.	Neuro-oncology	2015	17
25583473	Phosphatidylinositols	Hart JR	The butterfly effect in cancer: a single base mutation can remodel the cell.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
25650317	Phosphatidylinositols	Ghosh JC	Adaptive mitochondrial reprogramming and resistance to PI3K therapy.	Journal of the National Cancer Institute	2015	27
25877892	Phosphatidylinositols	McGranahan N	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.	Science translational medicine	2015	78
25937177	Phosphatidylinositols	Cuadrado A	Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/β-TrCP.	Free radical biology & medicine	2015	16
26117819	Phosphatidylinositols	Yap TA	Drugging PI3K in cancer: refining targets and therapeutic strategies.	Current opinion in pharmacology	2015	40
26124089	Phosphatidylinositols	Caino MC	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26253360	Phosphatidylinositols	Chang L	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.	Critical reviews in oncology/hematology	2015	18
26850495	Phosphatidylinositols	Mancina RM	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.	Gastroenterology	2016	26
26926684	Phosphatidylinositols	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	18
27159400	Phosphatidylinositols	Mirzaa GM	Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism.	JAMA neurology	2016	14
27844272	Phosphatidylinositols	Duran I	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.	Targeted oncology	2017	7
28518139	Phosphatidylinositols	Li N	MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer.	Cell death & disease	2017	10
12045200	Sirolimus	Goncharova EA	Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).	The Journal of biological chemistry	2002	125
14744976	Sirolimus	Virmani R	Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?	Circulation	2004	131
15156201	Sirolimus	Majumder PK	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.	Nature medicine	2004	282
15501954	Sirolimus	Zhou X	Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.	Clinical cancer research 	2004	90
15501983	Sirolimus	Mondesire WH	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.	Clinical cancer research 	2004	91
15623621	Sirolimus	Sahin F	mTOR and P70 S6 kinase expression in primary liver neoplasms.	Clinical cancer research 	2004	78
15723049	Sirolimus	Ohanna M	Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control.	Nature cell biology	2005	105
15800227	Sirolimus	Stallone G	Sirolimus for Kaposi's sarcoma in renal-transplant recipients.	The New England journal of medicine	2005	146
16075055	Sirolimus	Shiojima I	Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.	The Journal of clinical investigation	2005	271
16203860	Sirolimus	Yu WH	Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease.	The Journal of cell biology	2005	237
16267020	Sirolimus	Amornphimoltham P	Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.	Cancer research	2005	78
16397245	Sirolimus	Han S	Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.	Cancer research	2006	63
16567633	Sirolimus	Shillingford JM	The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.	Proceedings of the National Academy of Sciences of the United States of America	2006	209
16585191	Sirolimus	Wang L	Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.	Cancer research	2006	66
16714284	Sirolimus	Cao Y	Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis.	The Journal of biological chemistry	2006	79
16799564	Sirolimus	Androutsellis-Theotokis A	Notch signalling regulates stem cell numbers in vitro and in vivo.	Nature	2006	271
16849518	Sirolimus	Koumenis C	"Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways.	Molecular cancer research 	2006	71
16904612	Sirolimus	Sodhi A	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.	Cancer cell	2006	65
16904613	Sirolimus	Phung TL	Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.	Cancer cell	2006	152
16912159	Sirolimus	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	100
16959574	Sirolimus	Inoki K	TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.	Cell	2006	372
17010674	Sirolimus	Wei G	Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.	Cancer cell	2006	149
17041628	Sirolimus	Easton JB	mTOR and cancer therapy.	Oncogene	2006	128
17047067	Sirolimus	Cao C	Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.	Cancer research	2006	97
17047074	Sirolimus	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	104
17082322	Sirolimus	Sin SH	Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.	Blood	2007	67
17142730	Sirolimus	Battaglia M	Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.	Journal of immunology	2006	204
17273556	Sirolimus	Le Bacquer O	Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2.	The Journal of clinical investigation	2007	97
17275731	Sirolimus	Tsang CK	Targeting mammalian target of rapamycin (mTOR) for health and diseases.	Drug discovery today	2007	109
17361185	Sirolimus	Wilker EW	14-3-3sigma controls mitotic translation to facilitate cytokinesis.	Nature	2007	80
17363557	Sirolimus	Mabuchi S	RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.	Cancer research	2007	59
17463046	Sirolimus	Roos S	Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth.	The Journal of physiology	2007	72
17671177	Sirolimus	Ma L	Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.	Cancer research	2007	58
17699757	Sirolimus	Armengol G	4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.	Cancer research	2007	87
17913600	Sirolimus	Swiech L	Role of mTOR in physiology and pathology of the nervous system.	Biochimica et biophysica acta	2008	99
18080139	Sirolimus	Martignoni G	PEComas: the past, the present and the future.	Virchows Archiv 	2008	93
18089801	Sirolimus	Masri J	mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.	Cancer research	2007	92
18184959	Sirolimus	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	296
18276609	Sirolimus	Tang G	Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways.	Human molecular genetics	2008	53
18356598	Sirolimus	Zhou D	Human immunodeficiency virus type-1 infection inhibits autophagy.	AIDS	2008	66
18367868	Sirolimus	Mammucari C	Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle.	Autophagy	2008	76
18393362	Sirolimus	Yin XM	Autophagy in the liver.	Hepatology	2008	76
18424697	Sirolimus	Basu S	Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.	Journal of immunology	2008	57
18474609	Sirolimus	Narayanan U	S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.	The Journal of biological chemistry	2008	90
18583310	Sirolimus	Yung HW	Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction.	The American journal of pathology	2008	96
18653228	Sirolimus	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	689
18679422	Sirolimus	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	56
18684977	Sirolimus	Golovina TN	CD28 costimulation is essential for human T regulatory expansion and function.	Journal of immunology	2008	55
18768809	Sirolimus	Fujishita T	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	57
18787170	Sirolimus	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	138
18922904	Sirolimus	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
19185849	Sirolimus	Guertin DA	mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.	Cancer cell	2009	149
19211884	Sirolimus	Zhou J	Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice.	The Journal of neuroscience 	2009	149
19223493	Sirolimus	Yu G	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clinical cancer research 	2009	51
19261747	Sirolimus	Puzio-Kuter AM	Inactivation of p53 and Pten promotes invasive bladder cancer.	Genes & development	2009	98
19276368	Sirolimus	Chen RQ	CDC25B mediates rapamycin-induced oncogenic responses in cancer cells.	Cancer research	2009	46
19282848	Sirolimus	Dankort D	Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.	Nature genetics	2009	324
19420259	Sirolimus	Di Nardo A	Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.	The Journal of neuroscience 	2009	63
19451225	Sirolimus	James MF	NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.	Molecular and cellular biology	2009	69
19451229	Sirolimus	López-Lago MA	Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.	Molecular and cellular biology	2009	47
19458359	Sirolimus	Tamburini J	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.	Blood	2009	54
19470613	Sirolimus	Ljungberg MC	Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia.	Disease models & mechanisms	2009	68
19535919	Sirolimus	Zhu H	Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells.	Autophagy	2009	113
19543393	Sirolimus	Strauss L	Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.	PloS one	2009	59
19589955	Sirolimus	Mayhew DL	Translational signaling responses preceding resistance training-mediated myofiber hypertrophy in young and old humans.	Journal of applied physiology	2009	57
19644473	Sirolimus	Liu P	Targeting the phosphoinositide 3-kinase pathway in cancer.	Nature reviews. Drug discovery	2009	563
19687332	Sirolimus	Ellard SL	Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.	Journal of clinical oncology 	2009	60
19773376	Sirolimus	Kim KW	Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.	Clinical cancer research 	2009	47
19789339	Sirolimus	Kurmasheva RT	The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.	Cancer research	2009	60
19796751	Sirolimus	Rini BI	Resistance to targeted therapy in renal-cell carcinoma.	The Lancet. Oncology	2009	134
19963098	Sirolimus	Gibbons JJ	Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.	Seminars in oncology	2009	81
19995915	Sirolimus	Julien LA	mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.	Molecular and cellular biology	2010	141
20008787	Sirolimus	Kharas MG	Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.	Blood	2010	90
20008935	Sirolimus	Olive V	miR-19 is a key oncogenic component of mir-17-92.	Genes & development	2009	235
20018914	Sirolimus	Ghosh AK	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.	Blood	2010	64
20042677	Sirolimus	Deng L	A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis.	The American journal of pathology	2010	57
20075061	Sirolimus	Shillingford JM	Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.	Journal of the American Society of Nephrology 	2010	73
20080688	Sirolimus	Hung KE	Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20081105	Sirolimus	Nagaraja AK	A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.	Molecular endocrinology	2010	77
20089925	Sirolimus	Malagelada C	Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.	The Journal of neuroscience 	2010	107
20146692	Sirolimus	Orlova KA	The tuberous sclerosis complex.	Annals of the New York Academy of Sciences	2010	102
20174468	Sirolimus	Crews L	Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.	PloS one	2010	92
20231677	Sirolimus	Doi T	Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.	Journal of clinical oncology 	2010	56
20371474	Sirolimus	Amin DN	Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.	Science translational medicine	2010	69
20453062	Sirolimus	Aguado C	Laforin, the most common protein mutated in Lafora disease, regulates autophagy.	Human molecular genetics	2010	54
20466742	Sirolimus	Perico N	Sirolimus therapy to halt the progression of ADPKD.	Journal of the American Society of Nephrology 	2010	42
20473305	Sirolimus	Yoshida T	Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema.	Nature medicine	2010	61
20484036	Sirolimus	Doghman M	Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.	Cancer research	2010	66
20491627	Sirolimus	Zhou H	The complexes of mammalian target of rapamycin.	Current protein & peptide science	2010	42
20498714	Sirolimus	Squarize CH	Accelerated wound healing by mTOR activation in genetically defined mouse models.	PloS one	2010	40
20563248	Sirolimus	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	62
20581392	Sirolimus	Walz G	Everolimus in patients with autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	134
20615870	Sirolimus	Abe N	Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves.	The Journal of biological chemistry	2010	52
20661303	Sirolimus	Van Grol J	HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3.	PloS one	2010	46
20713600	Sirolimus	Cherra SJ 3rd	Regulation of the autophagy protein LC3 by phosphorylation.	The Journal of cell biology	2010	88
20810185	Sirolimus	Rautou PE	Autophagy in liver diseases.	Journal of hepatology	2010	99
20956938	Sirolimus	Dunn EF	Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.	Oncogene	2011	40
20978191	Sirolimus	Zhang F	mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.	Cancer research	2010	49
21047224	Sirolimus	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	226
21071439	Sirolimus	Carriere A	ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).	The Journal of biological chemistry	2011	72
21084617	Sirolimus	Osterweil EK	Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.	The Journal of neuroscience 	2010	128
21099108	Sirolimus	Badell IR	LFA-1-specific therapy prolongs allograft survival in rhesus macaques.	The Journal of clinical investigation	2010	53
21145759	Sirolimus	Procaccini C	An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.	Immunity	2010	96
21147110	Sirolimus	Calvisi DF	Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.	Gastroenterology	2011	98
21253593	Sirolimus	Golovina TN	Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.	PloS one	2011	48
21289308	Sirolimus	Yoshimi A	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.	Blood	2011	35
21331075	Sirolimus	Evangelisti C	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.	Leukemia	2011	37
21339483	Sirolimus	Grundmann S	MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells.	Circulation	2011	48
21346035	Sirolimus	Finley DS	Tumor biology and prognostic factors in renal cell carcinoma.	The oncologist	2011	39
21358673	Sirolimus	Weigelt B	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.	Oncogene	2011	69
21383697	Sirolimus	Oneyama C	MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.	Oncogene	2011	44
21525172	Sirolimus	Davies DM	Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.	Clinical cancer research 	2011	63
21690594	Sirolimus	Taveira-DaSilva AM	Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.	Annals of internal medicine	2011	46
21715679	Sirolimus	Cao K	Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.	Science translational medicine	2011	99
21730275	Sirolimus	Morrow PK	Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.	Journal of clinical oncology 	2011	65
21795477	Sirolimus	Uesugi A	The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.	Cancer research	2011	74
21841310	Sirolimus	Shuda M	Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator.	The Journal of clinical investigation	2011	100
21878679	Sirolimus	Chan JC	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	Science signaling	2011	41
21907282	Sirolimus	Carson RP	Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.	Neurobiology of disease	2012	57
21975930	Sirolimus	Patel V	Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.	Cancer research	2011	52
21993994	Sirolimus	Ho C	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.	Hepatology	2012	55
22025691	Sirolimus	Goto J	Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.	Proceedings of the National Academy of Sciences of the United States of America	2011	61
22034068	Sirolimus	Caramés B	Mechanical injury suppresses autophagy regulators and pharmacologic activation of autophagy results in chondroprotection.	Arthritis and rheumatism	2012	34
22147463	Sirolimus	Sasaki H	Autophagy modulates osteoarthritis-related gene expression in human chondrocytes.	Arthritis and rheumatism	2012	45
22193387	Sirolimus	Cinà DP	Inhibition of MTOR disrupts autophagic flux in podocytes.	Journal of the American Society of Nephrology 	2012	39
22234835	Sirolimus	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	103
22310280	Sirolimus	Serrano I	Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT).	Oncogene	2013	36
22355189	Sirolimus	Sun Y	Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection.	Science signaling	2012	50
22391571	Sirolimus	Kalvik TV	Protein N-terminal acetyltransferases in cancer.	Oncogene	2013	34
22397650	Sirolimus	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1714
22402744	Sirolimus	Weeraratne SD	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.	Acta neuropathologica	2012	57
22409888	Sirolimus	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	38
22431589	Sirolimus	Suh SS	MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.	Proceedings of the National Academy of Sciences of the United States of America	2012	41
22457330	Sirolimus	Menon S	Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.	Science signaling	2012	51
22473468	Sirolimus	Song MS	The functions and regulation of the PTEN tumour suppressor.	Nature reviews. Molecular cell biology	2012	494
22473592	Sirolimus	Seront E	Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.	Annals of oncology 	2012	33
22585904	Sirolimus	Baird TD	Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism.	Advances in nutrition	2012	119
22698676	Sirolimus	Mercier I	Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.	The American journal of pathology	2012	68
22711699	Sirolimus	Winbanks CE	Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin.	The Journal of cell biology	2012	32
22729223	Sirolimus	Lee JH	De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.	Nature genetics	2012	135
22729283	Sirolimus	Xian L	Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells.	Nature medicine	2012	106
22773827	Sirolimus	Fukuda A	Growth-dependent podocyte failure causes glomerulosclerosis.	Journal of the American Society of Nephrology 	2012	43
22826565	Sirolimus	Zeng Z	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	Blood	2012	38
22837538	Sirolimus	Ramos FJ	Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival.	Science translational medicine	2012	93
22859719	Sirolimus	Sun ZJ	Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.	Clinical cancer research 	2012	41
22885411	Sirolimus	Romagnoli A	ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells.	Autophagy	2012	64
22904304	Sirolimus	Procaccini C	Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses.	Journal of immunology	2012	30
22907434	Sirolimus	Du W	ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.	Oncogene	2013	27
22919032	Sirolimus	McInturff AM	Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α.	Blood	2012	50
22923433	Sirolimus	Iyer G	Genome sequencing identifies a basis for everolimus sensitivity.	Science	2012	174
22958932	Sirolimus	Iglesias-Bartolome R	mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.	Cell stem cell	2012	91
22980985	Sirolimus	Lu P	Long-distance growth and connectivity of neural stem cells after severe spinal cord injury.	Cell	2012	147
22983984	Sirolimus	Iwaya T	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012	50
22994804	Sirolimus	Akimova T	Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.	American journal of transplantation 	2012	32
23085539	Sirolimus	McCubrey JA	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	105
23123587	Sirolimus	Reith RM	Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex.	Neurobiology of disease	2013	42
23152448	Sirolimus	Kaul A	Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.	Genes & development	2012	33
23155049	Sirolimus	Avrahami L	Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.	The Journal of biological chemistry	2013	43
23173671	Sirolimus	Cui L	MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.	BMC cancer	2012	31
23325216	Sirolimus	Johnson SC	mTOR is a key modulator of ageing and age-related disease.	Nature	2013	329
23431193	Sirolimus	Posch C	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2013	70
23454761	Sirolimus	Lamming DW	Rapalogs and mTOR inhibitors as anti-aging therapeutics.	The Journal of clinical investigation	2013	122
23570274	Sirolimus	Theoharides TC	Focal brain inflammation and autism.	Journal of neuroinflammation	2013	30
23582881	Sirolimus	Templeton AJ	Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).	European urology	2013	27
23663782	Sirolimus	Csibi A	The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.	Cell	2013	122
23677068	Sirolimus	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	39
23686362	Sirolimus	Sandri M	Signalling pathways regulating muscle mass in ageing skeletal muscle: the role of the IGF1-Akt-mTOR-FoxO pathway.	Biogerontology	2013	55
23729812	Sirolimus	Balu DT	Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction.	Proceedings of the National Academy of Sciences of the United States of America	2013	53
23778311	Sirolimus	McCubrey JA	Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.	Leukemia	2014	41
23818547	Sirolimus	Lu J	Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.	Blood	2013	36
23818640	Sirolimus	Meckes DG Jr	Modulation of B-cell exosome proteins by gamma herpesvirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2013	57
23856247	Sirolimus	Cai J	miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.	Cancer research	2013	44
23902785	Sirolimus	Op den Kamp CM	Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia.	The American journal of clinical nutrition	2013	27
23903756	Sirolimus	Elkabets M	mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.	Science translational medicine	2013	76
23953116	Sirolimus	Thedieck K	Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells.	Cell	2013	52
24011086	Sirolimus	Tsubaki M	Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.	Journal of experimental & clinical cancer research 	2013	27
24014241	Sirolimus	Willems L	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.	Blood	2013	56
24052624	Sirolimus	Wang Q	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.	Journal of the National Cancer Institute	2013	31
24056770	Sirolimus	Canaud G	AKT2 is essential to maintain podocyte viability and function during chronic kidney disease.	Nature medicine	2013	46
24059496	Sirolimus	Sarkar S	Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers.	Biochemical Society transactions	2013	69
24092929	Sirolimus	Yamahara K	Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions.	Journal of the American Society of Nephrology 	2013	43
24161930	Sirolimus	Liu P	Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.	Nature cell biology	2013	72
24165795	Sirolimus	Lucas CL	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.	Nature immunology	2014	100
24185040	Sirolimus	Francipane MG	Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.	Oncotarget	2013	29
24270418	Sirolimus	Liu SC	Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.	The Journal of clinical investigation	2013	29
24311635	Sirolimus	Kahn J	The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.	Neuro-oncology	2014	23
24367027	Sirolimus	Takasaka N	Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence.	Journal of immunology	2014	33
24401568	Sirolimus	Liu B	Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation.	Autophagy	2014	29
24403067	Sirolimus	Neill T	Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin.	The Journal of biological chemistry	2014	23
24445654	Sirolimus	Chang L	Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.	Cancer metastasis reviews	2014	21
24469052	Sirolimus	Akeno N	p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.	Oncogene	2015	15
24470531	Sirolimus	Farid M	Malignant peripheral nerve sheath tumors.	The oncologist	2014	23
24481845	Sirolimus	Sciarretta S	Mammalian target of rapamycin signaling in cardiac physiology and disease.	Circulation research	2014	87
24508508	Sirolimus	Li J	Rapamycin: one drug, many effects.	Cell metabolism	2014	87
24603303	Sirolimus	Shimizu K	ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.	British journal of cancer	2014	25
24615500	Sirolimus	Rugo HS	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.	Annals of oncology 	2014	24
24631838	Sirolimus	Grabiner BC	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.	Cancer discovery	2014	83
24645945	Sirolimus	Senniappan S	Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia.	The New England journal of medicine	2014	25
24651621	Sirolimus	Zhang Y	Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis.	Annals of the rheumatic diseases	2015	45
24682598	Sirolimus	Schapansky J	Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.	Human molecular genetics	2014	29
24718867	Sirolimus	Patwardhan PP	Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.	Clinical cancer research 	2014	20
24728411	Sirolimus	Ota KT	REDD1 is essential for stress-induced synaptic loss and depressive behavior.	Nature medicine	2014	50
24841777	Sirolimus	Albiges L	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.	European urology	2015	30
24899720	Sirolimus	Caccamo A	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.	The Journal of neuroscience 	2014	34
24910242	Sirolimus	Umemura A	Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.	Cell metabolism	2014	27
24931163	Sirolimus	Dodd KM	mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.	Oncogene	2015	24
24943720	Sirolimus	Cholongitas E	Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.	Transplant international 	2014	22
24947615	Sirolimus	Park HW	Hepatoprotective role of Sestrin2 against chronic ER stress.	Nature communications	2014	26
24954509	Sirolimus	Chou SD	HSF1 regulation of β-catenin in mammary cancer cells through control of HuR/elavL1 expression.	Oncogene	2015	21
25082895	Sirolimus	Cornu M	Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
25099355	Sirolimus	Lu L	Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions.	Proceedings of the National Academy of Sciences of the United States of America	2014	33
25175012	Sirolimus	Zhu L	TSC1 controls macrophage polarization to prevent inflammatory disease.	Nature communications	2014	40
25202833	Sirolimus	Hsueh AJ	Intraovarian control of early folliculogenesis.	Endocrine reviews	2015	25
25295501	Sirolimus	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	76
25311365	Sirolimus	Oguro-Ando A	Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR.	Molecular psychiatry	2015	15
25341517	Sirolimus	Johnson SC	Modulating mTOR in aging and health.	Interdisciplinary topics in gerontology	2015	26
25403236	Sirolimus	Takayama K	Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis.	Arthritis research & therapy	2014	25
25444920	Sirolimus	Zheng B	Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.	Cancer letters	2015	21
25450580	Sirolimus	Xu K	mTOR signaling in tumorigenesis.	Biochimica et biophysica acta	2014	34
25477072	Sirolimus	Gao B	Translational control by oncogenic signaling pathways.	Biochimica et biophysica acta	2015	15
25524627	Sirolimus	Li J	Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
25531317	Sirolimus	Siu MK	Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.	Oncogene	2015	19
25557953	Sirolimus	Cornella H	Unique genomic profile of fibrolamellar hepatocellular carcinoma.	Gastroenterology	2015	20
25561726	Sirolimus	Marchand B	Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.	The Journal of biological chemistry	2015	22
25562323	Sirolimus	Karner CM	Increased glutamine catabolism mediates bone anabolism in response to WNT signaling.	The Journal of clinical investigation	2015	24
25593290	Sirolimus	Ranchoux B	Endothelial-to-mesenchymal transition in pulmonary hypertension.	Circulation	2015	57
25601637	Sirolimus	Kong B	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.	Gut	2016	14
25645581	Sirolimus	Tramutola A	Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.	Journal of neurochemistry	2015	25
25657110	Sirolimus	Cao Y	Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.	Cancer letters	2015	19
25688110	Sirolimus	Cargnello M	The expanding role of mTOR in cancer cell growth and proliferation.	Mutagenesis	2015	23
25739910	Sirolimus	Mercado N	Accelerated ageing of the lung in COPD: new concepts.	Thorax	2015	33
25749036	Sirolimus	Yang H	FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.	Oncotarget	2015	21
25791428	Sirolimus	Tang Z	mTor mediates tau localization and secretion: Implication for Alzheimer's disease.	Biochimica et biophysica acta	2015	19
25813405	Sirolimus	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	45
26018084	Sirolimus	Nakashima M	Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.	Annals of neurology	2015	26
26134657	Sirolimus	Du K	Pten Deletion Promotes Regrowth of Corticospinal Tract Axons 1 Year after Spinal Cord Injury.	The Journal of neuroscience 	2015	21
26147250	Sirolimus	Laberge RM	MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.	Nature cell biology	2015	103
26156073	Sirolimus	Bissler JJ	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.	Nephrology, dialysis, transplantation 	2016	28
26177051	Sirolimus	Leontieva OV	Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).	Oncotarget	2015	25
26277543	Sirolimus	Hsieh AL	MYC and metabolism on the path to cancer.	Seminars in cell & developmental biology	2015	31
26280535	Sirolimus	Herranz N	mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.	Nature cell biology	2015	48
26364551	Sirolimus	Powles T	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.	European urology	2016	13
26468183	Sirolimus	Huber KM	Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism.	The Journal of neuroscience 	2015	21
26476289	Sirolimus	Li L	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.	Journal of hepatology	2016	12
26540343	Sirolimus	Ji J	LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.	Oncotarget	2015	33
26563133	Sirolimus	Brunstein CG	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.	Blood	2016	46
26565512	Sirolimus	Qiang L	Autophagy positively regulates DNA damage recognition by nucleotide excision repair.	Autophagy	2016	12
26721390	Sirolimus	Lin AL	Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease.	Journal of cerebral blood flow and metabolism 	2017	12
26735353	Sirolimus	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	19
26884601	Sirolimus	Viel S	TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.	Science signaling	2016	24
26929424	Sirolimus	Kempf E	KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.	European respiratory review 	2016	12
27074878	Sirolimus	Scioli MG	Combined treatment with platelet-rich plasma and insulin favours chondrogenic and osteogenic differentiation of human adipose-derived stem cells in three-dimensional collagen scaffolds.	Journal of tissue engineering and regenerative medicine	2017	5
27221134	Sirolimus	Elkaim E	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.	The Journal of allergy and clinical immunology	2016	18
27226234	Sirolimus	Henske EP	Tuberous sclerosis complex.	Nature reviews. Disease primers	2016	22
27260250	Sirolimus	Li Q	Autophagy and Alzheimer's Disease.	Cellular and molecular neurobiology	2017	9
27465917	Sirolimus	Mao Y	IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.	Blood	2016	16
27472076	Sirolimus	Al-Sheikh M	Swept-Source OCT Angiography Imaging of the Foveal Avascular Zone and Macular Capillary Network Density in Diabetic Retinopathy.	Investigative ophthalmology & visual science	2016	13
27597759	Sirolimus	Sargent G	PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation.	The Journal of cell biology	2016	13
27628078	Sirolimus	McCormack FX	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.	American journal of respiratory and critical care medicine	2016	13
27663511	Sirolimus	Riedl A	Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses.	Journal of cell science	2017	8
27671674	Sirolimus	Clark CA	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.	Cancer research	2016	18
28007498	Sirolimus	Kapahi P	Dietary restriction and lifespan: Lessons from invertebrate models.	Ageing research reviews	2017	9
28027327	Sirolimus	Lefebvre C	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.	PLoS medicine	2016	20
28067669	Sirolimus	Brockhoff M	Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.	The Journal of clinical investigation	2017	6
28085563	Sirolimus	Sun A	The E3 ubiquitin ligase NEDD4 is an LC3-interactive protein and regulates autophagy.	Autophagy	2017	9
28094770	Sirolimus	Martin AR	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.	The Journal of clinical investigation	2017	9
28294596	Sirolimus	Bieri R	The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR.	ACS chemical biology	2017	6
8721615	Antioxidants	Berliner JA	The role of oxidized lipoproteins in atherogenesis.	Free radical biology & medicine	1996	126
10562656	Antioxidants	Winkler BS	Oxidative damage and age-related macular degeneration.	Molecular vision	1999	144
12708612	Antioxidants	Weber LW	Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model.	Critical reviews in toxicology	2003	208
12716823	Antioxidants	Ceriello A	New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy.	Diabetes care	2003	121
12821677	Antioxidants	Ling YH	Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.	The Journal of biological chemistry	2003	101
12885586	Antioxidants	Fattman CL	Extracellular superoxide dismutase in biology and medicine.	Free radical biology & medicine	2003	104
14976002	Antioxidants	Ceriello A	Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.	Arteriosclerosis, thrombosis, and vascular biology	2004	198
15535435	Antioxidants	Nelson WG	The role of inflammation in the pathogenesis of prostate cancer.	The Journal of urology	2004	86
15842582	Antioxidants	Bugianesi E	A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.	The American journal of gastroenterology	2005	111
16573358	Antioxidants	Finaud J	Oxidative stress : relationship with exercise and training.	Sports medicine	2006	60
16816350	Antioxidants	Rahman I	Oxidative stress and redox regulation of lung inflammation in COPD.	The European respiratory journal	2006	171
16825950	Antioxidants	Nunomura A	Involvement of oxidative stress in Alzheimer disease.	Journal of neuropathology and experimental neurology	2006	89
16923312	Antioxidants	Albano E	Alcohol, oxidative stress and free radical damage.	The Proceedings of the Nutrition Society	2006	97
17636022	Antioxidants	Sun Z	Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2.	Molecular and cellular biology	2007	80
17916769	Antioxidants	Sukhanov S	IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice.	Arteriosclerosis, thrombosis, and vascular biology	2007	64
18003920	Antioxidants	Fang J	S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2007	75
18072094	Antioxidants	Bonomini F	Atherosclerosis and oxidative stress.	Histology and histopathology	2008	62
18188018	Antioxidants	Riedl MA	Importance of oxidative stress in the pathogenesis and treatment of asthma.	Current opinion in allergy and clinical immunology	2008	55
18324353	Antioxidants	Hatcher H	Curcumin: from ancient medicine to current clinical trials.	Cellular and molecular life sciences 	2008	250
19116368	Antioxidants	Fisher GJ	Collagen fragmentation promotes oxidative stress and elevates matrix metalloproteinase-1 in fibroblasts in aged human skin.	The American journal of pathology	2009	69
19139406	Antioxidants	Gruhne B	The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
19162177	Antioxidants	Harrison FE	Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2.	Free radical biology & medicine	2009	93
19276355	Antioxidants	Yamaura M	NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression.	Cancer research	2009	58
19652361	Antioxidants	Sundaresan NR	Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice.	The Journal of clinical investigation	2009	256
19654589	Antioxidants	Ramirez SH	Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells.	Journal of cerebral blood flow and metabolism 	2009	59
19800967	Antioxidants	Liu RM	Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis.	Free radical biology & medicine	2010	73
19969067	Antioxidants	Barber SC	Oxidative stress in ALS: key role in motor neuron injury and therapeutic target.	Free radical biology & medicine	2010	102
20709907	Antioxidants	Sangokoya C	microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease.	Blood	2010	76
20805291	Antioxidants	Hardwick RN	Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.	Drug metabolism and disposition	2010	54
20847286	Antioxidants	Jurkunas UV	Evidence of oxidative stress in the pathogenesis of fuchs endothelial corneal dystrophy.	The American journal of pathology	2010	62
20939847	Antioxidants	Chandrasekharan B	Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress.	Neurogastroenterology and motility 	2011	38
21031546	Antioxidants	Bhogal RH	Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation.	Liver transplantation 	2010	41
21050132	Antioxidants	Cook-Mills JM	Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.	Antioxidants & redox signaling	2011	70
21163347	Antioxidants	Henriksen EJ	Oxidative stress and the etiology of insulin resistance and type 2 diabetes.	Free radical biology & medicine	2011	88
21294650	Antioxidants	Carrano A	Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy.	Antioxidants & redox signaling	2011	51
21441382	Antioxidants	Lee SJ	Carbon monoxide activates autophagy via mitochondrial reactive oxygen species formation.	American journal of respiratory cell and molecular biology	2011	45
21459041	Antioxidants	Boutten A	NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease.	Trends in molecular medicine	2011	39
21605374	Antioxidants	Sotgia F	Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?	BMC medicine	2011	36
21771249	Antioxidants	Sriram S	Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB.	Aging cell	2011	37
22036626	Antioxidants	Agrawal L	HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes.	Neurobiology of disease	2012	30
22052977	Antioxidants	Anastasiou D	Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses.	Science	2011	261
22271002	Antioxidants	Maes M	New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.	Inflammopharmacology	2012	41
22492997	Antioxidants	Im JY	DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway.	Human molecular genetics	2012	41
22739839	Antioxidants	Pandi-Perumal SR	Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.	Neurotoxicity research	2013	33
22848625	Antioxidants	Bray K	Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition.	PloS one	2012	46
23303309	Antioxidants	Watson J	Oxidants, antioxidants and the current incurability of metastatic cancers.	Open biology	2013	86
23485523	Antioxidants	Hernández-Gea V	Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy.	Journal of hepatology	2013	40
23547621	Antioxidants	Cornelius C	Traumatic brain injury: oxidative stress and neuroprotection.	Antioxidants & redox signaling	2013	46
23726973	Antioxidants	Cheung EC	TIGAR is required for efficient intestinal regeneration and tumorigenesis.	Developmental cell	2013	45
23840916	Antioxidants	García-Escudero V	Deconstructing mitochondrial dysfunction in Alzheimer disease.	Oxidative medicine and cellular longevity	2013	28
23849856	Antioxidants	Winterbourn CC	The biological chemistry of hydrogen peroxide.	Methods in enzymology	2013	39
23880293	Antioxidants	Cheng X	Regulation of the Nrf2 antioxidant pathway by microRNAs: New players in micromanaging redox homeostasis.	Free radical biology & medicine	2013	43
23915129	Antioxidants	Dashdorj A	Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines.	BMC medicine	2013	37
24100461	Antioxidants	Perl A	Oxidative stress in the pathology and treatment of systemic lupus erythematosus.	Nature reviews. Rheumatology	2013	47
24252614	Antioxidants	Gan X	Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell.	Biochimica et biophysica acta	2014	42
24300239	Antioxidants	Dunn L	Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease.	Neurobiology of aging	2014	23
24350853	Antioxidants	Rodríguez-Rodríguez A	Oxidative stress in traumatic brain injury.	Current medicinal chemistry	2014	31
24462787	Antioxidants	Huynh K	Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.	Pharmacology & therapeutics	2014	72
24465942	Antioxidants	Ahn HJ	Targeting cancer cells with reactive oxygen and nitrogen species generated by atmospheric-pressure air plasma.	PloS one	2014	36
24630991	Antioxidants	Edwards MR	The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway.	Cell reports	2014	29
24681256	Antioxidants	Levonen AL	Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics.	Free radical biology & medicine	2014	49
24718857	Antioxidants	Hecker L	Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance.	Science translational medicine	2014	111
24915862	Antioxidants	Hussain S	Inflammasome activation in airway epithelial cells after multi-walled carbon nanotube exposure mediates a profibrotic response in lung fibroblasts.	Particle and fibre toxicology	2014	38
24928512	Antioxidants	Ge X	High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD).	The Journal of biological chemistry	2014	31
24953182	Antioxidants	Paul MK	Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling.	Cell stem cell	2014	52
25140450	Antioxidants	Choi BH	Effect of redox modulating NRF2 activators on chronic kidney disease.	Molecules	2014	21
25244505	Antioxidants	Li H	Vascular oxidative stress, nitric oxide and atherosclerosis.	Atherosclerosis	2014	76
25288763	Antioxidants	Umanskaya A	Genetically enhancing mitochondrial antioxidant activity improves muscle function in aging.	Proceedings of the National Academy of Sciences of the United States of America	2014	48
25576182	Antioxidants	Ruszkiewicz J	Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders.	Neurochemistry international	2015	19
25590811	Antioxidants	Singer E	Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.	Cell death & disease	2015	18
25620030	Antioxidants	Harris IS	Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.	Cancer cell	2015	99
25644686	Antioxidants	Bar-Or D	Oxidative stress in severe acute illness.	Redox biology	2015	15
25667085	Antioxidants	Picone P	Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: Use of insulin to attenuate metformin's effect.	Biochimica et biophysica acta	2015	16
25792665	Antioxidants	Ahmad T	Impaired mitophagy leads to cigarette smoke stress-induced cellular senescence: implications for chronic obstructive pulmonary disease.	FASEB journal 	2015	26
25828268	Antioxidants	Wiegman CH	Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease.	The Journal of allergy and clinical immunology	2015	41
25985305	Antioxidants	Checconi P	Redox proteomics of the inflammatory secretome identifies a common set of redoxins and other glutathionylated proteins released in inflammation, influenza virus infection and oxidative stress.	PloS one	2015	15
26024535	Antioxidants	Deng R	Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells.	PloS one	2015	17
26233704	Antioxidants	Espinosa-Diez C	Antioxidant responses and cellular adjustments to oxidative stress.	Redox biology	2015	77
26335400	Antioxidants	Richter K	Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences.	Redox biology	2015	25
26768768	Antioxidants	Pan H	SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2.	Cell research	2016	28
26823952	Antioxidants	Sallam N	Exercise Modulates Oxidative Stress and Inflammation in Aging and Cardiovascular Diseases.	Oxidative medicine and cellular longevity	2016	20
28007895	Antioxidants	Semenza GL	Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.	The EMBO journal	2017	12
12941837	gemcitabine	Maloney EK	An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.	Cancer research	2003	81
15226328	gemcitabine	Xiong HQ	Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.	Journal of clinical oncology 	2004	93
15501974	gemcitabine	Spratlin J	The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.	Clinical cancer research 	2004	82
15897578	gemcitabine	Berberat PO	Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.	Clinical cancer research 	2005	67
16239320	gemcitabine	Haraguchi N	Characterization of a side population of cancer cells from human gastrointestinal system.	Stem cells	2006	170
16258101	gemcitabine	Kindler HL	Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.	Journal of clinical oncology 	2005	107
16762633	gemcitabine	Meng F	Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.	Gastroenterology	2006	296
17131328	gemcitabine	Nakahira S	Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.	International journal of cancer	2007	59
17224927	gemcitabine	Nakano Y	Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.	British journal of cancer	2007	72
17229776	gemcitabine	Bellmunt J	Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.	Annals of oncology 	2007	69
17332349	gemcitabine	Feldmann G	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.	Cancer research	2007	242
17404099	gemcitabine	Nomi T	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.	Clinical cancer research 	2007	211
17452677	gemcitabine	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	876
18089802	gemcitabine	Olmeda D	SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells.	Cancer research	2007	61
18245495	gemcitabine	Hwang RF	Cancer-associated stromal fibroblasts promote pancreatic tumor progression.	Cancer research	2008	289
18263769	gemcitabine	Ramalingam S	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.	The oncologist	2008	80
18281656	gemcitabine	Edelman MJ	Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.	Journal of clinical oncology 	2008	70
18413796	gemcitabine	Melisi D	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.	Molecular cancer therapeutics	2008	93
18509182	gemcitabine	Brunner TB	Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.	Journal of clinical oncology 	2008	51
18829536	gemcitabine	Ramachandran V	Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.	Cancer research	2008	51
19139112	gemcitabine	Parsels LA	Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.	Molecular cancer therapeutics	2009	51
19174553	gemcitabine	Jimeno A	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.	Molecular cancer therapeutics	2009	104
19237188	gemcitabine	Boren T	MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.	Gynecologic oncology	2009	50
19276344	gemcitabine	Wang Z	Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.	Cancer research	2009	195
19318496	gemcitabine	Maréchal R	Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.	Clinical cancer research 	2009	48
19366899	gemcitabine	Beltran PJ	AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.	Molecular cancer therapeutics	2009	52
19435867	gemcitabine	Moriyama T	MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.	Molecular cancer therapeutics	2009	118
19487279	gemcitabine	Costantino CL	The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.	Cancer research	2009	51
19501590	gemcitabine	Mueller MT	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.	Gastroenterology	2009	81
19584296	gemcitabine	Arumugam T	Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.	Cancer research	2009	241
19598259	gemcitabine	Hong SP	CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.	International journal of cancer	2009	80
19654003	gemcitabine	Crawford M	MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.	Biochemical and biophysical research communications	2009	60
19730150	gemcitabine	Park JK	Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.	Pancreas	2009	87
19908231	gemcitabine	Harikumar KB	Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.	International journal of cancer	2010	52
20072652	gemcitabine	Lin L	A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.	Neoplasia	2010	54
20150572	gemcitabine	Reck M	Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).	Annals of oncology 	2010	138
20388782	gemcitabine	Ali S	Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.	Cancer research	2010	130
20460539	gemcitabine	Giovannetti E	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.	Cancer research	2010	122
20501833	gemcitabine	Morgan MA	Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.	Cancer research	2010	100
20606093	gemcitabine	Philip PA	Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.	Journal of clinical oncology 	2010	167
20798217	gemcitabine	Hastak K	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.	Cancer research	2010	47
20803052	gemcitabine	Kindler HL	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.	Investigational new drugs	2012	31
20824720	gemcitabine	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	44
21045835	gemcitabine	Singh S	CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.	British journal of cancer	2010	59
21078544	gemcitabine	Arlt A	Targeting apoptosis pathways in pancreatic cancer.	Cancer letters	2013	27
21081113	gemcitabine	Kikuta K	Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells.	Biochemical and biophysical research communications	2010	54
21106054	gemcitabine	Zhang XJ	Dysregulation of miR-15a and miR-214 in human pancreatic cancer.	Journal of hematology & oncology	2010	57
21135251	gemcitabine	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	71
21148071	gemcitabine	Dangi-Garimella S	Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.	Cancer research	2011	37
21177151	gemcitabine	Bensouda Y	Treatment for metastatic nasopharyngeal carcinoma.	European annals of otorhinolaryngology, head and neck diseases	2011	46
21208101	gemcitabine	O'Shaughnessy J	Iniparib plus chemotherapy in metastatic triple-negative breast cancer.	The New England journal of medicine	2011	196
21306953	gemcitabine	Kindler HL	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.	The Lancet. Oncology	2011	101
21389100	gemcitabine	Rajeshkumar NV	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.	Clinical cancer research 	2011	71
21408027	gemcitabine	Bao B	Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.	PloS one	2011	73
21436454	gemcitabine	Beatty GL	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.	Science	2011	405
21525939	gemcitabine	Donadelli M	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.	Cell death & disease	2011	45
21594619	gemcitabine	Bodoky G	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 ARRY-142886) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.	Investigational new drugs	2012	51
21885862	gemcitabine	Taeger J	Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.	Molecular cancer therapeutics	2011	35
21969517	gemcitabine	Von Hoff DD	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.	Journal of clinical oncology 	2011	260
22019520	gemcitabine	Quoix E	Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.	The Lancet. Oncology	2011	73
22056140	gemcitabine	Lonardo E	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.	Cell stem cell	2011	102
22086681	gemcitabine	Bao B	Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.	Cancer prevention research	2012	101
22276821	gemcitabine	Bear HD	Bevacizumab added to neoadjuvant chemotherapy for breast cancer.	The New England journal of medicine	2012	104
22285168	gemcitabine	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	1030
22330686	gemcitabine	Postel-Vinay S	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.	Nature reviews. Clinical oncology	2012	31
22363658	gemcitabine	Zhang G	DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.	PloS one	2012	39
22458527	gemcitabine	Troiani T	Targeting EGFR in pancreatic cancer treatment.	Current drug targets	2012	33
22510406	gemcitabine	Hamada S	Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells.	Biochemical and biophysical research communications	2012	46
22580602	gemcitabine	Skrypek N	The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.	Oncogene	2013	29
22589274	gemcitabine	Kelber JA	KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.	Cancer research	2012	33
22700995	gemcitabine	Kindler HL	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.	Annals of oncology 	2012	55
22705007	gemcitabine	Maréchal R	Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.	Gastroenterology	2012	60
22778317	gemcitabine	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	64
22825331	gemcitabine	Prevo R	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.	Cancer biology & therapy	2012	57
23177026	gemcitabine	Wang P	The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.	Molecular oncology	2013	38
23318457	gemcitabine	Sia D	Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.	Oncogene	2013	49
23341531	gemcitabine	Herman JM	Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.	Journal of clinical oncology 	2013	36
23402593	gemcitabine	Lee GY	Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.	ACS nano	2013	47
23402814	gemcitabine	Yabuuchi S	Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.	Cancer letters	2013	41
23437065	gemcitabine	Proctor E	Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.	PloS one	2013	32
23520471	gemcitabine	Kreahling JM	Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.	PloS one	2013	26
23547081	gemcitabine	Ueno H	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.	Journal of clinical oncology 	2013	89
23548269	gemcitabine	Huntoon CJ	ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.	Cancer research	2013	38
23593991	gemcitabine	Thompson R	The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.	British journal of clinical pharmacology	2013	35
23661005	gemcitabine	Hage C	The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.	Cell death & disease	2013	39
23690416	gemcitabine	Bepler G	Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	40
23740244	gemcitabine	Arora S	An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.	The Journal of biological chemistry	2013	44
23782814	gemcitabine	Wu YL	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.	The Lancet. Oncology	2013	75
23849556	gemcitabine	Heinemann V	Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.	Cancer treatment reviews	2014	30
23995783	gemcitabine	Weizman N	Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.	Oncogene	2014	45
24178759	gemcitabine	Maftouh M	Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.	British journal of cancer	2014	23
24216611	gemcitabine	Hamada S	MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.	Cellular signalling	2014	25
24220555	gemcitabine	Poplin E	Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.	Journal of clinical oncology 	2013	39
24282274	gemcitabine	Fitzgerald JB	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.	Molecular cancer therapeutics	2014	26
24301456	gemcitabine	Greenhalf W	Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.	Journal of the National Cancer Institute	2014	52
24351397	gemcitabine	Valle JW	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.	Annals of oncology 	2014	52
24360787	gemcitabine	Earl HM	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.	The Lancet. Oncology	2014	23
24439929	gemcitabine	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	282
24448638	gemcitabine	Sausville E	Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.	Cancer chemotherapy and pharmacology	2014	31
24683721	gemcitabine	Thota R	Treatment of metastatic pancreatic adenocarcinoma: a review.	Oncology	2014	37
24859161	gemcitabine	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	29
24919854	gemcitabine	Gelbert LM	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	Investigational new drugs	2014	57
24954781	gemcitabine	Middleton G	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2014	52
25034785	gemcitabine	Zeuner A	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.	Cell death and differentiation	2014	27
25041791	gemcitabine	Philip PA	Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).	Cancer	2014	27
25056373	gemcitabine	Koido S	Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.	Clinical cancer research 	2014	26
25104095	gemcitabine	Bryant C	Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.	BMC cancer	2014	23
25117811	gemcitabine	Hasegawa S	MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.	British journal of cancer	2014	27
25149530	gemcitabine	Xu J	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.	Oncotarget	2014	24
25156567	gemcitabine	Franco J	CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.	Oncotarget	2014	31
25249556	gemcitabine	Yu G	Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.	Molecular cancer therapeutics	2014	44
25277192	gemcitabine	Khan S	MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.	Oncotarget	2014	33
25278454	gemcitabine	Kim EJ	Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.	Clinical cancer research 	2014	36
25366685	gemcitabine	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	192
25473894	gemcitabine	Suzuki S	JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.	Oncotarget	2015	18
25498218	gemcitabine	Sternberg CN	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	32
25589191	gemcitabine	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	226
25609246	gemcitabine	Fuchs CS	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.	Annals of oncology 	2015	25
25638153	gemcitabine	Ma J	Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.	Oncotarget	2015	29
25717063	gemcitabine	Cioffi M	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.	Clinical cancer research 	2015	20
25832687	gemcitabine	Tan T	Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.	International journal of radiation oncology, biology, physics	2015	35
25834145	gemcitabine	Duluc C	Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.	EMBO molecular medicine	2015	20
25840985	gemcitabine	Khan S	Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.	Cancer research	2015	19
25847929	gemcitabine	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	35
25889214	gemcitabine	Li Z	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.	Journal of translational medicine	2015	45
26036346	gemcitabine	Tréhoux S	Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.	Biochimica et biophysica acta	2015	20
26077591	gemcitabine	Miller BW	Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.	EMBO molecular medicine	2015	33
26169969	gemcitabine	Hidalgo M	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.	Clinical cancer research 	2015	30
26179201	gemcitabine	Valle JW	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.	The Lancet. Oncology	2015	23
26234680	gemcitabine	Calabretta S	Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.	Oncogene	2016	18
26255562	gemcitabine	Nagathihalli NS	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.	Gastroenterology	2015	16
26351344	gemcitabine	Hurwitz HI	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.	Journal of clinical oncology 	2015	35
26410730	gemcitabine	Oing C	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.	The Journal of urology	2016	10
26517239	gemcitabine	Vendetti FP	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.	Oncotarget	2015	26
26527777	gemcitabine	Catenacci DV	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.	Journal of clinical oncology 	2015	30
26546043	gemcitabine	Tyagi N	p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling.	Cancer letters	2016	13
26666820	gemcitabine	Wu ZH	MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.	Tumour biology 	2016	14
26817584	gemcitabine	Liu Y	MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.	Journal of experimental & clinical cancer research 	2016	11
26828016	gemcitabine	Fan P	MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.	Cancer letters	2016	10
26939701	gemcitabine	Gifford JB	Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.	Molecular cancer therapeutics	2016	11
26957554	gemcitabine	Telli ML	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.	Clinical cancer research 	2016	33
27003603	gemcitabine	Wörmann SM	Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.	Gastroenterology	2016	17
27007129	gemcitabine	Ciccolini J	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.	Cancer chemotherapy and pharmacology	2016	14
27216178	gemcitabine	Schultz MJ	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.	Cancer research	2016	12
27265347	gemcitabine	Uesaka K	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).	Lancet	2016	23
27502726	gemcitabine	Olaussen KA	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.	Annals of oncology 	2016	12
27576197	gemcitabine	Zhang Z	Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.	Cancer letters	2016	18
27591936	gemcitabine	Pan J	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.	Cancer letters	2016	20
27669441	gemcitabine	Richards KE	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.	Oncogene	2017	28
27742686	gemcitabine	Ireland L	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.	Cancer research	2016	16
28034748	gemcitabine	Zhang Y	MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.	Biochemical and biophysical research communications	2017	6
28108630	gemcitabine	Cullis J	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.	Cancer immunology research	2017	7
16118624	O-(6)-methylguanine	Ogino S	Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.	Modern pathology 	2006	78
18483356	O-(6)-methylguanine	Sarkaria JN	Mechanisms of chemoresistance to alkylating agents in malignant glioma.	Clinical cancer research 	2008	83
19088037	O-(6)-methylguanine	Pallini R	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.	Clinical cancer research 	2008	95
19107440	O-(6)-methylguanine	Ohgaki H	Epidemiology of brain tumors.	Methods in molecular biology	2009	92
19676044	O-(6)-methylguanine	Salnikov AV	CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.	International journal of cancer	2010	54
19805672	O-(6)-methylguanine	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	142
20150378	O-(6)-methylguanine	Rivera AL	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.	Neuro-oncology	2010	60
20309962	O-(6)-methylguanine	Pistollato F	Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.	Stem cells	2010	66
20714900	O-(6)-methylguanine	Riemenschneider MJ	Molecular diagnostics of gliomas: state of the art.	Acta neuropathologica	2010	47
20880848	O-(6)-methylguanine	Zhang WB	Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.	The Journal of biological chemistry	2010	43
21292686	O-(6)-methylguanine	Kunz M	Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.	Neuro-oncology	2011	37
23095825	O-(6)-methylguanine	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23348904	O-(6)-methylguanine	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	53
23785428	O-(6)-methylguanine	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	39
23904111	O-(6)-methylguanine	Wiestler B	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.	Acta neuropathologica	2013	51
24469053	O-(6)-methylguanine	Zhang LH	TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway.	Oncogene	2015	16
24510240	O-(6)-methylguanine	Molenaar RJ	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.	Neuro-oncology	2014	26
25178641	O-(6)-methylguanine	Millis SZ	Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.	Clinical genitourinary cancer	2015	15
25537990	O-(6)-methylguanine	Jansen NL	Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.	Journal of nuclear medicine 	2015	16
26948350	O-(6)-methylguanine	Masui K	Molecular classification of gliomas.	Handbook of clinical neurology	2016	14
8962091	Reactive Oxygen Species	Xiang J	BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases.	Proceedings of the National Academy of Sciences of the United States of America	1996	132
9633809	Reactive Oxygen Species	Hall ED	Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.	Glia	1998	124
9704769	Reactive Oxygen Species	Sacks GP	Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis.	American journal of obstetrics and gynecology	1998	146
10385613	Reactive Oxygen Species	Bouloumie A	Leptin induces oxidative stress in human endothelial cells.	FASEB journal 	1999	107
11304501	Reactive Oxygen Species	Dzau VJ	Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.	Hypertension	2001	96
12176889	Reactive Oxygen Species	Dekker RJ	Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2).	Blood	2002	160
15279799	Reactive Oxygen Species	Barzilai A	DNA damage responses to oxidative stress.	DNA repair	2004	111
15297389	Reactive Oxygen Species	De Larco JE	The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8.	Clinical cancer research 	2004	72
15647368	Reactive Oxygen Species	Petros JA	mtDNA mutations increase tumorigenicity in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	249
15738989	Reactive Oxygen Species	Krauss S	The mitochondrial uncoupling-protein homologues.	Nature reviews. Molecular cell biology	2005	145
15820197	Reactive Oxygen Species	Brandes RP	Endothelial aging.	Cardiovascular research	2005	123
16155123	Reactive Oxygen Species	Yang Y	Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling.	Proceedings of the National Academy of Sciences of the United States of America	2005	108
16163384	Reactive Oxygen Species	Achanta G	Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma.	The EMBO journal	2005	99
16166634	Reactive Oxygen Species	Storz P	Protein kinase D mediates mitochondrion-to-nucleus signaling and detoxification from mitochondrial reactive oxygen species.	Molecular and cellular biology	2005	82
16294028	Reactive Oxygen Species	Desouki MM	Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors.	Cancer biology & therapy	2005	66
16456579	Reactive Oxygen Species	Papa S	The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease.	Cell death and differentiation	2006	70
16636067	Reactive Oxygen Species	Cheng G	Nox1-dependent reactive oxygen generation is regulated by Rac1.	The Journal of biological chemistry	2006	86
16771662	Reactive Oxygen Species	Cave AC	NADPH oxidases in cardiovascular health and disease.	Antioxidants & redox signaling	2006	164
16950166	Reactive Oxygen Species	Festjens N	Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response.	Biochimica et biophysica acta	2006	155
16971498	Reactive Oxygen Species	Chen Q	Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion.	American journal of physiology. Cell physiology	2007	86
17116235	Reactive Oxygen Species	Lambert MP	Monoclonal antibodies that target pathological assemblies of Abeta.	Journal of neurochemistry	2007	109
17127365	Reactive Oxygen Species	Mancuso C	Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders.	Frontiers in bioscience 	2007	70
17160708	Reactive Oxygen Species	Wu WS	The signaling mechanism of ROS in tumor progression.	Cancer metastasis reviews	2006	175
17179479	Reactive Oxygen Species	Phillips TM	The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.	Journal of the National Cancer Institute	2006	416
17237347	Reactive Oxygen Species	Bedard K	The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.	Physiological reviews	2007	1434
17250680	Reactive Oxygen Species	Haorah J	Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction.	Journal of neurochemistry	2007	79
17292829	Reactive Oxygen Species	Dolado I	p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis.	Cancer cell	2007	115
17369289	Reactive Oxygen Species	Sturrock A	Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells.	American journal of physiology. Lung cellular and molecular physiology	2007	58
17456604	Reactive Oxygen Species	Zhou S	Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck.	Proceedings of the National Academy of Sciences of the United States of America	2007	56
17584843	Reactive Oxygen Species	Newsholme P	Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity.	The Journal of physiology	2007	114
17726019	Reactive Oxygen Species	Leclerc E	S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.	The Journal of biological chemistry	2007	56
17914462	Reactive Oxygen Species	Kumar A	Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species.	The EMBO journal	2007	74
17924549	Reactive Oxygen Species	Luo HR	Constitutive neutrophil apoptosis: mechanisms and regulation.	American journal of hematology	2008	77
17967865	Reactive Oxygen Species	Guzy RD	Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis.	Molecular and cellular biology	2008	113
17984303	Reactive Oxygen Species	Tsung A	HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling.	The Journal of experimental medicine	2007	176
18006487	Reactive Oxygen Species	Gustafsson AB	Heart mitochondria: gates of life and death.	Cardiovascular research	2008	95
18192505	Reactive Oxygen Species	Sallmyr A	Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.	Blood	2008	79
18245082	Reactive Oxygen Species	Devi L	Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.	The Journal of biological chemistry	2008	198
18339858	Reactive Oxygen Species	Kumar B	Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.	Cancer research	2008	157
18372916	Reactive Oxygen Species	Frohlich DA	The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.	Oncogene	2008	58
18394557	Reactive Oxygen Species	Duran A	The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.	Cancer cell	2008	181
18547751	Reactive Oxygen Species	Hsin YH	The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells.	Toxicology letters	2008	87
18791199	Reactive Oxygen Species	Cannito S	Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells.	Carcinogenesis	2008	91
18795165	Reactive Oxygen Species	Pacurari M	Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells.	Environmental health perspectives	2008	57
18801366	Reactive Oxygen Species	Lim SO	Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.	Gastroenterology	2008	80
18831567	Reactive Oxygen Species	Carlson C	Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species.	The journal of physical chemistry. B	2008	154
18979503	Reactive Oxygen Species	Tonissen KF	Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.	Molecular nutrition & food research	2009	48
19023330	Reactive Oxygen Species	Moisoi N	Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response.	Cell death and differentiation	2009	47
19047340	Reactive Oxygen Species	Hori M	Oxidative stress and left ventricular remodelling after myocardial infarction.	Cardiovascular research	2009	95
19059306	Reactive Oxygen Species	Garrido AM	NADPH oxidases and angiotensin II receptor signaling.	Molecular and cellular endocrinology	2009	99
19190247	Reactive Oxygen Species	Lucas DM	The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.	Blood	2009	55
19276362	Reactive Oxygen Species	Pelicano H	Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism.	Cancer research	2009	48
19285945	Reactive Oxygen Species	Gandhi S	PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.	Molecular cell	2009	170
19309263	Reactive Oxygen Species	Sorce S	NOX enzymes in the central nervous system: from signaling to disease.	Antioxidants & redox signaling	2009	122
19413947	Reactive Oxygen Species	Lebedeva MA	Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis.	Biochimica et biophysica acta	2009	62
19447517	Reactive Oxygen Species	Baffy G	Kupffer cells in non-alcoholic fatty liver disease: the emerging view.	Journal of hepatology	2009	107
19493276	Reactive Oxygen Species	Kamata T	Roles of Nox1 and other Nox isoforms in cancer development.	Cancer science	2009	49
19607894	Reactive Oxygen Species	Foldbjerg R	PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes.	Toxicology letters	2009	76
19706526	Reactive Oxygen Species	Bertout JA	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.	Proceedings of the National Academy of Sciences of the United States of America	2009	59
19715758	Reactive Oxygen Species	Gibson GE	Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.	Biochimica et biophysica acta	2010	64
19801454	Reactive Oxygen Species	Zhou G	Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1.	American journal of physiology. Lung cellular and molecular physiology	2009	62
19910640	Reactive Oxygen Species	Lassègue B	NADPH oxidases: functions and pathologies in the vasculature.	Arteriosclerosis, thrombosis, and vascular biology	2010	180
20179104	Reactive Oxygen Species	Mai S	Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1.	Journal of cell science	2010	49
20186336	Reactive Oxygen Species	Krebiehl G	Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1.	PloS one	2010	88
20354226	Reactive Oxygen Species	Vandenabeele P	The role of the kinases RIP1 and RIP3 in TNF-induced necrosis.	Science signaling	2010	148
20385539	Reactive Oxygen Species	Chu CT	A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease.	Human molecular genetics	2010	52
20453876	Reactive Oxygen Species	Bobrovnikova-Marjon E	PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage.	Oncogene	2010	78
20488920	Reactive Oxygen Species	Jutooru I	Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.	Molecular pharmacology	2010	44
20495074	Reactive Oxygen Species	Meissner F	Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease.	Blood	2010	81
20523116	Reactive Oxygen Species	Graham KA	NADPH oxidase 4 is an oncoprotein localized to mitochondria.	Cancer biology & therapy	2010	64
20535745	Reactive Oxygen Species	Toullec A	Oxidative stress promotes myofibroblast differentiation and tumour spreading.	EMBO molecular medicine	2010	74
20574517	Reactive Oxygen Species	Venkataraman S	MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence.	PloS one	2010	55
20639397	Reactive Oxygen Species	Irrcher I	Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics.	Human molecular genetics	2010	115
20655326	Reactive Oxygen Species	Mammucari C	Signaling pathways in mitochondrial dysfunction and aging.	Mechanisms of ageing and development	2010	67
20685750	Reactive Oxygen Species	Amara N	NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts.	Thorax	2010	73
20715845	Reactive Oxygen Species	Gianni D	A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells.	ACS chemical biology	2010	51
20861671	Reactive Oxygen Species	Lisanti MP	Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.	Cancer biology & therapy	2010	66
20880500	Reactive Oxygen Species	Lull ME	Microglial activation and chronic neurodegeneration.	Neurotherapeutics 	2010	124
20923773	Reactive Oxygen Species	Luanpitpong S	Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1.	The Journal of biological chemistry	2010	41
20965425	Reactive Oxygen Species	Wellen KE	Cellular metabolic stress: considering how cells respond to nutrient excess.	Molecular cell	2010	99
21071633	Reactive Oxygen Species	Indran IR	hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells.	Cancer research	2011	49
21098019	Reactive Oxygen Species	Lin W	HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB.	The Journal of biological chemistry	2011	39
21124315	Reactive Oxygen Species	Zhou R	A role for mitochondria in NLRP3 inflammasome activation.	Nature	2011	887
21224240	Reactive Oxygen Species	Powers SK	Reactive oxygen and nitrogen species as intracellular signals in skeletal muscle.	The Journal of physiology	2011	56
21235356	Reactive Oxygen Species	Giannoni E	Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness.	Antioxidants & redox signaling	2011	50
21300795	Reactive Oxygen Species	Kim MJ	Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation.	The Journal of biological chemistry	2011	76
21307839	Reactive Oxygen Species	Barnes JL	Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases.	Kidney international	2011	108
21320885	Reactive Oxygen Species	Jackson MJ	Age-related changes in skeletal muscle reactive oxygen species generation and adaptive responses to reactive oxygen species.	The Journal of physiology	2011	35
21350183	Reactive Oxygen Species	Chiang DJ	Obesity, diabetes mellitus, and liver fibrosis.	American journal of physiology. Gastrointestinal and liver physiology	2011	42
21397863	Reactive Oxygen Species	Finley LW	SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization.	Cancer cell	2011	221
21411759	Reactive Oxygen Species	Zou J	Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting.	Blood	2011	91
21555567	Reactive Oxygen Species	Shaw AT	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.	Proceedings of the National Academy of Sciences of the United States of America	2011	56
21567162	Reactive Oxygen Species	Shao L	Reactive oxygen species and hematopoietic stem cell senescence.	International journal of hematology	2011	39
21637292	Reactive Oxygen Species	Geering B	Peculiarities of cell death mechanisms in neutrophils.	Cell death and differentiation	2011	65
21853114	Reactive Oxygen Species	Hahm ER	Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species.	PloS one	2011	52
21878644	Reactive Oxygen Species	Achuthan S	Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.	The Journal of biological chemistry	2011	47
21916837	Reactive Oxygen Species	Arden GB	Hypoxia and oxidative stress in the causation of diabetic retinopathy.	Current diabetes reviews	2011	38
21951851	Reactive Oxygen Species	Li ZY	Mitochondrial ROS generation for regulation of autophagic pathways in cancer.	Biochemical and biophysical research communications	2011	58
22064655	Reactive Oxygen Species	Huang WC	Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.	Molecular cancer research 	2012	51
22072942	Reactive Oxygen Species	Chen SD	Roles of oxidative stress, apoptosis, PGC-1α and mitochondrial biogenesis in cerebral ischemia.	International journal of molecular sciences	2011	49
22079466	Reactive Oxygen Species	Piao LS	CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.	Cancer letters	2012	53
22170153	Reactive Oxygen Species	Mai S	Autophagy proteins LC3B, ATG5 and ATG12 participate in quality control after mitochondrial damage and influence lifespan.	Autophagy	2012	42
22313689	Reactive Oxygen Species	Hegde ML	Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases.	Mechanisms of ageing and development	2012	38
22331464	Reactive Oxygen Species	Ma J	PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.	Molecular and cellular biology	2012	37
22341444	Reactive Oxygen Species	Raimundo N	Mitochondrial stress engages E2F1 apoptotic signaling to cause deafness.	Cell	2012	58
22342343	Reactive Oxygen Species	Formentini L	The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response.	Molecular cell	2012	48
22366799	Reactive Oxygen Species	Fischer MT	NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury.	Brain 	2012	87
22367679	Reactive Oxygen Species	Kaur C	Roles of activated microglia in hypoxia induced neuroinflammation in the developing brain and the retina.	Journal of neuroimmune pharmacology 	2013	29
22388960	Reactive Oxygen Species	Wu LJ	The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke.	Nature neuroscience	2012	60
22411871	Reactive Oxygen Species	Nieborowska-Skorska M	Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.	Blood	2012	32
22411934	Reactive Oxygen Species	Salminen A	Inflammaging: disturbed interplay between autophagy and inflammasomes.	Aging	2012	79
22442078	Reactive Oxygen Species	Misko AL	Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration.	The Journal of neuroscience 	2012	39
22448145	Reactive Oxygen Species	Bayat V	Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans.	PLoS biology	2012	60
22522114	Reactive Oxygen Species	Kotsakis A	Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.	Journal of immunological methods	2012	51
22530599	Reactive Oxygen Species	Nguyen Dinh Cat A	Angiotensin II, NADPH oxidase, and redox signaling in the vasculature.	Antioxidants & redox signaling	2013	55
22549002	Reactive Oxygen Species	Barone E	Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment.	Free radical biology & medicine	2012	32
22581365	Reactive Oxygen Species	Surace MJ	Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors.	Cellular and molecular life sciences 	2012	32
22871044	Reactive Oxygen Species	Vernon PJ	Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling.	Antioxidants & redox signaling	2013	33
22897481	Reactive Oxygen Species	Sheng SL	Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.	The FEBS journal	2012	42
22917578	Reactive Oxygen Species	Frank M	Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner.	Biochimica et biophysica acta	2012	90
22986741	Reactive Oxygen Species	Jerby L	Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.	Cancer research	2012	31
23003569	Reactive Oxygen Species	Cheng G	Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies.	British journal of pharmacology	2012	39
23063463	Reactive Oxygen Species	Samarakoon R	TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.	Cellular signalling	2013	80
23092325	Reactive Oxygen Species	Tibullo D	Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.	Current pharmaceutical design	2013	27
23220288	Reactive Oxygen Species	Prosser BL	X-ROS signaling in the heart and skeletal muscle: stretch-dependent local ROS regulates Ca²⁺i.	Journal of molecular and cellular cardiology	2013	28
23239023	Reactive Oxygen Species	Qi X	A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity.	Journal of cell science	2013	68
23248151	Reactive Oxygen Species	Sun B	Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.	Hypertension	2013	28
23323860	Reactive Oxygen Species	Padgett LE	The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis.	Annals of the New York Academy of Sciences	2013	61
23333149	Reactive Oxygen Species	Lagadinou ED	BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.	Cell stem cell	2013	142
23334333	Reactive Oxygen Species	Nagano O	Redox regulation in stem-like cancer cells by CD44 variant isoforms.	Oncogene	2013	62
23347351	Reactive Oxygen Species	Liu G	Molecular basis of asbestos-induced lung disease.	Annual review of pathology	2013	32
23378588	Reactive Oxygen Species	Gasparre G	Relevance of mitochondrial genetics and metabolism in cancer development.	Cold Spring Harbor perspectives in biology	2013	30
23392169	Reactive Oxygen Species	Luo H	PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells.	Cell death & disease	2013	35
23514110	Reactive Oxygen Species	Kozieł R	Mitochondrial respiratory chain complex I is inactivated by NADPH oxidase Nox4.	The Biochemical journal	2013	32
23535601	Reactive Oxygen Species	Son J	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.	Nature	2013	342
23564668	Reactive Oxygen Species	Gray SP	NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis.	Circulation	2013	86
23634225	Reactive Oxygen Species	Freeman D	Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis.	PloS one	2013	39
23688501	Reactive Oxygen Species	Sid B	Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease.	Biochemical pharmacology	2013	31
23795962	Reactive Oxygen Species	Lerner C	Reduced mammalian target of rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts.	Aging cell	2013	26
23828498	Reactive Oxygen Species	Markowitz J	Myeloid-derived suppressor cells in breast cancer.	Breast cancer research and treatment	2013	32
23841983	Reactive Oxygen Species	Yu E	Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans.	Circulation	2013	34
23936814	Reactive Oxygen Species	Gurunathan S	Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells.	BioMed research international	2013	30
23954133	Reactive Oxygen Species	Iyer SS	Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation.	Immunity	2013	114
23970124	Reactive Oxygen Species	Sedeek M	NADPH oxidases, reactive oxygen species, and the kidney: friend and foe.	Journal of the American Society of Nephrology 	2013	48
23975169	Reactive Oxygen Species	Magenta A	Oxidative stress and microRNAs in vascular diseases.	International journal of molecular sciences	2013	40
23984879	Reactive Oxygen Species	Ishibashi Y	Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.	Cardiovascular diabetology	2013	35
24040957	Reactive Oxygen Species	Paik YH	Role of NADPH oxidases in liver fibrosis.	Antioxidants & redox signaling	2014	43
24056969	Reactive Oxygen Species	Hara H	Mitochondrial fragmentation in cigarette smoke-induced bronchial epithelial cell senescence.	American journal of physiology. Lung cellular and molecular physiology	2013	27
24080946	Reactive Oxygen Species	Stankov MV	Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.	Leukemia	2014	21
24121277	Reactive Oxygen Species	Venere M	Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.	Cell death and differentiation	2014	37
24133204	Reactive Oxygen Species	Kang T	MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells.	The Journal of biological chemistry	2013	33
24180474	Reactive Oxygen Species	Konior A	NADPH oxidases in vascular pathology.	Antioxidants & redox signaling	2014	52
24185179	Reactive Oxygen Species	Sato A	Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.	Stem cell research	2014	26
24186494	Reactive Oxygen Species	Xu Z	NRF2 plays a protective role in diabetic retinopathy in mice.	Diabetologia	2014	31
24300855	Reactive Oxygen Species	Kim YW	Oxidative stress in angiogenesis and vascular disease.	Blood	2014	54
24371120	Reactive Oxygen Species	Gouspillou G	Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans.	FASEB journal 	2014	35
24381719	Reactive Oxygen Species	Popa-Wagner A	ROS and brain diseases: the good, the bad, and the ugly.	Oxidative medicine and cellular longevity	2013	29
24418575	Reactive Oxygen Species	Mehla K	MUC1: a novel metabolic master regulator.	Biochimica et biophysica acta	2014	21
24455696	Reactive Oxygen Species	Hsieh HL	Role of redox signaling in neuroinflammation and neurodegenerative diseases.	BioMed research international	2013	59
24469051	Reactive Oxygen Species	Yin M	Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation.	Oncogene	2015	20
24509161	Reactive Oxygen Species	Crosas-Molist E	The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression.	Free radical biology & medicine	2014	20
24583638	Reactive Oxygen Species	Ogrunc M	Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.	Cell death and differentiation	2014	46
24610934	Reactive Oxygen Species	Aravamudan B	Cigarette smoke-induced mitochondrial fragmentation and dysfunction in human airway smooth muscle.	American journal of physiology. Lung cellular and molecular physiology	2014	32
24663091	Reactive Oxygen Species	Frangogiannis NG	The inflammatory response in myocardial injury, repair, and remodelling.	Nature reviews. Cardiology	2014	115
24675724	Reactive Oxygen Species	Tian FJ	Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis.	Cardiovascular research	2014	24
24692350	Reactive Oxygen Species	Bhattacharyya A	Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.	Physiological reviews	2014	99
24779584	Reactive Oxygen Species	Hazeldine J	Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals.	Aging cell	2014	28
24787293	Reactive Oxygen Species	Martinez-Outschoorn U	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.	Seminars in oncology	2014	40
24791940	Reactive Oxygen Species	Cortez MA	Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.	Molecular therapy 	2014	38
24813252	Reactive Oxygen Species	Wang G	Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.	Nature medicine	2014	139
24832602	Reactive Oxygen Species	Park EJ	β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.	Cell death & disease	2014	26
24836575	Reactive Oxygen Species	Schwab L	Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.	Nature medicine	2014	30
24875536	Reactive Oxygen Species	Zhang L	Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.	Toxicology letters	2014	28
24916152	Reactive Oxygen Species	Deffert C	Phagocyte NADPH oxidase, chronic granulomatous disease and mycobacterial infections.	Cellular microbiology	2014	26
25028121	Reactive Oxygen Species	Pal R	Src-dependent impairment of autophagy by oxidative stress in a mouse model of Duchenne muscular dystrophy.	Nature communications	2014	44
25078148	Reactive Oxygen Species	Marcos-Ramiro B	TNF-induced endothelial barrier disruption: beyond actin and Rho.	Thrombosis and haemostasis	2014	22
25091898	Reactive Oxygen Species	Bordt EA	NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair?	Free radical biology & medicine	2014	23
25186948	Reactive Oxygen Species	Ye J	Serine catabolism regulates mitochondrial redox control during hypoxia.	Cancer discovery	2014	58
25253673	Reactive Oxygen Species	Ebert AD	Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system.	Science translational medicine	2014	27
25341036	Reactive Oxygen Species	Huang H	Mcl-1 promotes lung cancer cell migration by directly interacting with VDAC to increase mitochondrial Ca2+ uptake and reactive oxygen species generation.	Cell death & disease	2014	23
25406339	Reactive Oxygen Species	Kawakami T	Deficient Autophagy Results in Mitochondrial Dysfunction and FSGS.	Journal of the American Society of Nephrology 	2015	27
25416158	Reactive Oxygen Species	Harischandra DS	α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.	Toxicological sciences 	2015	22
25497091	Reactive Oxygen Species	Baek G	MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.	Cell reports	2014	25
25521078	Reactive Oxygen Species	Olagnier D	Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells.	PLoS pathogens	2014	36
25541259	Reactive Oxygen Species	Mizuno T	Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.	Gynecologic oncology	2015	24
25592377	Reactive Oxygen Species	Liu X	NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer.	Tumour biology 	2015	16
25628390	Reactive Oxygen Species	Huang Q	Thioredoxin-2 inhibits mitochondrial reactive oxygen species generation and apoptosis stress kinase-1 activity to maintain cardiac function.	Circulation	2015	28
25651975	Reactive Oxygen Species	Hart PC	MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer.	Nature communications	2015	36
25714760	Reactive Oxygen Species	Ito S	PARK2-mediated mitophagy is involved in regulation of HBEC senescence in COPD pathogenesis.	Autophagy	2015	27
25767287	Reactive Oxygen Species	McMaster WG	Inflammation, immunity, and hypertensive end-organ damage.	Circulation research	2015	83
25782072	Reactive Oxygen Species	Zeng H	High-fat diet induces cardiac remodelling and dysfunction: assessment of the role played by SIRT3 loss.	Journal of cellular and molecular medicine	2015	17
26078812	Reactive Oxygen Species	Krstić J	Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression.	Oxidative medicine and cellular longevity	2015	22
26080835	Reactive Oxygen Species	Cottini F	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.	Cancer discovery	2015	22
26099526	Reactive Oxygen Species	Xu MJ	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans.	Gastroenterology	2015	23
26184557	Reactive Oxygen Species	Klotz LO	Redox regulation of FoxO transcription factors.	Redox biology	2015	45
26210446	Reactive Oxygen Species	O'Neill S	Genetic disorders coupled to ROS deficiency.	Redox biology	2015	19
26222337	Reactive Oxygen Species	Lan T	Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation.	PloS one	2015	26
26319899	Reactive Oxygen Species	Xu X	Aldehyde dehydrogenases and cancer stem cells.	Cancer letters	2015	19
26341399	Reactive Oxygen Species	Bronner DN	Endoplasmic Reticulum Stress Activates the Inflammasome via NLRP3- and Caspase-2-Driven Mitochondrial Damage.	Immunity	2015	36
26627594	Reactive Oxygen Species	Qian P	The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism.	Cell stem cell	2016	19
26631723	Reactive Oxygen Species	Yu W	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.	The Journal of biological chemistry	2016	12
26675351	Reactive Oxygen Species	Vinchi F	Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.	Blood	2016	27
26682001	Reactive Oxygen Species	Ryoo IG	Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.	Oxidative medicine and cellular longevity	2016	12
26711691	Reactive Oxygen Species	Portal-Núñez S	Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis.	Biochemical pharmacology	2016	12
26734996	Reactive Oxygen Species	Capello M	Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.	Oncotarget	2016	11
26791157	Reactive Oxygen Species	Blaser H	TNF and ROS Crosstalk in Inflammation.	Trends in cell biology	2016	32
26804906	Reactive Oxygen Species	Franco J	Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.	Cell reports	2016	11
26816492	Reactive Oxygen Species	Srikanthan K	Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.	International journal of medical sciences	2016	20
26876430	Reactive Oxygen Species	García-Bermúdez J	The ATPase Inhibitory Factor 1 (IF1): A master regulator of energy metabolism and of cell survival.	Biochimica et biophysica acta	2016	12
26934227	Reactive Oxygen Species	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	37
26947075	Reactive Oxygen Species	Liou GY	Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.	Cell reports	2016	17
26982722	Reactive Oxygen Species	Ravindran R	The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation.	Nature	2016	27
27127546	Reactive Oxygen Species	Minutoli L	ROS-Mediated NLRP3 Inflammasome Activation in Brain, Heart, Kidney, and Testis Ischemia/Reperfusion Injury.	Oxidative medicine and cellular longevity	2016	17
27157131	Reactive Oxygen Species	Chan TK	House dust mite-induced asthma causes oxidative damage and DNA double-strand breaks in the lungs.	The Journal of allergy and clinical immunology	2016	11
27225300	Reactive Oxygen Species	Fearon U	Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis.	Nature reviews. Rheumatology	2016	11
1484317	Formaldehyde	Cattoretti G	Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.	The Journal of pathology	1992	164
2453289	Formaldehyde	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	427
9065404	Formaldehyde	Taubenberger JK	Initial genetic characterization of the 1918 "Spanish" influenza virus.	Science	1997	128
10398123	Formaldehyde	Leers MP	Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis.	The Journal of pathology	1999	120
11135226	Formaldehyde	Soslow RA	COX-2 is expressed in human pulmonary, colonic, and mammary tumors.	Cancer	2000	127
11159180	Formaldehyde	Specht K	Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.	The American journal of pathology	2001	96
15305371	Formaldehyde	Santin AD	Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.	International journal of cancer	2004	87
15620353	Formaldehyde	Shi Y	Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.	Cell	2004	966
16416732	Formaldehyde	Hassan R	Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.	American journal of clinical pathology	2005	73
16912200	Formaldehyde	Chung CH	Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma.	Cancer research	2006	77
17518371	Formaldehyde	Zen Y	Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis.	Hepatology	2007	94
18058265	Formaldehyde	Tetzlaff MT	Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues.	Endocrine pathology	2007	60
18307259	Formaldehyde	Varnholt H	MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma.	Hepatology	2008	132
18422971	Formaldehyde	Hofmann M	Assessment of a HER2 scoring system for gastric cancer: results from a validation study.	Histopathology	2008	211
18495026	Formaldehyde	Do H	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.	BMC cancer	2008	55
18626651	Formaldehyde	Beach TG	Evaluation of alpha-synuclein immunohistochemical methods used by invited experts.	Acta neuropathologica	2008	58
18669866	Formaldehyde	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	114
18927145	Formaldehyde	Gouw AA	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology.	Brain 	2008	75
19056857	Formaldehyde	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	60
19204209	Formaldehyde	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	107
19345285	Formaldehyde	Protheroe C	A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis.	Clinical gastroenterology and hepatology 	2009	50
19528371	Formaldehyde	Jensen TO	Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.	Journal of clinical oncology 	2009	64
19917869	Formaldehyde	Denkert C	Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.	Journal of clinical oncology 	2010	286
20008640	Formaldehyde	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	300
20028859	Formaldehyde	Patnaik SK	Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.	Cancer research	2010	99
20056746	Formaldehyde	Krupa A	Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy.	Journal of the American Society of Nephrology 	2010	108
20228222	Formaldehyde	Neumeister V	In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.	The American journal of pathology	2010	47
20233430	Formaldehyde	Sboner A	Molecular sampling of prostate cancer: a dilemma for predicting disease progression.	BMC medical genomics	2010	79
20233444	Formaldehyde	Fumagalli D	A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.	BMC cancer	2010	52
20413677	Formaldehyde	Earle JS	Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.	The Journal of molecular diagnostics 	2010	56
20431034	Formaldehyde	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	116
20519626	Formaldehyde	Badalian-Very G	Recurrent BRAF mutations in Langerhans cell histiocytosis.	Blood	2010	127
20539282	Formaldehyde	de Planell-Saguer M	Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment.	Nature protocols	2010	41
20579395	Formaldehyde	Yu J	MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation.	Molecular cancer	2010	67
20664024	Formaldehyde	Sperinde J	Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.	Clinical cancer research 	2010	41
20710042	Formaldehyde	Aleksic T	Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.	Cancer research	2010	60
20823417	Formaldehyde	Northcott PA	Medulloblastoma comprises four distinct molecular variants.	Journal of clinical oncology 	2011	312
20921458	Formaldehyde	Ellison DW	Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.	Journal of clinical oncology 	2011	66
20940279	Formaldehyde	Dupont Jensen J	PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.	Clinical cancer research 	2011	59
21138945	Formaldehyde	Barrow J	Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.	Neuro-oncology	2011	42
21145831	Formaldehyde	Gao P	Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis.	Journal of hepatology	2011	43
21220479	Formaldehyde	Mortezavi A	KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.	Clinical cancer research 	2011	35
21267586	Formaldehyde	Ellison DW	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.	Acta neuropathologica	2011	108
21278610	Formaldehyde	Yi ES	Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.	Journal of thoracic oncology 	2011	62
21345667	Formaldehyde	Faber C	Overexpression of Dicer predicts poor survival in colorectal cancer.	European journal of cancer	2011	45
21572406	Formaldehyde	Brill LB 2nd	Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.	Modern pathology 	2011	43
21594665	Formaldehyde	Razis E	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.	Breast cancer research and treatment	2011	69
21621406	Formaldehyde	Belt EJ	Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.	European journal of cancer	2011	35
21631526	Formaldehyde	Gillis AJ	Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis.	International journal of andrology	2011	41
21638088	Formaldehyde	Capper D	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.	Acta neuropathologica	2011	79
21878536	Formaldehyde	Lotan TL	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.	Clinical cancer research 	2011	81
22018284	Formaldehyde	Nakata K	MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.	Surgery	2011	47
22025255	Formaldehyde	Jubb AM	Neuropilin-1 expression in cancer and development.	The Journal of pathology	2012	43
22173549	Formaldehyde	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	45
22261801	Formaldehyde	Walter K	DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.	Clinical cancer research 	2012	31
22331473	Formaldehyde	Lu Y	MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer.	Carcinogenesis	2012	51
22426079	Formaldehyde	Didelot A	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.	Experimental and molecular pathology	2012	34
22438992	Formaldehyde	Huang L	Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix.	PloS one	2012	36
22515559	Formaldehyde	Rizzardi AE	Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring.	Diagnostic pathology	2012	57
22534459	Formaldehyde	Bockmeyer CL	Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression.	The Journal of heart and lung transplantation 	2012	34
22643842	Formaldehyde	Do H	Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase.	Oncotarget	2012	49
22718308	Formaldehyde	Vargas AC	Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.	Breast cancer research and treatment	2012	34
22752992	Formaldehyde	Tjalma WA	Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.	International journal of cancer	2013	36
22782226	Formaldehyde	Lewis JS Jr	p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.	Head and neck pathology	2012	38
22878649	Formaldehyde	Schultz NA	MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.	Modern pathology 	2012	46
22908099	Formaldehyde	Soda M	A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer.	Clinical cancer research 	2012	30
22948049	Formaldehyde	Tan KL	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.	Blood	2012	40
22949073	Formaldehyde	Rietbergen MM	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm.	International journal of cancer	2013	30
22981675	Formaldehyde	Beltran H	Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.	European urology	2013	94
22996433	Formaldehyde	Kim BH	Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma.	Journal of surgical oncology	2013	36
23026937	Formaldehyde	Long GV	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.	The American journal of surgical pathology	2013	48
23133536	Formaldehyde	Chisholm KM	Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma.	PloS one	2012	46
23139264	Formaldehyde	Warneke VS	Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.	Annals of oncology 	2013	27
23144797	Formaldehyde	Perkins G	Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.	PloS one	2012	34
23154548	Formaldehyde	Heist RS	FGFR1 amplification in squamous cell carcinoma of the lung.	Journal of thoracic oncology 	2012	41
23195594	Formaldehyde	Prudente CN	Neuropathology of cervical dystonia.	Experimental neurology	2013	32
23295441	Formaldehyde	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	66
23320393	Formaldehyde	Rong M	Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.	BMC cancer	2013	44
23362162	Formaldehyde	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes & cancer	2013	35
23372687	Formaldehyde	Chen L	Role of deregulated microRNAs in breast cancer progression using FFPE tissue.	PloS one	2013	31
23441132	Formaldehyde	Paterson EL	Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression.	Neoplasia	2013	39
23592755	Formaldehyde	Cao J	DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer.	Cancer research	2013	27
23649127	Formaldehyde	Do H	Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates.	Clinical chemistry	2013	37
23674495	Formaldehyde	Chen BJ	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.	Clinical cancer research 	2013	121
23717203	Formaldehyde	Rossetto CC	Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells.	PLoS pathogens	2013	54
23830491	Formaldehyde	Choi SY	MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray.	Placenta	2013	30
23887298	Formaldehyde	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	41
23973117	Formaldehyde	Endris V	Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.	The Journal of molecular diagnostics 	2013	28
23979959	Formaldehyde	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	58
24039846	Formaldehyde	Nouraee N	Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma.	PloS one	2013	29
24076061	Formaldehyde	VanDussen KL	Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease.	Gastroenterology	2014	35
24122631	Formaldehyde	Oue N	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.	International journal of cancer	2014	31
24129059	Formaldehyde	Gill ON	Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey.	BMJ	2013	47
24189654	Formaldehyde	Pritchard CC	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.	The Journal of molecular diagnostics 	2014	66
24192927	Formaldehyde	Ross JS	A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.	Clinical cancer research 	2014	26
24242678	Formaldehyde	Heinzelmann J	MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.	Annals of surgical oncology	2014	21
24323898	Formaldehyde	Tan HL	Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.	Clinical cancer research 	2014	56
24357669	Formaldehyde	Venkatareddy M	Estimating podocyte number and density using a single histologic section.	Journal of the American Society of Nephrology 	2014	34
24412053	Formaldehyde	Visani M	Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III.	Molecular oncology	2014	23
24493713	Formaldehyde	Shih DJ	Cytogenetic prognostication within medulloblastoma subgroups.	Journal of clinical oncology 	2014	44
24520097	Formaldehyde	Filipits M	The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.	Clinical cancer research 	2014	26
24563076	Formaldehyde	Ross JS	New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.	The oncologist	2014	61
24563616	Formaldehyde	Blattner M	SPOP mutations in prostate cancer across demographically diverse patient cohorts.	Neoplasia	2014	33
24608573	Formaldehyde	Meric-Bernstam F	Concordance of genomic alterations between primary and recurrent breast cancer.	Molecular cancer therapeutics	2014	26
24625003	Formaldehyde	Nielsen T	Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.	BMC cancer	2014	45
24698267	Formaldehyde	Park CK	Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1.	Neuron	2014	52
24771647	Formaldehyde	Manceau G	Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2014	23
24838331	Formaldehyde	Lin MT	Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.	American journal of clinical pathology	2014	33
24842267	Formaldehyde	Muenst S	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2014	100
24885028	Formaldehyde	Wong SQ	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.	BMC medical genomics	2014	41
25314059	Formaldehyde	Singh RR	Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.	British journal of cancer	2014	22
25345567	Formaldehyde	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	40
25502898	Formaldehyde	Warrick JI	Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.	Virchows Archiv 	2015	16
25514803	Formaldehyde	Lo Iacono M	Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.	Journal of thoracic oncology 	2015	27
25593300	Formaldehyde	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	27
25641231	Formaldehyde	Stirzaker C	Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.	Nature communications	2015	28
25712460	Formaldehyde	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	19
25749524	Formaldehyde	Ono S	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.	Oncotarget	2015	15
25752754	Formaldehyde	Korshunov A	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.	Acta neuropathologica	2015	27
25823925	Formaldehyde	Han K	MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1.	Oncotarget	2015	33
25944800	Formaldehyde	Taube JM	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.	Clinical cancer research 	2015	42
26004934	Formaldehyde	Paydas S	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.	Annals of hematology	2015	15
26148801	Formaldehyde	Lad EM	Abundance of infiltrating CD163+ cells in the retina of postmortem eyes with dry and neovascular age-related macular degeneration.	Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie	2015	16
26150155	Formaldehyde	Schläfli AM	Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry.	European journal of histochemistry 	2015	18
26164662	Formaldehyde	Peck BC	MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic Utility.	Inflammatory bowel diseases	2015	16
26172027	Formaldehyde	Talhouk A	A clinically applicable molecular-based classification for endometrial cancers.	British journal of cancer	2015	25
26181193	Formaldehyde	McDaniel AS	Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.	JAMA oncology	2015	20
26182302	Formaldehyde	Ross JS	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.	JAMA oncology	2015	24
26253700	Formaldehyde	Cieslik M	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing.	Genome research	2015	16
26311741	Formaldehyde	Kim HS	Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.	Oncotarget	2015	21
26317305	Formaldehyde	Phillips T	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.	Applied immunohistochemistry & molecular morphology 	2015	32
26358176	Formaldehyde	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	28
26422389	Formaldehyde	Nuciforo P	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.	Molecular oncology	2016	13
26546452	Formaldehyde	Mahoney KM	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.	Cancer immunology research	2015	22
26605532	Formaldehyde	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	43
26724257	Formaldehyde	Mehra R	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.	European urology	2016	18
26913631	Formaldehyde	Howitt BE	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.	JAMA oncology	2016	10
26976201	Formaldehyde	Thompson EM	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.	The Lancet. Oncology	2016	13
27342566	Formaldehyde	Song Z	Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.	Journal of translational medicine	2016	12
27372395	Formaldehyde	Martines RB	Pathology of congenital Zika syndrome in Brazil: a case series.	Lancet	2016	42
27459899	Formaldehyde	Trinh A	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.	Clinical cancer research 	2017	9
27717372	Formaldehyde	Rebelatto MC	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.	Diagnostic pathology	2016	12
28043870	Formaldehyde	Johnston A	IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.	The Journal of allergy and clinical immunology	2017	9
28073897	Formaldehyde	Reguart N	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.	Clinical chemistry	2017	7
28463396	Formaldehyde	Pollack SM	T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.	Cancer	2017	6
9468139	trichostatin A	Brehm A	Retinoblastoma protein recruits histone deacetylase to repress transcription.	Nature	1998	337
10200307	trichostatin A	Saito A	A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
11283670	trichostatin A	Kim MS	Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.	Nature medicine	2001	145
12839967	trichostatin A	Sato N	Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.	Cancer research	2003	99
15899813	trichostatin A	Lodygin D	Functional epigenomics identifies genes frequently silenced in prostate cancer.	Cancer research	2005	89
17360565	trichostatin A	Li B	FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.	Proceedings of the National Academy of Sciences of the United States of America	2007	122
18286529	trichostatin A	Feng W	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.	Cancer	2008	64
18430739	trichostatin A	Fujii S	Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.	The Journal of biological chemistry	2008	67
18664505	trichostatin A	Peng DF	DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.	Gut	2009	54
19407485	trichostatin A	Lee KH	Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer.	Pancreatology 	2009	65
20100935	trichostatin A	Grabiec AM	Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.	Journal of immunology	2010	45
20842113	trichostatin A	Zhang J	microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.	British journal of cancer	2010	77
21051724	trichostatin A	Chen X	Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma.	Investigative ophthalmology & visual science	2011	37
21383005	trichostatin A	Fan T	EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.	Molecular cancer research 	2011	53
21491416	trichostatin A	Chen MY	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.	Cancer	2011	38
21654831	trichostatin A	Bovenschen HJ	Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.	The Journal of investigative dermatology	2011	56
21953341	trichostatin A	Grabiec AM	Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.	Annals of the rheumatic diseases	2012	34
21960261	trichostatin A	Tsai KW	Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer.	International journal of cancer	2011	59
22038994	trichostatin A	Landreville S	Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.	Clinical cancer research 	2012	66
22419664	trichostatin A	Coulouarn C	Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma.	Cancer research	2012	46
22641068	trichostatin A	Buurman R	Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.	Gastroenterology	2012	52
22699621	trichostatin A	Pérez-Mancera PA	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.	Nature	2012	101
23085757	trichostatin A	Su SF	miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.	Oncogene	2013	42
23379261	trichostatin A	Li Y	Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.	Molecular cancer	2013	37
23979134	trichostatin A	Yang Z	MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein.	The Journal of biological chemistry	2013	29
24481854	trichostatin A	Li Z	DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer.	Gastric cancer 	2015	59
26356327	trichostatin A	Karnezis AN	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.	The Journal of pathology	2016	16
26408027	trichostatin A	Cai D	Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis.	Arthritis research & therapy	2015	16
16735673	Histone Deacetylase Inhibitors	Kong Y	Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.	Circulation	2006	118
16802366	Histone Deacetylase Inhibitors	Wang Y	Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.	Arthritis and rheumatism	2006	68
19383284	Histone Deacetylase Inhibitors	Ropero S	The role of histone deacetylases (HDACs) in human cancer.	Molecular oncology	2007	159
19521961	Histone Deacetylase Inhibitors	Bandres E	Epigenetic regulation of microRNA expression in colorectal cancer.	International journal of cancer	2009	136
19826124	Histone Deacetylase Inhibitors	Lane AA	Histone deacetylase inhibitors in cancer therapy.	Journal of clinical oncology 	2009	247
20686575	Histone Deacetylase Inhibitors	Garcia-Perez JL	Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells.	Nature	2010	60
20833281	Histone Deacetylase Inhibitors	Selvi BR	Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases.	Biochimica et biophysica acta	2010	41
20956800	Histone Deacetylase Inhibitors	Roger T	Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.	Blood	2011	86
20962572	Histone Deacetylase Inhibitors	Liu YL	Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.	Autophagy	2010	52
21084276	Histone Deacetylase Inhibitors	Lopez G	Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.	Cancer research	2011	35
22096249	Histone Deacetylase Inhibitors	Sampath D	Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.	Blood	2012	60
22147512	Histone Deacetylase Inhibitors	Aghdassi A	Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.	Gut	2012	48
22210864	Histone Deacetylase Inhibitors	Hudson RS	MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.	Nucleic acids research	2012	63
22246031	Histone Deacetylase Inhibitors	Akimova T	Histone/protein deacetylases and T-cell immune responses.	Blood	2012	32
22422937	Histone Deacetylase Inhibitors	Pazolli E	Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.	Cancer research	2012	35
22605338	Histone Deacetylase Inhibitors	Wang Y	Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.	The Journal of biological chemistry	2012	49
23913134	Histone Deacetylase Inhibitors	Minami J	Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.	Leukemia	2014	24
25159818	Histone Deacetylase Inhibitors	Soragni E	Epigenetic therapy for Friedreich ataxia.	Annals of neurology	2014	26
25492968	Histone Deacetylase Inhibitors	Penney J	Histone deacetylases in memory and cognition.	Science signaling	2014	27
25540204	Histone Deacetylase Inhibitors	Campbell GR	Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.	The Journal of biological chemistry	2015	17
25704812	Histone Deacetylase Inhibitors	Tomazou EM	Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.	Cell reports	2015	27
25957812	Histone Deacetylase Inhibitors	Woan KV	Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.	Molecular oncology	2015	16
26032687	Histone Deacetylase Inhibitors	Liffers K	Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.	Targeted oncology	2016	11
26831668	Histone Deacetylase Inhibitors	Zhijun H	Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.	Tumour biology 	2016	11
15914560	fludarabine	Beyer M	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.	Blood	2005	108
16543464	fludarabine	Kojima K	Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.	Blood	2006	71
18000167	fludarabine	Lange BJ	Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.	Blood	2008	77
18003888	fludarabine	Chaudhuri A	STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier.	Blood	2008	57
18574029	fludarabine	Trachootham D	Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.	Blood	2008	57
18809613	fludarabine	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	417
18836097	fludarabine	Balakrishnan K	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.	Blood	2009	60
19549911	fludarabine	Buchner M	Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.	Cancer research	2009	62
19762485	fludarabine	Kurtova AV	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.	Blood	2009	89
20085940	fludarabine	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	129
20335218	fludarabine	Buchner M	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.	Blood	2010	62
20719934	fludarabine	Hong JJ	Successful treatment of melanoma brain metastases with adoptive cell therapy.	Clinical cancer research 	2010	47
21402714	fludarabine	Amrein PC	Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.	Clinical cancer research 	2011	41
21791425	fludarabine	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	81
21844497	fludarabine	Fischer K	Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.	Journal of clinical oncology 	2011	75
22039264	fludarabine	Rossi D	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.	Blood	2011	85
22128299	fludarabine	Tromp JM	Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.	Clinical cancer research 	2012	35
22740450	fludarabine	Mahoney E	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.	Blood	2012	32
23086750	fludarabine	Oscier DG	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.	Blood	2013	52
23530110	fludarabine	Federico M	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.	Journal of clinical oncology 	2013	31
23720127	fludarabine	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	38
24719405	fludarabine	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	71
25319501	fludarabine	Lee DW	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.	Lancet	2015	367
25415285	fludarabine	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	31
25908509	fludarabine	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	50
25940712	fludarabine	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	32
26002963	fludarabine	Treon SP	How I treat Waldenström macroglobulinemia.	Blood	2015	15
26675346	fludarabine	Ljungström V	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.	Blood	2016	17
26762740	fludarabine	Ikeda S	PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2016	16
27111235	fludarabine	Turtle CJ	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.	The Journal of clinical investigation	2016	120
28395880	fludarabine	Chandran SS	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.	The Lancet. Oncology	2017	8
8988170	polyglutamine	Zhuchenko O	Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.	Nature genetics	1997	188
9398841	polyglutamine	White JK	Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.	Nature genetics	1997	132
9620770	polyglutamine	Cummings CJ	Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.	Nature genetics	1998	178
9635424	polyglutamine	Warrick JM	Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila.	Cell	1998	166
9768849	polyglutamine	Jackson GR	Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.	Neuron	1998	133
10200309	polyglutamine	Scherzinger E	Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.	Proceedings of the National Academy of Sciences of the United States of America	1999	168
10581028	polyglutamine	Warrick JM	Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.	Nature genetics	1999	215
11007884	polyglutamine	Kegel KB	Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy.	The Journal of neuroscience 	2000	108
11081516	polyglutamine	Fernandez-Funez P	Identification of genes that modify ataxin-1-induced neurodegeneration.	Nature	2000	173
11394998	polyglutamine	Hara J	Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.	Neuron	2001	282
11967539	polyglutamine	Mantamadiotis T	Disruption of CREB function in brain leads to neurodegeneration.	Nature genetics	2002	174
12050113	polyglutamine	Nishitoh H	ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats.	Genes & development	2002	334
12062094	polyglutamine	Humbert S	The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.	Developmental cell	2002	116
12191472	polyglutamine	Lunkes A	Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.	Molecular cell	2002	93
12223539	polyglutamine	Wellington CL	Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.	The Journal of neuroscience 	2002	85
14527432	polyglutamine	Szebenyi G	Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.	Neuron	2003	81
14978262	polyglutamine	Lee WC	Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	99
15036808	polyglutamine	Li SH	Huntingtin-protein interactions and the pathogenesis of Huntington's disease.	Trends in genetics 	2004	137
15152038	polyglutamine	Chevalier-Larsen ES	Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy.	The Journal of neuroscience 	2004	72
15459747	polyglutamine	Landles C	Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series.	EMBO reports	2004	94
15483602	polyglutamine	Arrasate M	Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.	Nature	2004	553
15811941	polyglutamine	Harper SQ	RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.	Proceedings of the National Academy of Sciences of the United States of America	2005	195
16076956	polyglutamine	Slow EJ	Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.	Proceedings of the National Academy of Sciences of the United States of America	2005	76
16122429	polyglutamine	Tsuda H	The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins.	Cell	2005	77
16473015	polyglutamine	Chang DT	Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.	Neurobiology of disease	2006	75
16804541	polyglutamine	Moseley ML	Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8.	Nature genetics	2006	132
17034350	polyglutamine	Browne SE	Oxidative damage in Huntington's disease pathogenesis.	Antioxidants & redox signaling	2006	90
17041811	polyglutamine	Borrell-Pagès M	Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.	Cellular and molecular life sciences 	2006	62
17687326	polyglutamine	Bennett EJ	Global changes to the ubiquitin system in Huntington's disease.	Nature	2007	184
17984323	polyglutamine	Filimonenko M	Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease.	The Journal of cell biology	2007	198
18337722	polyglutamine	Lim J	Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.	Nature	2008	130
18418684	polyglutamine	Lastres-Becker I	Spinocerebellar ataxia 2 (SCA2).	Cerebellum	2008	56
18466116	polyglutamine	Imarisio S	Huntington's disease: from pathology and genetics to potential therapies.	The Biochemical journal	2008	113
18488016	polyglutamine	Yang SH	Towards a transgenic model of Huntington's disease in a non-human primate.	Nature	2008	115
18550760	polyglutamine	Gray M	Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.	The Journal of neuroscience 	2008	194
18636076	polyglutamine	Sarkar S	Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies.	Cell death and differentiation	2009	134
18638556	polyglutamine	Heng MY	Rodent genetic models of Huntington disease.	Neurobiology of disease	2008	62
18758459	polyglutamine	Lee Y	miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis.	Nature neuroscience	2008	70
18923047	polyglutamine	Benn CL	Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.	The Journal of neuroscience 	2008	58
19118166	polyglutamine	Packer AN	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.	The Journal of neuroscience 	2008	226
19334076	polyglutamine	Drouet V	Sustained effects of nonallele-specific Huntingtin silencing.	Annals of neurology	2009	78
19487684	polyglutamine	Nekooki-Machida Y	Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
19608102	polyglutamine	van der Burg JM	Beyond the brain: widespread pathology in Huntington's disease.	The Lancet. Neurology	2009	76
20236390	polyglutamine	Han I	Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.	Journal of neurochemistry	2010	41
20348093	polyglutamine	Wang AM	Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation.	The Journal of biological chemistry	2010	40
20383138	polyglutamine	Martinez-Vicente M	Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease.	Nature neuroscience	2010	194
20670829	polyglutamine	Miller JP	Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease.	Neuron	2010	54
20685997	polyglutamine	Miller J	Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.	The Journal of neuroscience 	2010	42
20723845	polyglutamine	Durr A	Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond.	The Lancet. Neurology	2010	94
20740007	polyglutamine	Elden AC	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.	Nature	2010	256
21048129	polyglutamine	Xie Y	BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.	The Journal of neuroscience 	2010	65
21163446	polyglutamine	Ross CA	Huntington's disease: from molecular pathogenesis to clinical treatment.	The Lancet. Neurology	2011	293
21555070	polyglutamine	Wilburn B	An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.	Neuron	2011	62
22113611	polyglutamine	Koch P	Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.	Nature	2011	80
22179319	polyglutamine	Jiang M	Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.	Nature medicine	2011	91
22200539	polyglutamine	Arrasate M	Protein aggregates in Huntington's disease.	Experimental neurology	2012	66
22306404	polyglutamine	Wetzel R	Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.	Journal of molecular biology	2012	59
22383888	polyglutamine	Bañez-Coronel M	A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.	PLoS genetics	2012	50
22446390	polyglutamine	Costa V	Shaping the role of mitochondria in the pathogenesis of Huntington's disease.	The EMBO journal	2012	37
22508507	polyglutamine	Orr HT	Cell biology of spinocerebellar ataxia.	The Journal of cell biology	2012	47
22590724	polyglutamine	Jia H	Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.	Neurobiology of disease	2012	40
22613578	polyglutamine	Juopperi TA	Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.	Molecular brain	2012	72
22684686	polyglutamine	Seidel K	Brain pathology of spinocerebellar ataxias.	Acta neuropathologica	2012	53
22748967	polyglutamine	An MC	Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.	Cell stem cell	2012	96
23160193	polyglutamine	Kwan W	Mutant huntingtin impairs immune cell migration in Huntington disease.	The Journal of clinical investigation	2012	37
23172909	polyglutamine	Farg MA	Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.	Human molecular genetics	2013	25
23222885	polyglutamine	Wang AM	Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation.	Nature chemical biology	2013	58
23438480	polyglutamine	Rüb U	Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7.	Progress in neurobiology	2013	45
23791384	polyglutamine	Park SH	PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone.	Cell	2013	103
23873212	polyglutamine	Tsvetkov AS	Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration.	Nature chemical biology	2013	45
24584051	polyglutamine	Crotti A	Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.	Nature neuroscience	2014	57
24742458	polyglutamine	Cortes CJ	Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.	Neuron	2014	38
24840975	polyglutamine	Deng H	The role of FUS gene variants in neurodegenerative diseases.	Nature reviews. Neurology	2014	36
24882209	polyglutamine	Guo L	A cellular system that degrades misfolded proteins and protects against neurodegeneration.	Molecular cell	2014	27
25108912	polyglutamine	Cortes CJ	Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA.	Nature neuroscience	2014	27
25437566	polyglutamine	Brehme M	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Cell reports	2014	69
25556834	polyglutamine	Lee JH	Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.	Neuron	2015	24
25723488	polyglutamine	Lim J	Proteotoxic stress induces phosphorylation of p62/SQSTM1 by ULK1 to regulate selective autophagic clearance of protein aggregates.	PLoS genetics	2015	38
26590344	polyglutamine	Bañez-Coronel M	RAN Translation in Huntington Disease.	Neuron	2015	39
26938440	polyglutamine	Saudou F	The Biology of Huntingtin.	Neuron	2016	37
27103069	polyglutamine	Sellier C	Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death.	The EMBO journal	2016	47
11588023	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Guzman ML	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.	Blood	2001	178
12451177	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Guzman ML	Preferential induction of apoptosis for primary human leukemic stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	98
17671210	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Jacquemont C	Proteasome function is required for DNA damage response and fanconi anemia pathway activation.	Cancer research	2007	73
18094054	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Hori T	CENP-O class proteins form a stable complex and are required for proper kinetochore function.	Molecular biology of the cell	2008	53
21362567	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Nguyen HN	LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.	Cell stem cell	2011	194
23585478	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Mahammad S	Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.	The Journal of clinical investigation	2013	25
23922739	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Viiri J	Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells.	PloS one	2013	42
24895455	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Shy D	PDZ domain-binding motif regulates cardiomyocyte compartment-specific NaV1.5 channel expression and function.	Circulation	2014	26
9129041	arsenic trioxide	Chen GQ	Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.	Blood	1997	132
9801394	arsenic trioxide	Soignet SL	Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.	The New England journal of medicine	1998	164
12727826	arsenic trioxide	Kanzawa T	Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.	Cancer research	2003	120
15592527	arsenic trioxide	Kanzawa T	Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3.	Oncogene	2005	95
17640917	arsenic trioxide	Lu J	Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.	Proceedings of the National Academy of Sciences of the United States of America	2007	94
18716620	arsenic trioxide	Song MS	The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.	Nature	2008	144
20574048	arsenic trioxide	Isakson P	Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.	Blood	2010	69
20599449	arsenic trioxide	Essers MA	Targeting leukemic stem cells by breaking their dormancy.	Molecular oncology	2010	51
20624968	arsenic trioxide	Kim J	Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20966922	arsenic trioxide	de Thé H	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.	Nature reviews. Cancer	2010	115
21183792	arsenic trioxide	Beauchamp EM	Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.	The Journal of clinical investigation	2011	74
24344243	arsenic trioxide	Dos Santos GA	Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.	The Journal of experimental medicine	2013	26
24859340	arsenic trioxide	Sweeney RT	Identification of recurrent SMO and BRAF mutations in ameloblastomas.	Nature genetics	2014	26
25795919	arsenic trioxide	Martelli MP	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.	Blood	2015	15
26772155	arsenic trioxide	Gu S	ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells.	Chemico-biological interactions	2016	15
11786564	Fluorodeoxyglucose F18	Bos R	Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.	Journal of clinical oncology 	2002	92
12057982	Fluorodeoxyglucose F18	Rudd JH	Imaging atherosclerotic plaque inflammation with 18F-fluorodeoxyglucose positron emission tomography.	Circulation	2002	175
15319715	Fluorodeoxyglucose F18	Fernandez FG	Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).	Annals of surgery	2004	81
17084256	Fluorodeoxyglucose F18	Tawakol A	In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients.	Journal of the American College of Cardiology	2006	142
17327884	Fluorodeoxyglucose F18	Capuron L	Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.	Neuropsychopharmacology 	2007	67
20375137	Fluorodeoxyglucose F18	Jayadev S	Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.	Brain 	2010	42
20484419	Fluorodeoxyglucose F18	Baum RP	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.	Journal of nuclear medicine 	2010	61
20947515	Fluorodeoxyglucose F18	Herbst RS	A first-in-human study of conatumumab in adult patients with advanced solid tumors.	Clinical cancer research 	2010	42
21057787	Fluorodeoxyglucose F18	Groheux D	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.	European journal of nuclear medicine and molecular imaging	2011	41
21670386	Fluorodeoxyglucose F18	Lo RY	Longitudinal change of biomarkers in cognitive decline.	Archives of neurology	2011	66
22047634	Fluorodeoxyglucose F18	Weiner MW	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.	Alzheimer's & dementia 	2012	181
22090163	Fluorodeoxyglucose F18	Dweck MR	Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis.	Circulation	2012	46
22331945	Fluorodeoxyglucose F18	Stacchiotti S	Phase II study of imatinib in advanced chordoma.	Journal of clinical oncology 	2012	35
22517990	Fluorodeoxyglucose F18	Timmers HJ	Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.	Journal of the National Cancer Institute	2012	38
22820791	Fluorodeoxyglucose F18	Subramanian S	Arterial inflammation in patients with HIV.	JAMA	2012	141
23232293	Fluorodeoxyglucose F18	Shaffer JL	Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.	Radiology	2013	42
23280791	Fluorodeoxyglucose F18	Vemuri P	Effect of lifestyle activities on Alzheimer disease biomarkers and cognition.	Annals of neurology	2012	43
23932184	Fluorodeoxyglucose F18	Weiner MW	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.	Alzheimer's & dementia 	2013	97
24009278	Fluorodeoxyglucose F18	Courtois A	18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture.	Journal of nuclear medicine 	2013	26
24029656	Fluorodeoxyglucose F18	Tamura K	64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.	Journal of nuclear medicine 	2013	37
24322510	Fluorodeoxyglucose F18	Michielsen K	Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.	European radiology	2014	22
24337604	Fluorodeoxyglucose F18	Mortimer JE	Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.	Journal of nuclear medicine 	2014	32
25736399	Fluorodeoxyglucose F18	Philipp-Abbrederis K	In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.	EMBO molecular medicine	2015	31
26073027	Fluorodeoxyglucose F18	Weiner MW	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.	Alzheimer's & dementia 	2015	46
26139022	Fluorodeoxyglucose F18	Yau WW	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.	The Lancet. Neurology	2015	16
26597325	Fluorodeoxyglucose F18	Jack CR Jr	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.	The Lancet. Neurology	2016	15
26598545	Fluorodeoxyglucose F18	Gebhart G	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.	Annals of oncology 	2016	28
26834099	Fluorodeoxyglucose F18	Avril S	¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.	Journal of nuclear medicine 	2016	13
11919237	docetaxel	Esteva FJ	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2002	99
16061678	docetaxel	Li Y	Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.	Cancer research	2005	95
16397019	docetaxel	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	81
16404427	docetaxel	Arnould L	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?	British journal of cancer	2006	120
16606824	docetaxel	Farokhzad OC	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	334
17308271	docetaxel	Beer TM	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.	Journal of clinical oncology 	2007	60
17325667	docetaxel	Mahadevan D	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.	Oncogene	2007	77
17606733	docetaxel	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	119
17909051	docetaxel	Loberg RD	Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.	Cancer research	2007	91
17909199	docetaxel	Herbst RS	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.	Journal of clinical oncology 	2007	94
18182665	docetaxel	Berthold DR	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.	Journal of clinical oncology 	2008	194
18645028	docetaxel	Meng Y	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.	Molecular cancer therapeutics	2008	60
19027483	docetaxel	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	278
19147587	docetaxel	Kim RH	Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.	Cancer research	2009	73
19150933	docetaxel	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	74
19204205	docetaxel	Hugh J	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.	Journal of clinical oncology 	2009	111
19380452	docetaxel	Penault-Llorca F	Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	50
19666588	docetaxel	Creighton CJ	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.	Proceedings of the National Academy of Sciences of the United States of America	2009	438
19826044	docetaxel	Gan L	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.	Cancer research	2009	52
19901561	docetaxel	Bayet-Robert M	Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.	Cancer biology & therapy	2010	52
19917839	docetaxel	Spielmann M	Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.	Journal of clinical oncology 	2009	59
20100966	docetaxel	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	108
20308670	docetaxel	Untch M	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.	Journal of clinical oncology 	2010	97
20406831	docetaxel	Riethdorf S	Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.	Clinical cancer research 	2010	111
20498403	docetaxel	Miles DW	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2010	205
20570559	docetaxel	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	106
20697801	docetaxel	Huober J	Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.	Breast cancer research and treatment	2010	52
20807808	docetaxel	Zhu ML	Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.	Cancer research	2010	87
20842666	docetaxel	Zhang HL	Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.	The Prostate	2011	89
20859283	docetaxel	Seruga B	Drug resistance in metastatic castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	74
20921363	docetaxel	Kolishetti N	Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.	Proceedings of the National Academy of Sciences of the United States of America	2010	100
21115860	docetaxel	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	52
21149267	docetaxel	Jeyapalan Z	Expression of CD44 3'-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis.	Nucleic acids research	2011	62
21197560	docetaxel	Xu B	miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.	Molecular and cellular biochemistry	2011	53
21325072	docetaxel	Song L	Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.	Clinical cancer research 	2011	50
21373875	docetaxel	Glück S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.	Breast cancer research and treatment	2012	62
21559013	docetaxel	Lee HE	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.	British journal of cancer	2011	50
21837479	docetaxel	Loibl S	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.	Breast cancer research and treatment	2011	39
21918169	docetaxel	Brunsvig PF	Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.	Clinical cancer research 	2011	40
22149875	docetaxel	Baselga J	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.	The New England journal of medicine	2012	444
22153890	docetaxel	Gianni L	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2012	275
22331954	docetaxel	Bergh J	First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.	Journal of clinical oncology 	2012	58
22377126	docetaxel	Pierga JY	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.	The Lancet. Oncology	2012	31
22387005	docetaxel	Shien K	Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.	Lung cancer	2012	33
22454414	docetaxel	Kelly WK	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.	Journal of clinical oncology 	2012	143
22907596	docetaxel	Pienta KJ	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.	Investigational new drugs	2013	46
22965962	docetaxel	Ramlau R	Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.	Journal of clinical oncology 	2012	38
22972611	docetaxel	Sehdev V	The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.	Cancer	2013	26
22975379	docetaxel	Domingo-Domenech J	Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.	Cancer cell	2012	120
22996738	docetaxel	Liu C	Functional p53 determines docetaxel sensitivity in prostate cancer cells.	The Prostate	2013	30
23032615	docetaxel	Mamounas EP	Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.	Journal of clinical oncology 	2012	45
23041061	docetaxel	Puhr M	Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.	The American journal of pathology	2012	68
23041621	docetaxel	Qiu M	Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.	Cancer letters	2013	26
23200175	docetaxel	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	181
23246022	docetaxel	Mackey JR	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.	The Lancet. Oncology	2013	44
23251413	docetaxel	Corcoran C	Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.	PloS one	2012	72
23340294	docetaxel	Schott AF	Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.	Clinical cancer research 	2013	44
23341518	docetaxel	Loi S	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.	Journal of clinical oncology 	2013	227
23368632	docetaxel	Chen J	Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.	BMC cell biology	2013	26
23382472	docetaxel	Hurvitz SA	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2013	80
23422754	docetaxel	Miles DW	Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.	British journal of cancer	2013	38
23475636	docetaxel	Swain SM	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.	The oncologist	2013	34
23569308	docetaxel	Fizazi K	Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2013	43
23569311	docetaxel	Gianni L	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.	Journal of clinical oncology 	2013	53
23576708	docetaxel	Loriot Y	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).	Annals of oncology 	2013	72
23602601	docetaxel	Swain SM	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2013	161
23957948	docetaxel	Sridhar SS	Castration-resistant prostate cancer: from new pathophysiology to new treatment.	European urology	2014	29
24149323	docetaxel	Yan W	Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer.	Epigenetics	2013	30
24200698	docetaxel	van Soest RJ	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.	European journal of cancer	2013	38
24309006	docetaxel	Stewart DJ	Wnt signaling pathway in non-small cell lung cancer.	Journal of the National Cancer Institute	2014	94
24321502	docetaxel	Heidenreich A	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2014	203
24366758	docetaxel	Koizumi W	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).	Journal of cancer research and clinical oncology	2014	27
24382803	docetaxel	Badrising S	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.	Cancer	2014	28
24411639	docetaxel	Reck M	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.	The Lancet. Oncology	2014	129
24577057	docetaxel	Liu Y	Lack of correlation of stem cell markers in breast cancer stem cells.	British journal of cancer	2014	24
24616308	docetaxel	Goldkorn A	Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2014	50
24659820	docetaxel	Marín-Aguilera M	Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.	Molecular cancer therapeutics	2014	27
24685829	docetaxel	Swain SM	Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.	Annals of oncology 	2014	22
24714754	docetaxel	Lin HM	Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.	British journal of cancer	2014	29
24740322	docetaxel	Liu C	Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.	Clinical cancer research 	2014	61
24799465	docetaxel	Giordano SH	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2014	52
24815864	docetaxel	Palena C	Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.	Journal of the National Cancer Institute	2014	25
24831979	docetaxel	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	44
24837187	docetaxel	Al Nakouzi N	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.	European urology	2015	20
24933332	docetaxel	Garon EB	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.	Lancet	2014	158
24985346	docetaxel	Ono M	Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.	Science signaling	2014	105
24996221	docetaxel	Pan B	HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma.	Molecular cancer	2014	24
25002723	docetaxel	Harari PM	Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.	Journal of clinical oncology 	2014	22
25018038	docetaxel	Azad AA	Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.	European urology	2015	26
25053345	docetaxel	Corcoran C	miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.	The Prostate	2014	39
25077924	docetaxel	Lv MM	Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein.	Tumour biology 	2014	29
25108579	docetaxel	Brasso K	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.	European urology	2015	17
25185099	docetaxel	Mackey JR	Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.	Journal of clinical oncology 	2015	22
25263564	docetaxel	Toso A	Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.	Cell reports	2014	38
25273343	docetaxel	Gligorov J	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	20
25301760	docetaxel	James ND	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).	European urology	2015	36
25310895	docetaxel	Chen D	MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.	European journal of cancer	2014	22
25327557	docetaxel	Soliman HH	A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.	Oncotarget	2014	31
25341040	docetaxel	Zhang Q	Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.	Cell death & disease	2014	24
25359780	docetaxel	Bhardwaj A	CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.	Oncotarget	2014	20
25439694	docetaxel	Hoskin P	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.	The Lancet. Oncology	2014	36
25484141	docetaxel	van Soest RJ	Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.	European urology	2015	22
25624429	docetaxel	Fizazi K	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.	Journal of clinical oncology 	2015	25
25693012	docetaxel	Swain SM	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.	The New England journal of medicine	2015	175
25722381	docetaxel	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	Annals of oncology 	2015	34
25771365	docetaxel	Vallabhajosula S	Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.	Current radiopharmaceuticals	2016	15
25975632	docetaxel	Earl HM	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2015	25
25997818	docetaxel	Ramalingam S	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).	Annals of oncology 	2015	18
26074382	docetaxel	Attard G	Prostate cancer.	Lancet	2016	92
26077235	docetaxel	Sparano JA	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.	Journal of clinical oncology 	2015	16
26117829	docetaxel	Nakazawa M	Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.	Annals of oncology 	2015	40
26160840	docetaxel	Zhang G	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.	Oncotarget	2015	20
26181238	docetaxel	Antonarakis ES	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.	JAMA oncology	2015	87
26196735	docetaxel	Crawford ED	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.	The Journal of urology	2015	24
26244877	docetaxel	Sweeney CJ	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.	The New England journal of medicine	2015	132
26253814	docetaxel	Prat A	Clinical implications of the intrinsic molecular subtypes of breast cancer.	Breast	2015	49
26324367	docetaxel	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	74
26351332	docetaxel	Durkee BY	Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2016	15
26617202	docetaxel	Takashima T	Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.	The Lancet. Oncology	2016	11
26847057	docetaxel	Von Hoff DD	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.	Clinical cancer research 	2016	15
26984449	docetaxel	Kazandjian D	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	The oncologist	2016	36
27179402	docetaxel	Gianni L	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.	The Lancet. Oncology	2016	21
27591931	docetaxel	Cornford P	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.	European urology	2017	44
27765535	docetaxel	Lee CK	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.	Journal of thoracic oncology 	2017	33
27776843	docetaxel	Al-Batran SE	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.	The Lancet. Oncology	2016	17
27964843	docetaxel	Luen SJ	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.	The Lancet. Oncology	2017	14
28212060	docetaxel	Bellmunt J	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	The New England journal of medicine	2017	70
28398846	docetaxel	Blum JL	Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).	Journal of clinical oncology 	2017	5
28407528	docetaxel	Giroux Leprieur E	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.	European journal of cancer	2017	7
7706234	Amyloid beta-Peptides	Gravina SA	Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).	The Journal of biological chemistry	1995	124
7845465	Amyloid beta-Peptides	Games D	Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.	Nature	1995	321
8043280	Amyloid beta-Peptides	Iwatsubo T	Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).	Neuron	1994	285
8103819	Amyloid beta-Peptides	Poirier J	Apolipoprotein E polymorphism and Alzheimer's disease.	Lancet	1993	169
8152488	Amyloid beta-Peptides	Lorenzo A	Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.	Nature	1994	165
8415756	Amyloid beta-Peptides	Schmechel DE	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	259
9037091	Amyloid beta-Peptides	Johnson-Wood K	Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1997	175
9190286	Amyloid beta-Peptides	Harper JD	Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.	Chemistry & biology	1997	148
9268388	Amyloid beta-Peptides	Walsh DM	Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.	The Journal of biological chemistry	1997	220
9354781	Amyloid beta-Peptides	Bales KR	Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.	Nature genetics	1997	144
10077666	Amyloid beta-Peptides	Hsia AY	Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.	Proceedings of the National Academy of Sciences of the United States of America	1999	283
10487842	Amyloid beta-Peptides	Lue LF	Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.	The American journal of pathology	1999	400
10735393	Amyloid beta-Peptides	Näslund J	Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.	JAMA	2000	260
10932230	Amyloid beta-Peptides	Bard F	Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.	Nature medicine	2000	454
11193794	Amyloid beta-Peptides	Selkoe DJ	Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.	Annals of the New York Academy of Sciences	2000	117
11815632	Amyloid beta-Peptides	Zhang Y	Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons.	The Journal of cell biology	2002	96
12084879	Amyloid beta-Peptides	Thal DR	Phases of A beta-deposition in the human brain and its relevance for the development of AD.	Neurology	2002	463
12196135	Amyloid beta-Peptides	Walsh DM	Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.	Biochemical Society transactions	2002	125
12415125	Amyloid beta-Peptides	Selkoe DJ	Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.	Annual review of pharmacology and toxicology	2003	176
12506200	Amyloid beta-Peptides	Bitan G	Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.	Proceedings of the National Academy of Sciences of the United States of America	2003	293
12840029	Amyloid beta-Peptides	Bitan G	Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization.	The Journal of biological chemistry	2003	90
12925731	Amyloid beta-Peptides	Gong Y	Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.	Proceedings of the National Academy of Sciences of the United States of America	2003	251
14742275	Amyloid beta-Peptides	Fukumoto H	Beta-secretase activity increases with aging in human, monkey, and mouse brain.	The American journal of pathology	2004	77
14978286	Amyloid beta-Peptides	Li R	Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.	Proceedings of the National Academy of Sciences of the United States of America	2004	149
15037694	Amyloid beta-Peptides	Ingelsson M	Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.	Neurology	2004	181
15339642	Amyloid beta-Peptides	Tanzi RE	Clearance of Alzheimer's Abeta peptide: the many roads to perdition.	Neuron	2004	115
15459432	Amyloid beta-Peptides	Deane R	RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier.	Stroke	2004	93
15708439	Amyloid beta-Peptides	Caccamo A	Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.	Neurobiology of aging	2005	79
15808355	Amyloid beta-Peptides	Zlokovic BV	Neurovascular mechanisms of Alzheimer's neurodegeneration.	Trends in neurosciences	2005	188
16567625	Amyloid beta-Peptides	Mahley RW	Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2006	230
17187063	Amyloid beta-Peptides	Fulga TA	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.	Nature cell biology	2007	121
17430246	Amyloid beta-Peptides	Deane R	Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.	Current Alzheimer research	2007	104
17664130	Amyloid beta-Peptides	Butterfield DA	Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.	Free radical biology & medicine	2007	111
17694066	Amyloid beta-Peptides	Sagare A	Clearance of amyloid-beta by circulating lipoprotein receptors.	Nature medicine	2007	119
18032783	Amyloid beta-Peptides	Nixon RA	Autophagy, amyloidogenesis and Alzheimer disease.	Journal of cell science	2007	191
18359102	Amyloid beta-Peptides	Selkoe DJ	Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.	Behavioural brain research	2008	318
18675468	Amyloid beta-Peptides	Bezprozvanny I	Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease.	Trends in neurosciences	2008	233
19319544	Amyloid beta-Peptides	Bell RD	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.	Acta neuropathologica	2009	198
19757208	Amyloid beta-Peptides	Ondrejcak T	Alzheimer's disease amyloid beta-protein and synaptic function.	Neuromolecular medicine	2010	43
20209079	Amyloid beta-Peptides	Soscia SJ	The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.	PloS one	2010	162
20232515	Amyloid beta-Peptides	Chow VW	An overview of APP processing enzymes and products.	Neuromolecular medicine	2010	70
20632195	Amyloid beta-Peptides	Heneka MT	Neuroinflammatory processes in Alzheimer's disease.	Journal of neural transmission	2010	92
20697045	Amyloid beta-Peptides	De Meyer G	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.	Archives of neurology	2010	137
21400565	Amyloid beta-Peptides	Shi M	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.	Annals of neurology	2011	114
22009041	Amyloid beta-Peptides	Cenini G	Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.	Biochimica et biophysica acta	2012	33
25744023	Amyloid beta-Peptides	Kaushal V	Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation.	Cell death and differentiation	2015	22
15193262	fulvestrant	Michalides R	Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.	Cancer cell	2004	73
15735034	fulvestrant	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	86
16333030	fulvestrant	Lewis JS	Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.	Journal of the National Cancer Institute	2005	78
16849584	fulvestrant	Frasor J	Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.	Cancer research	2006	73
18182067	fulvestrant	Pan Q	Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids.	Journal of cellular and molecular medicine	2008	51
19435893	fulvestrant	Miller TW	Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.	Cancer research	2009	57
20665103	fulvestrant	Kabos P	Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.	Breast cancer research and treatment	2011	45
21123450	fulvestrant	Rhodes LV	Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.	Cancer research	2011	59
21362200	fulvestrant	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	49
21908557	fulvestrant	Fox EM	A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.	Cancer research	2011	58
22853014	fulvestrant	Mehta RS	Combination anastrozole and fulvestrant in metastatic breast cancer.	The New England journal of medicine	2012	63
25380844	fulvestrant	van Kruchten M	Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.	Cancer discovery	2015	18
25991817	fulvestrant	Wardell SE	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.	Clinical cancer research 	2015	19
26358751	fulvestrant	Guichard SM	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.	Molecular cancer therapeutics	2015	15
26563128	fulvestrant	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	17
26947331	fulvestrant	Cristofanilli M	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	The Lancet. Oncology	2016	72
27155741	fulvestrant	Krop IE	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.	The Lancet. Oncology	2016	19
27368881	fulvestrant	Verma S	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).	The oncologist	2016	14
27879270	fulvestrant	Shibata T	Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.	Cancer research	2017	5
27908454	fulvestrant	Robertson JFR	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.	Lancet	2016	16
28147342	fulvestrant	McDermott MS	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.	Oncotarget	2017	5
7585152	decitabine	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	286
10811911	decitabine	Ferguson AT	High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2000	111
11196646	decitabine	Soengas MS	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.	Nature	2001	164
12006535	decitabine	Soria JC	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.	Clinical cancer research 	2002	90
12873976	decitabine	Vanaja DK	Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression.	Cancer research	2003	113
16007195	decitabine	Niwa Y	Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.	Oncogene	2005	93
16247458	decitabine	Ying J	Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.	Oncogene	2006	69
16449975	decitabine	Veeck J	Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.	Oncogene	2006	81
16491118	decitabine	Aguilera O	Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.	Oncogene	2006	93
16763620	decitabine	Mann J	Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.	Cell death and differentiation	2007	64
17079474	decitabine	Wehbe H	Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.	Cancer research	2006	60
17145863	decitabine	Muthusamy V	Epigenetic silencing of novel tumor suppressors in malignant melanoma.	Cancer research	2006	64
17241887	decitabine	Isomoto H	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.	Gastroenterology	2007	66
17875710	decitabine	Iorio MV	MicroRNA signatures in human ovarian cancer.	Cancer research	2007	470
17948228	decitabine	Lehmann U	Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.	The Journal of pathology	2008	136
17991895	decitabine	Palii SS	DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.	Molecular and cellular biology	2008	99
18221536	decitabine	Roll JD	DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.	Molecular cancer	2008	54
19109157	decitabine	Lal G	Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation.	Journal of immunology	2009	145
19221000	decitabine	Majid S	BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer.	Carcinogenesis	2009	60
19308264	decitabine	Garzia L	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.	PloS one	2009	79
19503096	decitabine	Saito Y	Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.	Oncogene	2009	54
19843643	decitabine	Furuta M	miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.	Carcinogenesis	2010	176
19877066	decitabine	Hashimoto K	DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes.	Arthritis and rheumatism	2009	47
19897574	decitabine	Kanduri M	Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.	Blood	2010	46
20103663	decitabine	Di Tomaso T	Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.	Clinical cancer research 	2010	63
20124447	decitabine	Zhang P	Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.	Molecular cancer therapeutics	2010	112
20126405	decitabine	Hollenbach PW	A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.	PloS one	2010	75
20427703	decitabine	Leshchenko VV	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.	Blood	2010	51
20529999	decitabine	Archer SL	Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target.	Circulation	2010	109
20980350	decitabine	Chik F	Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors.	Carcinogenesis	2011	37
21349819	decitabine	Suh SO	MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.	Carcinogenesis	2011	64
21368160	decitabine	Sproul D	Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	57
21703189	decitabine	Alpini G	Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer.	Journal of hepatology	2011	41
21747116	decitabine	Stefanska B	Definition of the landscape of promoter DNA hypomethylation in liver cancer.	Cancer research	2011	57
21772049	decitabine	Kalac M	HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.	Blood	2011	37
22002305	decitabine	Ramachandran I	Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.	Oncogene	2012	35
22237753	decitabine	Sun CY	Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.	Kidney international	2012	35
22249249	decitabine	Zeller C	Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.	Oncogene	2012	61
22461695	decitabine	Yang D	Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.	Journal of immunology	2012	30
22566605	decitabine	Blum W	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.	Blood	2012	47
22689435	decitabine	Neumann O	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.	Hepatology	2012	42
22821729	decitabine	Wang F	SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.	The Journal of pathology	2013	38
22876840	decitabine	Liu XH	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.	BMC cancer	2012	51
23079745	decitabine	Kim JK	Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.	Hepatology	2013	68
23297133	decitabine	Klco JM	Genomic impact of transient low-dose decitabine treatment on primary AML cells.	Blood	2013	51
23318422	decitabine	Xiang Y	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.	Oncogene	2014	49
23365201	decitabine	Dar AA	The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.	Journal of the National Cancer Institute	2013	30
23408834	decitabine	Heuck CJ	Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.	Journal of immunology	2013	25
23526416	decitabine	Estey EH	Acute myeloid leukemia: 2013 update on risk-stratification and management.	American journal of hematology	2013	70
23703729	decitabine	Song K	Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells.	Hepatology	2013	40
23971832	decitabine	Borges S	Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.	Breast cancer research 	2013	28
24030154	decitabine	Steinhart L	Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.	Cell death & disease	2013	25
24045501	decitabine	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	58
24077826	decitabine	Turcan S	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.	Oncotarget	2013	49
24283360	decitabine	Naito Y	MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer.	Cancer science	2014	20
24301681	decitabine	Watson CJ	Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype.	Human molecular genetics	2014	40
24484870	decitabine	Ufkin ML	miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.	Leukemia research	2014	22
24495951	decitabine	Cho Y	Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation.	Experimental biology and medicine	2014	20
24535937	decitabine	Odunsi K	Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.	Cancer immunology research	2014	31
24622842	decitabine	Roy DM	Driver mutations of cancer epigenomes.	Protein & cell	2014	28
24806409	decitabine	Liu EY	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.	Acta neuropathologica	2014	42
25106087	decitabine	Marcato P	Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.	Molecular oncology	2015	19
25210796	decitabine	Yan F	Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation.	Cell death & disease	2014	23
25502084	decitabine	Zhou X	The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression.	Medical oncology	2015	20
25822018	decitabine	Meldi K	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.	The Journal of clinical investigation	2015	25
26296954	decitabine	Issa JJ	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.	The Lancet. Oncology	2015	36
26859457	decitabine	Grandin M	Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers.	Cancer cell	2016	13
26934121	decitabine	Dong P	Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.	Oncotarget	2016	11
26968357	decitabine	Garcia-Manero G	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2016	12
27489122	decitabine	Wu Y	Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer.	Scientific reports	2016	13
27623509	decitabine	Lucarini V	Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.	The Journal of investigative dermatology	2017	7
27959731	decitabine	Welch JS	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.	The New England journal of medicine	2016	45
10749120	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhong H	Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.	Cancer research	2000	317
11139588	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Campbell RA	Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.	The Journal of biological chemistry	2001	191
11358816	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Brognard J	Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.	Cancer research	2001	209
11406568	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Cuello M	Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.	Cancer research	2001	88
11593406	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Hideshima T	Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.	Oncogene	2001	94
15059890	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Stiff T	ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation.	Cancer research	2004	300
15208673	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Altomare DA	AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.	Oncogene	2004	113
15896706	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Cao Y	Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo.	Biochemical and biophysical research communications	2005	129
15950905	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Samuels Y	Mutant PIK3CA promotes cell growth and invasion of human cancer cells.	Cancer cell	2005	297
16168105	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Wu G	Somatic mutation and gain of copy number of PIK3CA in human breast cancer.	Breast cancer research 	2005	66
16195373	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Singleton PA	Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin.	FASEB journal 	2005	99
16731745	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Smalley KS	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.	Molecular cancer therapeutics	2006	150
17234779	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Tabe Y	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.	Cancer research	2007	61
17310986	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Lue H	Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.	Oncogene	2007	89
17403556	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	De Felice FG	Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.	Neurobiology of aging	2008	109
17409395	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Wang H	PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.	Cancer research	2007	78
17551921	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Shukla S	Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.	International journal of cancer	2007	77
18676830	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	316
19435898	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Mukherjee B	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.	Cancer research	2009	74
19568240	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Meng XN	Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.	British journal of cancer	2009	56
19633047	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	61
20145128	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Ward CS	Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.	Cancer research	2010	66
20499340	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Chen L	Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation.	Journal of bone and mineral research 	2010	69
20547836	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Petersen SL	Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
21339740	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Kim EK	Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.	Oncogene	2011	41
21544242	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Liu LZ	MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression.	PloS one	2011	112
21713404	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Chen XF	Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways.	Molecular biology reports	2012	32
21862872	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Liu B	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.	Cell cycle	2011	41
21996732	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Shih MC	TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.	Oncogene	2012	46
22285928	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang C	Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells.	Gene	2012	60
22610073	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Li XJ	As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling.	Carcinogenesis	2012	38
23123500	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Liu J	PI3K/Akt-dependent phosphorylation of GSK3β and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration.	Cellular signalling	2013	31
23301033	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhou F	HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway.	PloS one	2013	27
23372675	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhao G	MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.	PloS one	2013	66
23643356	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Wei J	MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2013	32
23869765	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Luo X	Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.	Cell proliferation	2013	26
24700142	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang N	SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.	Oncology reports	2014	20
26568302	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yang CF	EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop.	Oncogene	2016	13
27919028	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Fu X	PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.	Bioscience reports	2014	20
2215562	Eosine Yellowish-(YS)	Bousquet J	Eosinophilic inflammation in asthma.	The New England journal of medicine	1990	285
11159189	Eosine Yellowish-(YS)	Alexander J	Histopathological identification of colon cancer with microsatellite instability.	The American journal of pathology	2001	91
11859199	Eosine Yellowish-(YS)	Amin MB	Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases.	The American journal of surgical pathology	2002	82
17075009	Eosine Yellowish-(YS)	Kawamoto A	CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells.	Circulation	2006	87
17143259	Eosine Yellowish-(YS)	Johnson JE	The histopathology of fatal untreated human respiratory syncytial virus infection.	Modern pathology 	2007	126
17620276	Eosine Yellowish-(YS)	Morris GJ	Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.	Cancer	2007	144
19830439	Eosine Yellowish-(YS)	Munoz DG	FUS pathology in basophilic inclusion body disease.	Acta neuropathologica	2009	69
19959644	Eosine Yellowish-(YS)	Shepard AR	Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes.	Investigative ophthalmology & visual science	2010	61
21304082	Eosine Yellowish-(YS)	Giuliano AE	Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.	JAMA	2011	342
21596774	Eosine Yellowish-(YS)	Nelson PT	Hippocampal sclerosis in advanced age: clinical and pathological features.	Brain 	2011	79
22261562	Eosine Yellowish-(YS)	Eto H	The fate of adipocytes after nonvascularized fat grafting: evidence of early death and replacement of adipocytes.	Plastic and reconstructive surgery	2012	42
22699204	Eosine Yellowish-(YS)	Kurahara H	M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer.	Pancreas	2013	32
24019550	Eosine Yellowish-(YS)	Kitagawa Y	Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.	Journal of clinical oncology 	2013	49
24647569	Eosine Yellowish-(YS)	Schalper KA	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.	Clinical cancer research 	2014	116
24748218	Eosine Yellowish-(YS)	Gurel B	Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.	Cancer epidemiology, biomarkers & prevention 	2014	46
24866169	Eosine Yellowish-(YS)	Shen JK	Programmed cell death ligand 1 expression in osteosarcoma.	Cancer immunology research	2014	33
25361613	Eosine Yellowish-(YS)	Ibrahim EM	The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.	Breast cancer research and treatment	2014	33
25394778	Eosine Yellowish-(YS)	Hussein YR	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.	Modern pathology 	2015	23
25527356	Eosine Yellowish-(YS)	Wimberly H	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.	Cancer immunology research	2015	46
25720324	Eosine Yellowish-(YS)	Nawaz S	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.	Modern pathology 	2015	16
26166714	Eosine Yellowish-(YS)	Vang R	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.	International journal of gynecological pathology 	2016	16
26408403	Eosine Yellowish-(YS)	Vassilakopoulou M	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.	Clinical cancer research 	2016	26
26562159	Eosine Yellowish-(YS)	McLaughlin J	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.	JAMA oncology	2016	87
27259015	Eosine Yellowish-(YS)	Tang LH	A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.	The American journal of surgical pathology	2016	16
27329602	Eosine Yellowish-(YS)	Diana A	Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.	Oncotarget	2016	13
15041700	temozolomide	Hegi ME	Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.	Clinical cancer research 	2004	146
15956649	temozolomide	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	137
17140455	temozolomide	Liu G	Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.	Molecular cancer	2006	509
17404084	temozolomide	Cahill DP	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.	Clinical cancer research 	2007	91
17505000	temozolomide	Ekeblad S	Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.	Clinical cancer research 	2007	70
18082451	temozolomide	Gorlia T	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.	The Lancet. Oncology	2008	95
18281670	temozolomide	Testori A	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.	Journal of clinical oncology 	2008	71
18445844	temozolomide	Brandes AA	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.	Journal of clinical oncology 	2008	146
18565887	temozolomide	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	233
18632623	temozolomide	Beier D	Temozolomide preferentially depletes cancer stem cells in glioblastoma.	Cancer research	2008	83
19221744	temozolomide	Banissi C	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.	Cancer immunology, immunotherapy 	2009	57
19265662	temozolomide	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	239
19584161	temozolomide	Yip S	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.	Clinical cancer research 	2009	83
19884534	temozolomide	Senzer NN	Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.	Journal of clinical oncology 	2009	162
19901110	temozolomide	Wick W	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.	Journal of clinical oncology 	2009	140
20423999	temozolomide	Keating AK	Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.	Molecular cancer therapeutics	2010	56
20439646	temozolomide	Stupp R	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	99
20587533	temozolomide	Voss V	The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.	Molecular cancer research 	2010	49
20633539	temozolomide	Shi L	MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.	Brain research	2010	67
20935218	temozolomide	Gaspar N	MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.	Cancer research	2010	44
21116835	temozolomide	Zhu X	Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.	Journal of neuro-oncology	2011	39
21325076	temozolomide	Ma XH	Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.	Clinical cancer research 	2011	67
21737504	temozolomide	Grossman SA	Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.	Clinical cancer research 	2011	84
21768296	temozolomide	Mitchell DA	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.	Blood	2011	45
21988793	temozolomide	Beier D	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.	Molecular cancer	2011	80
22034964	temozolomide	SongTao Q	IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.	Cancer science	2012	39
22048237	temozolomide	Kirkwood JM	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.	Clinical cancer research 	2012	77
22128301	temozolomide	Liu X	Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.	Clinical cancer research 	2012	41
22197930	temozolomide	Stark MS	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.	Nature genetics	2011	74
22469979	temozolomide	Wagner L	Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.	Oncogene	2013	28
22532597	temozolomide	Kohsaka S	STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.	Molecular cancer therapeutics	2012	31
22877848	temozolomide	Malmström A	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.	The Lancet. Oncology	2012	134
22984531	temozolomide	Safdie F	Fasting enhances the response of glioma to chemo- and radiotherapy.	PloS one	2012	33
23047041	temozolomide	Triscott J	Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.	Oncotarget	2012	33
23115158	temozolomide	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	38
23258846	temozolomide	Miranda-Gonçalves V	Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.	Neuro-oncology	2013	52
23370117	temozolomide	Curtin NJ	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.	Molecular aspects of medicine	2013	75
23423489	temozolomide	Plummer R	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.	Cancer chemotherapy and pharmacology	2013	32
23792642	temozolomide	Comincini S	microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.	Cancer biology & therapy	2013	32
24336570	temozolomide	Johnson BE	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Science	2014	244
24608791	temozolomide	Auffinger B	Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.	Cell death and differentiation	2014	58
24675463	temozolomide	Munoz JL	Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.	Cell death & disease	2014	25
24821329	temozolomide	Di Ieva A	Aggressive pituitary adenomas--diagnosis and emerging treatments.	Nature reviews. Endocrinology	2014	24
24861879	temozolomide	Shi Z	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.	Neuro-oncology	2014	36
24980823	temozolomide	Wang L	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.	Oncotarget	2014	43
24991839	temozolomide	Rangwala R	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.	Autophagy	2014	73
25093489	temozolomide	Han S	Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.	British journal of cancer	2014	26
25135958	temozolomide	Bao ZS	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.	Genome research	2014	41
25163906	temozolomide	Stupp R	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	126
25283382	temozolomide	Shi J	Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.	Tumour biology 	2015	22
25468223	temozolomide	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	30
25500058	temozolomide	Smith MA	Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.	Clinical cancer research 	2015	20
25526733	temozolomide	Ma DJ	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.	Neuro-oncology	2015	18
25595896	temozolomide	Munoz JL	Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.	Oncotarget	2015	17
25605243	temozolomide	Wang Z	Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.	Oncotarget	2015	18
25609063	temozolomide	Pokorny JL	The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.	Clinical cancer research 	2015	16
25609769	temozolomide	Suchorska B	Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.	Neurology	2015	17
25646366	temozolomide	Caplin ME	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.	Annals of oncology 	2015	35
25762461	temozolomide	Nabors LB	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.	Neuro-oncology	2015	30
25867026	temozolomide	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	25
26115796	temozolomide	Ribas A	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.	The Lancet. Oncology	2015	208
26188279	temozolomide	Yu Z	NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.	Cancer letters	2015	19
26431379	temozolomide	Yu Z	Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.	Oncotarget	2015	22
26846818	temozolomide	Phillips AC	ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.	Molecular cancer therapeutics	2016	15
26878385	temozolomide	Garros-Regulez L	mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.	Expert opinion on therapeutic targets	2016	14
27440269	temozolomide	Lok BH	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.	Clinical cancer research 	2017	13
27503138	temozolomide	Arita H	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.	Acta neuropathologica communications	2016	12
27686946	temozolomide	Baumert BG	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.	The Lancet. Oncology	2016	15
27690220	temozolomide	Kawaguchi K	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.	Oncotarget	2016	26
28106277	temozolomide	Kawaguchi K	Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.	Journal of cellular biochemistry	2017	15
28187000	temozolomide	Chen W	MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.	Oncotarget	2017	8
28622068	temozolomide	Kawaguchi K	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.	Cell cycle	2017	8
28668966	temozolomide	Li H	Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.	Cellular physiology and biochemistry 	2017	7
28844499	temozolomide	Weller M	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.	The Lancet. Oncology	2017	11
14744787	resveratrol	Opipari AW Jr	Resveratrol-induced autophagocytosis in ovarian cancer cells.	Cancer research	2004	79
16356836	resveratrol	Garvin S	Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.	Cancer letters	2006	67
17164350	resveratrol	Bhardwaj A	Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.	Blood	2007	93
17897053	resveratrol	Das S	Anti-inflammatory responses of resveratrol.	Inflammation & allergy drug targets	2007	64
18421301	resveratrol	Scarlatti F	Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells.	Cell death and differentiation	2008	125
18801740	resveratrol	Lukiw WJ	An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells.	The Journal of biological chemistry	2008	143
18835033	resveratrol	Wang RH	Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.	Cancer cell	2008	260
19047049	resveratrol	Bourguignon LY	Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.	The Journal of biological chemistry	2009	51
19326431	resveratrol	Narayanan NK	Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.	International journal of cancer	2009	60
19714620	resveratrol	Takayama K	SIRT1 regulation of apoptosis of human chondrocytes.	Arthritis and rheumatism	2009	48
19968965	resveratrol	Villarreal G Jr	Defining the regulation of KLF4 expression and its downstream transcriptional targets in vascular endothelial cells.	Biochemical and biophysical research communications	2010	53
20068143	resveratrol	de Kreutzenberg SV	Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms.	Diabetes	2010	64
20089851	resveratrol	Tanno M	Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure.	The Journal of biological chemistry	2010	88
20103647	resveratrol	Puissant A	Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.	Cancer research	2010	93
20157535	resveratrol	Armour SM	Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy.	Aging	2009	65
20306310	resveratrol	Sun AY	Resveratrol as a therapeutic agent for neurodegenerative diseases.	Molecular neurobiology	2010	49
20504360	resveratrol	Vanamala J	Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.	BMC cancer	2010	51
20644332	resveratrol	Kao CL	Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation.	Journal of atherosclerosis and thrombosis	2010	54
21224864	resveratrol	Morris KC	Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning.	Journal of cerebral blood flow and metabolism 	2011	36
21241768	resveratrol	Fröjdö S	Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1.	Molecular and cellular endocrinology	2011	38
21304978	resveratrol	Shankar S	Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.	PloS one	2011	79
21695150	resveratrol	Filippi-Chiela EC	Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells.	PloS one	2011	44
22052357	resveratrol	Menendez JA	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.	Cell cycle	2011	58
22138609	resveratrol	Lukiw WJ	NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells.	Experimental neurology	2012	41
22410781	resveratrol	Yu YH	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.	Oncogene	2013	33
23359184	resveratrol	Liu P	Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression.	Clinical & translational oncology 	2013	26
23533664	resveratrol	Luo H	Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage.	PloS one	2013	33
23884882	resveratrol	Fiori JL	Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet.	Diabetes	2013	31
23897750	resveratrol	Paschalaki KE	Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence.	Stem cells	2013	29
23992306	resveratrol	Li W	Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.	Current medicinal chemistry	2013	26
24023672	resveratrol	Venturelli S	Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone corrected proteins in human-derived hepatoblastoma cells.	PloS one	2013	28
24184811	resveratrol	Li Y	Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.	Gastroenterology	2014	44
24244343	resveratrol	Ji Q	Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway.	PloS one	2013	60
24439680	resveratrol	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	89
24582567	resveratrol	Chachay VS	Resveratrol does not benefit patients with nonalcoholic fatty liver disease.	Clinical gastroenterology and hepatology 	2014	36
24629563	resveratrol	Yang SJ	Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation.	Metabolism	2014	20
24819981	resveratrol	Semba RD	Resveratrol levels and all-cause mortality in older community-dwelling adults.	JAMA internal medicine	2014	23
25143940	resveratrol	Wu J	The role of oxidative stress and inflammation in cardiovascular aging.	BioMed research international	2014	27
25311610	resveratrol	Faghihzadeh F	Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.	Nutrition research	2014	30
25375374	resveratrol	Hasima N	Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer.	Cell death & disease	2014	41
25440059	resveratrol	Scheibye-Knudsen M	A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome.	Cell metabolism	2014	52
25447541	resveratrol	Dhar S	Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.	Biochimica et biophysica acta	2015	19
25527776	resveratrol	Chen T	Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway.	American journal of physiology. Heart and circulatory physiology	2015	29
25605016	resveratrol	Yang SF	Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas.	Oncotarget	2015	16
25737402	resveratrol	Li W	Intra-articular resveratrol injection prevents osteoarthritis progression in a mouse model by activating SIRT1 and thereby silencing HIF-2α.	Journal of orthopaedic research 	2015	17
25869442	resveratrol	Ferguson LR	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.	Seminars in cancer biology	2015	27
25884904	resveratrol	Ji Q	Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.	BMC cancer	2015	28
25938543	resveratrol	Dai W	By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.	Oncotarget	2015	24
26223300	resveratrol	Cai H	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.	Science translational medicine	2015	23
26318586	resveratrol	Dhar S	Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer.	Oncotarget	2015	24
26704305	resveratrol	Gwak H	Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.	Cancer letters	2016	11
26759241	resveratrol	Li CW	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation.	Cancer research	2016	13
26959057	resveratrol	Buhrmann C	Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells.	Nutrients	2016	13
27522058	resveratrol	Sosulski ML	Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis.	The journals of gerontology. Series A, Biological sciences and medical sciences	2017	9
28075467	resveratrol	Gao F	Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.	Oncology reports	2017	6
28197628	resveratrol	Chang CH	Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling.	International journal of oncology	2017	6
28611316	resveratrol	McCubrey JA	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.	Aging	2017	6
10485474	Paraffin	McMenamin ME	Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.	Cancer research	1999	141
10595928	Paraffin	De Marzo AM	Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.	The American journal of pathology	1999	167
10766191	Paraffin	Wilentz RE	Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.	Cancer research	2000	136
11948129	Paraffin	Malik SN	Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.	Clinical cancer research 	2002	87
12466114	Paraffin	van de Rijn M	Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.	The American journal of pathology	2002	121
12576453	Paraffin	Bui MH	Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.	Clinical cancer research 	2003	104
15709183	Paraffin	Abraham BK	Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.	Clinical cancer research 	2005	138
15897568	Paraffin	Atkins M	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.	Clinical cancer research 	2005	71
16049314	Paraffin	Ogino S	Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.	The Journal of molecular diagnostics 	2005	197
16888288	Paraffin	Tsuji T	Alveolar cell senescence in patients with pulmonary emphysema.	American journal of respiratory and critical care medicine	2006	102
17099880	Paraffin	Petersen RP	Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.	Cancer	2006	84
17200343	Paraffin	Savage K	Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.	Clinical cancer research 	2007	55
17255298	Paraffin	Thompson RH	Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.	Clinical cancer research 	2007	60
17287515	Paraffin	Kramer ML	Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.	The Journal of neuroscience 	2007	132
17360651	Paraffin	Hamanishi J	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	331
17363526	Paraffin	Henry LR	Clinical implications of fibroblast activation protein in patients with colon cancer.	Clinical cancer research 	2007	74
17487835	Paraffin	Lawrie CH	MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.	International journal of cancer	2007	120
18195146	Paraffin	Axelrad JE	Reduced Purkinje cell number in essential tremor: a postmortem study.	Archives of neurology	2008	60
18343725	Paraffin	Vergis R	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.	The Lancet. Oncology	2008	69
18544678	Paraffin	Rimsza LM	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.	Blood	2008	52
19304953	Paraffin	Yu C	Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis.	Carcinogenesis	2009	52
19318487	Paraffin	Bandres E	microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells.	Clinical cancer research 	2009	110
19342367	Paraffin	Maru DM	MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.	The American journal of pathology	2009	51
19474676	Paraffin	Zou C	Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.	Annals of surgery	2009	56
19765725	Paraffin	Kurahara H	Significance of M2-polarized tumor-associated macrophage in pancreatic cancer.	The Journal of surgical research	2011	135
20022135	Paraffin	Chen X	Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients.	Lung cancer	2010	49
20631605	Paraffin	Sholl LM	Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.	The American journal of surgical pathology	2010	49
20842526	Paraffin	Campbell MJ	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.	Breast cancer research and treatment	2011	66
21225432	Paraffin	Vogt M	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.	Virchows Archiv 	2011	83
21523733	Paraffin	Gadiot J	Overall survival and PD-L1 expression in metastasized malignant melanoma.	Cancer	2011	48
21752896	Paraffin	Korpershoek E	SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas.	The Journal of clinical endocrinology and metabolism	2011	49
22088988	Paraffin	Schmidt LH	The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.	Journal of thoracic oncology 	2011	131
22184391	Paraffin	van Gaal JC	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.	Journal of clinical oncology 	2012	35
22389665	Paraffin	Puget S	Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.	PloS one	2012	67
22675169	Paraffin	Zeng Z	Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.	Clinical cancer research 	2012	37
22977193	Paraffin	Terashima M	Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.	Clinical cancer research 	2012	63
23391413	Paraffin	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	41
23762387	Paraffin	Wang L	Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.	PloS one	2013	64
23825651	Paraffin	Kluk MJ	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	PloS one	2013	32
23901018	Paraffin	Engstrøm MJ	Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.	Breast cancer research and treatment	2013	38
23964099	Paraffin	Deuring JJ	Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn's disease.	Gut	2014	30
24033439	Paraffin	Mondragón-Rodríguez S	Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome.	Neuropathology and applied neurobiology	2014	25
24177760	Paraffin	Walline HM	High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.	JAMA otolaryngology-- head & neck surgery	2013	31
24209998	Paraffin	Dey N	Wnt signaling in triple negative breast cancer is associated with metastasis.	BMC cancer	2013	43
24239208	Paraffin	Zhang JX	Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.	The Lancet. Oncology	2013	91
24548766	Paraffin	Yang CY	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	European journal of cancer	2014	79
25895031	Paraffin	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	45
26056355	Paraffin	Matamala N	Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.	Clinical chemistry	2015	25
26489445	Paraffin	Kuboki Y	Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.	Annals of oncology 	2016	12
26745875	Paraffin	Mafficini A	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.	Oncotarget	2016	11
26823521	Paraffin	Castellsagué X	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.	Journal of the National Cancer Institute	2016	46
15710622	sphingosine 1-phosphate	Finigan JH	Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.	The Journal of biological chemistry	2005	135
16106218	sphingosine 1-phosphate	Van Brocklyn JR	Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines.	Journal of neuropathology and experimental neurology	2005	108
16194537	sphingosine 1-phosphate	Sarkar S	Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells.	FEBS letters	2005	73
16319132	sphingosine 1-phosphate	Kawamori T	Sphingosine kinase 1 is up-regulated in colon carcinogenesis.	FASEB journal 	2006	75
16855590	sphingosine 1-phosphate	Carlson CM	Kruppel-like factor 2 regulates thymocyte and T-cell migration.	Nature	2006	187
17090686	sphingosine 1-phosphate	Oskouian B	Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	76
17303574	sphingosine 1-phosphate	Baran Y	Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.	The Journal of biological chemistry	2007	58
18058224	sphingosine 1-phosphate	Ruckhäberle E	Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.	Breast cancer research and treatment	2008	95
18815359	sphingosine 1-phosphate	Snider AJ	A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis.	FASEB journal 	2009	69
18824518	sphingosine 1-phosphate	Kawamori T	Role for sphingosine kinase 1 in colon carcinogenesis.	FASEB journal 	2009	86
19814729	sphingosine 1-phosphate	Brinkmann V	FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.	British journal of pharmacology	2009	96
20081052	sphingosine 1-phosphate	Shea BS	Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.	American journal of respiratory cell and molecular biology	2010	45
20555359	sphingosine 1-phosphate	Pyne NJ	Sphingosine 1-phosphate and cancer.	Nature reviews. Cancer	2010	257
22098666	sphingosine 1-phosphate	Bao M	Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma.	Liver international 	2012	32
22298596	sphingosine 1-phosphate	Nagahashi M	Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis.	Cancer research	2012	90
22986288	sphingosine 1-phosphate	Xiang SY	Lysophospholipid receptor activation of RhoA and lipid signaling pathways.	Biochimica et biophysica acta	2013	29
23290781	sphingosine 1-phosphate	Heffernan-Stroud LA	Sphingosine kinase 1 in cancer.	Advances in cancer research	2013	29
23615526	sphingosine 1-phosphate	Schneider G	Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy.	Molecular cancer research 	2013	25
23638983	sphingosine 1-phosphate	Neubauer HA	Roles, regulation and inhibitors of sphingosine kinase 2.	The FEBS journal	2013	40
23861887	sphingosine 1-phosphate	Rex K	Sphingosine kinase activity is not required for tumor cell viability.	PloS one	2013	26
24798342	sphingosine 1-phosphate	Heo MJ	microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression.	Oncotarget	2014	23
25347472	sphingosine 1-phosphate	Degagné E	Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs.	The Journal of clinical investigation	2014	34
25624457	sphingosine 1-phosphate	Mackay LK	Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention.	Journal of immunology	2015	56
26053034	sphingosine 1-phosphate	Hait NC	The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.	Oncogenesis	2015	23
26082434	sphingosine 1-phosphate	Panneer Selvam S	Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.	Science signaling	2015	20
26268607	sphingosine 1-phosphate	Galvani S	HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation.	Science signaling	2015	34
26621917	sphingosine 1-phosphate	Kakazu E	Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner.	Journal of lipid research	2016	18
26715391	sphingosine 1-phosphate	Hunter SF	The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.	CNS drugs	2016	11
27771292	sphingosine 1-phosphate	Coant N	Ceramidases, roles in sphingolipid metabolism and in health and disease.	Advances in biological regulation	2017	6
27879252	sphingosine 1-phosphate	Ruiz M	High-Density Lipoprotein-Associated Apolipoprotein M Limits Endothelial Inflammation by Delivering Sphingosine-1-Phosphate to the Sphingosine-1-Phosphate Receptor 1.	Arteriosclerosis, thrombosis, and vascular biology	2017	7
27956387	sphingosine 1-phosphate	Powell JA	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.	Blood	2017	5
28052056	sphingosine 1-phosphate	van der Weyden L	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization.	Nature	2017	19
28108260	sphingosine 1-phosphate	Maiti A	Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.	Cellular signalling	2017	11
28420720	sphingosine 1-phosphate	Britten CD	A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.	Clinical cancer research 	2017	8
10815932	oxaliplatin	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	110
11731512	oxaliplatin	Shirota Y	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.	Journal of clinical oncology 	2001	112
14998849	oxaliplatin	Rubbia-Brandt L	Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.	Annals of oncology 	2004	141
16622265	oxaliplatin	Zhu AX	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	75
16857785	oxaliplatin	Yang AD	Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.	Clinical cancer research 	2006	139
17050875	oxaliplatin	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	92
17060484	oxaliplatin	Rubbia-Brandt L	Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.	Annals of oncology 	2007	62
18272912	oxaliplatin	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	57
18390971	oxaliplatin	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	175
18718806	oxaliplatin	Sabbah M	Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.	Drug resistance updates 	2008	99
19196673	oxaliplatin	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	301
19217207	oxaliplatin	Costantino E	TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.	Cancer letters	2009	47
19230702	oxaliplatin	Catalano V	Gastric cancer.	Critical reviews in oncology/hematology	2009	100
19383922	oxaliplatin	Kopetz S	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.	Cancer research	2009	48
19786657	oxaliplatin	Chibaudel B	Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.	Journal of clinical oncology 	2009	58
19881547	oxaliplatin	Tesniere A	Immunogenic death of colon cancer cells treated with oxaliplatin.	Oncogene	2010	142
19884549	oxaliplatin	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	152
20386463	oxaliplatin	Correale P	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.	Journal of immunotherapy	2010	61
20530282	oxaliplatin	McLeod HL	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.	Journal of clinical oncology 	2010	50
20648559	oxaliplatin	Ning Y	Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.	International journal of cancer	2011	87
21151176	oxaliplatin	Martins I	Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress.	Oncogene	2011	67
21228335	oxaliplatin	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	181
21430067	oxaliplatin	Gulhati P	mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.	Cancer research	2011	165
21555371	oxaliplatin	Asiedu MK	TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.	Cancer research	2011	76
21606427	oxaliplatin	Aschele C	Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.	Journal of clinical oncology 	2011	133
21641636	oxaliplatin	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	219
21684283	oxaliplatin	Tan IB	Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.	Gastroenterology	2011	73
21709185	oxaliplatin	Crane CH	Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.	Journal of clinical oncology 	2011	68
22172905	oxaliplatin	Della Vittoria Scarpati G	A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.	International journal of radiation oncology, biology, physics	2012	43
22391039	oxaliplatin	Ning Y	The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.	Molecular cancer therapeutics	2012	31
22473163	oxaliplatin	Dewdney A	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).	Journal of clinical oncology 	2012	61
22698403	oxaliplatin	O'Brien CA	ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21.	Cancer cell	2012	62
22811078	oxaliplatin	Wang L	First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.	Cancer	2013	36
22825584	oxaliplatin	Julien S	Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.	Clinical cancer research 	2012	77
22949147	oxaliplatin	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	212
23017669	oxaliplatin	Foxtrot Collaborative Group	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.	The Lancet. Oncology	2012	42
23045248	oxaliplatin	Gavin PG	Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.	Clinical cancer research 	2012	60
23056401	oxaliplatin	Takahashi M	The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.	PloS one	2012	46
23168366	oxaliplatin	Bennouna J	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.	The Lancet. Oncology	2013	205
23510984	oxaliplatin	Cohn AL	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.	Annals of oncology 	2013	30
23574723	oxaliplatin	Qian X	MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.	Cell cycle	2013	41
23723074	oxaliplatin	Dong Y	Tumor suppressor functions of miR-133a in colorectal cancer.	Molecular cancer research 	2013	31
23788041	oxaliplatin	Bullock MD	Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.	Cell death & disease	2013	31
23881988	oxaliplatin	Hurwitz HI	Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.	The oncologist	2013	31
24119443	oxaliplatin	Kjersem JB	Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.	Molecular oncology	2014	33
24122958	oxaliplatin	Huang D	miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.	Journal of cellular biochemistry	2014	26
24225157	oxaliplatin	Yamada Y	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.	The Lancet. Oncology	2013	37
24356622	oxaliplatin	Peeters M	Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.	Annals of oncology 	2014	23
24448818	oxaliplatin	Cristóbal I	PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.	Molecular cancer therapeutics	2014	25
24585723	oxaliplatin	Goldstein J	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).	Annals of oncology 	2014	32
24717919	oxaliplatin	Primrose J	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.	The Lancet. Oncology	2014	46
25420066	oxaliplatin	Wainger BJ	Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts.	Nature neuroscience	2015	32
25446103	oxaliplatin	Wan LY	miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.	Biochemical and biophysical research communications	2015	16
25616665	oxaliplatin	Zhang Y	MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.	The Journal of biological chemistry	2015	22
25632066	oxaliplatin	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	21
25862517	oxaliplatin	Simkens LH	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.	Lancet	2015	49
25877855	oxaliplatin	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	92
25918279	oxaliplatin	Heestand GM	Approach to patients with pancreatic cancer without detectable metastases.	Journal of clinical oncology 	2015	16
25918287	oxaliplatin	Dienstmann R	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.	Journal of clinical oncology 	2015	38
25924065	oxaliplatin	Shalapour S	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.	Nature	2015	50
25943534	oxaliplatin	Stewart R	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.	Cancer immunology research	2015	20
25979230	oxaliplatin	James MI	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.	Cancer letters	2015	16
26189067	oxaliplatin	Rödel C	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.	The Lancet. Oncology	2015	41
26338525	oxaliplatin	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	55
26387536	oxaliplatin	Blanco FF	The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.	Oncogene	2016	19
26540314	oxaliplatin	Leone F	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).	Cancer	2016	11
26541320	oxaliplatin	Goldstein DA	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.	Clinical colorectal cancer	2016	11
26626800	oxaliplatin	Shitara K	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.	Gastric cancer 	2017	7
26628478	oxaliplatin	Hecht JR	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Journal of clinical oncology 	2016	77
26830752	oxaliplatin	Kamisawa T	Pancreatic cancer.	Lancet	2016	93
26872698	oxaliplatin	Pfirschke C	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.	Immunity	2016	49
27055731	oxaliplatin	Nywening TM	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.	The Lancet. Oncology	2016	40
27633443	oxaliplatin	Yue B	Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer.	Molecular therapy 	2016	22
27856123	oxaliplatin	Sunakawa Y	Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.	Clinical colorectal cancer	2017	5
28094194	oxaliplatin	Hickish T	MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2017	6
15814656	epigallocatechin gallate	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	69
17570133	epigallocatechin gallate	Berletch JB	Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.	Journal of cellular biochemistry	2008	64
17942911	epigallocatechin gallate	Pyrko P	The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.	Cancer research	2007	125
17998943	epigallocatechin gallate	Siddiqui IA	Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.	Oncogene	2008	56
20015867	epigallocatechin gallate	Balasubramanian S	The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.	Carcinogenesis	2010	42
20730621	epigallocatechin gallate	Jomova K	Metals, oxidative stress and neurodegenerative disorders.	Molecular and cellular biochemistry	2010	164
21209038	epigallocatechin gallate	Nandakumar V	(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.	Carcinogenesis	2011	69
21796625	epigallocatechin gallate	Tang SN	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.	International journal of cancer	2012	50
21798853	epigallocatechin gallate	Choudhury SR	(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.	Carcinogenesis	2011	41
21965273	epigallocatechin gallate	Wang H	Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α.	Carcinogenesis	2011	45
23201840	epigallocatechin gallate	Du GJ	Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea.	Nutrients	2012	33
24481780	epigallocatechin gallate	Deb G	Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.	Molecular carcinogenesis	2015	16
24518414	epigallocatechin gallate	Saldanha SN	Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate.	Experimental cell research	2014	22
26499783	epigallocatechin gallate	Zhu K	Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.	Tumour biology 	2016	10
26930714	epigallocatechin gallate	Toden S	Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.	Oncotarget	2016	14
26933999	epigallocatechin gallate	Yu CC	Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis.	Oncotarget	2016	15
27200496	epigallocatechin gallate	Yuan CH	Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.	Environmental toxicology	2017	10
10477620	Curcumin	Jobin C	Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity.	Journal of immunology	1999	121
12393461	Curcumin	Bharti AC	Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.	Blood	2003	132
12466962	Curcumin	Jaiswal AS	Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells.	Oncogene	2002	91
15070700	Curcumin	Bharti AC	Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.	Blood	2004	82
15668484	Curcumin	Garcea G	Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.	Cancer epidemiology, biomarkers & prevention 	2005	83
16023083	Curcumin	Shishodia S	Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.	Biochemical pharmacology	2005	84
16092118	Curcumin	Li L	Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.	Cancer	2005	99
16151628	Curcumin	Elsharkawy AM	The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis.	Apoptosis 	2005	98
16243823	Curcumin	Aggarwal BB	Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.	Clinical cancer research 	2005	105
16628653	Curcumin	Wang Z	Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells.	Cancer	2006	82
16757216	Curcumin	Cruz-Correa M	Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.	Clinical gastroenterology and hepatology 	2006	72
17395690	Curcumin	Aoki H	Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.	Molecular pharmacology	2007	130
17439648	Curcumin	Bisht S	Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy.	Journal of nanobiotechnology	2007	146
18347134	Curcumin	Sun M	Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.	Molecular cancer therapeutics	2008	110
19516890	Curcumin	Gupta V	Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy.	International journal of nanomedicine	2009	46
19590964	Curcumin	Ravindran J	Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?	The AAPS journal	2009	125
20726007	Curcumin	Shehzad A	Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.	Archiv der Pharmazie	2010	82
20815812	Curcumin	Mudduluru G	Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer.	Bioscience reports	2011	60
20934487	Curcumin	Li YY	Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models.	Neuroscience letters	2011	36
21193839	Curcumin	Lim KJ	A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors.	Cancer biology & therapy	2011	41
21299897	Curcumin	Wilken R	Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.	Molecular cancer	2011	111
21836020	Curcumin	Saini S	Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer.	Cancer prevention research	2011	43
22030090	Curcumin	Tu SP	Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth.	Cancer prevention research	2012	40
22108826	Curcumin	Bao B	Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.	Cancer research	2012	95
22622204	Curcumin	Han J	Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage.	Autophagy	2012	38
22637745	Curcumin	Soubani O	Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.	Carcinogenesis	2012	30
22662257	Curcumin	Yang CL	Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.	PloS one	2012	40
22952749	Curcumin	Bao B	Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.	PloS one	2012	43
22992310	Curcumin	Roy S	Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF.	Journal of hematology & oncology	2012	44
23076367	Curcumin	Huang T	Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells.	Oncology reports	2013	26
23451189	Curcumin	Shakibaei M	Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways.	PloS one	2013	30
23457487	Curcumin	Yu J	Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.	PloS one	2013	31
23509976	Curcumin	Singh PK	Curcumin modulates α-synuclein aggregation and toxicity.	ACS chemical neuroscience	2013	30
23548270	Curcumin	Yu CC	miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.	Cancer research	2013	40
24138392	Curcumin	Zheng J	Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation--a novel mechanism suppressing liver fibrosis.	The FEBS journal	2014	20
24371229	Curcumin	Charpentier MS	Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment.	Cancer research	2014	27
24626093	Curcumin	Kantara C	Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.	Cancer research	2014	26
25256401	Curcumin	Ma J	Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells.	Toxicology letters	2014	26
25444916	Curcumin	Ye M	Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.	Cancer letters	2015	33
25653233	Curcumin	Toden S	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.	Carcinogenesis	2015	21
25714022	Curcumin	Zou P	ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer.	Oncotarget	2015	20
26046466	Curcumin	Wang L	Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells.	Oncotarget	2015	21
26116834	Curcumin	Taverna S	Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.	Oncotarget	2015	15
26703799	Curcumin	Suresh R	The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.	Advances in experimental medicine and biology	2016	14
27866850	Curcumin	Lim SO	Deubiquitination and Stabilization of PD-L1 by CSN5.	Cancer cell	2016	18
28236692	Curcumin	Gawde KA	Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue.	Journal of colloid and interface science	2017	7
10363963	bicalutamide	Taplin ME	Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.	Cancer research	1999	118
17566103	bicalutamide	Nickols NG	Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
19359544	bicalutamide	Tran C	Development of a second-generation antiandrogen for treatment of advanced prostate cancer.	Science	2009	469
19366804	bicalutamide	Steinkamp MP	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.	Cancer research	2009	64
22355276	bicalutamide	Yamashita S	ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.	Neoplasia	2012	44
23687298	bicalutamide	Lin TH	Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.	The Journal of biological chemistry	2013	33
23928703	bicalutamide	Lin TH	Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.	Cell death & disease	2013	38
23965901	bicalutamide	Gucalp A	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.	Clinical cancer research 	2013	104
23966621	bicalutamide	Thomas C	Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.	Molecular cancer therapeutics	2013	36
24451109	bicalutamide	Cochrane DR	Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.	Breast cancer research 	2014	60
24874833	bicalutamide	Yu Z	Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.	Clinical cancer research 	2014	23
25103565	bicalutamide	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	38
27503005	bicalutamide	Statz CM	mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.	Targeted oncology	2017	7
9463399	Poly Adenosine Diphosphate Ribose	Fan T	Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation.	The Journal of experimental medicine	1998	172
16079129	Poly Adenosine Diphosphate Ribose	Petit A	Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations.	The Journal of biological chemistry	2005	86
17431114	Poly Adenosine Diphosphate Ribose	Liu TJ	Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.	Molecular cancer therapeutics	2007	59
20142589	Poly Adenosine Diphosphate Ribose	Zarghooni M	Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.	Journal of clinical oncology 	2010	94
20609467	Poly Adenosine Diphosphate Ribose	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	435
20609468	Poly Adenosine Diphosphate Ribose	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	336
20877296	Poly Adenosine Diphosphate Ribose	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	197
21458083	Poly Adenosine Diphosphate Ribose	Garrett MD	Anticancer therapy with checkpoint inhibitors: what, where and when?	Trends in pharmacological sciences	2011	63
21555554	Poly Adenosine Diphosphate Ribose	Krawczyk PM	Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2011	49
21646373	Poly Adenosine Diphosphate Ribose	Ohanna M	Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).	Genes & development	2011	57
21821475	Poly Adenosine Diphosphate Ribose	Helleday T	The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.	Molecular oncology	2011	141
22416035	Poly Adenosine Diphosphate Ribose	Williamson CT	Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.	EMBO molecular medicine	2012	41
22460902	Poly Adenosine Diphosphate Ribose	Garnett MJ	Systematic identification of genomic markers of drug sensitivity in cancer cells.	Nature	2012	620
22472897	Poly Adenosine Diphosphate Ribose	Galia A	PARP-1 protein expression in glioblastoma multiforme.	European journal of histochemistry 	2012	32
22641215	Poly Adenosine Diphosphate Ribose	Tobin LA	Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.	Oncogene	2013	30
22711857	Poly Adenosine Diphosphate Ribose	Alsop K	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.	Journal of clinical oncology 	2012	170
22942173	Poly Adenosine Diphosphate Ribose	Linkermann A	Programmed necrosis in acute kidney injury.	Nephrology, dialysis, transplantation 	2012	33
22993403	Poly Adenosine Diphosphate Ribose	Schiewer MJ	Dual roles of PARP-1 promote cancer growth and progression.	Cancer discovery	2012	74
23097248	Poly Adenosine Diphosphate Ribose	Ebrahimi KB	Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration.	The Journal of pathology	2013	35
23656790	Poly Adenosine Diphosphate Ribose	Bisso A	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.	Cell cycle	2013	33
25422887	Poly Adenosine Diphosphate Ribose	Gong Z	LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2.	PloS one	2014	33
26091341	Poly Adenosine Diphosphate Ribose	Feng FY	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.	Molecular cell	2015	32
26091342	Poly Adenosine Diphosphate Ribose	Barkauskaite E	Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation.	Molecular cell	2015	33
26100884	Poly Adenosine Diphosphate Ribose	Henneman L	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
26268938	Poly Adenosine Diphosphate Ribose	Livraghi L	PARP inhibitors in the management of breast cancer: current data and future prospects.	BMC medicine	2015	41
26373281	Poly Adenosine Diphosphate Ribose	Ramamoorthy M	Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells.	Cancer cell	2015	17
26594843	Poly Adenosine Diphosphate Ribose	Esposito MT	Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.	Nature medicine	2015	17
26759228	Poly Adenosine Diphosphate Ribose	Park KJ	Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis.	Gastric cancer 	2017	5
26779812	Poly Adenosine Diphosphate Ribose	Du Y	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.	Nature medicine	2016	22
26811421	Poly Adenosine Diphosphate Ribose	Moudry P	TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.	The Journal of cell biology	2016	12
28186131	Poly Adenosine Diphosphate Ribose	Viziteu E	RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.	Leukemia	2017	5
28288110	Poly Adenosine Diphosphate Ribose	Davies H	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.	Nature medicine	2017	10
11544480	U 0126	MacDonald TJ	Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.	Nature genetics	2001	93
12970315	U 0126	Namba H	Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.	The Journal of clinical endocrinology and metabolism	2003	84
17363736	U 0126	Liu J	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.	Blood	2007	122
17652623	U 0126	Wang YF	Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.	Clinical cancer research 	2007	77
17694057	U 0126	Shukla V	RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.	Nature genetics	2007	61
17875706	U 0126	Andarawewa KL	Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition.	Cancer research	2007	58
19816559	U 0126	Smout MJ	A granulin-like growth factor secreted by the carcinogenic liver fluke, Opisthorchis viverrini, promotes proliferation of host cells.	PLoS pathogens	2009	46
19920183	U 0126	Chen H	Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression.	Cancer research	2009	63
21558393	U 0126	Besmer DM	Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.	Cancer research	2011	47
21618587	U 0126	Latifi A	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.	Journal of cellular biochemistry	2011	70
22927430	U 0126	Fang WB	CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms.	The Journal of biological chemistry	2012	44
24967732	U 0126	Li R	Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation.	PloS one	2014	38
27462868	U 0126	Liao T	BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.	Oncotarget	2017	8
28366557	U 0126	Hu X	FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer.	Cancer letters	2017	8
10766168	hydrogen sulfite	Ueki T	Hypermethylation of multiple genes in pancreatic adenocarcinoma.	Cancer research	2000	90
11984524	hydrogen sulfite	Hawkins N	CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.	Gastroenterology	2002	97
15717292	hydrogen sulfite	Abdolmaleky HM	Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report.	American journal of medical genetics. Part B, Neuropsychiatric genetics 	2005	117
16174854	hydrogen sulfite	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	157
16645207	hydrogen sulfite	Ogino S	Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.	The Journal of molecular diagnostics 	2006	156
16951683	hydrogen sulfite	Chan TL	Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer.	Nature genetics	2006	68
17408664	hydrogen sulfite	Park IY	Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.	Gastroenterology	2007	73
17471289	hydrogen sulfite	Kuratomi G	Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins.	Molecular psychiatry	2008	52
17875690	hydrogen sulfite	Taylor KH	Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing.	Cancer research	2007	77
17947713	hydrogen sulfite	Lu Q	Demethylation of CD40LG on the inactive X in T cells from women with lupus.	Journal of immunology	2007	91
18045775	hydrogen sulfite	Al-Mahdawi S	The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.	Human molecular genetics	2008	90
19084528	hydrogen sulfite	Yu J	Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.	Gastroenterology	2009	53
19124685	hydrogen sulfite	Ernst C	Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers.	Archives of general psychiatry	2009	52
19491193	hydrogen sulfite	Koga Y	Genome-wide screen of promoter methylation identifies novel markers in melanoma.	Genome research	2009	73
19519716	hydrogen sulfite	Ouko LA	Effect of alcohol consumption on CpG methylation in the differentially methylated regions of H19 and IG-DMR in male gametes: implications for fetal alcohol spectrum disorders.	Alcoholism, clinical and experimental research	2009	69
19535783	hydrogen sulfite	Melotte V	N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.	Journal of the National Cancer Institute	2009	50
21317930	hydrogen sulfite	Mudduluru G	Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.	Oncogene	2011	75
21350001	hydrogen sulfite	Li D	Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer.	Clinical cancer research 	2011	94
21969817	hydrogen sulfite	He Y	Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.	Neoplasia	2011	37
22233696	hydrogen sulfite	Kimura T	A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma.	The American journal of gastroenterology	2012	32
22589488	hydrogen sulfite	Mahapatra S	Global methylation profiling for risk prediction of prostate cancer.	Clinical cancer research 	2012	39
23916847	hydrogen sulfite	Murphy SK	Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.	Gastroenterology	2013	52
24098911	hydrogen sulfite	Lu KH	Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.	BMC cancer	2013	80
24500968	hydrogen sulfite	Nones K	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.	International journal of cancer	2014	29
24504172	hydrogen sulfite	Kim HC	Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells.	Oncotarget	2014	26
24662927	hydrogen sulfite	Nagy C	Astrocytic abnormalities and global DNA methylation patterns in depression and suicide.	Molecular psychiatry	2015	39
24929637	hydrogen sulfite	Dempster EL	Genome-wide methylomic analysis of monozygotic twins discordant for adolescent depression.	Biological psychiatry	2014	31
25608619	hydrogen sulfite	Zhang Z	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.	Molecular cancer	2015	20
25613496	hydrogen sulfite	Hu L	Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.	Journal of experimental & clinical cancer research 	2015	52
25641194	hydrogen sulfite	Zhuo H	The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma.	Molecular carcinogenesis	2016	33
25663388	hydrogen sulfite	Steponaitiene R	Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis.	Molecular carcinogenesis	2016	16
25822089	hydrogen sulfite	Liao J	Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells.	Nature genetics	2015	71
26012557	hydrogen sulfite	Andoh-Noda T	Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage.	Molecular brain	2015	18
26206665	hydrogen sulfite	Wang K	MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome.	Gut	2016	10
26437030	hydrogen sulfite	Kretzmer H	DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.	Nature genetics	2015	29
26707824	hydrogen sulfite	Fang S	Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells.	Laboratory investigation; a journal of technical methods and pathology	2016	13
26923874	hydrogen sulfite	Johann PD	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.	Cancer cell	2016	31
26977886	hydrogen sulfite	Chun HE	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.	Cancer cell	2016	14
27582487	hydrogen sulfite	Min HY	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.	Clinical cancer research 	2017	5
28215704	hydrogen sulfite	Spencer DH	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.	Cell	2017	12
16406676	Angiogenesis Inhibitors	Ren B	Regulation of tumor angiogenesis by thrombospondin-1.	Biochimica et biophysica acta	2006	68
17363594	Angiogenesis Inhibitors	Jain RK	Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.	Cancer research	2007	142
18539962	Angiogenesis Inhibitors	Eyler CE	Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.	Journal of clinical oncology 	2008	179
19074844	Angiogenesis Inhibitors	Ma J	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.	Molecular cancer therapeutics	2008	85
19249675	Angiogenesis Inhibitors	Loges S	Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.	Cancer cell	2009	118
19305413	Angiogenesis Inhibitors	Reynolds AR	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.	Nature medicine	2009	117
19671869	Angiogenesis Inhibitors	Ebos JM	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.	Clinical cancer research 	2009	73
20194633	Angiogenesis Inhibitors	Helfrich I	Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.	The Journal of experimental medicine	2010	50
20368560	Angiogenesis Inhibitors	Hainsworth JD	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.	Journal of clinical oncology 	2010	49
20940405	Angiogenesis Inhibitors	Dews M	The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.	Cancer research	2010	90
21593862	Angiogenesis Inhibitors	Carmeliet P	Molecular mechanisms and clinical applications of angiogenesis.	Nature	2011	923
23208836	Angiogenesis Inhibitors	Al-Husein B	Antiangiogenic therapy for cancer: an update.	Pharmacotherapy	2012	35
23512266	Angiogenesis Inhibitors	Soda Y	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.	Journal of molecular medicine	2013	40
23908119	Angiogenesis Inhibitors	Welti J	Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.	The Journal of clinical investigation	2013	120
24029605	Angiogenesis Inhibitors	Middleton K	Interleukin-6: an angiogenic target in solid tumours.	Critical reviews in oncology/hematology	2014	26
24964992	Angiogenesis Inhibitors	Xu L	COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.	Science translational medicine	2014	28
25117977	Angiogenesis Inhibitors	Baker GJ	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.	Neoplasia	2014	30
26001391	Angiogenesis Inhibitors	Zhao Y	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.	The oncologist	2015	55
26908627	Angiogenesis Inhibitors	Bid HK	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.	Molecular cancer therapeutics	2016	11
18985363	isocitric acid	Balss J	Analysis of the IDH1 codon 132 mutation in brain tumors.	Acta neuropathologica	2008	234
19554337	isocitric acid	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	240
19636000	isocitric acid	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	197
19903171	isocitric acid	Capper D	Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.	Brain pathology	2010	89
20410924	isocitric acid	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	43
20428194	isocitric acid	Tefferi A	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.	Leukemia	2010	125
20805365	isocitric acid	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	43
21163902	isocitric acid	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	92
21446051	isocitric acid	Huse JT	Molecular subclassification of diffuse gliomas: seeing order in the chaos.	Glia	2011	77
21596855	isocitric acid	Green CL	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.	Blood	2011	50
22289988	isocitric acid	Renneville A	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.	Leukemia	2012	30
22343889	isocitric acid	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	444
22360810	isocitric acid	Filipp FV	Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.	Pigment cell & melanoma research	2012	52
23071355	isocitric acid	Teicher BA	Targeting cancer metabolism.	Clinical cancer research 	2012	34
23104868	isocitric acid	Kannan K	Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.	Oncotarget	2012	60
23550148	isocitric acid	Killian JK	Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.	Cancer discovery	2013	78
23801749	isocitric acid	Hughes LA	The CpG island methylator phenotype: what's in a name?	Cancer research	2013	45
24440599	isocitric acid	Kats LM	Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.	Cell stem cell	2014	44
25081751	isocitric acid	Chan AK	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.	Modern pathology 	2015	21
25225364	isocitric acid	Chen R	Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
25701198	isocitric acid	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	21
25783747	isocitric acid	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	28
25852056	isocitric acid	Thol F	How I treat refractory and early relapsed acute myeloid leukemia.	Blood	2015	22
26188014	isocitric acid	Waitkus MS	Isocitrate dehydrogenase mutations in gliomas.	Neuro-oncology	2016	25
26389676	isocitric acid	Ferdaoussi M	Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells.	The Journal of clinical investigation	2015	24
26945349	isocitric acid	Chen JR	Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.	Medicine	2016	13
27049945	isocitric acid	Jiang L	Reductive carboxylation supports redox homeostasis during anchorage-independent growth.	Nature	2016	56
27245312	isocitric acid	Birendra KC	Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.	Clinical lymphoma, myeloma & leukemia	2016	10
27353503	isocitric acid	Zhang B	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.	Neuro-oncology	2017	8
27370400	isocitric acid	Garber ST	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.	Neuro-oncology	2016	11
27820599	isocitric acid	Miroshnikova YA	Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression.	Nature cell biology	2016	12
28043904	isocitric acid	Sia D	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.	Gastroenterology	2017	17
28124097	isocitric acid	Pusch S	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.	Acta neuropathologica	2017	7
28193778	isocitric acid	Yen K	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.	Cancer discovery	2017	14
28360267	isocitric acid	Venteicher AS	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.	Science	2017	29
15930289	thiazolyl blue	Jiang JG	Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors.	Cancer research	2005	65
17804744	thiazolyl blue	Wang Z	Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.	Cancer research	2007	99
18318443	thiazolyl blue	Fransvea E	Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.	Hepatology	2008	56
19363643	thiazolyl blue	Du Y	Down-regulation of miR-141 in gastric cancer and its involvement in cell growth.	Journal of gastroenterology	2009	53
21822301	thiazolyl blue	Xu Y	MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.	Oncogene	2012	56
22270966	thiazolyl blue	Li J	MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.	Journal of cancer research and clinical oncology	2012	43
22498306	thiazolyl blue	Cheng W	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.	The FEBS journal	2012	64
23342249	thiazolyl blue	Fan F	Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.	Cancer medicine	2012	58
24338509	thiazolyl blue	Hadad SM	Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.	Clinical & translational oncology 	2014	23
24650096	thiazolyl blue	Song Y	Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma.	Molecular cancer	2014	37
26832883	thiazolyl blue	Mukai S	Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.	Annals of surgical oncology	2017	10
28451917	thiazolyl blue	Guo JQ	Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Apoptosis of Gastric Cancer Cells via PTEN/p-AKT Pathway.	Digestive diseases and sciences	2017	8
8290962	SERPIN-B5	Zou Z	Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.	Science	1994	183
10655109	SERPIN-B5	Zhang M	Maspin is an angiogenesis inhibitor.	Nature medicine	2000	98
17377533	SERPIN-B5	Luo JL	Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.	Nature	2007	139
23770133	SERPIN-B5	Yuan K	Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice.	Gastroenterology	2013	30
14713959	3-methyladenine	Kanzawa T	Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.	Cell death and differentiation	2004	255
15197260	3-methyladenine	Guo HH	Protein tolerance to random amino acid change.	Proceedings of the National Academy of Sciences of the United States of America	2004	100
15809734	3-methyladenine	Ito H	Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells.	International journal of oncology	2005	72
16415355	3-methyladenine	Lavieu G	Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation.	The Journal of biological chemistry	2006	82
16886061	3-methyladenine	Espert L	Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4.	The Journal of clinical investigation	2006	140
19116755	3-methyladenine	Li J	Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells.	Annals of surgical oncology	2009	73
20634405	3-methyladenine	Li X	The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.	Cancer research	2010	60
20637264	3-methyladenine	Chen S	Autophagy is a therapeutic target in anticancer drug resistance.	Biochimica et biophysica acta	2010	78
22162830	3-methyladenine	Ireland JM	Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells.	The Journal of experimental medicine	2011	56
22406827	3-methyladenine	Guo XL	Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells.	Cancer letters	2012	44
22437840	3-methyladenine	Ordonez MP	Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1.	Human molecular genetics	2012	31
22498478	3-methyladenine	Kobayashi S	Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury.	Autophagy	2012	31
22719070	3-methyladenine	Wojtkowiak JW	Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments.	Cancer research	2012	45
24125861	3-methyladenine	Kumar D	Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway.	Cancer letters	2014	30
24145604	3-methyladenine	Chen ML	Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway.	Autophagy	2013	36
25484094	3-methyladenine	Mitter SK	Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD.	Autophagy	2014	51
25653352	3-methyladenine	Fields J	HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders.	The Journal of neuroscience 	2015	19
25789971	3-methyladenine	Ghavami S	Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts.	Cell death & disease	2015	29
25807554	3-methyladenine	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	17
26085147	3-methyladenine	Hamel R	Biology of Zika Virus Infection in Human Skin Cells.	Journal of virology	2015	208
26311737	3-methyladenine	Tsai JP	Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.	Oncotarget	2015	22
26804739	3-methyladenine	Subramani R	Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.	Scientific reports	2016	17
27098600	3-methyladenine	Zou M	Autophagy inhibition of hsa-miR-19a-3p/19b-3p by targeting TGF-β R II during TGF-β1-induced fibrogenesis in human cardiac fibroblasts.	Scientific reports	2016	13
10728709	sulforafan	Gamet-Payrastre L	Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells.	Cancer research	2000	105
14514658	sulforafan	Singh AV	Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.	Carcinogenesis	2004	94
15572695	sulforafan	Zhang DD	Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.	Molecular and cellular biology	2004	342
15764812	sulforafan	Singh SV	Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.	The Journal of biological chemistry	2005	94
15856023	sulforafan	Xu C	Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.	Oncogene	2005	80
16740722	sulforafan	Herman-Antosiewicz A	Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells.	Cancer research	2006	93
17339367	sulforafan	Pledgie-Tracy A	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.	Molecular cancer therapeutics	2007	72
21374800	sulforafan	Clarke JD	Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.	Molecular nutrition & food research	2011	49
22703534	sulforafan	Artaud-Macari E	Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis.	Antioxidants & redox signaling	2013	29
23029396	sulforafan	Rodova M	Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal.	PloS one	2012	30
23129257	sulforafan	Li SH	Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.	Molecular and cellular biochemistry	2013	30
23752191	sulforafan	Li Q	Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.	Oncogene	2014	53
23770684	sulforafan	Rajendran P	HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.	Epigenetics	2013	30
24025640	sulforafan	Jiang T	Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response.	Kidney international	2014	25
24297178	sulforafan	Li Q	Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions.	The Journal of biological chemistry	2014	29
24637114	sulforafan	Pekovic-Vaughan V	The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis.	Genes & development	2014	44
25593219	sulforafan	Sun C	Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2.	Journal of applied physiology	2015	20
27427974	sulforafan	Pajares M	Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.	Autophagy	2016	28
11016644	vorinostat	Butler LM	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.	Cancer research	2000	143
12189205	vorinostat	Butler LM	The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.	Proceedings of the National Academy of Sciences of the United States of America	2002	128
15173093	vorinostat	Pei XY	Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.	Clinical cancer research 	2004	102
15596714	vorinostat	Shao Y	Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2004	169
15964800	vorinostat	Dai Y	Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.	Molecular and cellular biology	2005	70
16960145	vorinostat	Duvic M	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).	Blood	2007	228
17363733	vorinostat	Carew JS	Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.	Blood	2007	183
17962618	vorinostat	Mann BS	FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.	The oncologist	2007	260
18413790	vorinostat	Fournel M	MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.	Molecular cancer therapeutics	2008	75
18541724	vorinostat	Buglio D	Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.	Blood	2008	59
19307505	vorinostat	Galanis E	Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.	Journal of clinical oncology 	2009	89
19671864	vorinostat	Badros A	Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.	Clinical cancer research 	2009	69
19789319	vorinostat	Palmieri D	Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.	Clinical cancer research 	2009	47
20378407	vorinostat	Ree AH	Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.	The Lancet. Oncology	2010	40
21637290	vorinostat	Li D	SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.	Cell death and differentiation	2011	77
21653597	vorinostat	Singh MM	Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.	Neuro-oncology	2011	38
21660961	vorinostat	Bruzzese F	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.	Journal of cellular physiology	2011	43
21909380	vorinostat	Nalls D	Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.	PloS one	2011	67
21926171	vorinostat	Eades G	miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.	The Journal of biological chemistry	2011	62
22002311	vorinostat	Zhang X	Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.	Oncogene	2012	46
22711276	vorinostat	Zhao L	Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.	Circulation	2012	47
23382048	vorinostat	Nakagawa T	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.	Cancer research	2013	44
24055414	vorinostat	Dimopoulos M	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.	The Lancet. Oncology	2013	49
24319254	vorinostat	Tian Z	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.	Blood	2014	65
24991835	vorinostat	Mahalingam D	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.	Autophagy	2014	68
25428224	vorinostat	Choi SW	Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.	Blood	2015	17
28193631	vorinostat	Pipalia NH	Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells.	Journal of lipid research	2017	6
12384559	JM 3100	Scotton CJ	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.	Cancer research	2002	118
14595012	JM 3100	Rubin JB	A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.	Proceedings of the National Academy of Sciences of the United States of America	2003	172
15087398	JM 3100	Tavor S	CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.	Cancer research	2004	78
15548713	JM 3100	Marchesi F	Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4.	Cancer research	2004	91
15574767	JM 3100	Smith MC	CXCR4 regulates growth of both primary and metastatic breast cancer.	Cancer research	2004	213
16489019	JM 3100	Yasumoto K	Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.	Cancer research	2006	62
17119115	JM 3100	Alsayed Y	Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.	Blood	2007	116
17893878	JM 3100	Kajiyama H	Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.	International journal of cancer	2008	79
18538590	JM 3100	Tsuboi N	Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases.	Immunity	2008	50
19119139	JM 3100	Casteel DE	A DNA polymerase-{alpha}{middle dot}primase cofactor with homology to replication protein A-32 regulates DNA replication in mammalian cells.	The Journal of biological chemistry	2009	64
19588204	JM 3100	Matsusue R	Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.	Annals of surgical oncology	2009	45
19641136	JM 3100	Zabel BA	Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.	Journal of immunology	2009	92
20460522	JM 3100	Nimmagadda S	Molecular imaging of CXCR4 receptor expression in human cancer xenografts with 64CuAMD3100 positron emission tomography.	Cancer research	2010	45
20631066	JM 3100	Kozin SV	Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.	Cancer research	2010	82
21349998	JM 3100	Duda DG	CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?	Clinical cancer research 	2011	124
21618540	JM 3100	Ping YF	The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.	The Journal of pathology	2011	52
21742774	JM 3100	Righi E	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.	Cancer research	2011	51
22370645	JM 3100	Jung MJ	Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.	Oncogene	2013	54
22370717	JM 3100	Schiraldi M	HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4.	The Journal of experimental medicine	2012	133
22648473	JM 3100	Zhang Q	A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime.	Lab on a chip	2012	31
22871210	JM 3100	Zhang SS	CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.	BMC medicine	2012	46
23630186	JM 3100	Gassenmaier M	CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.	Stem cells	2013	27
24157575	JM 3100	Gatti M	Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.	Toxicology	2013	27
25444927	JM 3100	Guan G	The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells.	Cancer letters	2015	16
26199389	JM 3100	Scala S	Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.	Clinical cancer research 	2015	19
26414794	JM 3100	Izumi D	CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin β1 clustering and invasiveness in gastric cancer.	International journal of cancer	2016	11
26517945	JM 3100	Fontanella R	A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.	Cancer letters	2016	10
26851944	JM 3100	Teng F	Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.	Journal of hematology & oncology	2016	14
11559718	letrozole	Ellis MJ	Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.	Journal of clinical oncology 	2001	104
16033851	letrozole	Boulay A	Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.	Clinical cancer research 	2005	77
17200148	letrozole	Coates AS	Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.	Journal of clinical oncology 	2007	182
17679725	letrozole	Viale G	Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.	Journal of clinical oncology 	2007	80
18509175	letrozole	Azim AA	Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.	Journal of clinical oncology 	2008	79
19380449	letrozole	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	148
19561322	letrozole	Calado RT	Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.	Blood	2009	57
19786658	letrozole	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	201
21916582	letrozole	Cook KL	Autophagy and endocrine resistance in breast cancer.	Expert review of anticancer therapy	2011	38
21987386	letrozole	Brufsky AM	Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.	Cancer	2012	39
23233719	letrozole	Wolff AC	Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2013	61
23569315	letrozole	Rimawi MF	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.	Journal of clinical oncology 	2013	45
24663045	letrozole	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	49
25524798	letrozole	Finn RS	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.	The Lancet. Oncology	2015	236
25633049	letrozole	Vilquin P	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.	Breast cancer research 	2015	17
25792301	letrozole	Dhillon S	Palbociclib: first global approval.	Drugs	2015	18
26324739	letrozole	Beaver JA	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	Clinical cancer research 	2015	33
26342236	letrozole	Le Tourneau C	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.	The Lancet. Oncology	2015	94
27126994	letrozole	Mayer IA	A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.	Clinical cancer research 	2017	22
27349747	letrozole	Finn RS	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.	Breast cancer research 	2016	15
27717303	letrozole	Hortobagyi GN	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.	The New England journal of medicine	2016	63
28113032	letrozole	Smith I	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.	Journal of clinical oncology 	2017	7
19935646	alpha-hydroxyglutarate	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	751
20513808	alpha-hydroxyglutarate	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	110
21045145	alpha-hydroxyglutarate	Seltzer MJ	Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.	Cancer research	2010	148
21289278	alpha-hydroxyglutarate	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	164
21326614	alpha-hydroxyglutarate	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	49
21598255	alpha-hydroxyglutarate	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	176
21913188	alpha-hydroxyglutarate	Capper D	2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.	International journal of cancer	2012	36
22015945	alpha-hydroxyglutarate	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	62
22166263	alpha-hydroxyglutarate	Luchman HA	An in vivo patient-derived model of endogenous IDH1-mutant glioma.	Neuro-oncology	2012	47
22180306	alpha-hydroxyglutarate	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	142
22238332	alpha-hydroxyglutarate	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	85
22238333	alpha-hydroxyglutarate	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	53
22343896	alpha-hydroxyglutarate	Koivunen P	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.	Nature	2012	198
22343901	alpha-hydroxyglutarate	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	439
23204232	alpha-hydroxyglutarate	Jin G	Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.	Cancer research	2013	35
23264629	alpha-hydroxyglutarate	Ward PS	The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.	The Journal of biological chemistry	2013	40
23558169	alpha-hydroxyglutarate	Rohle D	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.	Science	2013	275
23558173	alpha-hydroxyglutarate	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	176
23863747	alpha-hydroxyglutarate	Guilhamon P	Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.	Nature communications	2013	41
23877318	alpha-hydroxyglutarate	Zhang C	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.	Neuro-oncology	2013	29
23999439	alpha-hydroxyglutarate	Andronesi OC	Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.	The Journal of clinical investigation	2013	32
24077805	alpha-hydroxyglutarate	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	37
24366912	alpha-hydroxyglutarate	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	32
24478380	alpha-hydroxyglutarate	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	24
24986863	alpha-hydroxyglutarate	Reitman ZJ	Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.	The Journal of biological chemistry	2014	23
25043045	alpha-hydroxyglutarate	Saha SK	Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.	Nature	2014	66
25182153	alpha-hydroxyglutarate	Shim EH	L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.	Cancer discovery	2014	45
26190651	alpha-hydroxyglutarate	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	21
26212717	alpha-hydroxyglutarate	Intlekofer AM	Hypoxia Induces Production of L-2-Hydroxyglutarate.	Cell metabolism	2015	53
26534967	alpha-hydroxyglutarate	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	14
26669865	alpha-hydroxyglutarate	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	19
26678339	alpha-hydroxyglutarate	Tateishi K	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.	Cancer cell	2015	40
26691210	alpha-hydroxyglutarate	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	22
26700815	alpha-hydroxyglutarate	Flavahan WA	Insulator dysfunction and oncogene activation in IDH mutant gliomas.	Nature	2016	130
27005468	alpha-hydroxyglutarate	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	26
27355333	alpha-hydroxyglutarate	Fujii T	Targeting isocitrate dehydrogenase (IDH) in cancer.	Discovery medicine	2016	13
28148839	alpha-hydroxyglutarate	Sulkowski PL	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.	Science translational medicine	2017	18
28588019	alpha-hydroxyglutarate	Amatangelo MD	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.	Blood	2017	10
28588020	alpha-hydroxyglutarate	Stein EM	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.	Blood	2017	20
10851053	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Hirano T	Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.	Oncogene	2000	254
11121117	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Jostock T	Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.	European journal of biochemistry	2001	118
12434062	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Chatterjee M	Viral IL-6-induced cell proliferation and immune evasion of interferon activity.	Science	2002	83
18060032	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	209
19020503	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Rebouissou S	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.	Nature	2009	108
19155309	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Shain KH	Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.	Cancer research	2009	55
19173740	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Savale L	Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice.	Respiratory research	2009	57
19189867	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Fonseca JE	Interleukin-6 as a key player in systemic inflammation and joint destruction.	Autoimmunity reviews	2009	66
20713517	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Inda MM	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.	Genes & development	2010	172
20953899	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Seike T	Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis.	Clinical & experimental metastasis	2011	38
21408055	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Toth KG	IL-6 induced STAT3 signalling is associated with the proliferation of human muscle satellite cells following acute muscle damage.	PloS one	2011	38
22891351	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Couto JP	STAT3 negatively regulates thyroid tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	43
23136553	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Waldner MJ	Interleukin-6--a key regulator of colorectal cancer development.	International journal of biological sciences	2012	60
24082147	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Wang Y	STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24735922	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Pilati C	Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.	Cancer cell	2014	36
24804649	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Judd LM	Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.	PloS one	2014	20
25731159	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Taniguchi K	A gp130-Src-YAP module links inflammation to epithelial regeneration.	Nature	2015	84
25966666	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Hossain A	Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.	Stem cells	2015	24
26750536	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Zhao G	IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer.	Oncology reports	2016	14
26945971	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Bharti R	Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement.	Cancer letters	2016	29
27096320	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Zhang C	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.	Immunity	2016	13
27737952	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Sereti I	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.	Clinical infectious diseases 	2017	15
27893707	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Miller A	Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.	Oncogene	2017	6
11927289	tanespimycin	Neckers L	Hsp90 inhibitors as novel cancer chemotherapeutic agents.	Trends in molecular medicine	2002	136
15514006	tanespimycin	George P	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.	Blood	2005	77
17363532	tanespimycin	Solit DB	Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.	Clinical cancer research 	2007	55
17645779	tanespimycin	Tsutsumi S	Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.	Cancer science	2007	79
20413784	tanespimycin	Naito AT	Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury.	Circulation research	2010	41
20683637	tanespimycin	Pacey S	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.	Investigational new drugs	2012	38
21478269	tanespimycin	Li D	Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.	Molecular cancer research 	2011	68
21558407	tanespimycin	Modi S	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.	Clinical cancer research 	2011	106
22144665	tanespimycin	Ying W	Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.	Molecular cancer therapeutics	2012	64
22538852	tanespimycin	Mimura N	Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.	Blood	2012	94
26639656	tanespimycin	Gower A	EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.	Molecular oncology	2016	10
15599396	lysophosphatidic acid	Boucharaba A	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.	The Journal of clinical investigation	2004	103
19001604	lysophosphatidic acid	Yu S	Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.	Journal of the National Cancer Institute	2008	62
19011242	lysophosphatidic acid	Chen M	Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin.	The Journal of biological chemistry	2009	56
19147812	lysophosphatidic acid	Xu MY	Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).	The American journal of pathology	2009	55
19386608	lysophosphatidic acid	Yanagida K	Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6.	The Journal of biological chemistry	2009	61
19509223	lysophosphatidic acid	Zhang H	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.	Cancer research	2009	45
19609003	lysophosphatidic acid	Li TT	Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells.	Molecular cancer research 	2009	52
21041624	lysophosphatidic acid	Su F	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	56
21978933	lysophosphatidic acid	Ward Y	LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.	Cancer research	2011	36
22499993	lysophosphatidic acid	Gonçalves I	Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation.	Arteriosclerosis, thrombosis, and vascular biology	2012	31
22867755	lysophosphatidic acid	Sevastou I	Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.	Biochimica et biophysica acta	2013	44
23611148	lysophosphatidic acid	Willier S	Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.	Biology of the cell	2013	35
24706986	lysophosphatidic acid	Haak AJ	Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.	The Journal of pharmacology and experimental therapeutics	2014	26
25024203	lysophosphatidic acid	Xiong S	Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
25904553	lysophosphatidic acid	Yu OM	G Protein-Coupled Receptor and RhoA-Stimulated Transcriptional Responses: Links to Inflammation, Differentiation, and Cell Proliferation.	Molecular pharmacology	2015	19
26740622	lysophosphatidic acid	Kedziora KM	Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.	The Journal of biological chemistry	2016	12
26947063	lysophosphatidic acid	Qin H	YAP Induces Human Naive Pluripotency.	Cell reports	2016	14
27981605	lysophosphatidic acid	Kaffe E	Hepatocyte autotaxin expression promotes liver fibrosis and cancer.	Hepatology	2017	8
12901945	temsirolimus	Huang S	Targeting mTOR signaling for cancer therapy.	Current opinion in pharmacology	2003	80
15585641	temsirolimus	deGraffenried LA	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.	Clinical cancer research 	2004	82
15955899	temsirolimus	Chan S	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2005	105
15998902	temsirolimus	Galanis E	Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.	Journal of clinical oncology 	2005	155
16341243	temsirolimus	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	169
16740688	temsirolimus	Del Bufalo D	Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.	Cancer research	2006	63
17031397	temsirolimus	Duran I	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.	British journal of cancer	2006	76
19229667	temsirolimus	Dutcher JP	Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.	Medical oncology	2009	57
20068177	temsirolimus	Yu K	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	Cancer research	2010	58
20630061	temsirolimus	Javle MM	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.	BMC cancer	2010	41
21289267	temsirolimus	Liu R	The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.	The Journal of clinical endocrinology and metabolism	2011	36
21690471	temsirolimus	Spunt SL	Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.	Journal of clinical oncology 	2011	36
21750201	temsirolimus	Naing A	Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.	Clinical cancer research 	2011	44
21752435	temsirolimus	Behbakht K	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.	Gynecologic oncology	2011	41
21952069	temsirolimus	Coppin C	Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.	BJU international	2011	55
22378068	temsirolimus	Shi WY	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.	Cell death & disease	2012	56
22408430	temsirolimus	Pópulo H	The mTOR signalling pathway in human cancer.	International journal of molecular sciences	2012	128
23477833	temsirolimus	Schwartz GK	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2013	46
23633458	temsirolimus	von Roemeling CA	Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.	Clinical cancer research 	2013	49
24297945	temsirolimus	Rini BI	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.	Journal of clinical oncology 	2014	34
24333502	temsirolimus	Polivka J Jr	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.	Pharmacology & therapeutics	2014	89
24422672	temsirolimus	Subbiah V	Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.	Journal of hematology & oncology	2014	21
24470557	temsirolimus	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	30
24480319	temsirolimus	Santoni M	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.	Biochimica et biophysica acta	2014	21
24991838	temsirolimus	Rangwala R	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.	Autophagy	2014	91
25446280	temsirolimus	Wagner LM	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.	Pediatric blood & cancer	2015	18
25724518	temsirolimus	McKay RR	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2015	16
25867072	temsirolimus	He K	mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.	Oncogene	2016	20
11585753	gefitinib	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	91
11751413	gefitinib	Moulder SL	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.	Cancer research	2001	99
12409327	gefitinib	Baselga J	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.	Journal of clinical oncology 	2002	108
12743152	gefitinib	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	99
14638850	gefitinib	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	134
15078990	gefitinib	Ono M	Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.	Molecular cancer therapeutics	2004	70
15284455	gefitinib	Sordella R	Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.	Science	2004	355
15492241	gefitinib	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	90
15709185	gefitinib	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	100
15710947	gefitinib	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	141
15728811	gefitinib	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	914
15731348	gefitinib	Engelman JA	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.	Proceedings of the National Academy of Sciences of the United States of America	2005	156
15738541	gefitinib	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	182
15939921	gefitinib	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	83
16049312	gefitinib	Pan Q	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.	The Journal of molecular diagnostics 	2005	76
16051952	gefitinib	Cappuzzo F	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.	Journal of clinical oncology 	2005	71
16204011	gefitinib	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	123
16278407	gefitinib	Lassman AB	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.	Clinical cancer research 	2005	68
16322287	gefitinib	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	73
16333527	gefitinib	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	66
16424029	gefitinib	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	145
16540667	gefitinib	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	66
16648858	gefitinib	Ferby I	Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.	Nature medicine	2006	95
16705038	gefitinib	Politi K	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.	Genes & development	2006	130
16785471	gefitinib	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	119
16906227	gefitinib	Engelman JA	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.	The Journal of clinical investigation	2006	153
17047648	gefitinib	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	68
17085664	gefitinib	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	213
17440163	gefitinib	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	101
17463250	gefitinib	Engelman JA	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.	Science	2007	1311
17470737	gefitinib	Arpino G	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.	Journal of the National Cancer Institute	2007	62
17888036	gefitinib	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	129
17973573	gefitinib	Cragg MS	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.	PLoS medicine	2007	118
18297114	gefitinib	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	168
18381447	gefitinib	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	94
18413800	gefitinib	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	60
18458038	gefitinib	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	246
18509184	gefitinib	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	58
18568074	gefitinib	Guix M	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.	The Journal of clinical investigation	2008	177
18599154	gefitinib	Rho JK	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.	Lung cancer	2009	64
18836087	gefitinib	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	90
19157632	gefitinib	Kim JE	Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.	Lung cancer	2009	48
19238210	gefitinib	Gandhi J	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.	PloS one	2009	75
19276163	gefitinib	McGovern UB	Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.	Molecular cancer therapeutics	2009	49
19276373	gefitinib	Iorio MV	microRNA-205 regulates HER3 in human breast cancer.	Cancer research	2009	114
19276389	gefitinib	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	73
19332730	gefitinib	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	55
19414683	gefitinib	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	96
19447865	gefitinib	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	61
19680293	gefitinib	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	191
19917871	gefitinib	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	145
19922469	gefitinib	Mitsudomi T	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.	The FEBS journal	2010	111
20108024	gefitinib	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	47
20146086	gefitinib	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	57
20351699	gefitinib	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	58
20573926	gefitinib	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	1115
20959484	gefitinib	Yamamoto C	Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.	Cancer research	2010	43
21030498	gefitinib	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	50
21062933	gefitinib	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	55
21123652	gefitinib	Tigno-Aranjuez JT	Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.	Genes & development	2010	49
21152424	gefitinib	Ware KE	Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.	PloS one	2010	54
21220474	gefitinib	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	38
21220480	gefitinib	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	53
21248303	gefitinib	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	48
21573178	gefitinib	Querings S	Benchmarking of mutation diagnostics in clinical lung cancer specimens.	PloS one	2011	37
21597390	gefitinib	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	81
21655094	gefitinib	Han W	EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.	PloS one	2011	66
21670455	gefitinib	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	326
21764376	gefitinib	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	93
21788562	gefitinib	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	64
22011650	gefitinib	Thongprasert S	Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).	Journal of thoracic oncology 	2011	35
22057914	gefitinib	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	40
22119437	gefitinib	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	37
22157681	gefitinib	Garofalo M	EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.	Nature medicine	2011	120
22167408	gefitinib	Jamal-Hanjani M	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.	Clinical cancer research 	2012	37
22173954	gefitinib	Xie M	Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.	Journal of cellular biochemistry	2012	45
22228822	gefitinib	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	36
22281684	gefitinib	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	428
22414764	gefitinib	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	39
22436374	gefitinib	Chen G	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.	BMC medicine	2012	36
22586683	gefitinib	Cheung HW	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.	Cancer discovery	2011	49
22677429	gefitinib	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	63
22733536	gefitinib	Heon S	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.	Clinical cancer research 	2012	36
22806307	gefitinib	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	42
22810899	gefitinib	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	34
22844075	gefitinib	Nakagawa T	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.	Molecular cancer therapeutics	2012	31
23154553	gefitinib	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	39
23172555	gefitinib	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	58
23307622	gefitinib	Cufí S	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.	Oncotarget	2012	33
23461856	gefitinib	Ma L	Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.	The FEBS journal	2013	26
23470965	gefitinib	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	343
23542356	gefitinib	Shien K	Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.	Cancer research	2013	72
23555954	gefitinib	Chen G	miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.	PloS one	2013	74
23563269	gefitinib	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	320
23619944	gefitinib	Peled N	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.	Cellular oncology	2013	27
23695170	gefitinib	Morgillo F	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.	Clinical cancer research 	2013	32
23816963	gefitinib	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	68
23872583	gefitinib	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.	Cancer research	2013	33
23927790	gefitinib	Kim HR	Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.	Journal of experimental & clinical cancer research 	2013	28
23980091	gefitinib	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	48
24021541	gefitinib	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	38
24108744	gefitinib	Buonato JM	ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.	Cancer research	2014	39
24165158	gefitinib	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	30
24258346	gefitinib	Kitamura K	MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.	Molecular cancer therapeutics	2014	40
24355409	gefitinib	Gelsomino F	Targeting the MET gene for the treatment of non-small-cell lung cancer.	Critical reviews in oncology/hematology	2014	21
24486412	gefitinib	Zhao D	Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.	Cellular signalling	2014	25
24489728	gefitinib	Murakami A	Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.	PloS one	2014	28
24535670	gefitinib	de Bruin EC	Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.	Cancer discovery	2014	42
24644001	gefitinib	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	54
24919575	gefitinib	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	31
24939055	gefitinib	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental & clinical cancer research 	2014	24
24983493	gefitinib	Zhou JY	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.	Cancer letters	2014	21
25058005	gefitinib	Shen H	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.	PloS one	2014	22
25294908	gefitinib	Capelletti M	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.	Clinical cancer research 	2014	27
25349974	gefitinib	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	102
25359280	gefitinib	Lin GN	Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.	Asia-Pacific journal of clinical oncology	2017	14
25403583	gefitinib	Won JK	Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.	Annals of oncology 	2015	19
25695221	gefitinib	Ichihara E	Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.	Journal of thoracic oncology 	2015	20
25760142	gefitinib	Bae SY	Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.	Oncotarget	2015	16
25925741	gefitinib	Dong S	The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.	Journal of hematology & oncology	2015	26
25928246	gefitinib	Wen W	Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.	Molecular cancer	2015	15
26159065	gefitinib	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	69
26160838	gefitinib	Cheng N	Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.	Oncotarget	2015	28
26282169	gefitinib	Soucheray M	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.	Cancer research	2015	19
26308162	gefitinib	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	38
26370354	gefitinib	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	50
26537995	gefitinib	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	31
26707383	gefitinib	Han JJ	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.	Clinical lung cancer	2016	13
26724471	gefitinib	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	24
26980062	gefitinib	Kazandjian D	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.	Clinical cancer research 	2016	16
27022112	gefitinib	Urata Y	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.	Journal of clinical oncology 	2016	13
27083334	gefitinib	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	78
27125283	gefitinib	Zhu X	Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.	Medical science monitor 	2016	13
27323238	gefitinib	Kobayashi Y	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.	Cancer science	2016	12
27507876	gefitinib	Cheng Y	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.	Journal of clinical oncology 	2016	17
27663586	gefitinib	Scarborough HA	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.	Clinical cancer research 	2017	5
28096505	gefitinib	Gemmill RM	The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.	Science signaling	2017	6
28271729	gefitinib	Ahn MJ	EGFR TKI combination with immunotherapy in non-small cell lung cancer.	Expert opinion on drug safety	2017	10
15834418	Alanine	Chen L	Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.	Nature neuroscience	2005	162
15879138	Alanine	Hart ML	Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q.	Journal of immunology	2005	66
16627622	Alanine	Kauppinen TM	Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2.	Proceedings of the National Academy of Sciences of the United States of America	2006	69
18400849	Alanine	Keck ZY	Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.	Journal of virology	2008	58
18571548	Alanine	Tremoulet AH	Resistance to intravenous immunoglobulin in children with Kawasaki disease.	The Journal of pediatrics	2008	64
19013463	Alanine	Patton HM	Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.	Gastroenterology	2008	53
19585618	Alanine	Feldstein AE	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.	Hepatology	2009	128
21319198	Alanine	Brunt EM	Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.	Hepatology	2011	138
23633921	Alanine	Khan AP	The role of sarcosine metabolism in prostate cancer progression.	Neoplasia	2013	34
23696515	Alanine	Noureddin M	Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.	Hepatology	2013	65
23761443	Alanine	Bélanger K	Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses.	Nucleic acids research	2013	26
24086778	Alanine	Huy NT	Factors associated with dengue shock syndrome: a systematic review and meta-analysis.	PLoS neglected tropical diseases	2013	38
24352239	Alanine	Tessarz P	Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification.	Nature	2014	40
24436062	Alanine	Konerman MA	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.	Hepatology	2014	23
25251399	Alanine	Dongiovanni P	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.	Hepatology	2015	52
25873639	Alanine	Kwok R	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.	Gut	2016	18
26352813	Alanine	Burton BK	A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.	The New England journal of medicine	2015	19
26409216	Alanine	Liang HW	Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122.	Journal of hepatology	2016	13
26455325	Alanine	van Geldermalsen M	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.	Oncogene	2016	46
26553503	Alanine	Fox JM	Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.	Cell	2015	17
26677985	Alanine	Imajo K	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.	Gastroenterology	2016	30
26714945	Alanine	Sun JJ	Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion.	Annals of surgical oncology	2016	15
26809794	Alanine	Mullins FM	The inactivation domain of STIM1 is functionally coupled with the Orai1 pore to enable Ca2+-dependent inactivation.	The Journal of general physiology	2016	11
26858122	Alanine	Antonia S	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.	The Lancet. Oncology	2016	75
27002799	Alanine	Nelson JE	Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB?	The American journal of gastroenterology	2016	15
27081703	Alanine	Yang Z	MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.	Oncotarget	2016	11
27224670	Alanine	Mikus M	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.	Liver international 	2017	7
27247226	Alanine	Seiwert TY	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.	The Lancet. Oncology	2016	106
27670892	Alanine	Masuishi T	Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.	Clinical colorectal cancer	2017	9
27725647	Alanine	McPherson S	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.	The American journal of gastroenterology	2017	8
27908641	Alanine	Clark AJ	Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1.	Journal of molecular biology	2017	6
27995906	Alanine	Kwo PY	ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.	The American journal of gastroenterology	2017	8
28264872	Alanine	Kristeleit R	A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.	Clinical cancer research 	2017	8
28576675	Alanine	Baselga J	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2017	10
28602779	Alanine	Shaw AT	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2017	18
12183421	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	163
12499271	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Carlomagno F	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.	Cancer research	2002	115
14760102	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Ciardiello F	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.	Clinical cancer research 	2004	77
20065189	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	100
20371662	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Robinson BG	Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2010	44
22025146	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wells SA Jr	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2012	212
22327624	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Kohno T	KIF5B-RET fusions in lung adenocarcinoma.	Nature medicine	2012	189
22370318	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	74
22898678	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	62
23454747	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Chatterjee S	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.	The Journal of clinical investigation	2013	43
23584301	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Gautschi O	A patient with lung adenocarcinoma and RET fusion treated with vandetanib.	Journal of thoracic oncology 	2013	36
27015562	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Booth L	Pemetrexed + Sorafenib lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.	Oncotarget	2016	10
27549930	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Sobrino A	3D microtumors in vitro supported by perfused vascular networks.	Scientific reports	2016	14
27803005	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Lee SH	Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.	Annals of oncology 	2017	9
27825616	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Yoh K	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.	The Lancet. Respiratory medicine	2017	21
8918887	BH 3	Wang K	BID: a novel BH3 domain-only death agonist.	Genes & development	1996	202
9727492	BH 3	Li H	Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.	Cell	1998	789
10587660	BH 3	Vander Heiden MG	Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?	Nature cell biology	1999	102
14699081	BH 3	Kim JY	BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha.	The Journal of experimental medicine	2004	81
16478725	BH 3	Han J	Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.	The Journal of biological chemistry	2006	60
16608847	BH 3	Ming L	PUMA Dissociates Bax and Bcl-X(L) to induce apoptosis in colon cancer cells.	The Journal of biological chemistry	2006	65
16778220	BH 3	Naresh A	The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.	Cancer research	2006	76
19043450	BH 3	Lessene G	BCL-2 family antagonists for cancer therapy.	Nature reviews. Drug discovery	2008	159
19371598	BH 3	Morselli E	Anti- and pro-tumor functions of autophagy.	Biochimica et biophysica acta	2009	93
19620789	BH 3	Besch R	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.	The Journal of clinical investigation	2009	100
19671867	BH 3	Gramantieri L	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.	Clinical cancer research 	2009	89
20023629	BH 3	Schwickart M	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.	Nature	2010	209
20080742	BH 3	Rasola A	Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
20460269	BH 3	Pedrini S	ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2.	Human molecular genetics	2010	43
20555361	BH 3	Ri M	Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.	Leukemia	2010	55
21041309	BH 3	Du H	BH3 domains other than Bim and Bid can directly activate Bax/Bak.	The Journal of biological chemistry	2011	56
21056595	BH 3	Lindsay J	Bcl-2 proteins and mitochondria--specificity in membrane targeting for death.	Biochimica et biophysica acta	2011	79
21132008	BH 3	Zhang H	Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines.	Oncogene	2011	36
21195116	BH 3	Westphal D	Molecular biology of Bax and Bak activation and action.	Biochimica et biophysica acta	2011	77
22152474	BH 3	Rubinstein AD	The autophagy protein Atg12 associates with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosis.	Molecular cell	2011	69
23063124	BH 3	Vo TT	Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.	Cell	2012	91
23420005	BH 3	Fu LL	Beclin-1: autophagic regulator and therapeutic target in cancer.	The international journal of biochemistry & cell biology	2013	42
23607990	BH 3	Ryan J	BH3 profiling in whole cells by fluorimeter or FACS.	Methods	2013	42
23680104	BH 3	Cao X	The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.	Molecular cancer	2013	25
24019208	BH 3	Abulwerdi F	A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.	Molecular cancer therapeutics	2014	49
24074954	BH 3	Sarosiek KA	BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.	Molecular cell	2013	59
24141421	BH 3	Maejima Y	Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2.	Nature medicine	2013	92
24488097	BH 3	Fiori ME	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer.	Cell death and differentiation	2014	24
24682005	BH 3	Colak S	Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells.	Cell death and differentiation	2014	22
24749893	BH 3	Abulwerdi FA	3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.	Journal of medicinal chemistry	2014	23
25048785	BH 3	Anderson MA	Targeting BCL2 for the treatment of lymphoid malignancies.	Seminars in hematology	2014	37
25740983	BH 3	Shinozaki-Ushiku A	Profiling of Virus-Encoded MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma and Their Roles in Gastric Carcinogenesis.	Journal of virology	2015	17
26174630	BH 3	Touzeau C	BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.	Leukemia	2016	20
26215860	BH 3	Dummer PD	APOL1 Kidney Disease Risk Variants: An Evolving Landscape.	Seminars in nephrology	2015	18
27126996	BH 3	Karpel-Massler G	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.	Clinical cancer research 	2016	12
27343252	BH 3	Khaw SL	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.	Blood	2016	13
27528605	BH 3	Zhang T	BNIP3 Protein Suppresses PINK1 Kinase Proteolytic Cleavage to Promote Mitophagy.	The Journal of biological chemistry	2016	14
27760111	BH 3	Kotschy A	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.	Nature	2016	63
27843137	BH 3	Carter MJ	PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.	Leukemia	2017	6
28017613	BH 3	Sarosiek KA	Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.	Cancer cell	2017	15
28111464	BH 3	Deng J	Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.	Leukemia	2017	8
12483741	Amino Acids	Aksentijevich I	De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.	Arthritis and rheumatism	2002	143
12525533	Amino Acids	Balk SP	Biology of prostate-specific antigen.	Journal of clinical oncology 	2003	91
12682293	Amino Acids	Sudhakar A	Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.	Proceedings of the National Academy of Sciences of the United States of America	2003	111
12714972	Amino Acids	Eriksson M	Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.	Nature	2003	476
15014901	Amino Acids	Ponomarev V	A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging.	European journal of nuclear medicine and molecular imaging	2004	80
15572176	Amino Acids	Barbeito LH	A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis.	Brain research. Brain research reviews	2004	84
15689365	Amino Acids	Pauleit D	O-(2-18Ffluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.	Brain 	2005	70
15916903	Amino Acids	Fuchs BC	Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?	Seminars in cancer biology	2005	131
16724053	Amino Acids	Shaw RJ	Ras, PI(3)K and mTOR signalling controls tumour cell growth.	Nature	2006	571
16879967	Amino Acids	Boudeau J	Emerging roles of pseudokinases.	Trends in cell biology	2006	177
16963735	Amino Acids	Yanagi Y	Measles virus: cellular receptors, tropism and pathogenesis.	The Journal of general virology	2006	69
17156977	Amino Acids	Bendikov I	A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia.	Schizophrenia research	2007	66
17261713	Amino Acids	Bano D	Ca2+ signals and neuronal death in brain ischemia.	Stroke	2007	56
17339482	Amino Acids	Laine M	Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein.	Journal of immunology	2007	83
17646408	Amino Acids	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	157
18091991	Amino Acids	Ma X	Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease.	PloS one	2007	62
18234728	Amino Acids	Toro JR	BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports.	Journal of medical genetics	2008	84
18349828	Amino Acids	Rennel E	The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.	British journal of cancer	2008	50
18488027	Amino Acids	Gudbjartsson DF	ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.	Nature genetics	2008	102
18559588	Amino Acids	Jeong EG	Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.	Clinical cancer research 	2008	59
18722121	Amino Acids	Carrière A	Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation.	Current biology 	2008	119
19167434	Amino Acids	Chen N	Role and regulation of autophagy in cancer.	Biochimica et biophysica acta	2009	84
19228619	Amino Acids	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	1088
19709627	Amino Acids	Jackson WS	Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice.	Neuron	2009	49
20023659	Amino Acids	Brown EJ	Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis.	Nature genetics	2010	129
20159109	Amino Acids	Giannandrea M	Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.	American journal of human genetics	2010	61
20161710	Amino Acids	Aste-Amézaga M	Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.	PloS one	2010	55
20570890	Amino Acids	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	98
20580095	Amino Acids	Miguel-Hidalgo JJ	Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.	Journal of affective disorders	2010	46
20674093	Amino Acids	Gal J	Nuclear localization sequence of FUS and induction of stress granules by ALS mutants.	Neurobiology of aging	2011	71
20724292	Amino Acids	Costigan M	Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1.	Brain 	2010	71
20920668	Amino Acids	McLaughlin HM	Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy.	American journal of human genetics	2010	64
20940299	Amino Acids	Chen HJ	Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis.	The Journal of biological chemistry	2010	41
21179087	Amino Acids	Ngo VN	Oncogenically active MYD88 mutations in human lymphoma.	Nature	2011	287
21270408	Amino Acids	Jones DC	HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding.	Journal of immunology	2011	38
21521612	Amino Acids	Kohli MA	The neuronal transporter gene SLC6A15 confers risk to major depression.	Neuron	2011	52
21543495	Amino Acids	Sabo MC	Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.	Journal of virology	2011	49
21775626	Amino Acids	Ward HH	A conserved signal and GTPase complex are required for the ciliary transport of polycystin-1.	Molecular biology of the cell	2011	44
22346768	Amino Acids	Leblond CS	Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders.	PLoS genetics	2012	112
22389730	Amino Acids	Haddow AD	Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage.	PLoS neglected tropical diseases	2012	180
22734070	Amino Acids	Payne EM	L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.	Blood	2012	45
23103253	Amino Acids	Elorza A	HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.	Molecular cell	2012	33
23150676	Amino Acids	Jansson N	Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies.	The Journal of clinical endocrinology and metabolism	2013	50
23540691	Amino Acids	Kadoch C	Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.	Cell	2013	70
23630012	Amino Acids	Nemazanyy I	Defects of Vps15 in skeletal muscles lead to autophagic vacuolar myopathy and lysosomal disease.	EMBO molecular medicine	2013	29
23708968	Amino Acids	Lukens JR	RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3.	Nature	2013	46
23842546	Amino Acids	Chae YC	Landscape of the mitochondrial Hsp90 metabolome in tumours.	Nature communications	2013	39
23933118	Amino Acids	Thakker RV	Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).	Molecular and cellular endocrinology	2014	46
24113281	Amino Acids	Tsai YC	Sirtuin 7 plays a role in ribosome biogenesis and protein synthesis.	Molecular & cellular proteomics 	2014	28
24387989	Amino Acids	Mayes MD	Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis.	American journal of human genetics	2014	40
24504062	Amino Acids	Kropski JA	A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia.	Chest	2014	25
24622670	Amino Acids	Roberts LD	Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome.	The lancet. Diabetes & endocrinology	2014	28
24698316	Amino Acids	Sassi A	Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels.	The Journal of allergy and clinical immunology	2014	29
24762957	Amino Acids	Toyoda M	Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.	British journal of cancer	2014	22
24781901	Amino Acids	Tong M	Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism.	The ISME journal	2014	44
24861026	Amino Acids	Wree A	NLRP3 inflammasome activation is required for fibrosis development in NAFLD.	Journal of molecular medicine	2014	42
24911150	Amino Acids	Baple EL	Hypomorphic PCNA mutation underlies a human DNA repair disorder.	The Journal of clinical investigation	2014	22
25070946	Amino Acids	Okada Y	Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations.	Human molecular genetics	2014	22
25233904	Amino Acids	Kocak H	Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1.	Genes & development	2014	29
25340798	Amino Acids	Kauwe JS	Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.	PLoS genetics	2014	26
25375093	Amino Acids	Audet J	Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.	Scientific reports	2014	30
25411794	Amino Acids	Refsland EW	Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.	PLoS genetics	2014	27
25581430	Amino Acids	Zhang MY	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.	Nature genetics	2015	44
25651891	Amino Acids	Bowes J	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.	Nature communications	2015	29
25683120	Amino Acids	Chong JX	De novo mutations in NALCN cause a syndrome characterized by congenital contractures of the limbs and face, hypotonia, and developmental delay.	American journal of human genetics	2015	27
25751625	Amino Acids	Michailidou K	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.	Nature genetics	2015	129
25898173	Amino Acids	Sharma S	APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages.	Nature communications	2015	26
25919528	Amino Acids	Viatte S	Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response.	JAMA	2015	21
25956028	Amino Acids	Hiramatsu N	Multiple Mechanisms of Unfolded Protein Response-Induced Cell Death.	The American journal of pathology	2015	40
26092931	Amino Acids	Nabi IR	The galectin lattice at a glance.	Journal of cell science	2015	37
26168013	Amino Acids	Hu X	Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk.	Nature genetics	2015	31
26168401	Amino Acids	Perera RM	Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.	Nature	2015	84
26173027	Amino Acids	Tanner RE	Age-related differences in lean mass, protein synthesis and skeletal muscle markers of proteolysis after bed rest and exercise rehabilitation.	The Journal of physiology	2015	19
26186743	Amino Acids	Yeung AW	Role of indoleamine 2,3-dioxygenase in health and disease.	Clinical science	2015	20
26216125	Amino Acids	Andersen LL	Functional IRF3 deficiency in a patient with herpes simplex encephalitis.	The Journal of experimental medicine	2015	18
26389641	Amino Acids	Park YY	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.	Hepatology	2016	14
26603296	Amino Acids	Bott AJ	Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation.	Cell metabolism	2015	25
26691987	Amino Acids	Okosun J	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	Nature genetics	2016	16
26701267	Amino Acids	Wang QJ	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.	Cancer immunology research	2016	15
26724171	Amino Acids	Parks SK	Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export.	Molecular aspects of medicine	2016	13
26838717	Amino Acids	Engel D	Reconstruction of the Evolutionary History and Dispersal of Usutu Virus, a Neglected Emerging Arbovirus in Europe and Africa.	mBio	2016	13
26865710	Amino Acids	Donahue DA	SUN2 Overexpression Deforms Nuclear Shape and Inhibits HIV.	Journal of virology	2016	12
26878238	Amino Acids	Loayza-Puch F	Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.	Nature	2016	21
26902204	Amino Acids	Hinrich AJ	Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides.	EMBO molecular medicine	2016	13
27114849	Amino Acids	Plummer S	The Neuroprotective Properties of the Amyloid Precursor Protein Following Traumatic Brain Injury.	Aging and disease	2016	17
27220847	Amino Acids	Fukumori A	Substrate recruitment of γ-secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping.	The EMBO journal	2016	11
27240091	Amino Acids	Li B	Landscape of tumor-infiltrating T cell repertoire of human cancers.	Nature genetics	2016	26
27247400	Amino Acids	Li H	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.	Proceedings of the National Academy of Sciences of the United States of America	2016	26
27259050	Amino Acids	Chen DH	Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L.	American journal of human genetics	2016	13
27277824	Amino Acids	Mahley RW	Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.	Journal of molecular medicine	2016	24
27374770	Amino Acids	Fenwick AL	Mutations in CDC45, Encoding an Essential Component of the Pre-initiation Complex, Cause Meier-Gorlin Syndrome and Craniosynostosis.	American journal of human genetics	2016	14
27442752	Amino Acids	Garwood CJ	Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role.	Neuropathology and applied neurobiology	2017	7
27617932	Amino Acids	Pan M	Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation.	Nature cell biology	2016	19
27749844	Amino Acids	Majithia AR	Prospective functional classification of all possible missense variants in PPARG.	Nature genetics	2016	15
27797973	Amino Acids	Bachmayr-Heyda A	Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer.	Clinical cancer research 	2017	7
27824355	Amino Acids	Mechawar N	Neuropathology of mood disorders: do we see the stigmata of inflammation?	Translational psychiatry	2016	17
27974423	Amino Acids	Ganta VC	VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.	Circulation research	2017	10
28089725	Amino Acids	Zhenyukh O	High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation.	Free radical biology & medicine	2017	7
28148781	Amino Acids	Khayati K	The amino acid metabolite homocysteine activates mTORC1 to inhibit autophagy and form abnormal proteins in human neurons and mice.	FASEB journal 	2017	6
28190768	Amino Acids	Bonfiglio JJ	Serine ADP-Ribosylation Depends on HPF1.	Molecular cell	2017	11
28249940	Amino Acids	Yerabham ASK	A structural organization for the Disrupted in Schizophrenia 1 protein, identified by high-throughput screening, reveals distinctly folded regions, which are bisected by mental illness-related mutations.	The Journal of biological chemistry	2017	5
28261941	Amino Acids	Takahashi RH	Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.	Pathology international	2017	10
28333144	Amino Acids	Jones VC	Aberrant iPSC-derived human astrocytes in Alzheimer's disease.	Cell death & disease	2017	8
28389532	Amino Acids	Harrison AF	RNA-binding proteins with prion-like domains in health and disease.	The Biochemical journal	2017	11
28496185	Amino Acids	Fermo E	'Gardos Channelopathy': a variant of hereditary Stomatocytosis with complex molecular regulation.	Scientific reports	2017	6
16452222	lapatinib	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	223
16682622	lapatinib	Xia W	A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	113
17308062	lapatinib	Nahta R	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Molecular cancer therapeutics	2007	69
18421051	lapatinib	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	101
18445819	lapatinib	Li X	Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.	Journal of the National Cancer Institute	2008	530
18664652	lapatinib	Gril B	Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.	Journal of the National Cancer Institute	2008	78
18955454	lapatinib	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
19047149	lapatinib	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	73
19169683	lapatinib	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	60
19179558	lapatinib	Blackwell KL	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Annals of oncology 	2009	51
19228746	lapatinib	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	115
19346299	lapatinib	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	218
19671800	lapatinib	Liu L	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Cancer research	2009	128
19718025	lapatinib	Prickett TD	Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.	Nature genetics	2009	131
20009104	lapatinib	Guo D	EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.	Science signaling	2009	82
20124187	lapatinib	Blackwell KL	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.	Journal of clinical oncology 	2010	188
20501798	lapatinib	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	88
20571069	lapatinib	Hirai H	MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.	Molecular cancer therapeutics	2010	292
20730488	lapatinib	Junttila TT	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Breast cancer research and treatment	2011	71
21245432	lapatinib	Spraggs CF	HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.	Journal of clinical oncology 	2011	56
21699723	lapatinib	Giuliano M	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.	Breast cancer research 	2011	46
21741829	lapatinib	von Minckwitz G	Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.	European journal of cancer	2011	41
21847123	lapatinib	Pandya K	Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.	British journal of cancer	2011	46
21884573	lapatinib	Huang C	β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.	Breast cancer research 	2011	58
22059152	lapatinib	Guo D	An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.	Cancer discovery	2011	70
22161825	lapatinib	Eccles SA	The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.	The International journal of developmental biology	2011	41
22178589	lapatinib	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	86
22248472	lapatinib	McDonagh CF	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	Molecular cancer therapeutics	2012	79
22257523	lapatinib	Untch M	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.	The Lancet. Oncology	2012	74
22257673	lapatinib	Baselga J	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	236
22407832	lapatinib	García-García C	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.	Clinical cancer research 	2012	54
22461506	lapatinib	Vaught DB	HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.	Cancer research	2012	38
22461643	lapatinib	Stern HM	Improving treatment of HER2-positive cancers: opportunities and challenges.	Science translational medicine	2012	44
22649126	lapatinib	Krop IE	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.	Journal of clinical oncology 	2012	63
22689807	lapatinib	Blackwell KL	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.	Journal of clinical oncology 	2012	115
22745588	lapatinib	Clark PA	Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.	Neoplasia	2012	45
23020162	lapatinib	Verma S	Trastuzumab emtansine for HER2-positive advanced breast cancer.	The New England journal of medicine	2012	432
23071597	lapatinib	Nowsheen S	Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.	PloS one	2012	33
23122784	lapatinib	Bachelot T	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	The Lancet. Oncology	2013	84
23149820	lapatinib	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	51
23441129	lapatinib	Walters DM	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Neoplasia	2013	28
23940356	lapatinib	Hanker AB	Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.	Proceedings of the National Academy of Sciences of the United States of America	2013	43
24080156	lapatinib	Kümler I	A systematic review of dual targeting in HER2-positive breast cancer.	Cancer treatment reviews	2014	36
24095300	lapatinib	Robidoux A	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2013	61
24097864	lapatinib	Phillips GD	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.	Clinical cancer research 	2014	36
24222194	lapatinib	Welslau M	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.	Cancer	2014	22
24360619	lapatinib	Figueroa-Magalhães MC	Treatment of HER2-positive breast cancer.	Breast	2014	29
24379439	lapatinib	Steinkamp MP	erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.	Molecular and cellular biology	2014	27
24656976	lapatinib	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	45
24868024	lapatinib	Satoh T	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.	Journal of clinical oncology 	2014	99
24919460	lapatinib	Balduzzi S	Trastuzumab-containing regimens for metastatic breast cancer.	The Cochrane database of systematic reviews	2014	27
24973425	lapatinib	Zhang Z	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Clinical cancer research 	2014	24
25086636	lapatinib	Müller V	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.	Breast cancer research and treatment	2014	29
25130998	lapatinib	de Azambuja E	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	The Lancet. Oncology	2014	50
25199759	lapatinib	Loibl S	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.	Journal of clinical oncology 	2014	47
25355722	lapatinib	Krop IE	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.	Annals of oncology 	2015	24
25467182	lapatinib	Scaltriti M	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.	Clinical cancer research 	2015	18
25492965	lapatinib	Haskins JW	Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.	Science signaling	2014	29
25559818	lapatinib	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	46
25605838	lapatinib	Pivot X	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2015	23
25622903	lapatinib	Zhang L	Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.	Neoplasia	2015	17
25779558	lapatinib	Gelmon KA	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.	Journal of clinical oncology 	2015	18
26181252	lapatinib	Salgado R	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	JAMA oncology	2015	46
26204261	lapatinib	Moasser MM	The Evolving Landscape of HER2 Targeting in Breast Cancer.	JAMA oncology	2015	15
26598744	lapatinib	Piccart-Gebhart M	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.	Journal of clinical oncology 	2016	25
26647992	lapatinib	Wang M	N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.	International journal of oncology	2016	21
26920887	lapatinib	Baselga J	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	19
27034004	lapatinib	Li W	Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.	Oncotarget	2016	22
27108243	lapatinib	Sartore-Bianchi A	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	45
28034079	lapatinib	Powles T	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.	Journal of clinical oncology 	2017	8
28238593	lapatinib	Llombart-Cussac A	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.	The Lancet. Oncology	2017	8
15703420	lenalidomide	List A	Efficacy of lenalidomide in myelodysplastic syndromes.	The New England journal of medicine	2005	133
17576924	lenalidomide	Pellagatti A	Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.	Proceedings of the National Academy of Sciences of the United States of America	2007	58
18843284	lenalidomide	Podar K	Bone marrow microenvironment and the identification of new targets for myeloma therapy.	Leukemia	2009	98
20825315	lenalidomide	Tehranchi R	Persistent malignant stem cells in del(5q) myelodysplasia in remission.	The New England journal of medicine	2010	68
20978269	lenalidomide	Hsu AK	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.	Blood	2011	45
21109694	lenalidomide	van der Veer MS	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.	Haematologica	2011	36
21189262	lenalidomide	Bjorklund CC	Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.	The Journal of biological chemistry	2011	37
21321360	lenalidomide	Jakubikova J	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.	Blood	2011	61
21707574	lenalidomide	Lopez-Girona A	Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.	British journal of haematology	2011	50
22698399	lenalidomide	Yang Y	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.	Cancer cell	2012	106
22975377	lenalidomide	Chauhan D	A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.	Cancer cell	2012	100
22975686	lenalidomide	Rushworth SA	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.	Cellular signalling	2013	33
23321256	lenalidomide	Görgün GT	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.	Blood	2013	64
24532337	lenalidomide	Dispenzieri A	POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.	American journal of hematology	2014	30
24569262	lenalidomide	Tai YT	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.	Blood	2014	32
24625454	lenalidomide	Vaidya R	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.	Annals of oncology 	2014	21
24831981	lenalidomide	Vitolo U	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.	The Lancet. Oncology	2014	24
25135992	lenalidomide	Nowakowski GS	Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.	Journal of clinical oncology 	2015	36
25510242	lenalidomide	Nijhof IS	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.	Haematologica	2015	17
25979485	lenalidomide	Görgün G	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.	Clinical cancer research 	2015	40
25999435	lenalidomide	Benson DM Jr	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.	Clinical cancer research 	2015	30
27127303	lenalidomide	Tai YT	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.	Blood	2016	12
28699668	lenalidomide	Dispenzieri A	POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management.	American journal of hematology	2017	8
15208680	sorafenib	Karasarides M	B-RAF is a therapeutic target in melanoma.	Oncogene	2004	100
15781657	sorafenib	Sharma A	Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.	Cancer research	2005	98
16880785	sorafenib	Eisen T	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.	British journal of cancer	2006	146
16908937	sorafenib	Abou-Alfa GK	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	269
17178882	sorafenib	Liu L	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.	Cancer research	2006	298
17470685	sorafenib	Strumberg D	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.	The oncologist	2007	97
17548474	sorafenib	Rahmani M	The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.	Molecular and cellular biology	2007	76
18165647	sorafenib	Choueiri TK	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.	Journal of clinical oncology 	2008	89
18200035	sorafenib	Zhang W	Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.	Leukemia	2008	61
18219225	sorafenib	Flaherty KT	Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.	Cancer biology & therapy	2008	50
18304676	sorafenib	Llovet JM	Novel advancements in the management of hepatocellular carcinoma in 2008.	Journal of hepatology	2008	202
18483389	sorafenib	Agaram NP	Molecular characterization of pediatric gastrointestinal stromal tumors.	Clinical cancer research 	2008	58
18669456	sorafenib	Azad NS	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.	Journal of clinical oncology 	2008	82
18676833	sorafenib	Ding Q	Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.	Cancer research	2008	53
19001320	sorafenib	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	425
19064974	sorafenib	Golshayan AR	Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.	Journal of clinical oncology 	2009	51
19171708	sorafenib	Escudier B	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	105
19255327	sorafenib	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	128
19652055	sorafenib	Blumenschein GR Jr	Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2009	51
19665249	sorafenib	Newell P	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.	Journal of hepatology	2009	52
19726678	sorafenib	Bai S	MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.	The Journal of biological chemistry	2009	157
19773371	sorafenib	Hoftijzer H	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.	European journal of endocrinology	2009	49
19826129	sorafenib	Heng DY	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.	Journal of clinical oncology 	2009	268
19935794	sorafenib	Bengala C	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.	British journal of cancer	2010	49
20212254	sorafenib	Ravandi F	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	100
20347499	sorafenib	Shimizu S	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.	Journal of hepatology	2010	87
20368568	sorafenib	Lam ET	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.	Journal of clinical oncology 	2010	69
20371721	sorafenib	Yang F	Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.	Molecular cancer therapeutics	2010	46
20616044	sorafenib	Wüstehube J	Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20696054	sorafenib	Jones SJ	Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.	Genome biology	2010	62
20952518	sorafenib	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	47
21187475	sorafenib	Gedaly R	PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.	Anticancer research	2010	45
21205925	sorafenib	Chen KF	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.	The Journal of pharmacology and experimental therapeutics	2011	69
21220499	sorafenib	Nagai T	Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.	Molecular cancer therapeutics	2011	39
21334406	sorafenib	Chen X	Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations.	Journal of hepatology	2011	38
21352471	sorafenib	Meng F	Functional analysis of microRNAs in human hepatocellular cancer stem cells.	Journal of cellular and molecular medicine	2012	41
21368833	sorafenib	Inuzuka H	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	Nature	2011	195
21538283	sorafenib	Nault JC	Genetics of hepatobiliary carcinogenesis.	Seminars in liver disease	2011	50
21576636	sorafenib	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	44
21622715	sorafenib	Bareford MD	Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.	Cancer research	2011	40
21748296	sorafenib	El-Khoueiry AB	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.	Investigational new drugs	2012	39
21816126	sorafenib	Sangro B	Radioembolization for hepatocellular carcinoma.	Journal of hepatology	2012	62
21858812	sorafenib	Shimizu S	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.	International journal of cancer	2012	56
21985599	sorafenib	Marra M	Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.	Journal of translational medicine	2011	46
22067401	sorafenib	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	81
22130231	sorafenib	Takahashi S	Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.	Biological & pharmaceutical bulletin	2011	48
22146883	sorafenib	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	41
22180308	sorafenib	Tai WT	Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.	Molecular cancer therapeutics	2012	36
22322234	sorafenib	Lachenmayer A	Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.	Journal of hepatology	2012	44
22368270	sorafenib	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	62
22412143	sorafenib	Baselga J	Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2012	39
22446485	sorafenib	Rahmani M	Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.	Blood	2012	36
22451120	sorafenib	Xie B	Sorafenib for treatment of hepatocellular carcinoma: a systematic review.	Digestive diseases and sciences	2012	36
22473773	sorafenib	Shan J	Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.	Hepatology	2012	74
22504140	sorafenib	Metzelder SK	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.	Leukemia	2012	40
22617245	sorafenib	Yasuda H	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.	Journal of thoracic oncology 	2012	34
22711876	sorafenib	Shaik S	SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.	The Journal of experimental medicine	2012	32
22890726	sorafenib	Arao T	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	2013	25
22994652	sorafenib	Welker MW	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.	Transplant international 	2013	35
23103770	sorafenib	Subramaniam A	Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma.	Biochimica et biophysica acta	2013	42
23111106	sorafenib	van Malenstein H	Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.	Cancer letters	2013	36
23113752	sorafenib	Savvides P	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.	Thyroid 	2013	35
23392173	sorafenib	Tai WT	Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.	Cell death & disease	2013	46
23471579	sorafenib	Xia H	MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.	Hepatology	2013	89
23835194	sorafenib	Pez F	Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.	Journal of hepatology	2013	56
23890088	sorafenib	Botton T	Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.	Pigment cell & melanoma research	2013	30
23958557	sorafenib	Govaere O	Keratin 19: a key role player in the invasion of human hepatocellular carcinomas.	Gut	2014	53
23980084	sorafenib	Johnson PJ	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.	Journal of clinical oncology 	2013	112
23980090	sorafenib	Llovet JM	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.	Journal of clinical oncology 	2013	107
24019545	sorafenib	Motzer RJ	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.	Journal of clinical oncology 	2013	59
24045150	sorafenib	Giordano S	Met as a therapeutic target in HCC: facts and hopes.	Journal of hepatology	2014	29
24233839	sorafenib	Lee HJ	Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.	Carcinogenesis	2014	21
24687604	sorafenib	Horwitz E	Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.	Cancer discovery	2014	21
24700742	sorafenib	Xiang Q	Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.	Clinical cancer research 	2014	26
24705351	sorafenib	Zhai B	Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.	Molecular cancer therapeutics	2014	45
24803676	sorafenib	Karajannis MA	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.	Neuro-oncology	2014	32
25017943	sorafenib	Sounni NE	Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.	Cell metabolism	2014	34
25040368	sorafenib	Vaira V	MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.	Liver international 	2015	17
25053293	sorafenib	Fernando J	A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.	International journal of cancer	2015	23
25216638	sorafenib	Rudalska R	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.	Nature medicine	2014	43
25422324	sorafenib	Wu Q	Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity.	The Journal of biological chemistry	2015	15
25498219	sorafenib	Grignani G	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.	The Lancet. Oncology	2015	34
25633810	sorafenib	Ohta K	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.	Oncotarget	2015	34
25704960	sorafenib	Tavallai M	Nexavar/Stivarga and viagra interact to kill tumor cells.	Journal of cellular physiology	2015	20
25712526	sorafenib	Zheng B	MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.	Biochemical and biophysical research communications	2015	21
25865556	sorafenib	Han T	PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.	Journal of hepatology	2015	19
26045065	sorafenib	Liu K	miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.	Oncology reports	2015	25
26095784	sorafenib	Zhu AX	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.	The Lancet. Oncology	2015	58
26311740	sorafenib	He C	MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.	Oncotarget	2015	22
26314551	sorafenib	Ross JS	The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.	International journal of cancer	2016	21
26514126	sorafenib	Lou G	Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.	Journal of hematology & oncology	2015	38
26566875	sorafenib	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	28
26592953	sorafenib	Govaere O	Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.	Journal of hepatology	2016	13
26655273	sorafenib	Xu Y	MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.	Cancer letters	2016	17
26790028	sorafenib	Firtina Karagonlar Z	Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.	Cancer science	2016	14
26809111	sorafenib	Lencioni R	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.	Journal of hepatology	2016	54
26811478	sorafenib	Xu IM	Transketolase counteracts oxidative stress to drive cancer development.	Proceedings of the National Academy of Sciences of the United States of America	2016	18
26924089	sorafenib	Zhou SL	Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.	Gastroenterology	2016	22
27100895	sorafenib	Zhang PF	Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.	Cell death & disease	2016	15
27399335	sorafenib	Tong J	FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.	Oncogene	2017	13
27484637	sorafenib	Prieto-Domínguez N	Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.	Journal of pineal research	2016	11
27770556	sorafenib	Parikh ND	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.	Hepatology	2017	6
27849562	sorafenib	Bollard J	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.	Gut	2017	8
28177886	sorafenib	Zhang X	Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.	Oncotarget	2017	7
12531805	sunitinib	O'Farrell AM	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.	Blood	2003	170
12748309	sunitinib	Abrams TJ	SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.	Molecular cancer therapeutics	2003	147
17202116	sunitinib	Rini BI	Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2007	56
17512858	sunitinib	Rubin BP	Gastrointestinal stromal tumour.	Lancet	2007	93
17942672	sunitinib	Ebos JM	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
18235126	sunitinib	Socinski MA	Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	84
18312355	sunitinib	Lasota J	Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.	Histopathology	2008	74
18612155	sunitinib	Kulke MH	Activity of sunitinib in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2008	114
18623623	sunitinib	Liegl B	Heterogeneity of kinase inhibitor resistance mechanisms in GIST.	The Journal of pathology	2008	80
18669461	sunitinib	Rini BI	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.	Journal of clinical oncology 	2008	113
18955458	sunitinib	Heinrich MC	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.	Journal of clinical oncology 	2008	132
19487381	sunitinib	Motzer RJ	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	449
20103629	sunitinib	Huang D	Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.	Cancer research	2010	63
20103651	sunitinib	Huang D	Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.	Cancer research	2010	114
20165865	sunitinib	Liegl-Atzwanger B	Gastrointestinal stromal tumors.	Virchows Archiv 	2010	50
20339913	sunitinib	Barrios CH	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.	Breast cancer research and treatment	2010	50
20501804	sunitinib	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	56
20657034	sunitinib	Patil S	Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.	Annals of oncology 	2011	40
20872043	sunitinib	Neyns B	Phase II study of sunitinib malate in patients with recurrent high-grade glioma.	Journal of neuro-oncology	2011	44
20948437	sunitinib	Adotevi O	A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.	Journal of immunotherapy	2010	42
21237299	sunitinib	Greten TF	Myeloid derived suppressor cells in human diseases.	International immunopharmacology	2011	112
21315783	sunitinib	Finke J	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.	International immunopharmacology	2011	73
21527770	sunitinib	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	122
21882181	sunitinib	Kim JJ	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.	Cancer	2012	37
21898375	sunitinib	Molina AM	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.	Cancer	2012	35
22015057	sunitinib	Garcia-Donas J	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.	The Lancet. Oncology	2011	64
22308314	sunitinib	Conley SJ	Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	2012	160
22573349	sunitinib	Griffioen AW	Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.	Clinical cancer research 	2012	40
22614970	sunitinib	George S	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.	Journal of clinical oncology 	2012	48
23177515	sunitinib	Demetri GD	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.	Lancet	2013	203
23378344	sunitinib	Hollier BG	FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.	Cancer research	2013	75
23610448	sunitinib	Guerin E	A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.	Cancer research	2013	25
24384849	sunitinib	Corless CL	Gastrointestinal stromal tumors: what do we know now?	Modern pathology 	2014	25
24925196	sunitinib	von Mehren M	Gastrointestinal stromal tumors, version 2.2014.	Journal of the National Comprehensive Cancer Network 	2014	26
25123505	sunitinib	Mikami S	Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.	International journal of cancer	2015	22
25200065	sunitinib	Zhang D	Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.	Molecular cancer	2014	25
25361735	sunitinib	Huang H	VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.	FASEB journal 	2015	22
25381264	sunitinib	Ciamporcero E	Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.	Molecular cancer therapeutics	2015	19
25538263	sunitinib	Choueiri TK	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research 	2015	34
25583177	sunitinib	Beuselinck B	Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.	Clinical cancer research 	2015	18
25861727	sunitinib	Costa PM	MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.	Journal of controlled release 	2015	22
26201448	sunitinib	Khella HWZ	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.	Molecular therapy 	2015	15
26364599	sunitinib	Zhou L	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.	Oncogene	2016	39
26626617	sunitinib	Tannir NM	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.	European urology	2016	26
26794930	sunitinib	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	25
27117758	sunitinib	Qu L	Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.	Cancer cell	2016	63
27297795	sunitinib	Oppermann S	High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.	Blood	2016	11
27487138	sunitinib	Goto Y	The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.	Oncotarget	2016	15
27595394	sunitinib	Chen W	Targeting renal cell carcinoma with a HIF-2 antagonist.	Nature	2016	39
27751729	sunitinib	Hsieh JJ	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.	European urology	2017	13
28199818	sunitinib	Choueiri TK	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.	Journal of clinical oncology 	2017	15
19339269	abiraterone	Attard G	Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.	Cancer research	2009	174
19470933	abiraterone	Attard G	Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.	Journal of clinical oncology 	2009	152
21612468	abiraterone	de Bono JS	Abiraterone and increased survival in metastatic prostate cancer.	The New England journal of medicine	2011	837
21632851	abiraterone	Ryan CJ	Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.	Clinical cancer research 	2011	57
24101480	abiraterone	Nyquist MD	TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	41
24139549	abiraterone	Egan A	Castration-resistant prostate cancer: adaptive responses in the androgen axis.	Cancer treatment reviews	2014	39
25048254	abiraterone	Nakazawa M	Androgen receptor splice variants in the era of enzalutamide and abiraterone.	Hormones & cancer	2014	26
25184630	abiraterone	Antonarakis ES	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.	The New England journal of medicine	2014	322
25306226	abiraterone	Karantanos T	Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.	European urology	2015	40
25489091	abiraterone	He B	GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.	Proceedings of the National Academy of Sciences of the United States of America	2014	28
25601341	abiraterone	Ryan CJ	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.	The Lancet. Oncology	2015	109
25712683	abiraterone	Azad AA	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.	Clinical cancer research 	2015	66
26030522	abiraterone	Li Z	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.	Nature	2015	44
27430478	abiraterone	Hegemann M	Liquid biopsy: ready to guide therapy in advanced prostate cancer?	BJU international	2016	11
27733296	abiraterone	Del Re M	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.	European urology	2017	12
19372391	5-hydroxymethylcytosine	Tahiliani M	Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.	Science	2009	1432
21734233	5-hydroxymethylcytosine	Pronier E	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.	Blood	2011	51
22052461	5-hydroxymethylcytosine	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	121
22688054	5-hydroxymethylcytosine	Müller T	Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.	The American journal of pathology	2012	31
22824796	5-hydroxymethylcytosine	Wang P	Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.	Oncogene	2013	81
22829908	5-hydroxymethylcytosine	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	44
22902501	5-hydroxymethylcytosine	Doege CA	Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2.	Nature	2012	110
22980977	5-hydroxymethylcytosine	Lian CG	Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.	Cell	2012	195
23671639	5-hydroxymethylcytosine	Liu C	Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.	PloS one	2013	45
23827711	5-hydroxymethylcytosine	Song SJ	The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.	Cell stem cell	2013	95
23828890	5-hydroxymethylcytosine	Lister R	Global epigenomic reconfiguration during mammalian brain development.	Science	2013	449
24012631	5-hydroxymethylcytosine	Bradley-Whitman MA	Epigenetic changes in the progression of Alzheimer's disease.	Mechanisms of ageing and development	2013	33
24077167	5-hydroxymethylcytosine	Liu R	Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity.	Circulation	2013	29
24270360	5-hydroxymethylcytosine	Jeong M	Large conserved domains of low DNA methylation maintained by Dnmt3a.	Nature genetics	2014	88
24448211	5-hydroxymethylcytosine	Zhubi A	Increased binding of MeCP2 to the GAD1 and RELN promoters may be mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum.	Translational psychiatry	2014	45
25087872	5-hydroxymethylcytosine	Arab K	Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A.	Molecular cell	2014	46
25284789	5-hydroxymethylcytosine	Takai H	5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex.	Cell reports	2014	22
25482556	5-hydroxymethylcytosine	Rampal R	DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.	Cell reports	2014	55
25862091	5-hydroxymethylcytosine	Ichiyama K	The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells.	Immunity	2015	31
25922306	5-hydroxymethylcytosine	Yang Q	The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.	Reproductive sciences	2016	15
26268241	5-hydroxymethylcytosine	Wang C	IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.	Blood	2015	24
26472283	5-hydroxymethylcytosine	Hoekstra AS	Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.	Oncotarget	2015	18
26680004	5-hydroxymethylcytosine	Chen K	Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer.	Cell research	2016	13
27573823	5-hydroxymethylcytosine	Liu M	Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.	Proceedings of the National Academy of Sciences of the United States of America	2016	16
28823558	5-hydroxymethylcytosine	Cimmino L	Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.	Cell	2017	14
28826859	5-hydroxymethylcytosine	Cull AH	Tet2 restrains inflammatory gene expression in macrophages.	Experimental hematology	2017	6
16443686	nutlin 3	Tovar C	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.	Proceedings of the National Academy of Sciences of the United States of America	2006	210
17700533	nutlin 3	Lau LM	HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.	Oncogene	2008	57
21068437	nutlin 3	Dutt S	Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.	Blood	2011	108
21212465	nutlin 3	Leontieva OV	DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.	Aging	2010	96
21317459	nutlin 3	Rao B	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.	Oncotarget	2010	50
21960059	nutlin 3	Nakatani F	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.	The Journal of pathology	2012	48
23775793	nutlin 3	Menendez D	Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.	Nucleic acids research	2013	63
24419302	nutlin 3	Gasparini C	NF-κB pathways in hematological malignancies.	Cellular and molecular life sciences 	2014	38
25924068	nutlin 3	Drost J	Sequential cancer mutations in cultured human intestinal stem cells.	Nature	2015	100
15542782	palbociclib	Fry DW	Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.	Molecular cancer therapeutics	2004	271
16885367	palbociclib	Baughn LB	A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.	Cancer research	2006	64
19435910	palbociclib	Agirre X	Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.	Cancer research	2009	85
19874578	palbociclib	Finn RS	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.	Breast cancer research 	2009	228
20473330	palbociclib	Dean JL	Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.	Oncogene	2010	84
22711607	palbociclib	Cen L	p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.	Neuro-oncology	2012	36
22767154	palbociclib	Dean JL	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.	Cell cycle	2012	48
22869556	palbociclib	Liu F	Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.	Molecular cancer therapeutics	2012	34
22935696	palbociclib	Capparelli C	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.	Cell cycle	2012	46
23569312	palbociclib	Dickson MA	Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.	Journal of clinical oncology 	2013	83
24369047	palbociclib	Rocca A	Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.	Expert opinion on pharmacotherapy	2014	23
24444383	palbociclib	Kang J	Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.	BMC cancer	2014	29
24495407	palbociclib	Young RJ	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment cell & melanoma research	2014	27
25501126	palbociclib	DeMichele A	CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.	Clinical cancer research 	2015	57
26923330	palbociclib	Johnson J	Targeting the RB-E2F pathway in breast cancer.	Oncogene	2016	16
27124835	palbociclib	Dickson MA	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.	JAMA oncology	2016	13
28039467	palbociclib	Bonuccelli G	Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.	Oncotarget	2017	11
28174091	palbociclib	Whittaker SR	Inhibitors of cyclin-dependent kinases as cancer therapeutics.	Pharmacology & therapeutics	2017	11
28249908	palbociclib	Jansen VM	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.	Cancer research	2017	8
18390968	AZD 6244	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	169
19029981	AZD 6244	Engelman JA	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.	Nature medicine	2008	484
20802351	AZD 6244	Hainsworth JD	A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.	Journal of thoracic oncology 	2010	48
20959481	AZD 6244	Gopal YN	Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.	Cancer research	2010	100
21124782	AZD 6244	Meng J	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.	PloS one	2010	57
21215703	AZD 6244	Chang CJ	EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.	Cancer cell	2011	134
21519026	AZD 6244	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	64
22392911	AZD 6244	Migliardi G	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.	Clinical cancer research 	2012	48
22872574	AZD 6244	Roberts PJ	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.	Clinical cancer research 	2012	65
22972589	AZD 6244	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	29
23406027	AZD 6244	Ho AL	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.	The New England journal of medicine	2013	98
23436801	AZD 6244	Liu Q	Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.	Cancer research	2013	33
23735514	AZD 6244	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	38
23918606	AZD 6244	Renshaw J	Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.	Clinical cancer research 	2013	45
24178622	AZD 6244	Jain N	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.	Clinical cancer research 	2014	31
25297634	AZD 6244	Gopal YN	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.	Cancer research	2014	32
25348516	AZD 6244	Alagesan B	Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.	Clinical cancer research 	2015	29
25638158	AZD 6244	Weingart MF	Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.	Oncotarget	2015	15
26802155	AZD 6244	Carter CA	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.	Annals of oncology 	2016	14
18408761	afatinib	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	282
19759520	afatinib	Regales L	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.	The Journal of clinical investigation	2009	119
22257651	afatinib	Ou SH	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.	Critical reviews in oncology/hematology	2012	32
22418700	afatinib	Lin NU	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.	Breast cancer research and treatment	2012	46
22891040	afatinib	Kim SM	Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.	Molecular cancer therapeutics	2012	38
23610105	afatinib	Mazières J	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.	Journal of clinical oncology 	2013	107
23816960	afatinib	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	472
23816967	afatinib	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	59
24813888	afatinib	Pirazzoli V	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.	Cell reports	2014	23
25247337	afatinib	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	42
25892145	afatinib	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	46
26051236	afatinib	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	57
26545934	afatinib	Suzawa K	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.	Cancer science	2016	15
26716903	afatinib	Nanjo S	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.	Oncotarget	2016	12
26823294	afatinib	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	17
26852079	afatinib	van der Wekken AJ	Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.	Critical reviews in oncology/hematology	2016	18
26862733	afatinib	Wu SG	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.	Oncotarget	2016	29
27601237	afatinib	Yang JC	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.	Annals of oncology 	2016	12
10391242	beta-amyloid peptide 1-42 (E22delta) click peptide	Vidal R	A stop-codon mutation in the BRI gene associated with familial British dementia.	Nature	1999	97
15731448	beta-amyloid peptide 1-42 (E22delta) click peptide	Stokin GB	Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.	Science	2005	310
16279840	beta-amyloid peptide 1-42 (E22delta) click peptide	Jankowsky JL	Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease.	PLoS medicine	2005	96
17082448	beta-amyloid peptide 1-42 (E22delta) click peptide	Roberson ED	100 years and counting: prospects for defeating Alzheimer's disease.	Science	2006	96
17204939	beta-amyloid peptide 1-42 (E22delta) click peptide	Ramsey CP	Expression of Nrf2 in neurodegenerative diseases.	Journal of neuropathology and experimental neurology	2007	104
17360908	beta-amyloid peptide 1-42 (E22delta) click peptide	Shankar GM	Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.	The Journal of neuroscience 	2007	469
17412999	beta-amyloid peptide 1-42 (E22delta) click peptide	Yerbury JJ	The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures.	FASEB journal 	2007	70
17478722	beta-amyloid peptide 1-42 (E22delta) click peptide	Roberson ED	Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.	Science	2007	519
17553989	beta-amyloid peptide 1-42 (E22delta) click peptide	Klunk WE	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.	The Journal of neuroscience 	2007	117
17894374	beta-amyloid peptide 1-42 (E22delta) click peptide	Josephs KA	Beta-amyloid burden is not associated with rates of brain atrophy.	Annals of neurology	2008	56
18218341	beta-amyloid peptide 1-42 (E22delta) click peptide	Reddy PH	Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.	Trends in molecular medicine	2008	185
18234899	beta-amyloid peptide 1-42 (E22delta) click peptide	Wang WX	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.	The Journal of neuroscience 	2008	226
18343778	beta-amyloid peptide 1-42 (E22delta) click peptide	Zhang J	CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.	American journal of clinical pathology	2008	65
18458217	beta-amyloid peptide 1-42 (E22delta) click peptide	Bian H	CSF biomarkers in frontotemporal lobar degeneration with known pathology.	Neurology	2008	59
18497889	beta-amyloid peptide 1-42 (E22delta) click peptide	Pickford F	The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice.	The Journal of clinical investigation	2008	267
18579078	beta-amyloid peptide 1-42 (E22delta) click peptide	Cheung KH	Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating.	Neuron	2008	152
18586353	beta-amyloid peptide 1-42 (E22delta) click peptide	Simpson JE	Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain.	Neurobiology of aging	2010	63
18955133	beta-amyloid peptide 1-42 (E22delta) click peptide	Waxman EA	Molecular mechanisms of alpha-synuclein neurodegeneration.	Biochimica et biophysica acta	2009	60
19038212	beta-amyloid peptide 1-42 (E22delta) click peptide	Small SA	Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.	Neuron	2008	134
19104446	beta-amyloid peptide 1-42 (E22delta) click peptide	Julien C	Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease.	Journal of neuropathology and experimental neurology	2009	63
19139294	beta-amyloid peptide 1-42 (E22delta) click peptide	Sonnen JA	Different patterns of cerebral injury in dementia with or without diabetes.	Archives of neurology	2009	64
19204726	beta-amyloid peptide 1-42 (E22delta) click peptide	Chapuis J	Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease.	Molecular psychiatry	2009	48
19225789	beta-amyloid peptide 1-42 (E22delta) click peptide	Revesz T	Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.	Acta neuropathologica	2009	51
19228952	beta-amyloid peptide 1-42 (E22delta) click peptide	Meilandt WJ	Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.	The Journal of neuroscience 	2009	58
19288297	beta-amyloid peptide 1-42 (E22delta) click peptide	Achim CL	Increased accumulation of intraneuronal amyloid beta in HIV-infected patients.	Journal of neuroimmune pharmacology 	2009	62
19293237	beta-amyloid peptide 1-42 (E22delta) click peptide	Mahad DJ	Mitochondrial changes within axons in multiple sclerosis.	Brain 	2009	82
19465477	beta-amyloid peptide 1-42 (E22delta) click peptide	Johnson BS	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.	The Journal of biological chemistry	2009	198
19470939	beta-amyloid peptide 1-42 (E22delta) click peptide	Pierce BL	Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.	Journal of clinical oncology 	2009	160
19587325	beta-amyloid peptide 1-42 (E22delta) click peptide	Okello A	Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.	Neurology	2009	116
19605646	beta-amyloid peptide 1-42 (E22delta) click peptide	Wang X	Impaired balance of mitochondrial fission and fusion in Alzheimer's disease.	The Journal of neuroscience 	2009	280
19725828	beta-amyloid peptide 1-42 (E22delta) click peptide	Soontornniyomkij V	Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy.	Brain pathology	2010	45
19815015	beta-amyloid peptide 1-42 (E22delta) click peptide	Hampel H	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.	Experimental neurology	2010	45
19828810	beta-amyloid peptide 1-42 (E22delta) click peptide	Abdul HM	Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.	The Journal of neuroscience 	2009	77
19937043	beta-amyloid peptide 1-42 (E22delta) click peptide	Schrag M	Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study.	Acta neuropathologica	2010	57
19951690	beta-amyloid peptide 1-42 (E22delta) click peptide	Sun B	Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.	Cell stem cell	2009	52
20037584	beta-amyloid peptide 1-42 (E22delta) click peptide	Stewart CR	CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer.	Nature immunology	2010	358
20147537	beta-amyloid peptide 1-42 (E22delta) click peptide	Fjell AM	CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.	The Journal of neuroscience 	2010	74
20164570	beta-amyloid peptide 1-42 (E22delta) click peptide	Butterfield DA	Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration.	Journal of Alzheimer's disease 	2010	58
20186853	beta-amyloid peptide 1-42 (E22delta) click peptide	Morris JC	APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.	Annals of neurology	2010	277
20234357	beta-amyloid peptide 1-42 (E22delta) click peptide	Chen-Plotkin AS	TAR DNA-binding protein 43 in neurodegenerative disease.	Nature reviews. Neurology	2010	132
20308787	beta-amyloid peptide 1-42 (E22delta) click peptide	Li Y	GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.	Journal of Alzheimer's disease 	2010	65
20573181	beta-amyloid peptide 1-42 (E22delta) click peptide	Pham E	Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.	The FEBS journal	2010	66
20581818	beta-amyloid peptide 1-42 (E22delta) click peptide	Palop JJ	Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.	Nature neuroscience	2010	324
20603455	beta-amyloid peptide 1-42 (E22delta) click peptide	Thambisetty M	Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.	Archives of general psychiatry	2010	94
20720189	beta-amyloid peptide 1-42 (E22delta) click peptide	Siderowf A	CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.	Neurology	2010	81
20844121	beta-amyloid peptide 1-42 (E22delta) click peptide	Crews L	Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis.	The Journal of neuroscience 	2010	44
20847408	beta-amyloid peptide 1-42 (E22delta) click peptide	Valla J	Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene.	Journal of Alzheimer's disease 	2010	57
20854368	beta-amyloid peptide 1-42 (E22delta) click peptide	Zlokovic BV	Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain.	Journal of neurochemistry	2010	67
20861373	beta-amyloid peptide 1-42 (E22delta) click peptide	Jana A	Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease.	The Journal of neuroscience 	2010	48
21035623	beta-amyloid peptide 1-42 (E22delta) click peptide	Craig-Schapiro R	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.	Biological psychiatry	2010	86
21158978	beta-amyloid peptide 1-42 (E22delta) click peptide	Morgan D	Immunotherapy for Alzheimer's disease.	Journal of internal medicine	2011	56
21273420	beta-amyloid peptide 1-42 (E22delta) click peptide	Zhu Y	CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.	The Journal of neuroscience 	2011	39
21391232	beta-amyloid peptide 1-42 (E22delta) click peptide	Chibnik LB	CR1 is associated with amyloid plaque burden and age-related cognitive decline.	Annals of neurology	2011	67
21846727	beta-amyloid peptide 1-42 (E22delta) click peptide	Emmer KL	E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.	The Journal of biological chemistry	2011	38
21969589	beta-amyloid peptide 1-42 (E22delta) click peptide	Johnson LV	Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2011	52
22116809	beta-amyloid peptide 1-42 (E22delta) click peptide	Hartz AM	Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.	Stroke	2012	38
22305802	beta-amyloid peptide 1-42 (E22delta) click peptide	Sperling R	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.	The Lancet. Neurology	2012	78
23272651	beta-amyloid peptide 1-42 (E22delta) click peptide	Fontana M	Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR.	Journal of cardiovascular magnetic resonance 	2012	38
23539189	beta-amyloid peptide 1-42 (E22delta) click peptide	Ryan NS	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease.	Brain 	2013	46
23703910	beta-amyloid peptide 1-42 (E22delta) click peptide	Cohen SI	Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.	Proceedings of the National Academy of Sciences of the United States of America	2013	170
24713533	beta-amyloid peptide 1-42 (E22delta) click peptide	Romero JR	Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study.	Stroke	2014	35
26251237	beta-amyloid peptide 1-42 (E22delta) click peptide	Gold M	β-amyloid, microglia, and the inflammasome in Alzheimer's disease.	Seminars in immunopathology	2015	17
9267033	thymosin beta(1)	Davies SW	Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.	Cell	1997	464
9528852	thymosin beta(1)	Jensen DE	BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.	Oncogene	1998	143
10835629	thymosin beta(1)	Bignell GR	Identification of the familial cylindromatosis tumour-suppressor gene.	Nature genetics	2000	148
12600911	thymosin beta(1)	Hein S	Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms.	Circulation	2003	175
12890688	thymosin beta(1)	Wu-Baer F	The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin.	The Journal of biological chemistry	2003	84
15916961	thymosin beta(1)	Kraft C	The WD40 propeller domain of Cdh1 functions as a destruction box receptor for APC/C substrates.	Molecular cell	2005	92
16613895	thymosin beta(1)	Josephs KA	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech.	Brain 	2006	156
16949367	thymosin beta(1)	Jin J	A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1.	Molecular cell	2006	258
17218260	thymosin beta(1)	Wang X	NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.	Cell	2007	205
17469116	thymosin beta(1)	Mackenzie IR	Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.	Annals of neurology	2007	216
17575125	thymosin beta(1)	Malyukova A	The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.	Cancer research	2007	61
17597759	thymosin beta(1)	Jin J	Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging.	Nature	2007	95
17826340	thymosin beta(1)	Rademakers R	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative.	The Lancet. Neurology	2007	66
18166704	thymosin beta(1)	Josephs KA	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.	Neurology	2008	65
18354483	thymosin beta(1)	Westbrook TF	SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation.	Nature	2008	127
18391962	thymosin beta(1)	Kordower JH	Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.	Nature medicine	2008	358
18701681	thymosin beta(1)	Bedford L	Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies.	The Journal of neuroscience 	2008	86
18931663	thymosin beta(1)	Gyrd-Hansen M	IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis.	Nature cell biology	2008	66
18997792	thymosin beta(1)	Vallabhapurapu S	Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.	Nature immunology	2008	214
19228967	thymosin beta(1)	Carrettiero DC	The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule.	The Journal of neuroscience 	2009	56
19270695	thymosin beta(1)	Gao D	Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.	Nature cell biology	2009	108
19380227	thymosin beta(1)	Weihl CC	Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia.	Neuromuscular disorders 	2009	52
19917254	thymosin beta(1)	Shan J	Suppression of cancer cell growth by promoting cyclin D1 degradation.	Molecular cell	2009	64
22246324	thymosin beta(1)	Thurston TL	Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion.	Nature	2012	201
23103054	thymosin beta(1)	Buckley SM	Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system.	Cell stem cell	2012	66
18701483	dactolisib	Schnell CR	Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.	Cancer research	2008	63
18829560	dactolisib	Serra V	NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.	Cancer research	2008	259
19116269	dactolisib	Dubrovska A	The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.	Proceedings of the National Academy of Sciences of the United States of America	2009	155
19372546	dactolisib	Breuleux M	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.	Molecular cancer therapeutics	2009	75
19584292	dactolisib	McMillin DW	Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.	Cancer research	2009	46
19789349	dactolisib	Konstantinidou G	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.	Cancer research	2009	56
20007781	dactolisib	Brachmann SM	Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	107
20068094	dactolisib	Manara MC	NVP-BEZ235 as a new therapeutic option for sarcomas.	Clinical cancer research 	2010	55
20569503	dactolisib	Creighton CJ	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.	Breast cancer research 	2010	78
20857497	dactolisib	Sunayama J	Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.	Stem cells	2010	61
20876803	dactolisib	Chiarini F	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.	Cancer research	2010	56
21372221	dactolisib	Santiskulvong C	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clinical cancer research 	2011	43
21876152	dactolisib	Ilic N	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.	Proceedings of the National Academy of Sciences of the United States of America	2011	86
23012248	dactolisib	Acquaviva J	Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.	Molecular cancer therapeutics	2012	36
23246963	dactolisib	Montero JC	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.	Oncogene	2014	29
23319457	dactolisib	Figlin RA	Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.	International journal of cancer	2013	29
23619167	dactolisib	Lui VW	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.	Cancer discovery	2013	123
24157869	dactolisib	Chang L	Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.	Cell death & disease	2013	72
24448243	dactolisib	Lin A	FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.	Cancer research	2014	23
25590803	dactolisib	Choudhary GS	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.	Cell death & disease	2015	60
26451606	dactolisib	Sharma N	PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.	Oncotarget	2015	40
28321130	dactolisib	Lu X	Effective combinatorial immunotherapy for castration-resistant prostate cancer.	Nature	2017	16
20130243	INCB018424	Quintás-Cardama A	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.	Blood	2010	164
20843246	INCB018424	Verstovsek S	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.	The New England journal of medicine	2010	275
24258498	INCB018424	Verstovsek S	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.	Cancer	2014	31
24497534	INCB018424	Wang T	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.	Blood	2014	23
24711661	INCB018424	Spoerl S	Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.	Blood	2014	37
24857661	INCB018424	Albrengues J	LIF mediates proinvasive activation of stromal fibroblasts in cancer.	Cell reports	2014	25
25129481	INCB018424	Xing L	Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.	Nature medicine	2014	58
25207766	INCB018424	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	178
25572172	INCB018424	Kleppe M	JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.	Cancer discovery	2015	41
25616577	INCB018424	Verstovsek S	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.	Haematologica	2015	35
25671252	INCB018424	Ortmann CA	Effect of mutation order on myeloproliferative neoplasms.	The New England journal of medicine	2015	70
26124496	INCB018424	Patel KP	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.	Blood	2015	18
26228487	INCB018424	Deininger M	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.	Blood	2015	22
27613527	INCB018424	Yu HA	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.	Journal of thoracic oncology 	2017	5
27677740	INCB018424	Saenz DT	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.	Leukemia	2017	7
27777238	INCB018424	Tasian SK	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.	Blood	2017	15
27916398	INCB018424	Passamonti F	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.	The Lancet. Oncology	2017	12
20149136	vemurafenib	Halaban R	PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.	Pigment cell & melanoma research	2010	122
20551065	vemurafenib	Yang H	RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.	Cancer research	2010	106
20818844	vemurafenib	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	991
20823850	vemurafenib	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	468
21107323	vemurafenib	Nazarian R	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.	Nature	2010	647
21169256	vemurafenib	Comin-Anduix B	The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.	Clinical cancer research 	2010	53
21383288	vemurafenib	Wagle N	Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.	Journal of clinical oncology 	2011	286
21803746	vemurafenib	Shi H	Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.	Cancer research	2011	70
22113612	vemurafenib	Poulikakos PI	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).	Nature	2011	385
22217739	vemurafenib	Nikolaou VA	Melanoma: new insights and new therapies.	The Journal of investigative dermatology	2012	50
22256804	vemurafenib	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	219
22306669	vemurafenib	Halait H	Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.	Diagnostic molecular pathology 	2012	38
22332713	vemurafenib	Anderson S	Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.	Archives of pathology & laboratory medicine	2012	40
22351686	vemurafenib	Paraiso KH	The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.	Clinical cancer research 	2012	53
22385436	vemurafenib	Finn L	Therapy for metastatic melanoma: the past, present, and future.	BMC medicine	2012	50
22448344	vemurafenib	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	195
22454415	vemurafenib	McArthur GA	Marked, homogeneous, and early 18Ffluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	Journal of clinical oncology 	2012	37
22640478	vemurafenib	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	31
22693252	vemurafenib	Koya RC	BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.	Cancer research	2012	64
22743296	vemurafenib	Gautschi O	A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.	Journal of thoracic oncology 	2012	40
22763448	vemurafenib	Wilson TR	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.	Nature	2012	365
22850568	vemurafenib	Khalili JS	Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.	Clinical cancer research 	2012	66
22945644	vemurafenib	Sullivan RJ	MAP kinase signaling and inhibition in melanoma.	Oncogene	2013	29
23060265	vemurafenib	Bollag G	Vemurafenib: the first drug approved for BRAF-mutant cancer.	Nature reviews. Drug discovery	2012	133
23237741	vemurafenib	Klein O	BRAF inhibitor activity in V600R metastatic melanoma.	European journal of cancer	2013	27
23239741	vemurafenib	Held MA	Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.	Cancer discovery	2013	35
23242808	vemurafenib	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	106
23258922	vemurafenib	Haroche J	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.	Blood	2013	81
23302800	vemurafenib	Das Thakur M	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.	Nature	2013	185
23362240	vemurafenib	Beck D	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.	Science signaling	2013	30
23489023	vemurafenib	Kim KB	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.	Thyroid 	2013	50
23569304	vemurafenib	Trunzer K	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.	Journal of clinical oncology 	2013	92
23733758	vemurafenib	Peters S	Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.	Journal of clinical oncology 	2013	28
23764003	vemurafenib	Roesch A	Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.	Cancer cell	2013	124
24077405	vemurafenib	Phan GQ	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.	Cancer control 	2013	25
24133630	vemurafenib	Niessner H	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.	Cancer medicine	2013	29
24265153	vemurafenib	Van Allen EM	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.	Cancer discovery	2014	189
24295639	vemurafenib	Dummer R	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.	European journal of cancer	2014	43
24325952	vemurafenib	Hertzman Johansson C	BRAF inhibitors in cancer therapy.	Pharmacology & therapeutics	2014	21
24410877	vemurafenib	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	52
24463458	vemurafenib	Rizos H	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.	Clinical cancer research 	2014	78
24582505	vemurafenib	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	33
24589925	vemurafenib	Abdel-Wahab O	Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.	Cancer discovery	2014	23
24652991	vemurafenib	Nelson DS	Somatic activating ARAF mutations in Langerhans cell histiocytosis.	Blood	2014	30
24662767	vemurafenib	South AP	NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.	The Journal of investigative dermatology	2014	37
24725538	vemurafenib	Robinson GW	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.	BMC cancer	2014	29
24823863	vemurafenib	Levy JM	Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.	Cancer discovery	2014	40
24871132	vemurafenib	Chung SS	Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.	Science translational medicine	2014	20
24879157	vemurafenib	Goodall ML	Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.	Autophagy	2014	20
25037139	vemurafenib	Ribas A	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.	The Lancet. Oncology	2014	36
25096067	vemurafenib	Kim G	FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.	Clinical cancer research 	2014	21
25353071	vemurafenib	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	21
25399551	vemurafenib	Robert C	Improved overall survival in melanoma with combined dabrafenib and trametinib.	The New England journal of medicine	2015	311
25502142	vemurafenib	Müller J	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.	Nature communications	2014	69
25520039	vemurafenib	Maverakis E	Metastatic melanoma - a review of current and future treatment options.	Acta dermato-venereologica	2015	19
25542448	vemurafenib	Miao B	EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.	Cancer discovery	2015	17
25589621	vemurafenib	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	47
25807485	vemurafenib	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	81
25855536	vemurafenib	Witkiewicz AK	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.	Nature communications	2015	120
25980496	vemurafenib	Stark MS	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.	Oncotarget	2015	19
25980594	vemurafenib	Puzanov I	Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.	European journal of cancer	2015	24
26073081	vemurafenib	Fedorenko IV	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.	Oncogene	2016	14
26105199	vemurafenib	Kemper K	Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.	EMBO molecular medicine	2015	26
26139106	vemurafenib	Hernandez-Davies JE	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.	Journal of translational medicine	2015	19
26352686	vemurafenib	Tiacci E	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.	The New England journal of medicine	2015	30
26433819	vemurafenib	Grob JJ	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.	The Lancet. Oncology	2015	20
26460303	vemurafenib	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	57
26498038	vemurafenib	Zheng G	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.	BMC cancer	2015	19
26524482	vemurafenib	Gray ES	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.	Oncotarget	2015	31
26608120	vemurafenib	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	28
27042933	vemurafenib	Kaur A	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.	Nature	2016	34
27181209	vemurafenib	Bianchi-Smiraglia A	Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.	Oncogene	2017	6
27325282	vemurafenib	Pietrantonio F	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.	Cancer discovery	2016	14
27367293	vemurafenib	Garbe C	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.	European journal of cancer	2016	18
27460442	vemurafenib	Brose MS	Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	13
27480103	vemurafenib	Ascierto PA	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2016	27
27580028	vemurafenib	Luo C	A PGC1α-mediated transcriptional axis suppresses melanoma metastasis.	Nature	2016	16
28094001	vemurafenib	Mulcahy Levy JM	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.	eLife	2017	8
20979469	crizotinib	Kwak EL	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.	The New England journal of medicine	2010	1124
21288922	crizotinib	Shaw AT	Targeting anaplastic lymphoma kinase in lung cancer.	Clinical cancer research 	2011	51
21623265	crizotinib	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	106
21933749	crizotinib	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	230
22042947	crizotinib	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	126
22071784	crizotinib	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	47
22072639	crizotinib	Bresler SC	Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.	Science translational medicine	2011	70
22683780	crizotinib	Kentsis A	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.	Nature medicine	2012	53
22919003	crizotinib	Davies KD	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.	Clinical cancer research 	2012	77
23154552	crizotinib	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	97
23344087	crizotinib	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	40
23499337	crizotinib	Minca EC	ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.	The Journal of molecular diagnostics 	2013	26
23598171	crizotinib	Mossé YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	127
23669222	crizotinib	Pailler E	Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.	Journal of clinical oncology 	2013	67
23719267	crizotinib	Davies KD	Molecular pathways: ROS1 fusion proteins in cancer.	Clinical cancer research 	2013	54
23724914	crizotinib	Awad MM	Acquired resistance to crizotinib from a mutation in CD74-ROS1.	The New England journal of medicine	2013	64
23729361	crizotinib	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	97
23743928	crizotinib	Selinger CI	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.	Modern pathology 	2013	33
23931927	crizotinib	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	39
23993685	crizotinib	Kim HR	Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.	Molecular oncology	2013	29
24284055	crizotinib	Cañadas I	Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.	Clinical cancer research 	2014	32
24418728	crizotinib	Lira ME	A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.	The Journal of molecular diagnostics 	2014	21
24443522	crizotinib	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	32
24456475	crizotinib	Warth A	ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.	Histopathology	2014	20
24478318	crizotinib	Ou SH	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.	Annals of oncology 	2014	41
24518086	crizotinib	Cabillic F	Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.	Journal of thoracic oncology 	2014	25
24556908	crizotinib	Ji C	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.	Cancer biology & therapy	2014	23
24675041	crizotinib	Friboulet L	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	Cancer discovery	2014	158
24736079	crizotinib	Ignatius Ou SH	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.	Journal of thoracic oncology 	2014	40
24875859	crizotinib	Lovly CM	Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.	Cancer discovery	2014	40
24887559	crizotinib	Kodama T	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.	Cancer letters	2014	36
25153538	crizotinib	Gadgeel SM	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.	The Lancet. Oncology	2014	126
25173427	crizotinib	Lovly CM	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.	Nature medicine	2014	65
25228534	crizotinib	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	56
25234288	crizotinib	Lee SE	Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.	Modern pathology 	2015	17
25344360	crizotinib	Ilie MI	Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.	Annals of oncology 	2015	17
25351743	crizotinib	Katayama R	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.	Clinical cancer research 	2015	25
25526238	crizotinib	Gainor JF	Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.	Journal of thoracic oncology 	2015	30
25721120	crizotinib	Pekar-Zlotin M	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.	The oncologist	2015	29
25733882	crizotinib	Zou HY	PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
25759024	crizotinib	Wilson FH	A functional landscape of resistance to ALK inhibition in lung cancer.	Cancer cell	2015	42
25846554	crizotinib	Pailler E	High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.	Annals of oncology 	2015	28
25882375	crizotinib	Ali SM	Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.	The oncologist	2015	18
26215952	crizotinib	Liu X	Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.	Journal of clinical oncology 	2016	26
26464158	crizotinib	Ou SH	ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.	Lung cancer	2016	10
26544515	crizotinib	Nilsson RJ	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.	Oncotarget	2016	20
26598747	crizotinib	Ou SH	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.	Journal of clinical oncology 	2016	97
26729443	crizotinib	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	42
26751586	crizotinib	Fujita S	Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.	Journal of thoracic oncology 	2016	14
26993609	crizotinib	Tan CL	Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.	Oncotarget	2016	16
27245569	crizotinib	Ali SM	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.	The oncologist	2016	15
27432227	crizotinib	Gainor JF	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.	Cancer discovery	2016	54
27432917	crizotinib	Crinò L	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.	Journal of clinical oncology 	2016	38
27498387	crizotinib	Ito K	Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.	Journal of thoracic oncology 	2017	7
27507192	crizotinib	Zhang Z	Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.	Journal of thoracic oncology 	2017	5
27697581	crizotinib	Ou SI	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2017	6
27863201	crizotinib	Gadgeel SM	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	16
28039177	crizotinib	Woo CG	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.	Annals of oncology 	2017	11
28461563	crizotinib	Pailler E	Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.	Cancer research	2017	8
28475456	crizotinib	Kim DW	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.	Journal of clinical oncology 	2017	24
28520527	crizotinib	Lim SM	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.	Journal of clinical oncology 	2017	8
21752263	PCI 32765	Chang BY	The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.	Arthritis research & therapy	2011	50
22180443	PCI 32765	Ponader S	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.	Blood	2012	171
22279054	PCI 32765	de Rooij MF	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.	Blood	2012	134
22689860	PCI 32765	Tai YT	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.	Blood	2012	48
23045577	PCI 32765	Advani RH	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.	Journal of clinical oncology 	2013	210
24270740	PCI 32765	Cheng S	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.	Leukemia	2014	45
24332241	PCI 32765	O'Brien S	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.	The Lancet. Oncology	2014	104
24469833	PCI 32765	Mathews Griner LA	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	73
24659631	PCI 32765	Herman SE	Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.	Blood	2014	46
24829205	PCI 32765	Wodarz D	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.	Blood	2014	23
24869598	PCI 32765	Woyach JA	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.	The New England journal of medicine	2014	164
24912431	PCI 32765	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	21
25082755	PCI 32765	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	41
25138588	PCI 32765	Kamel S	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.	Leukemia	2015	31
25150798	PCI 32765	Burger JA	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.	The Lancet. Oncology	2014	66
25189416	PCI 32765	Cheng S	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	Leukemia	2015	24
25284608	PCI 32765	Zhao X	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.	British journal of haematology	2015	16
25344523	PCI 32765	Da Roit F	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.	Haematologica	2015	32
25555420	PCI 32765	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	62
25582069	PCI 32765	Cao Y	The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.	British journal of haematology	2015	18
25797245	PCI 32765	Chiron D	Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.	Oncotarget	2015	19
25829398	PCI 32765	Cervantes-Gomez F	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2015	37
25838351	PCI 32765	Hing ZA	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.	Blood	2015	16
25853747	PCI 32765	Treon SP	Ibrutinib in previously treated Waldenström's macroglobulinemia.	The New England journal of medicine	2015	88
25972157	PCI 32765	Liu TM	Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.	Blood	2015	21
26116658	PCI 32765	Jaglowski SM	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.	Blood	2015	21
26182309	PCI 32765	Maddocks KJ	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.	JAMA oncology	2015	55
26193078	PCI 32765	Ten Hacken E	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.	Biochimica et biophysica acta	2016	26
26193343	PCI 32765	Wilson WH	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.	Nature medicine	2015	87
26563132	PCI 32765	Kwok M	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.	Blood	2016	19
26628631	PCI 32765	Wiestner A	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.	Haematologica	2015	18
26641137	PCI 32765	Byrd JC	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	58
26655421	PCI 32765	Chanan-Khan A	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.	The Lancet. Oncology	2016	28
26717038	PCI 32765	Guo A	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.	Oncotarget	2016	13
26813675	PCI 32765	Fraietta JA	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.	Blood	2016	23
26819453	PCI 32765	Ruella M	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.	Clinical cancer research 	2016	11
26957112	PCI 32765	Wu J	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.	Journal of hematology & oncology	2016	15
27127301	PCI 32765	Saba NS	Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.	Blood	2016	13
27198718	PCI 32765	Winqvist M	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.	Haematologica	2016	11
27535981	PCI 32765	Amin NA	Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2017	6
27677739	PCI 32765	Ruella M	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.	Leukemia	2017	7
27904138	PCI 32765	Yu J	Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.	Leukemia	2017	7
28034907	PCI 32765	Patel V	Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.	Clinical cancer research 	2017	6
28049639	PCI 32765	Ahn IE	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.	Blood	2017	8
28167659	PCI 32765	Noy A	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.	Blood	2017	6
28199309	PCI 32765	Compagno M	Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.	Nature	2017	14
28424162	PCI 32765	Ding W	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.	Blood	2017	8
21245089	trametinib	Gilmartin AG	GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.	Clinical cancer research 	2011	144
21523318	trametinib	Yamaguchi T	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.	International journal of oncology	2011	51
22805291	trametinib	Infante JR	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	94
22805292	trametinib	Falchook GS	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	114
23248257	trametinib	Kim KB	Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.	Journal of clinical oncology 	2013	99
24055054	trametinib	Villanueva J	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.	Cell reports	2013	53
25452114	trametinib	Long GV	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.	Nature communications	2014	47
26392102	trametinib	Corcoran RB	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.	Journal of clinical oncology 	2015	60
26498373	trametinib	Brastianos PK	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.	Journal of the National Cancer Institute	2016	13
26644315	trametinib	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	40
26811525	trametinib	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	36
27283860	trametinib	Planchard D	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.	The Lancet. Oncology	2016	43
27338794	trametinib	Manchado E	A combinatorial strategy for treating KRAS-mutant lung cancer.	Nature	2016	39
28108460	trametinib	Zawistowski JS	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.	Cancer discovery	2017	13
28178529	trametinib	Wang B	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.	Cell reports	2017	6
28268064	trametinib	Schreuer M	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.	The Lancet. Oncology	2017	13
28475671	trametinib	Long GV	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.	Annals of oncology 	2017	10
9381178	cholecystokinin C-terminal flanking peptide	del Peso L	Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.	Science	1997	419
9407038	cholecystokinin C-terminal flanking peptide	Siliciano JD	DNA damage induces phosphorylation of the amino terminus of p53.	Genes & development	1997	199
9488451	cholecystokinin C-terminal flanking peptide	Weaver BK	Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1.	Molecular and cellular biology	1998	106
11237521	cholecystokinin C-terminal flanking peptide	Simpson L	PTEN: life as a tumor suppressor.	Experimental cell research	2001	134
11432833	cholecystokinin C-terminal flanking peptide	Wulf GM	Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.	The EMBO journal	2001	133
11533658	cholecystokinin C-terminal flanking peptide	Ryo A	Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.	Nature cell biology	2001	132
15800615	cholecystokinin C-terminal flanking peptide	Esashi F	CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.	Nature	2005	142
15854913	cholecystokinin C-terminal flanking peptide	Guse A	Phosphorylation of ZEN-4/MKLP1 by aurora B regulates completion of cytokinesis.	Current biology 	2005	79
16226704	cholecystokinin C-terminal flanking peptide	She QB	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.	Cancer cell	2005	133
16446383	cholecystokinin C-terminal flanking peptide	Radomska HS	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.	The Journal of experimental medicine	2006	64
16751189	cholecystokinin C-terminal flanking peptide	Qin W	Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.	The Journal of biological chemistry	2006	163
16818723	cholecystokinin C-terminal flanking peptide	Ku NO	A disease- and phosphorylation-related nonmechanical function for keratin 8.	The Journal of cell biology	2006	62
17317136	cholecystokinin C-terminal flanking peptide	Itoh S	Negative regulation of TGF-beta receptor/Smad signal transduction.	Current opinion in cell biology	2007	108
17483355	cholecystokinin C-terminal flanking peptide	Zou HY	An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.	Cancer research	2007	171
17562708	cholecystokinin C-terminal flanking peptide	Hanger DP	Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.	The Journal of biological chemistry	2007	86
17906618	cholecystokinin C-terminal flanking peptide	Plun-Favreau H	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.	Nature cell biology	2007	151
18023328	cholecystokinin C-terminal flanking peptide	Takahashi-Yanaga F	GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy.	Cellular signalling	2008	82
18184780	cholecystokinin C-terminal flanking peptide	Terunuma M	Deficits in phosphorylation of GABA(A) receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus.	The Journal of neuroscience 	2008	57
19085907	cholecystokinin C-terminal flanking peptide	Kaplan FS	Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.	Human mutation	2009	90
19243594	cholecystokinin C-terminal flanking peptide	Eiseler T	Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion.	Breast cancer research 	2009	58
19372545	cholecystokinin C-terminal flanking peptide	Park HU	AMP-activated protein kinase promotes human prostate cancer cell growth and survival.	Molecular cancer therapeutics	2009	56
19372583	cholecystokinin C-terminal flanking peptide	Boisvert-Adamo K	Mcl-1 is required for melanoma cell resistance to anoikis.	Molecular cancer research 	2009	52
19573808	cholecystokinin C-terminal flanking peptide	Miao H	EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.	Cancer cell	2009	121
19738052	cholecystokinin C-terminal flanking peptide	Saetrom P	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.	Cancer research	2009	52
20140016	cholecystokinin C-terminal flanking peptide	Wang J	Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.	Oncogene	2010	46
20346680	cholecystokinin C-terminal flanking peptide	Moquin D	The molecular regulation of programmed necrotic cell injury.	Trends in biochemical sciences	2010	48
20580720	cholecystokinin C-terminal flanking peptide	Lee G	Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.	Gastroenterology	2010	57
21095632	cholecystokinin C-terminal flanking peptide	Wang H	Glycogen synthase kinase 3: a point of convergence for the host inflammatory response.	Cytokine	2011	50
21098708	cholecystokinin C-terminal flanking peptide	Ustach CV	A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.	Cancer research	2010	41
21430779	cholecystokinin C-terminal flanking peptide	Ceol CJ	The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.	Nature	2011	145
21502402	cholecystokinin C-terminal flanking peptide	Hong J	Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness.	Cancer research	2011	62
21637291	cholecystokinin C-terminal flanking peptide	Dagda RK	Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease.	Cell death and differentiation	2011	39
21813756	cholecystokinin C-terminal flanking peptide	Tomlins SA	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.	Science translational medicine	2011	107
21855797	cholecystokinin C-terminal flanking peptide	Joo JH	Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy.	Molecular cell	2011	66
22325354	cholecystokinin C-terminal flanking peptide	Yata K	Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.	Molecular cell	2012	46
22736790	cholecystokinin C-terminal flanking peptide	Pettersson A	The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.	Cancer epidemiology, biomarkers & prevention 	2012	80
23075850	cholecystokinin C-terminal flanking peptide	Liu GH	Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.	Nature	2012	82
23277200	cholecystokinin C-terminal flanking peptide	Barrett A	p130Cas: a key signalling node in health and disease.	Cellular signalling	2013	28
23306062	cholecystokinin C-terminal flanking peptide	Laine A	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.	Cancer discovery	2013	32
11320250	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	101
15042359	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Zhang BH	Randomized controlled trial of screening for hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2004	213
15508073	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Daniele B	Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.	Gastroenterology	2004	74
17000670	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Lee TK	Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.	Clinical cancer research 	2006	98
17570225	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ma S	Identification and characterization of tumorigenic liver cancer stem/progenitor cells.	Gastroenterology	2007	312
17681183	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Meng F	MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.	Gastroenterology	2007	746
17891174	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ma S	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.	Oncogene	2008	209
18069697	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Forner A	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.	Hepatology	2008	134
18263735	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Tang Y	Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2008	106
18313787	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kim M	Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells.	Journal of hepatology	2008	65
19111019	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Mishra L	Liver stem cells and hepatocellular carcinoma.	Hepatology	2009	99
19723656	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	195
19852728	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	van Zijl F	Epithelial-mesenchymal transition in hepatocellular carcinoma.	Future oncology	2009	85
20066715	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Carr BI	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.	Cancer	2010	46
20371487	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Wei W	S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis.	Science translational medicine	2010	46
20637208	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Saxena NK	Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.	Gastroenterology	2010	45
21397858	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Sawey ET	Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.	Cancer cell	2011	81
21712406	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Raychaudhuri P	FoxM1: a master regulator of tumor metastasis.	Cancer research	2011	78
21721029	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kogure T	Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth.	Hepatology	2011	151
22728651	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Lee CW	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.	Cancer research	2012	54
22807686	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Li S	GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers.	PLoS genetics	2012	52
23649629	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Wang Y	Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes.	The Journal of biological chemistry	2013	33
